Potential Health Benefits of GH and IGF-1

• Improves Symptoms of Diabetes [61-89]
• Lowers Blood Pressure [90-105]
• Boosts Sexual Vitality and Improves Sexual Health [106-114]
• Accelerates Recovery from Injury [115-122]
• Speeds Up Wound Healing [123-139]
• Prevents and Treats Nerve Damage [140-162]
• Lowers Risk for Stroke [163-179]
• Improves Kidney Function and Treats Chronic Kidney Disease (CKD) [180-191]
• Lowers Risk for Cardiovascular Diseases [192-216]
• Prevents Muscle Wasting [217-231]
• Prevents Alzheimer’s Disease (AD) and Boosts Cognitive Health [232-268]
• Prevents Cancer [269-288]
• Improves Sleep Quality [289-299]
• Decreases Organ Atrophy and Dysfunction of Organs [300-316]
• Wards off Depression and Improves Mood [317-325]
• Improves Energy Levels [329-350]
• Lowers Risk for Cardiovascular Diseases and Related Deaths [351-366]
• Improves Body Composition and Metabolic Abnormalities [367-380]
• Treats Muscular Abnormalities [381-387]
• Prevents Bone Abnormalities and Lowers Risk for Fractures [388-399]
• Improves Blood Sugar Levels [400]

GH and IGF-1 Production

The release of GH in the pituitary gland, a pea-sized gland located below the brain, is governed by two hormones: growth hormone-releasing hormone and growth hormone-inhibiting hormone. [3] Different external stimulatory and inhibitory factors may affect the release of GH including: [4]

• Fasting, low blood sugar and vigorous exercise
• Ghrelin (an enzyme that stimulates appetite)
• Growth hormone-releasing hormone (somatocrinin)
• Sex hormones such as androgens and estrogen

Some inhibitors of growth hormone secretion include: [5]

• Circulating concentrations of GH and IGF-1 (Insulin-like growth factor 1)
• Dihydrotestosterone (active form of testosterone)
• Growth hormone-inhibiting hormone (somatostatin)
• Glucocorticoids (powerful anti-inflammatory compounds)
• Hyperglycemia (high blood sugar)

Young adolescents especially those in the puberty period, secrete GH at the rate of about 700 μg/day, while healthy adults secrete GH at a lower rate of about 400 μg/day – these surges of GH secretion occur during the day every 3 to 5 hours. [6] When secreted into the bloodstream, GH remains active for only a few minutes, but this is enough time for the liver to convert it into growth factors, which are necessary for the stimulation of growth in living cells. [7]
The most essential of all growth factors is the insulin-like growth factor 1 (IGF-1), also called somatomedin C, which boasts a host of anabolic properties. IGF-1 is a hormone that resembles the molecular structure of insulin. It supports cellular division, growth of muscles and organs, helps repair nerve damage in different vital organs, reduces body fat by using fat as a source of energy instead of glucose, and it helps increase the number and size of cells in the body. [8] IGF-1 is produced primarily by the liver as an endocrine hormone. Its production is stimulated by GH and can be retarded by a number of factors such as malnutrition, growth hormone insensitivity and lack of growth hormone receptors. [9]
Measurements of IGF-1 are adjusted for age because its levels tend to decline over time. Normal ranges of IGF-1 by age are: [10]

• 16 to 24 years old: 182 to 780 ng/mL
• 25 to 39 years old: 114 to 492 ng/mL
• 40 to 54 years old: 90 to 360 ng/mL
• 55 years old and above: 71 to 290 ng/mL

Relationship between HGH and IGF-1

GH stimulates the production of IGF-1. GH is broken down in the liver and is converted to IGF-1. Additional IGF-1 is also generated within target tissues. IGF-1 by itself and in combination with other growth factors play an important role in healing, muscle and bone growth, repair processes, and other essential functions in the body. Most of the effects of GH are mediated through IGF-1. [11] When the levels of GH rise or fall below the normal, the same thing will happen to IGF-1. [12] The GH/IGF1 system is dynamic and its activity is greatly influenced by age, sexual maturation, body composition and other factors.

Growth Hormone Deficiency

Growth hormone deficiency (GHD) is a disorder characterized by an absent or insufficient secretion of growth hormone from the pituitary gland, resulting in slower growth and development. [13] Both children and adults can be diagnosed with GHD, and the exams and tests used are the same for all age groups. Diagnosing GHD typically starts with a physical exam to assess signs and symptoms of slowed growth. The doctor will check the patient’s weight, height, and body proportions as individuals with GHD are much shorter than normal persons. Other than a physical exam, there are a wide range of tests and exams required in order to come up with a GHD diagnosis.
Blood tests for GHD include the following:

• Binding protein levels (IGF-I and IGFBP-3): This is used to show whether GHD is caused by a problem in the pituitary gland. [14]
• GH stimulation test: This test is used to diagnose GHD and hypopituitarism (diminished hormone secretion by the pituitary gland). The test makes use of an intravenous solution to stimulate GH release from the pituitary gland and check whether GH release is at normal levels. [15]
• GH suppression test: This test helps to diagnose GH excess. The patient is given a standard dose of glucose to drink and blood is drawn at timed intervals to check if the pituitary gland is sufficiently suppressed. [16]
• Insulin tolerance test: This test involves injection of insulin into a patient’s vein to assess pituitary function. [17]

In addition to blood tests, the doctor can also perform additional exams and tests such as X-rays and MRI to help diagnose GHD.

Causes

It is normal for the pituitary gland to produce lesser amounts of GH, sex hormones, and other essential hormones in the body as a person ages. Physicians therefore distinguish between age-related GHD and those with identifiable causes which can be present at birth (congenital), or acquired at some point in life.
Congenital causes of GHD are:

• • Brain tumors
  • Abnormal pituitary gland
  • Cleft lips or cleft palates (children with these conditions often have poorly developed pituitary glands) [18]
  • Gene mutations (e.g. Growth-hormone-releasing hormone receptor, GH1)
  • Congenital diseases such as Prader-Willi syndrome, Turner syndrome, [19] or short stature homeobox gene (SHOX) deficiency [20]
  • Chronic kidney disease (CKD) [21]

Acquired causes of GHD include the following:

• Serious head injuries or trauma
• Infections
• Surgery
• Radiation

Symptoms

In children, symptoms of GHD include the following: [22]

• Children with GHD are shorter than their peers
• Delayed puberty
• Increased fat around the face and stomach
• Slow tooth development
• Sluggish hair growth
• Younger, rounder faces
• Small penis

In adults, the symptoms can vary, and most of them can experience the following: [23]

• Baldness
• Decrease in sexual function and interest
• Decreased muscle mass and strength
• Difficulty concentrating
• Dry, thin skin
• Fatigue related to low energy levels
• Cardiovascular problems
• High levels of bad cholesterol
• Insulin resistance
• Memory problems
• Mood changes
• Reduced bone density
• Sensitivity to heat and cold
• Weight gain

IGF-1 Deficiency

This medical condition happens when there is insufficient conversion of GH to IGF-1 by the liver. [24] To determine IGF-1-deficiency, your doctor will order an IGF-1 blood test, or also known as SM-C/IGF-1, Somatomedin-C, and Sulfation factor. IGF-1 blood test is primarily ordered to check for pituitary gland disorders and to assess abnormalities in growth hormone production. [25] An IGF-1 blood test is commonly ordered for patients with symptoms of insufficient or excess production of GH and IGF-1. Unlike GH, the levels of IGF-1 are stable throughout the day, making it a significant indicator of average GH levels. [26]

Causes

Several factors can affect the conversion of GH to IGF-1 by the liver, leading to deficient IGF-1 levels. First and foremost, if there is an existing problem in the principal site of GH to IGF-1 conversion which is the liver, [27] then such conversion may not happen or the liver can only produce little amounts of IGF-1. Also, if there is insufficient amount of GH in the blood, the levels of IGF-1 can fall below the normal. Other factors which can affect IGF-1 levels are pituitary tumors, gene mutations, head injuries or trauma, infections, radiation and surgery. [28] Also, caloric or protein restriction in the diet can decrease the levels of IGF-1 by decreasing the liver cells’ sensitivity to GH stimulation. [29]

Symptoms

In children, the following may indicate IGF-1 deficiency: [30]

• Slowed growth rate in early childhood relative to group norms
• Shorter stature than others of the same chronological age
• Delayed puberty
• X-rays showing delayed bone development

In adults, abnormally low levels of IGF-1 may cause subtle, nonspecific symptoms such as: [31]

• Adverse lipid changes
• Decreased bone density
• Fatigue
• Reduced exercise tolerance

Anti-Aging Research

The billion-dollar anti-aging hormone-therapy industry is based on a simple principle: As people age, levels of various hormones in the body decrease significantly; so replenishing youthful levels of those hormones is the key to slowing down the process of aging. The anti-aging hormone-therapy began as an industry in 1990, in New England, when 12 men over age 60 were injected with growth hormones. [32] All of the subjects experienced an increase in muscle mass and bone density, and had a significant reduction in body fat. Entrepreneurs quickly took on the study and repackaged it as a form of “anti-aging” and began offering it in cosmetic clinics and other pharmaceutical companies. Since then, thousands of research studies have been conducted on GH and IGF-1, linking it to an ever-expanding list of health-related benefits.

Anti-Aging Effect of Growth Hormone

Among its many biological effects, GH injection promotes an increase in muscle mass, bone density, exercise capacity, and a decrease in body fat. [33-34] Studies show that people with significant GH deficiency secondary to pituitary disease, have increased body fat and decreased muscle mass and bone density. [35] These body changes in GH-deficient patients mimic aging.
The landmark study of Rudman and colleagues in 1990 reported that 6 months GH injections in men over 65 years of age who have low levels of plasma IGF-1, showed increased muscle mass and bone mineral density in some of the examined sites of the skeleton and showed improved general well-being. [36] These promising results elicited enormous general interest in large pharmaceutical companies and wellness clinics, and raised the possibility of using GH replacement therapy to slow down, or perhaps reverse the process of aging, or at least some symptoms related to it. These exciting possibilities were consistent with well-documented and beneficial effects of GH supplementation in GH-deficient patients, [37] and with the ability of GH therapy to improve age-related changes in metabolic characteristics, brain vascularity and cognitive function. [38] The actions of GH have already been related to longevity in other mammals such as carnivores, rodents and ungulates. [39]

Anti-Aging Effect of IGF-1

The major role of IGF-1, insulin and other homologous molecules in the control of longevity has been conclusively documented in a wide variety of organisms such as worms, insects, and mammals. [40] In mammals, the natural decline in circulating IGF-1 levels due to aging has been associated with neuronal aging and symptoms of neurodegeneration. [41]
Signaling through the insulin/IGF-1 pro-survival pathway is known to demonstrate protective effects in nerve cells (neurons) and it plays an important role in neuronal growth and physiology. [42-43] Suspected mechanisms of IGF-1 action in aging include reduced insulin signaling and enhanced sensitivity to insulin, thus, slowing the aging process. [44] Aging is associated with increased vascular oxidative stress and vascular disease. [45] One of the mechanisms in which IGF-1 can slow the process of aging is that IGF-1 can reduce oxidative stress. [46]

IGF-1 Supplementation

As people age, there are a wide array of health issues they face. These include loss of muscle and bone mass, slow recovery from injury, decreased sexual function and desire, mood changes and other symptoms related with aging. Fortunately, recent advances in the anti-aging industry showed that an effective IGF-1 supplement can address all of these concerns by supporting muscle and bone growth, [47] increasing nerve regeneration, and ramping up sexual power.

Route of Administration

No matter what value and how potent an IGF-1 supplement has, it is useless if the method of delivery is not viable. IGF-1, like all growth factor hormones, is difficult to supplement due to the fragility of the compounds. Oral supplementation of IGF-1 is ineffective because they are typically destroyed in the gastrointestinal tract due to their extreme sensitivity to decomposition during digestion. [48] IGF-1, whether artificial or natural, must be administered via subcutaneous (between the skin and muscle) or intramuscular injections to avoid stomach acids and for it to be effective.

Variants

IGF-1 variants are classified into two groups: IGF-1 LR3 and DES IGF-1. Base IGF-1 has a very short half-life which only lasts about 10 to 20 minutes, [49] as a result, it is quickly destroyed by the body. To solve this issue, IGF-1 was modified leading to the creation of the amino acid analog IGF-1 LR3 (Long). The other variant of IGF-1 is known as DES IGF-1, which is a truncated version that is 10 times more potent than IGF-1. These variants have different actions which allow them to function in specific ways.

IGF-1 LR3

IGF-1 LR3 is also known as Insulin-Like Growth Factor-I Long Arg3 or Long R3 IGF-1. The IGF-1 LR3 is a long-term analog of human IGF-1 which has a half-life of about 20 to 30 hours and is much more potent than base IGF-1. [50] The enhanced potency of IGF-1 LR3 is due to its decreased binding action to all known IGF binding proteins – these binding proteins normally inhibit the biological actions of IGF. Since the half-life of IGF-1 LR3 is about a day, it will circulate in the body for longer periods of time and will bind to receptors and activate cell communication that improves muscle growth and fat reduction.
IGF-1 LR3 helps build new muscle tissue in the body by promoting nitrogen retention and protein synthesis. [51] This in turn causes muscle growth through both hyperplasia (increase in muscle cells) and mitogenesis (actual growth of new muscle fibers). Thus, IGF-1 LR3 does not only make muscle fibers grow bigger, but it also makes more of them.
When IGF-1 LR3 is active, it plays multiple roles on the tissues in muscle cells. IGF-1 LR3 increases the activity of satellite cells (precursors to skeletal muscle cells), muscle protein content, muscle DNA, muscle weight and muscle cross sectional area – all of these induce muscle growth and their effects are enhanced when combined with weight training.

IGF-1 DES

IGF-1 DES is the shorter version of the IGF-1 chain, which is 5 times more potent than IGF-LR3 and 10 times more potent than regular base IGF-1. [52] The half-life for IGF-1 DES is about 20-30 minutes. [53] It has the ability to stimulate muscle hyperplasia better than IGF-1 LR3 so it is best used for site injections where you want to see muscle growth rather than overall growth. In addition, IGF-1 DES is known to bind to receptors that have been deformed by lactic acid, which occurs during workouts. [54] This allows IGF-1 DES to bind itself to a mutated receptor and signal growth of tissues during training. IGF-1 DES can be used for longer periods of time and more frequently than IGF-1 LR3.

IGF-1 versus GH/HGH

GH actually is a precursor to IGF-1. GH does not directly cause muscle growth, but indirectly causes muscle growth by signaling the release of IGF-1. [55] There are several theories as to how GH affects muscle growth. One is called the Dual Effectory Theory, which states that GH has direct anabolic effects on different tissues of the body. [56] In one study involving genetically altered mice, GH has been shown to have more growth potential than 1GF-1, but when an element that destroys IGF-1 was administered together with GH, the anabolic effects weren’t present. [57] This shows that IGF-1 is involved somewhere between the pituitary gland and the target tissue.
A second theory is the Somatomedin theory. This states that GH exerts its anabolic effects through IGF-1. [58] When GH is first released into the bloodstream, it travels to the liver and other surrounding tissues where it begins the synthesis and release of IGF-1. A study performed to support this theory showed that GH-deficient animals were able to reach normal growth levels after IGF-1 administration. [59]
It is a well-known fact that the levels of IGF-1 are significantly raised after GH administration. It would seem logical that one could skip GH administration and take IGF-1 instead as IGF-1 is considered as a potential promoter of growth and lipolysis (lipid breakdown). [60] Due to the lower cost of IGF-1, many have opted to replace GH supplementation with IGF-1. Skipping the sequences involved with synthesizing IGF-1 from GH will yield results that are equal or greater than GH administration.

Benefits of IGF-1 in Specific Medical Conditions

IGF-1 may be implicated in various pathological conditions. IGF-1 and synthetic IGF-1 analogues have therapeutic medical applications aside from its benefits in bodybuilding, growth and development, and other essential biochemical processes. An overwhelming body of research supports the following benefits of IGF-1:

• Improves Symptoms of Diabetes

IGF-1 has significant structural homology with insulin. It has been shown to bind to insulin receptors to stimulate the transport of blood sugar (glucose) into fat and muscle, inhibit excessive glucose production by the liver and lower blood glucose while simultaneously suppressing the secretion of insulin. [61] Studies in diabetic patients who are in insulin-deficient states have shown that their IGF-1 concentrations in the blood were also low and were increased with insulin therapy. [62] Similarly, administration of insulin via the portal vein (a vessel that moves blood from the spleen and gastrointestinal tract to the liver) results in optimization of plasma IGF-1 concentrations. In one study involving a patient with a partial gene deletion (a mutation in which a chromosome or a sequence of DNA is lost) of the insulin-like growth factor-1 (IGF-1) gene, Woods et al. reported that the lack of IGF-1 gene results in IGF-1 deficiency, severe insulin resistance, and short stature, and that IGF-1 therapy resulted in beneficial effects on insulin sensitivity, body composition, bone size, and linear growth. [63] Administration of IGF-1 in diabetic patients has also been shown to result in an improvement not only in insulin sensitivity and quality of life, but it significantly reduced the dose of the required insulin to maintain balance in glucose levels. [64-89] Taken together, these findings support that IGF-1 administration is necessary to maintain normal insulin sensitivity, and impairment in the synthesis of IGF-1 results in a worsening state of insulin resistance.

• Lowers Blood Pressure

Low levels of IGF-1 are associated with hypertension. [90] Several clinical trials have suggested that IGF-1 may have a role in preventing the development of hypertension. [91] In vitro and in vivo experiments have shown that IGF-1 has vasodilatory properties. [92-93] Normally, blood pressure increases if blood cannot flow freely inside the blood vessels due to narrowing of the opening, fat deposits, plaques and other causes. [94] Vasodilatory action of IGF-1 causes the blood vessels to relax or widen, thereby allowing more blood to flow freely inside it. This in turn leads to a reduction in the blood pressure. IGF-1 also attenuates the contractile action of the powerful vasoconstrictor known as endothelin-1 by altering the signaling activity of its receptors in smooth muscle cells. [95] Moreover, the role of IGF-1 in improving blood glucose levels can also help lower blood pressure. High blood glucose causes the blood to become thick and sticky, thus affecting its normal flow. [96] This in turn increases the pressure within the blood vessels and can lead to rupture if not treated. Because of these powerful mechanisms, numerous high-quality studies have shown that IGF-1 replacement therapy in patients with hypertension may help normalize blood pressure, thereby reducing their risk of developing serious medical conditions. [97-105]

• Boosts Sexual Vitality and Improves Sexual Health

IGF-1 levels, like testosterone, decline in an age-dependent manner. This progressive decline leads to various symptoms including erectile dysfunction (ED). Interestingly, IGF-1 is known to mediate endothelial nitric oxide production. Nitric oxide is considered to be a principal mediator of penile erection by causing relaxation of vascular smooth muscle which leads to engorgement of the penis with blood, thereby developing an erection. [106] The relationship of IGF-1 and penile erection has been described in otherwise healthy male subjects, and recent in vitro studies suggest that IGF-1 increases nitric oxide and may help maintain erectile function. [107-112] In one study, Pastuszak et al. reported that IGF-1 levels correlate significantly with sexual function scores in 65 men who completed the Sexual Health Inventory for Men (SHIM) and Expanded Prostate Cancer Index Composite (EPIC) questionnaires. [113] Other studies even reported that restoring IGF-1 levels through IGF-1 supplementation may help treat erectile dysfunction and increase libido. [114]

• Accelerates Recovery from Injury

In recent years, there have been rapid developments in the use of growth factors such as IGF-1 for accelerated healing of injury. The crucial role of IGF-1 in wound healing and tissue repair has been successfully used in plastic surgery and the technology is now being developed for orthopedics and sports medicine applications. [115] Growth factors mediate the biological processes necessary for repair of muscles, tendons and ligaments following acute traumatic or overuse injury. In one study, Provenzano et al. reported that systemic administration of IGF-1 improved healing in collagenous connective tissue, such as ligament. [116] In a similar study, Kurtz et al. found out that IGF-1 has an anti-inflammatory mechanism which reduces maximum functional deficit and accelerates recovery after Achilles tendon injury. [117] In another study, Emel et al. investigated the effects of local administration of IGF-1 on the functional recovery of paralyzed muscles. [118] The results of the study showed that IGF-1 administration increased the rate of axon (nerve fiber) regeneration in crush-injured and freeze-injured sciatic nerves of the lower spine, buttocks and back of the thigh. Furthermore, numerous studies even show that IGF-1 can accelerate the regeneration of damaged body structures. [119-122]

• Speeds Up Wound Healing

Wound healing is a complex process which is affected by IGF-1 bound to insulin-like growth factor-binding protein (IGFBP). [123] This growth factor has receptors which stimulate local collagen formation necessary for wound healing. [124] In addition, IGF-1 and other growth factors modulate skin cell survival and regeneration. [125] A study performed to support the wound healing effects of IGF-1 showed that patients receiving 0.2 mg/kg/day recombinant human growth hormone (rHGH) demonstrated significantly higher IGF-1 blood levels and a significant decrease in donor-site healing times and length of hospital stay. [126] In another study, Aydin et al. reported that diabetic patients who had higher levels of IGF-1 had improved wound healing rate compared to those with lower levels. [127] Other studies assessing the therapeutic benefits of IGF-1 in patients with chronic wound have shown that the treatment speeds up the repair of damaged tissues by increasing the number of cells necessary for the wound healing process. [128-139]

• Prevents and Treats Nerve Damage

Neuropathy is the term used to describe a problem with the nerves, typically causing numbness and problems with mobility. [140] Preclinical studies suggest that IGF-1 can be useful for the treatment of mixed motor and sensory neuropathies. The successful use of IGF-1 in the treatment of peripheral neuropathies may provide the first true therapy for this previously untreatable group of neurological disorders. In one study, Schmidt et al. reported that IGF-1 treatment for a period of 2 months resulted in nearly complete normalization of diabetic neuropathy without altering the severity of diabetes. [141] In another study, therapeutic administration of IGF-1 slowed the degeneration of spinal cord motor neuron axons by reducing the incidence of programmed cell death.[142] Several recent studies involving IGF-1 treatment for Duchenne Muscular Dystrophy (DMD), one of the most prevalent muscle disorders, have also shown significant improvements in muscle functional recovery after the treatment. [143] Similarly, other studies assessing the therapeutic benefits of IGF-1 therapy in a wide array of medical conditions related to nerve damage have shown that the treatment may help restore nerve function and sensation. [144-162]

• Lowers Risk for Stroke

Recent studies have shown that patients who suffered from acute stroke and those who are at increased risk for stroke have depressed blood levels of IGF-1. [163-172] It seems also that post-stroke IGF-1 blood levels are correlated with the outcome from ischemic brain injury (insufficient blood flow to the brain), with higher IGF-1 levels reducing lethality. [173] Many studies have shown the benefits of IGF-1 administration in post-stroke patients by reducing loss of neurons, infarct volume (extent of ischemic brain injury), while increasing glial proliferation (glial cells supply essential nutrients and protect the neurons). [174] Moreover, IGF-1 appears to be linked with repair processes following brain damage by controlling the regeneration of injured peripheral nerves. [175] In one study, Sohrabji et al. reported that estrogen-mediated neuroprotection in neural injury models is critically dependent on IGF-1 signaling. [176] The results of the study showed that estrogen and IGF-1 act cooperatively to influence cell survival. When given alone, posttraumatic administration of IGF-1 may be efficacious in ameliorating neurobehavioral dysfunction in traumatic brain injury. [177-178] A study by Lioutas et al. even found that intranasal IGF-1 administration has demonstrated a benefit for prevention of cognitive decline in older people, and has shown to improve functional outcomes in patients who suffered from stroke. [179]

• Improves Kidney Function and Treats Chronic Kidney Disease (CKD)

IGF-1 and IGFBP (Insulin-like Growth Factor Binding Protein) axis plays a critical role in the maintenance of normal kidney function and progression of chronic kidney disease (CKD). [180] In fact, the levels of IGF-1 and IGFBPs are altered in different stages of CKD. One study revealed that short-term administration of recombinant IGF-1 (rhIGF-1) in patients with end-stage renal disease (ESRD) and in healthy subjects has been shown to increase glomerular filtration rate (GFR) and blood flow to the kidneys. [181] In another study, Vijayan et al. reported that IGF-1 supplementation in 15 patients with advanced CKD at a dose of 100 micrograms per kilogram twice daily for 31 days improved the kidney’s ability to filter waste products and toxins as evidenced by an increase in GFR. [182] Other clinical trials assessing the therapeutic benefits of IGF-1 supplementation in patients with kidney disorders have also shown that the treatment may help improve symptoms and overall kidney function. [183-191]

• Lowers Risk for Cardiovascular Diseases

Recent advances in the field of cardiology have focused on proliferation and regeneration as potential cardiovascular defense mechanisms. Endothelial dysfunction (malfunctioning of the inner lining of blood vessels known as endothelium) is considered an initial step in the development of atherosclerotic lesions (plaque build-up), through activation of a suicidal pathway that leads to programmed cell death of endothelial cells known as apoptosis. [192] IGF-1 can directly oppose endothelial dysfunction in several ways:
1. By increasing the production of nitric oxide, thereby improving blood flow to the heart. [193]
2. By promoting insulin sensitivity [194]
3. By promoting potassium-channel opening [195]
4. By improving lipid profiles [196]
5. Through IGF-1’s anti-apoptotic and anti-inflammatory properties. [197-201]

A large body of research has linked IGF-1 levels and prevalence of cardiovascular diseases. For instance, a cross-sectional study of 122 young subjects revealed that low level of IGF-1 is associated with coronary artery disease (CAD). [202-203] A prospective, nested, case-control study involving more than 600 healthy individuals with 15 years follow-up period showed that lower circulating IGF-1 levels are associated with increased risk of ischemic heart disease. [204] In patients with acute myocardial infarction (AMI), IGF-1 levels on hospital admission were markedly reduced and were significantly lower in those with a worse prognosis. [205] These observations uniformly support the possibility that IGF-1 deficiency may increase one’s risk for cardiovascular diseases. Interestingly, several research groups have studied the effects of IGF-1 in patients with impaired cardiac function. IGF-1 is known to induce vasodilation, thereby contributing to regulation of vascular tone and arterial blood pressure, as well as preservation of coronary blood flow. [206] Other studies also support that IGF-1 supplementation in patients with heart disease may help improve heart function by boosting the heart’s pumping power, thus improving blood circulation. [207-216] These beneficial effects of IGF-1 supplementation can help prevent the development of cardiovascular diseases and help treat its related symptoms.

• Prevents Muscle Wasting

Most muscle pathologies are characterized by the progressive loss of muscle tissue due to a chronic illness combined with the inability to regenerate the damaged muscle. These pathological changes, known as muscle wasting, can be attributed to alteration in muscle growth factors, specifically IGF-1. The administration of IGF-1 has been considered as a promising therapeutic intervention for advanced muscle weakness and wasting because of IGF-1’s role in skeletal muscle growth, survival, and regeneration. [217] Muscle wasting results primarily from accelerated protein degradation and is associated with increased synthesis of two muscle-specific ubiquitin ligases (a type of protein) known as atrogin-1 and muscle ring finger 1 (MuRF1). [218] Sacheck et al. reported that IGF-1 administration can prevent muscle wasting by stimulating muscle growth through suppression of protein breakdown and atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. [219] Similarly, Nystom et al. found that IGF-1 attenuates sepsis-induced muscle wasting apparently by increasing muscle protein synthesis and potentially decreasing protein breakdown. [220] Numerous high-quality studies assessing the therapeutic benefits of IGF-1 in patients with muscle wasting have also proved that the treatment may stimulate muscle repair, increase muscle mass, and improve muscle strength. [221-231]

• Prevents Alzheimer’s Disease (AD) and Boosts Cognitive Health

The search for a cure for AD is restless. Researchers suggest that in order to prevent or slow the progression of AD, medical interventions should be focused on treating the root cause of the disease. Normally, the brains of people with AD have an abundance of abnormal structure called amyloid plaques (sticky buildup of abnormal proteins outside nerve cells or neurons). [232] Recent advances in medicine have shown that brain amyloid clearance is modulated by IGF-1. [233-234] An overwhelming body of clinical research even found that patients with low IGF-1 levels in the blood are at higher risk for AD. [235-243] Interestingly, numerous studies found that higher levels of IGF-1 may help protect against degeneration of brain cells and can lower one’s risk for AD. [244-248] According to other studies assessing the therapeutic benefits of IGF-1 on brain health, the specific mechanisms by which IGF-1 may help protect against AD and other neurological disorder is that IGF-1 promotes nerve cell regeneration and prevents programmed cell death of brain cells. [249-267] These neuroprotective effects may be the reason why IGF-1 administration in patients with AD resulted in significant improvement in memory and thinking skills. [268]

• Prevents Cancer

A large body of clinical trials suggests that IGF-1 has anti-cancer properties. In one of the largest studies ever conducted on IGF-1 and cancer, a long-term follow-up surveillance data involving 13,581 patients diagnosed with common cancers who are treated with IGF-1, did not show any increase in the risk of disease recurrence or death in cancer survivors. [269] In another large study by Swerdlow et al., GH and IGF-1 treatment in patients with brain tumors did not increase the risk of recurrence. [270] Data from the Childhood Cancer Survivor Study (CCSS) are also consistent with the finding that IGF-1 and GH administration do not increase risk of disease recurrence in patients with primary brain tumors and acute leukemia. [271] Furthermore, data from the two largest international databases and surveillance studies involving 86,000 patients on GH and IGF-1 therapy have shown no significant increase in cancer incidence. [272] In another study, researchers revealed that GH and IGF-1 levels approximately 10% that of normal showed almost complete growth suppression of transplanted human breast cancer cells. [273] Finally, there is compelling evidence that IGF-1 regulates hematopoiesis, a process that gives rise to all the other blood cells including neutrophils, macrophages, cytotoxic natural killer cells, and granulocytes – all of which helps protect the body against disease-causing microorganisms such as cancer cells. [274] Also, IGF-1 reduces inflammation [275] and blood sugar. It is a well-known fact that long-term inflammation [276-285] and elevated blood sugar levels [286-294] are risk factors that feed cancer growth or development. In addition, studies show that the anti-tumor properties of IGF-1 can be attributed to its ability to enhance natural killer cell activity of the immune system. [286-288]

• Improves Sleep Quality

During sleep, the body releases a cascade of hormones that are necessary for recovery and growth. One of the most important hormones released during this process is IGF-1. The age-related decline in IGF-1 leads to the development of sleep problems and poor sleep quality in both men and women. In fact, studies have shown that low levels of IGF-1 were associated with poor sleep quality and prevalence of sleeping difficulties. [289-293] On the other hand, studies show that higher levels of IGF-1 were associated with improved sleeping pattern and sleep quality. [294-298] This may be the reason why restoring IGF-1 levels in older patients through hormone replacement therapy has been shown to improve energy levels, emotions and sleep quality. [299]

• Decreases Organ Atrophy and Dysfunction of Organs

With advancing age, all cells in the body are less able to divide and multiply. [300] In addition to this, many cells lose their ability to function, or they function abnormally. Aside from these changes, many tissues and organs lose mass and fail to function normally. This process is medically known as organ atrophy. When an organ loses mass and is worked harder than usual, it may lead to sudden failure or other life-threatening problems. There is increasing body of evidence that aside from aging, a process known as endothelial dysfunction can potentially contribute to organ atrophy and dysfunction. [301-306] Of note, studies show that IGF-1 can directly oppose endothelial dysfunction by increasing the production of nitric oxide, promoting insulin sensitivity, promoting potassium-channel opening, improving lipid profiles, and through IGF-1’s anti-apoptotic and anti-inflammatory properties. [307-311] Other studies assessing the therapeutic benefits of IGF-1 have also shown that this hormone may help prevent atrophy of the gut and brain. [312-316] These findings suggest that IGF-1 does have the ability to fight internal signs of aging.

• Wards off Depression and Improves Mood

Depression and low mood are related to dysregulation of many physiological processes including changes in the levels of brain chemicals and a disturbance in the endocrine system. Recent studies indicate that impairment and changes in specific structures of the brain, particularly the hippocampus, may be an important factor in the development of depression and low mood. [317-318] The abnormal changes in the brain structures may be related to alterations in the levels of IGF-1, with a number of high-quality studies supporting that low level of IGF-1 is a major risk factor for these medical conditions. [319-322] There is increasing evidence that IGF-1 does have an anti-depressant effect, possibly due to its ability to increase the levels of certain brain chemicals including serotonin, which helps regulate mood. [323] A study by Malberg et al. even found that IGF-1 also has anti-anxiety effect aside from its anti-depressant effect. [324] These mechanisms may be the reason why IGF-1 administration in patients with major depressive disorder resulted in improved mood, cognitive abilities, and quality of life. [325]

Growth Hormone Supplementation

Human growth hormone can turn back your body’s internal clock by helping you build muscle fast, slash fat, and restore sexual vitality to increase your self-confidence and improve your quality of life. GH plays numerous roles in the body that are critical for survival including regulation of body composition, body fluids, sugar and fat metabolism, heart function, and growth of muscles and bones. Produced synthetically, GH is the active ingredient in several prescription drugs and in other health products.

Route of Administration

Approved indications for GH therapy include treatment of growth hormone deficiency, chronic renal insufficiency, idiopathic short stature, AIDS-related muscle wasting and fat accumulation. GH therapy usually begins at a low dose and is gradually adjusted to obtain optimal efficacy. [326]

Today, subcutaneous injection is the route of choice for GH administration. [327] In addition to this, trials for alternative less invasive modes of GH administration such as the nasal, pulmonary and transdermal routes are under way. [328] Oral route of GH administration is ineffective because they are typically destroyed in the gastrointestinal tract during the process of digestion.

Benefits of HGH Supplementation

GH plays a major role in muscle growth, increasing bone density, regulating body fluids, sugar and fat metabolism, and maintaining the health of all human tissues, including vital organs such as the heart and brain. The effects of HGH supplementation depend on the dosage and start gradually. First ones are usually noticeable within days or weeks of starting the daily injections.

An extensive body of high-quality research shows the benefits of GH in a wide array of diseases and abnormalities:

• Improves Cognition and Energy Levels

Patients with Growth Hormone Deficiency (GHD) often suffer from low energy levels, mood changes, mental fatigue, and cognitive impairment. [329-333] Interestingly, a study by Wallymahmed et al. have shown that GH replacement therapy in GHD patients for 6 to 12 months led to significant improvements in body composition, muscle strength, energy levels, emotional reactions, and self-esteem scores. [334] In another study, Sathiavageeswaran et al. demonstrated that up to 70% of patients with the fibromyalgia syndrome (long-term condition that causes pain all over the body) who received GH replacement therapy had significant improvements in perceived energy levels, body image, pain level and cognition. [335] Other studies have also shown that GH replacement therapy in GH-deficient individuals resulted in significant improvements in various parameters of cognitive health such as memory, language function, attentional performance, thinking skills, and quality of life. [336-341] Numerous studies even found that GH replacement therapy in patients with traumatic brain injury induced reduction of depression, social dysfunction, and certain cognitive domains. [342-350]

• Lowers Risk for Cardiovascular Diseases and Related Deaths

Numerous studies have shown that lower GH levels are strongly linked with a higher risk of cardiovascular disease and related deaths. [351-360] The degree of GHD is directly related to elevated levels of total cholesterol and low-density lipoprotein (bad cholesterol), increased truncal fat, abnormal waist–hip ratio, and risk of hypertension – all of these factors can increase one’s risk for death related to heart diseases. [361] Interestingly, a meta-analysis of clinical studies assessing various cardiovascular parameters were investigated in patients treated with GH and the results of the study showed significant improvements in lean body mass, total cholesterol, LDL cholesterol, and diastolic blood pressure. [362-363] Similarly, a study by Agarwal et al. has shown that treatment of GH deficiency through GH replacement therapy may help improve outcomes in heart failure. [364] In another study, Tritos et al. reported that patients with congestive heart failure (CHF) who received recombinant human growth hormone (rhGH) therapy had improved exercise duration and increased cardiac output. [365] Finally, in a meta-analysis of several clinical trials assessing the therapeutic benefits of GH therapy on cardiac function, Volterrani et al. reported that patients with CHF who received the treatment experienced a significant improvement in their symptoms without any adverse side effects. [366]

• Improves Body Composition and Metabolic Abnormalities

In adults with GHD, there is a reduction in lean body mass and an increase in abdominal adiposity, which ultimately lead to obesity. [367-373] In a study of 15 healthy adult women, Miller et al. showed that the secretion of GH was much lesser in patients with high truncal fat compared to those with low truncal fat. [375] In another study, researchers found that GH deficiency is associated with high triglyceride levels, hypertension, and low levels of high-density lipoprotein (good cholesterol), and that recombinant GH replacement may help improve these body parameters. [376] In a meta-analysis of 37 blinded, randomized, placebo-controlled trials, Maison et al. found that GH replacement therapy has an overall beneficial effect on LDL cholesterol and total cholesterol profiles. [377] Other studies have also shown that GH therapy in patients with GHD resulted in significant reduction in body fat percentage as well as LDL cholesterol levels. [378-380]

• Treats Muscular Abnormalities

There is a significant association between reduced lean muscle mass and impaired neuromuscular function. [381] In one study, a significant improvement in lean mass and neuromuscular function was observed after more than 10 years of GH replacement therapy. [382] In a very interesting study of patients with the fibromyalgia syndrome, 70% of patients with GHD showed a marked improvement in symptoms following GH replacement therapy. [383] In states of GH deficiency, Weber et al. reported that reduced muscle mass and strength can be reversed successfully with supplementation of GH. [384] In men over 50 years old, GH supplementation is associated with a statistically significant increase in muscle strength in the lower body part, suggesting that GH may help prevent the age-related decline in muscle function. [385-386] In patients with adult-onset and childhood-onset adult GH deficiency, GH therapy can significantly improve symptoms of neuromuscular dysfunction. [387]

• Prevents Bone Abnormalities and Lowers Risk for Fractures

Adult Growth Hormone Deficiency (AGHD) causes osteoporosis, which increases one’s risk for various fractures and low bone mass. [388-394] In order to preserve bone mass and decrease the prevalence of fractures especially in the older population, GH supplementation may be considered as a therapeutic option. In one study, Giustina et al. reported that GH replacement may help reverse bone abnormalities by increasing markers of bone formation and bone resorption [395-396] (process by which osteoclasts break down bone and release minerals, resulting in a transfer of calcium from bone fluid to the blood). In another study, Gillberg et al. found that two years of treatment with recombinant human growth hormone increased bone mineral density in men with osteoporosis of unknown cause. [397] In a meta-analysis of several clinical trials assessing the therapeutic benefits of GH, Barake et al. found that GH treatment resulted in significant increase in osteocalcin (a cell that helps build bones) and in bone resorption markers. [398] Moreover, patients who received GH had a significant decrease in fracture risk. In patients with GHD, Wuster et al. found that GH treatment significantly increased bone metabolism and improved bone geometry. [399]

• Improves Blood Sugar Levels

There is strong scientific evidence supporting the beneficial effects of GH on blood sugar levels. Studies show that GH deficiency is highly associated with impaired insulin sensitivity, indicating that GH has a role in the regulation of insulin as well as blood sugar levels. [400]

Growth Hormone and IGF-1 in Athletics

IGF-1 has a growth stimulating effect, independent of and in conjunction with GH. According to researchers, IGF-1 achieves this effect by suppressing the breakdown of protein and preserving skeletal muscle. [401] Such effect can lead to increased muscle mass, strength and performance. Even though it is tightly controlled by law, GH and IGF-1 supplements are wildly attractive to both pro and amateur weightlifters and athletes. The reasons are simple. These supplements build lean muscle faster, increase recovery rate and makes you train harder. Taking GH and IGF-1 supplements can give athletes an edge over other competitors by boosting their performance in their field of sports.

Anabolic Effect in Athletes

GH and IGF-1 compounds bind to specific receptors, initiating cell division, which in turn causes muscle growth and an increase in muscle mass. [402] IGF-1 has a specific role in protein synthesis which leads to bone formation, and has a major role in muscle and bone repair. Both GH and IGF-1 exert the following anabolic effects which can benefit pros and amateur athletes alike: [403]

• Boosts protein synthesis, leading to improved muscle mass and strength
• Causes significant fat reduction
• Inhibits the catabolic effects (breakdown phase) of athletic training
• Causes significant height increase
• Causes a synergistic anabolic effect when used with anabolic steroids

Controversy and History of HGH in Athletics

HGH is a prescription medication, meaning that its distribution and use without the prescription of a certified doctor is illegal. Use of exogenous GH, via injection, was originally used for medical purposes such as GH deficiency until athletes began abusing GH with the goal of enhancing their abilities and performance. Before recombinant human growth hormone (rHGH) was developed in 1981, cadavers are the only source of HGH. In 1982, the first description of GH use as a doping agent was Dan Duchaine’s “Underground Steroid handbook”; it is not known where and when GH was first used this way. [404] In 1989, the use of anabolic steroids became increasingly popular among Olympic athletes and professional sports players that’s why the International Olympic Committee banned the use of HGH. [405] Although abuse of HGH for athletic purposes is illegal in the U.S., over the past decade it appears that such abuse is present in all levels of sport. [406] This is fueled at least in part by the fact that the use of GH is more difficult to detect than most other performance-enhancing drugs.
According to a report from the United States House Committee on Oversight and Government Reform on steroid and GH use, it was found out that the inappropriate use of HGH and other performance-enhancing drugs by professional athletes and entertainers was fuelling the industry peddling these banned substances to the general public for medically inappropriate uses. [407]

Current Status of IGF-1 in Athletics

For the time being, public opinion seems to believe that the use of IGF-1 is comparable to anabolic steroids. IGF-1 is a prohibited substance on the list of World Anti-Doping Agency (WADA). [408] The WADA Prohibited List bans the use of exogenous IGF-1 and any substance containing IGF-1 in any competition and even out-of-competition. According to the ban, IGF-1 violates the following criteria: [409]
1. It enhances sport performance.
2. It violates the spirit of sport.
For the general public, any form of IGF-1 may be used legally, provided there is a prescription from a qualified medical doctor.

References:

1. Firdos Alam Khan (8 May 2014). Biotechnology in Medical Sciences. CRC Press. pp. 389–. ISBN 978-1-4822-2368-2.
   View Summary +

   Biotechnology in Medical Sciences

   Biotechnology in Medical Sciences” is a book authored by Firdos Alam Khan and published by CRC Press on May 8, 2014. The book explores the application of biotechnology in the field of medical sciences. Covering a wide range of topics, it provides valuable insights into the advancements and contributions of biotechnology in various aspects of medicine. With a page range starting from 389, the book offers comprehensive information on the subject matter. The ISBN for the book is 978-1-4822-2368-2. It serves as a valuable resource for researchers, students, and professionals interested in the intersection of biotechnology and medical sciences.

2. Suzanne C. O’Connell Smeltzer; Brenda G. Bare; Janice L. Hinkle; Kerry H. Cheever (2010). Brunner & Suddarth’s Textbook of Medical-surgical Nursing. Lippincott Williams & Wilkins. pp. 1788–. ISBN 978-0-7817-8589-1.
   View Summary +

   Brunner & Suddarth’s Textbook of Medical-surgical Nursing
   

   Brunner & Suddarth’s Textbook of Medical-surgical Nursing” is a comprehensive textbook authored by Suzanne C. O’Connell Smeltzer, Brenda G. Bare, Janice L. Hinkle, and Kerry H. Cheever. Published by Lippincott Williams & Wilkins, the book offers a detailed understanding of medical-surgical nursing. With a page range starting from 1788, it covers a wide range of topics related to medical-surgical nursing practice. The book provides essential information and updates on nursing care for various medical conditions and surgical procedures. The ISBN for the book is 978-0-7817-8589-1. It serves as a valuable resource for nursing students, educators, and professionals in the field of medical-surgical nursing.

3. APH Publishing. pp. 127–. ISBN 978-81-313-0305-4.
   View Summary +

   APH Publishing
   

   The book published by APH Publishing has a page range starting from 127 onwards. The ISBN for the book is 978-81-313-0305-4. Unfortunately, without the specific title or author information, it is difficult to provide further details about the content or subject matter of the book. However, APH Publishing is known for publishing a wide range of academic and scholarly works across various disciplines. The book may cover diverse topics such as literature, history, social sciences, or other subject areas. To gain more insights into the specific content and relevance of the book, it is recommended to refer to the book’s title, author, or additional information provided.

4. Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (30 November 2015). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 188–. ISBN 978-0-323-29738-7.
   View Summary +

   Williams Textbook of Endocrinology
   

   Williams Textbook of Endocrinology” is a renowned book authored by Shlomo Melmed, Kenneth S. Polonsky, P. Reed Larsen, and Henry M. Kronenberg. Published by Elsevier Health Sciences, the book serves as a comprehensive resource in the field of endocrinology. With a page range starting from 188, it covers a wide range of topics related to hormones, endocrine disorders, and their clinical management. The book provides in-depth insights into the principles and practice of endocrinology, making it valuable for medical students, researchers, and healthcare professionals. The ISBN for the book is 978-0-323-29738-7. “Williams Textbook of Endocrinology” is widely recognized as a trusted reference in the field, offering up-to-date information and authoritative guidance.

5. Kenneth B. Storey (25 February 2005). Functional Metabolism: Regulation and Adaptation. John Wiley & Sons. pp. 280–. ISBN 978-0-471-67557-0.
   View Summary +

   Functional Metabolism: Regulation and Adaptation
   

   Functional Metabolism: Regulation and Adaptation” is a book written by Kenneth B. Storey. Published by John Wiley & Sons on February 25, 2005, the book explores the topic of metabolism and its regulation and adaptation mechanisms. With a page range starting from 280, it delves into the intricate processes of metabolism and how organisms adjust and adapt to different environmental conditions. The book provides insights into the molecular and cellular aspects of metabolic regulation, making it a valuable resource for students and researchers in the field of biochemistry and physiology. The ISBN for the book is 978-0-471-67557-0. “Functional Metabolism” offers a comprehensive understanding of the subject matter and contributes to the scientific literature in the field.

6. Gardner DG, Shoback D (2007). Greenspan’s Basic and Clinical Endocrinology (8th ed.). New York: McGraw-Hill Medical. pp. 193–201. ISBN 0-07-144011-9.
   View Summary +

   Greenspan’s Basic and Clinical Endocrinology (8th ed.)
   

   Greenspan’s Basic and Clinical Endocrinology” is a widely recognized textbook written by David G. Gardner and Dolores Shoback. This eighth edition, published by McGraw-Hill Medical, provides a comprehensive overview of endocrinology. With a page range starting from 193 to 201, the book covers essential topics related to the basic principles and clinical applications of endocrinology. It offers insights into the diagnosis, management, and treatment of endocrine disorders. The ISBN for the book is 0-07-144011-9. “Greenspan’s Basic and Clinical Endocrinology” serves as a valuable resource for medical students, practitioners, and researchers in the field, offering up-to-date information and in-depth understanding of endocrine physiology and pathology.

7. Ridha Arem (8 January 2013). The Protein Boost Diet: Improve Your Hormone Efficiency for a Fast Metabolism and Weight Loss. Simon and Schuster. pp. 66–. ISBN 978-1-4516-9954-8.
   View Summary +

   The Protein Boost Diet: Improve Your Hormone Efficiency for a Fast Metabolism and Weight Loss.
   

   The Protein Boost Diet: Improve Your Hormone Efficiency for a Fast Metabolism and Weight Loss” is a book authored by Ridha Arem. Published by Simon and Schuster on January 8, 2013, the book focuses on the relationship between protein consumption, hormone efficiency, metabolism, and weight loss. With a page range starting from 66, the book provides insights into how optimizing protein intake can enhance hormonal balance, boost metabolism, and facilitate healthy weight management. The book offers practical advice, tips, and dietary recommendations for individuals looking to improve their overall health and achieve weight loss goals. The ISBN for the book is 978-1-4516-9954-8. “The Protein Boost Diet” serves as a resource for those interested in understanding the role of protein in optimizing metabolism and promoting weight loss.

8. Leslie J. DeGroot; J. Larry Jameson (2006). Endocrinology. Elsevier Saunders. ISBN 978-0-7216-0376-6.
   View Summary +

   Endocrinology

   “Endocrinology” is a book co-authored by Leslie J. DeGroot and J. Larry Jameson. Published by Elsevier Saunders, this book provides comprehensive coverage of the field of endocrinology. With a focus on the study of hormones and their effects on the body, the book offers in-depth insights into the various endocrine systems, their regulation, and related disorders. The ISBN for the book is 978-0-7216-0376-6. “Endocrinology” serves as a valuable resource for students, researchers, and healthcare professionals seeking a thorough understanding of the complex field of endocrinology. It covers a wide range of topics, including hormonal signaling, diagnostic techniques, and therapeutic interventions, making it an authoritative reference in the field.

9. Max Corradi (3 February 2014). Low dose medicine: Healing without side effects using low dose homeopathic cytokines, interleukins, hormones, and neurotrophines. Jaborandi Publishing. pp. 56–. ISBN 978-0-9927304-3-7.
   View Summary +

   Low dose medicine: Healing without side effects using low dose homeopathic cytokines, interleukins, hormones, and neurotrophines.
   

   “Low Dose Medicine: Healing without Side Effects Using Low Dose Homeopathic Cytokines, Interleukins, Hormones, and Neurotrophines” is a book authored by Max Corradi. Published by Jaborandi Publishing on February 3, 2014, the book explores the concept of low dose medicine and its potential for healing without adverse effects. Focusing on homeopathic preparations of cytokines, interleukins, hormones, and neurotrophines, the book discusses the principles and applications of this approach. With a page range starting from 56, the book delves into the theory, research, and clinical use of low dose medicine. The ISBN for the book is 978-0-9927304-3-7. “Low Dose Medicine” serves as a resource for individuals interested in alternative approaches to healing and offers insights into the potential benefits of low dose homeopathic treatments.

10. Normal Ranges for Insulin-Like Growth Factor. (n.d.). Retrieved February 04, 2016, from https://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=167.
    View Summary +

    Normal Ranges for Insulin-Like Growth Factor.
    

    The provided information is a reference to a webpage titled “Normal Ranges for Insulin-Like Growth Factor” from the website of the University of Rochester Medical Center. It is a resource that provides information about the normal ranges of insulin-like growth factor (IGF) in the body. Unfortunately, without accessing the actual webpage, I cannot provide specific details about the content or the date it was published. It is important to note that the information may have been updated or changed since February 4, 2016. To obtain accurate and current information, it is recommended to visit the provided website directly.

11. Donald G. Barceloux (3 February 2012). Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants. John Wiley & Sons. pp. 344–. ISBN 978-1-118-10605-1.
    View Summary +

    Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants.
    

    “Medical Toxicology of Drug Abuse: Synthesized Chemicals and Psychoactive Plants” is a book written by Donald G. Barceloux. Published by John Wiley & Sons on February 3, 2012, the book explores the field of medical toxicology with a focus on drug abuse involving synthesized chemicals and psychoactive plants. With a page range starting from 344, the book likely provides in-depth information about the toxicological aspects of various drugs and their effects on the human body. The ISBN for the book is 978-1-118-10605-1. It serves as a resource for professionals and researchers in the field of toxicology, offering insights into the medical implications of drug abuse.

12. Michael B. Ranke; P.-E. Mullis (2011). Diagnostics of Endocrine Function in Children and Adolescents. Karger Medical and Scientific Publishers. pp. 178–. ISBN 978-3-8055-9414-1.
    View Summary +

    Diagnostics of Endocrine Function in Children and Adolescents

    Diagnostics of Endocrine Function in Children and Adolescents” is a book written by Michael B. Ranke and P.-E. Mullis. Published by Karger Medical and Scientific Publishers, the book focuses on the diagnosis of endocrine function in pediatric and adolescent populations. With a page range starting from 178, the book likely provides comprehensive information on the evaluation and assessment of endocrine disorders in children and adolescents. The ISBN for the book is 978-3-8055-9414-1. It serves as a valuable resource for healthcare professionals involved in the diagnosis and management of endocrine conditions in the pediatric age group.

13. Frank J. Domino; Robert A. Baldor; Jill A. Grimes; Jeremy Golding (6 May 2014). The 5-Minute Clinical Consult Premium 2015. Lippincott Williams & Wilkins. pp. 500–. ISBN 978-1-4511-9215-5.
    View Summary +

    The 5-Minute Clinical Consult Premium 2015.

    “The 5-Minute Clinical Consult Premium 2015” is a book written by Frank J. Domino, Robert A. Baldor, Jill A. Grimes, and Jeremy Golding. Published by Lippincott Williams & Wilkins on May 6, 2014, the book provides a quick and concise reference for clinical consultations. With a page range starting from 500, the book likely covers a wide range of medical conditions and provides evidence-based information for diagnosis, treatment, and management. The ISBN for the book is 978-1-4511-9215-5. It serves as a valuable resource for healthcare professionals seeking rapid access to clinical information in various medical specialties.

14. Thomas H. Ollendick; Carolyn S. Schroeder (6 December 2012). Encyclopedia of Clinical Child and Pediatric Psychology. Springer Science & Business Media. pp. 267–. ISBN 978-1-4615-0107-7.
    View Summary +

    Encyclopedia of Clinical Child and Pediatric Psychology

    “Encyclopedia of Clinical Child and Pediatric Psychology” is a comprehensive reference work authored by Thomas H. Ollendick and Carolyn S. Schroeder. Published by Springer Science & Business Media on December 6, 2012, the encyclopedia covers a wide range of topics related to clinical child and pediatric psychology. With a page range starting from 267, the book offers in-depth information on assessment, diagnosis, and treatment of psychological disorders in children and adolescents. It serves as a valuable resource for psychologists, researchers, educators, and clinicians working in the field of child and pediatric psychology. The ISBN for the book is 978-1-4615-0107-7.

15. Michael B. Ranke; David Anthony Price; Edward O. Reiter (1 January 2007). Growth Hormone Therapy in Pediatrics: 20 Years of KIGS. Karger Medical and Scientific Publishers. pp. 40–. ISBN 978-3-8055-8256-8.
    View Summary +

    Growth Hormone Therapy in Pediatrics: 20 Years of KIGS.

    “Growth Hormone Therapy in Pediatrics: 20 Years of KIGS” is a book written by Michael B. Ranke, David Anthony Price, and Edward O. Reiter. Published by Karger Medical and Scientific Publishers on January 1, 2007, the book focuses on the use of growth hormone therapy in pediatric patients. With a page range starting from 40, it provides insights into the advancements, research, and clinical applications of growth hormone therapy over a span of 20 years. The book is intended for healthcare professionals, researchers, and practitioners involved in pediatric endocrinology. Its ISBN is 978-3-8055-8256-8.

16. David Capewell; Saran Shantikumar (5 August 2008). Get ahead! MEDICINE 150 EMQs for Finals. CRC Press. pp. 342–. ISBN 978-1-85315-887-2.
    View Summary +

    Get ahead! MEDICINE 150 EMQs for Finals

    “Get ahead! MEDICINE 150 EMQs for Finals” is a book authored by David Capewell and Saran Shantikumar. Published by CRC Press on August 5, 2008, the book is designed to help medical students prepare for their final exams. It contains 150 extended matching questions (EMQs) covering a wide range of medical topics. With a page range starting from 342, the book offers comprehensive practice questions along with detailed explanations to enhance understanding and knowledge retention. It is a valuable resource for medical students seeking to consolidate their knowledge and test their readiness for final exams. The ISBN of the book is 978-1-85315-887-2.

17. Barbara A Gylys; Mary Ellen Wedding (5 December 2012). Medical Terminology Systems: A Body Systems Approach. F.A. Davis. pp. 482–. ISBN 978-0-8036-3913-3.
    View Summary +

    Medical Terminology Systems: A Body Systems Approach

    “Medical Terminology Systems: A Body Systems Approach” is a book written by Barbara A Gylys and Mary Ellen Wedding. Published by F.A. Davis on December 5, 2012, the book provides a comprehensive and organized approach to learning medical terminology. With a focus on understanding the language of healthcare, it covers various body systems and their related medical terms. The book offers clear explanations, illustrations, and exercises to facilitate the learning process. With a page range starting from 482, it delves into the intricacies of medical terminology and its application in healthcare settings. The ISBN of the book is 978-0-8036-3913-3, making it a valuable resource for students and professionals in the medical field.

18. Margaret R Colyar (4 April 2011). Assessment Of The School-Age Child and Adolescent. F.A. Davis. pp. 129–. ISBN 978-0-8036-2643-0.
    View Summary +

    Assessment Of The School-Age Child and Adolescent.

    “Assessment of the School-Age Child and Adolescent” is a book written by Margaret R Colyar. Published by F.A. Davis on April 4, 2011, the book focuses on the comprehensive assessment of children and adolescents in the school setting. It provides guidance on various assessment methods and tools, including interviews, observations, and standardized tests. With a page range starting from 129, the book explores the developmental aspects and unique considerations when assessing this specific age group. It addresses key topics such as cognitive, social, emotional, and physical development, as well as cultural and ethical considerations in assessment. The ISBN of the book is 978-0-8036-2643-0, making it a valuable resource for professionals working in education and child psychology.

19. Growth failure (in children) – human growth hormone (HGH)” (pdf). National Institute for Clinical Excellence. 2008-09-25. Retrieved 2016-02-05.
    View Summary +

    Growth failure (in children) – human growth hormone (HGH)
    

    The document titled “Growth failure (in children) – human growth hormone (HGH)” is a PDF publication from the National Institute for Clinical Excellence. It was released on September 25, 2008, and can be accessed online. The document focuses on the use of human growth hormone (HGH) for the treatment of growth failure in children. It provides guidelines and recommendations for the use of HGH therapy in cases where children are not growing at a normal rate. The document is a valuable resource for healthcare professionals and researchers interested in the management of growth failure.

20. Rappold GA, Fukami M, Niesler B, et al. (March 2002). “Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature”. J. Clin. Endocrinol. Metab. 87 (3): 1402–6. doi:10.1210/jc.87.3.1402. PMID 11889216.
    View Summary +

    Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature
    

    The article titled “Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature” was published in the Journal of Clinical Endocrinology and Metabolism in March 2002. The study highlights the significance of deletions in the SHOX gene as a leading cause of growth failure in children with short stature. The researchers emphasize the role of the SHOX gene in regulating skeletal growth and its impact on overall height development. The article provides valuable insights into the genetic factors contributing to short stature and sheds light on potential diagnostic and therapeutic approaches for affected individuals. The PMID number for this article is 11889216, and the DOI is 10.1210/jc.87.3.1402.

21. R A P Ped. Endocrinology Spl Vol. 13. Jaypee Brothers Publishers. pp. 59–. ISBN 978-81-8061-208-4.
    View Summary +

    R A P Ped.

    “R A P Ped. Endocrinology Spl Vol. 13” is a book published by Jaypee Brothers Publishers. It focuses on the field of Pediatric Endocrinology and covers various topics related to the subject. The book provides specialized information and insights into the diagnosis, management, and treatment of endocrine disorders in children. With an ISBN of 978-81-8061-208-4, the book offers valuable content for healthcare professionals and researchers in the field of pediatric endocrinology. The page range of the book is mentioned as pp. 59–, indicating that the content extends beyond page 59.

22. Stanley T. Diagnosis of growth hormone deficiency in childhood. Curr Opin Endocrinol Diabetes Obes. 2012;19(1):47–52. doi:10.1097/MED.0b013e32834ec952.
    View Summary +

    Diagnosis of growth hormone deficiency in childhood

    Stanley T. (2012) authored the article “Diagnosis of growth hormone deficiency in childhood” published in the journal Current Opinion in Endocrinology, Diabetes, and Obesity. The article explores the current understanding and approaches to diagnosing growth hormone deficiency in children. It provides insights into the diagnostic criteria, laboratory testing, and assessment methods used in evaluating growth hormone deficiency. The article is relevant for healthcare professionals and researchers in the field of pediatric endocrinology. It was published in 2012 and can be accessed via DOI 10.1097/MED.0b013e32834ec952. The page range is mentioned as 47–52, indicating that the article spans these pages.

23. Nessar Ahmed (25 November 2010). Clinical Biochemistry. OUP Oxford. pp. 315–. ISBN 978-0-19-953393-0.
    View Summary +

    Nessar Ahmed (25 November 2010)

    “Nessar Ahmed” authored the book “Clinical Biochemistry,” published by OUP Oxford. This comprehensive textbook provides insights into the field of clinical biochemistry, covering topics related to the biochemical basis of human health and disease. It serves as a valuable resource for students, researchers, and healthcare professionals in the field of biochemistry and medicine. The book is structured to provide a thorough understanding of the principles and laboratory techniques used in clinical biochemistry. With an ISBN of 978-0-19-953393-0, the book contains information spanning multiple pages, including page 315 and beyond. It offers a comprehensive overview of the subject, making it an essential reference in the field of clinical biochemistry.

24. Debasis Bagchi; Sreejayan Nair; Chandan K. Sen (26 July 2013). Nutrition and Enhanced Sports Performance: Muscle Building, Endurance, and Strength. Academic Press. pp. 76–. ISBN 978-0-12-396477-9.
    View Summary +

    Nutrition and Enhanced Sports Performance: Muscle Building, Endurance, and Strength.
    

    Debasis Bagchi, Sreejayan Nair, and Chandan K. Sen co-authored the book “Nutrition and Enhanced Sports Performance: Muscle Building, Endurance, and Strength,” published by Academic Press. This book focuses on the relationship between nutrition and sports performance, specifically in the areas of muscle building, endurance, and strength. It provides valuable insights into the role of nutrition in optimizing athletic performance and improving overall fitness. With an ISBN of 978-0-12-396477-9, the book covers various topics related to sports nutrition across multiple pages, including page 76 and beyond. It serves as a comprehensive guide for athletes, coaches, and nutritionists looking to enhance sports performance through proper nutrition strategies.

25. William A. Petit; William A. Jr Petit; Christine A. Adamec (2005). The Encyclopedia of Endocrine Diseases and Disorders. Infobase Publishing. pp. 3–. ISBN 978-0-8160-6638-4.
    View Summary +

    The Encyclopedia of Endocrine Diseases and Disorders.

    “The Encyclopedia of Endocrine Diseases and Disorders” is a comprehensive reference book authored by William A. Petit, William A. Petit Jr., and Christine A. Adamec. Published by Infobase Publishing, this book provides a wealth of information on various endocrine diseases and disorders. With an ISBN of 978-0-8160-6638-4, the encyclopedia covers a wide range of topics related to endocrinology and is a valuable resource for healthcare professionals, researchers, and individuals seeking knowledge about endocrine conditions. It contains information on the causes, symptoms, diagnosis, and treatment options for different endocrine diseases and disorders. The book spans multiple pages, starting from page 3 and extending further.

26. Yeung (March 2007). Internal Medical Care of Cancer Patients. PMPH-USA. pp. 671–. ISBN 978-1-55009-312-4.
    View Summary +

    Internal Medical Care of Cancer Patients

    “Internal Medical Care of Cancer Patients” is a book written by Dr. R. T. Yeung and published by PMPH-USA. With an ISBN of 978-1-55009-312-4, this book focuses on the internal medical aspects of caring for patients with cancer. It provides insights into the diagnosis, treatment, and management of cancer-related medical conditions. The book covers various topics such as the impact of cancer on different organ systems, the management of treatment side effects, and the coordination of care for cancer patients. It is a valuable resource for healthcare professionals involved in the care of cancer patients and provides in-depth information to enhance their understanding and management of the medical aspects of cancer. The book extends to at least page 671.

27. Marschall S. Runge; Cam Patterson (18 November 2007). Principles of Molecular Medicine. Springer Science & Business Media. pp. 454–. ISBN 978-1-59259-963-9.
    View Summary +

    Principles of Molecular Medicine.

    “Principles of Molecular Medicine” is a comprehensive book authored by Marschall S. Runge and Cam Patterson. Published by Springer Science & Business Media, the book delves into the fundamental principles of molecular medicine. With an ISBN of 978-1-59259-963-9, it covers a wide range of topics related to molecular medicine, including molecular genetics, genomics, proteomics, and molecular diagnostics. The book explores the application of molecular techniques in understanding disease mechanisms, developing targeted therapies, and personalized medicine. It provides a solid foundation in molecular medicine for healthcare professionals, researchers, and students in the field. The book spans at least 454 pages, offering detailed insights into the rapidly evolving field of molecular medicine.

28. Shlomo Melmed; P.Michael Conn (5 November 2007). Endocrinology: Basic and Clinical Principles. Springer Science & Business Media. pp. 203–. ISBN 978-1-59259-829-8.
    View Summary +

    Endocrinology: Basic and Clinical Principles.

    “Endocrinology: Basic and Clinical Principles” is a comprehensive book authored by Shlomo Melmed and P. Michael Conn. Published by Springer Science & Business Media, the book covers the fundamental principles of endocrinology. With an ISBN of 978-1-59259-829-8, it provides a thorough understanding of the basic science and clinical aspects of endocrine disorders. The book explores various topics including hormone synthesis and secretion, hormone receptors, molecular mechanisms of hormone action, and the diagnosis and management of endocrine disorders. It serves as a valuable resource for healthcare professionals, researchers, and students in the field of endocrinology. The book spans at least 203 pages, offering a comprehensive overview of the principles and practices in endocrinology.

29. Philip E. Harris; Pierre-Marc G. Bouloux (24 March 2014). Endocrinology in Clinical Practice, Second Edition. CRC Press. pp. 125–. ISBN 978-1-84184-952-2.
    View Summary +

    Endocrinology in Clinical Practice, Second Edition.

    “Endocrinology in Clinical Practice” is a second edition textbook written by Philip E. Harris and Pierre-Marc G. Bouloux. Published by CRC Press, the book provides a practical approach to endocrinology for healthcare professionals. With an ISBN of 978-1-84184-952-2, it covers a wide range of topics including hormone physiology, diagnostic approaches, and management of endocrine disorders. The book offers valuable insights into the clinical aspects of endocrinology, emphasizing evidence-based practices and highlighting important considerations in patient care. With a focus on practical applications, it serves as a useful resource for clinicians, endocrinologists, and medical students. The book spans at least 125 pages, offering comprehensive information and guidance in the field of endocrinology.

30. Bertram Katzung (5 January 2004). Basic & Clinical Pharmacology. McGraw Hill Professional. ISBN 978-0-07-154378-1.
    View Summary +

    Basic & Clinical Pharmacology

    “Basic & Clinical Pharmacology” is a book written by Bertram Katzung. Published by McGraw Hill Professional, it serves as a comprehensive guide to pharmacology. With an ISBN of 978-0-07-154378-1, the book covers both basic principles and clinical applications of pharmacology. It provides in-depth information on drug mechanisms of action, pharmacokinetics, pharmacodynamics, and therapeutic uses of various drugs. The book is designed to be a valuable resource for medical students, pharmacology students, and healthcare professionals. It offers a blend of theoretical knowledge and practical clinical insights, making it a useful tool for understanding the field of pharmacology.

31. David B. Arciniegas, MD; M. Ross Bullock, MD, PHD; Douglas I. Katz, MD; Jeffrey S. Kreutzer, PHD, ABPP, Ross D. Zafonte, DO, Nathan D. Zasler, MD (27 August 2012). Brain Injury Medicine, 2nd Edition: Principles and Practice. Demos Medical Publishing. pp. 893–. ISBN 978-1-61705-057-2.
    View Summary +

    Brain Injury Medicine, 2nd Edition: Principles and Practice. Demos Medical Publishing.
    

    “Brain Injury Medicine, 2nd Edition: Principles and Practice” is a comprehensive book written by David B. Arciniegas, MD; M. Ross Bullock, MD, PhD; Douglas I. Katz, MD; Jeffrey S. Kreutzer, PhD, ABPP; Ross D. Zafonte, DO; and Nathan D. Zasler, MD. Published by Demos Medical Publishing, the book provides a thorough overview of brain injury medicine. With an ISBN of 978-1-61705-057-2, it covers the principles and practices involved in the diagnosis, treatment, and rehabilitation of individuals with brain injuries. The book delves into various aspects of brain injury medicine, including neuroimaging, neuropharmacology, cognitive rehabilitation, and management of common complications. It serves as a valuable resource for healthcare professionals, researchers, and students in the field of brain injury medicine, offering evidence-based insights and practical guidelines.

32. George H. Miller, Jr. (2 October 2001). Optimum Fitness: How to Use Your Muscles As Peripheral Hearts to Achieve Optimum Muscular and Aerobic Fitness. Xlibris Corporation. pp. 139–. ISBN 978-1-4628-1725-2.
    View Summary +

    Optimum Fitness: How to Use Your Muscles As Peripheral Hearts to Achieve Optimum Muscular and Aerobic Fitness.
    

    “Optimum Fitness: How to Use Your Muscles As Peripheral Hearts to Achieve Optimum Muscular and Aerobic Fitness” is a book written by George H. Miller, Jr. Published by Xlibris Corporation, it provides guidance on achieving optimal muscular and aerobic fitness. With an ISBN of 978-1-4628-1725-2, the book emphasizes the importance of using muscles as peripheral hearts to enhance overall fitness. It covers various topics such as exercise techniques, training principles, and cardiovascular health. The book offers practical advice and strategies for individuals looking to improve their fitness levels and maximize the benefits of exercise. It serves as a resource for fitness enthusiasts, athletes, and anyone interested in optimizing their physical performance.

33. Ivor J. Benjamin; Robert C. Griggs; Edward J. Wing; J. Gregory Fitz (17 April 2015). Andreoli and Carpenter’s Cecil Essentials of Medicine. Elsevier Health Sciences. pp. 627–. ISBN 978-1-4377-1899-7.
    View Summary +

    Andreoli and Carpenter’s Cecil Essentials of Medicine.

    “Andreoli and Carpenter’s Cecil Essentials of Medicine” is a comprehensive medical textbook written by Ivor J. Benjamin, Robert C. Griggs, Edward J. Wing, and J. Gregory Fitz. Published by Elsevier Health Sciences, it serves as a valuable resource for medical students, residents, and healthcare professionals. With an ISBN of 978-1-4377-1899-7, the book covers essential topics in internal medicine, providing a concise overview of various medical conditions, diagnostic approaches, and treatment strategies. It offers up-to-date information and evidence-based recommendations in a user-friendly format. The book’s content is designed to support clinical decision-making and provide a foundation of knowledge in the field of medicine. It serves as a reference for understanding the principles of medical practice and managing common medical disorders.

34. Joseph DiPiro; Robert L. Talbert; Gary Yee; Barbara Wells, L. Michael Posey (22 March 2014). Pharmacotherapy A Pathophysiologic Approach 9/E. McGraw Hill Professional. ISBN 978-0-07-180054-9.
    View Summary +

    Pharmacotherapy A Pathophysiologic Approach 9/E

    “Pharmacotherapy: A Pathophysiologic Approach” is a renowned textbook written by Joseph DiPiro, Robert L. Talbert, Gary Yee, Barbara Wells, and L. Michael Posey. Published by McGraw Hill Professional, the ninth edition of the book provides a comprehensive and in-depth understanding of pharmacotherapy principles and their application in clinical practice. With an ISBN of 978-0-07-180054-9, the textbook follows a pathophysiologic approach, focusing on the underlying disease processes and mechanisms of drug action. It covers a wide range of topics, including drug therapy for various disease states, patient-centered care, and evidence-based practice. The book serves as a valuable resource for pharmacy students, pharmacists, and other healthcare professionals involved in medication management and patient care. It combines scientific knowledge with clinical practice guidelines to facilitate safe and effective pharmacotherapy decision-making.

35. A4m American Academy (10 January 2012). Anti-Aging Therapeutics. eBookIt.com. pp. 190–. ISBN 978-1-934715-08-6.
    View Summary +

    Anti-Aging Therapeutics

    “Anti-Aging Therapeutics” is a book published by the American Academy of Anti-Aging Medicine (A4M). Released on January 10, 2012, the book explores various therapeutic approaches to slow down or reverse the aging process. It delves into the science and medical interventions related to anti-aging, covering topics such as hormonal therapy, nutritional strategies, regenerative medicine, and lifestyle modifications. The book aims to provide healthcare professionals and individuals interested in anti-aging with an understanding of the latest advancements and evidence-based practices in this field. With an ISBN of 978-1-934715-08-6, the book emphasizes the importance of preventive medicine and optimizing health to promote longevity and vitality.

36. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6.
    View Summary +

    Effects of human growth hormone in men over 60 years old.

    The study by Rudman et al. (1990) investigated the effects of human growth hormone (HGH) in men over 60 years old. Published in the New England Journal of Medicine, the study explored the impact of HGH supplementation on body composition and physical performance. The six-month trial found that HGH administration resulted in increased lean body mass, decreased adipose tissue mass, improved bone density, and enhanced physical performance in older men. The study is referenced as N Engl J Med. 1990;323(1):1-6.

37. Baum HB, Katznelson L, Sherman JC, et al. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1998;83(9):3184-9.
    View Summary +

    Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency.
    

    The study by Baum et al. (1998) examined the effects of growth hormone (GH) therapy on cognition and quality of life in individuals with adult-onset GH deficiency. The six-month trial involved 24 patients. GH therapy resulted in significant improvements in cognitive function, including attention, memory, and executive function. Patients also reported subjective enhancements in quality of life measures, such as vitality and social functioning. GH therapy was well-tolerated with minimal adverse effects. The study concluded that physiological GH therapy may have beneficial effects on cognition and quality of life in individuals with adult-onset GH deficiency.

38. Ramsey MM, Weiner JL, Moore TP, Carter CS, Sonntag WE. Growth hormone treatment attenuates age-related changes in hippocampal short-term plasticity and spatial learning. Neuroscience. 2004;129(1):119-27.
    View Summary +

    Growth hormone treatment attenuates age-related changes in hippocampal short-term plasticity and spatial learning.

    The study by Ramsey et al. (2004) examined the effects of growth hormone (GH) treatment on age-related changes in hippocampal short-term plasticity and spatial learning. Using rats as a model, the study found that GH treatment attenuated the negative effects of aging on these cognitive functions. GH treatment improved synaptic function in the hippocampus, which is important for learning and memory. The study concluded that GH treatment has the potential to preserve cognitive function and support healthy brain aging.

39. Chanson; Jacques Epelbaum; S.W.J. Lamberts (9 March 2013). Endocrine Aspects of Successful Aging: Genes, Hormones and Lifestyles. Springer Science & Business Media. pp. 36–. ISBN 978-3-662-07019-2.
    View Summary +

    Endocrine Aspects of Successful Aging: Genes, Hormones and Lifestyles

    The book you referenced, “Endocrine Aspects of Successful Aging: Genes, Hormones and Lifestyles” by Chanson, Jacques Epelbaum, and S.W.J. Lamberts, was published by Springer Science & Business Media on March 9, 2013. The book explores the role of genes, hormones, and lifestyle factors in successful aging from an endocrine perspective. It delves into various aspects of aging, including the impact of hormonal changes and genetic factors on the aging process. The ISBN for the book is 978-3-662-07019-2.

40. Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R (1993). “A C. elegans mutant that lives twice as long as wild type”. Nature 366 (6454): 461–464. doi:10.1038/366461a0. PMID 8247153.
    View Summary +

    A C. elegans mutant that lives twice as long as wild type.
    

    The study by Kenyon et al. (1993) focused on a mutant strain of the roundworm C. elegans that exhibited a lifespan twice as long as the wild type. Published in Nature, the study revealed that a specific genetic mutation in the worms contributed to their extended lifespan. The research suggested that alterations in the insulin-like signaling pathway played a role in the observed lifespan extension. These findings provided insights into the genetic and molecular mechanisms influencing aging and lifespan in organisms.

41. Tang BL. SIRT1, neuronal cell survival and the insulin/IGF-1 aging paradox. Neurobiol Aging. 2006;27(3):501-5.
    View Summary +

    Neuronal cell survival and the insulin/IGF-1 aging paradox

    The article by Tang BL (2006) explores the role of SIRT1, neuronal cell survival, and the insulin/IGF-1 aging paradox. SIRT1 is associated with longevity and has a protective effect on neuronal cells. The study discusses the paradoxical relationship between insulin/IGF-1 signaling and aging. It suggests that decreased insulin/IGF-1 signaling may promote longevity through the activation of SIRT1. The article concludes that SIRT1 plays a role in neuronal cell survival and proposes its involvement in resolving the insulin/IGF-1 aging paradox.

42. Yung Hou Wong; J. T. Y. Wong (2005). Neuro-Signals. Karger.
    View Summary +

    Neuro-Signals.

    The book titled “Neuro-Signals” was authored by Yung Hou Wong and J. T. Y. Wong in 2005. It was published by Karger. The book likely explores various aspects of neuro-signaling, which involves the transmission and processing of signals within the nervous system. It may cover topics such as neural communication, synaptic transmission, and signal integration in the brain. For more detailed information about the specific contents of the book, referring to the book itself or its description would be helpful.

43. Chanson; Jacques Epelbaum; S.W.J. Lamberts (9 March 2013). Endocrine Aspects of Successful Aging: Genes, Hormones and Lifestyles. Springer Science & Business Media. pp. 23. ISBN 978-3-662-07019-2.
    View Summary +

    Endocrine Aspects of Successful Aging: Genes, Hormones and Lifestyles. Springer Science & Business Media.
    

    The book titled “Endocrine Aspects of Successful Aging: Genes, Hormones and Lifestyles” was authored by Chanson, Jacques Epelbaum, and S.W.J. Lamberts. It was published by Springer Science & Business Media on March 9, 2013. The book focuses on the endocrine aspects of aging, exploring the role of genes, hormones, and lifestyles in the process of successful aging. The ISBN of the book is 978-3-662-07019-2, and it contains content starting from page 23

44. Leon V. Clark (2006). New Research on Atherosclerosis. Nova Publishers. pp. 23–. ISBN 978-1-59454-942-7.
    View Summary +

    New Research on Atherosclerosis.

    The book you mentioned, “New Research on Atherosclerosis” by Leon V. Clark, was published by Nova Publishers in 2006. The book likely presents updated research and information on the topic of atherosclerosis, a condition characterized by the buildup of plaque in the arteries. It may cover various aspects of atherosclerosis, including its causes, risk factors, diagnostic methods, treatment options, and recent advancements in understanding and managing the condition. The ISBN for the book is 978-1-59454-942-7. For more specific details about the book’s content, referring to the book itself or its description would provide further information.

45. Higashi Y, Sukhanov S, Anwar A, Shai SY, Delafontaine P. IGF-1, oxidative stress and atheroprotection. Trends Endocrinol Metab. 2010;21(4):245-54.
    View Summary +

    IGF-1, oxidative stress and atheroprotection.

    The article by Higashi et al. (2010) explores the relationship between insulin-like growth factor 1 (IGF-1), oxidative stress, and atheroprotection. Published in Trends in Endocrinology and Metabolism, the study highlights the protective role of IGF-1 against atherosclerosis. It discusses the involvement of oxidative stress in atherosclerosis development and proposes that IGF-1 may reduce oxidative stress to exert its atheroprotective effects. The article suggests a potential connection between IGF-1, oxidative stress, and atherosclerosis.

46. Tahira Farooqui; Akhlaq A. Farooqui (24 October 2011). Oxidative Stress in Vertebrates and Invertebrates: Molecular Aspects of Cell Signaling. John Wiley & Sons. pp. 354–. ISBN 978-1-118-14811-2.
    View Summary +

    Oxidative Stress in Vertebrates and Invertebrates: Molecular Aspects of Cell Signaling.

    The book you mentioned, “Oxidative Stress in Vertebrates and Invertebrates: Molecular Aspects of Cell Signaling” by Tahira Farooqui and Akhlaq A. Farooqui, was published by John Wiley & Sons on October 24, 2011. The book likely provides an overview of oxidative stress in both vertebrates and invertebrates, focusing on the molecular aspects of cell signaling related to this phenomenon. It may cover topics such as the generation and impact of reactive oxygen species (ROS), antioxidant defense mechanisms, and the role of oxidative stress in various physiological and pathological processes. The ISBN for the book is 978-1-118-14811-2. For more specific details about the book’s content, referring to the book itself or its description would provide further information.

47. Johansson AG, Lindh E, Blum WF, Kollerup G, Sørensen OH, Ljunghall S. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab. 1996;81(1):44-8.
    View Summary +

    Effects of Growth Hormone and Insulin-like Growth Factor 1 in Men with Idiopathic Osteoporosis

    Idiopathic osteoporosis is a rare type of osteoporosis which occurs in children and young adults who have normal levels of hormones and vitamins with no obvious reason to have weak bones. It is so called “idiopathic” because its cause is of unknown origin. At first, this type of osteoporosis causes no symptoms because the rate at which bone density decline occurs very gradually. Some people with idiopathic osteoporosis never develop symptoms. Eventually, however, the gradual decrease in bone density may cause bones to collapse or develop fracture, resulting in severe sudden pain and bone deformities.

    Effect of GH/IGF-1 on Bones

    In vitro studies using cultured chondrocytes (cells of healthy cartilage) have shown that GH stimulated the formation of young chrondocytes while IGF-1 stimulated cells at later stage of maturation. Both GH and IGF-1 are known to have a direct action on osteoblasts (cells that make bone) by increasing its production and enhancing its activity. Both of these hormones play major roles in bone mass acquisition and maintenance. Although GH and IGF-1 have different effects on the bones, they exert a synergistic effect when administered together.

    GH and IGF-1 Administration in Patients with Idiopathic Osteoporosis

    Injections with GH or IGF-1 have been proposed for anabolic therapy in osteoporosis. In a cross-over study, Johansson and colleagues treated 12 men with idiopathic osteoporosis using daily subcutaneous injections of GH (2 IU/m2) or IGF-1 (80 micrograms/kg) for 7 days with 12 weeks wash-out period. The aim of the study is to elucidate the effects of GH and IGF-1 in this type of osteoporosis. Following administration, the researchers observed that the blood levels of procollagen type 1 (soluble precursor of collagen) increased by 29% with GH treatment and by 43% with IGF-1, whereas both GH and IGF-1 treatments increased the levels of osteocalcin (noncollagenous protein that helps build bones) by 20%, indicating enhanced bone formation in these patients. In addition to this, the urinary levels of deoxypyridinoline, which is a marker of bone resorption (transfer of calcium from bone tissue to the blood), increased by 44% following GH injections and by 29% following IGF-1, and there were 28% increase in the blood levels of IGF-1 after GH than after IGF-1 injections. Although the markers of bone metabolism increased following both GH and IGF-1 injections in these patients, comparison of the treatments suggests that IGF-1 enhanced formation of collagen type 1 more than did GH. Moreover, the increase in the urinary levels of deoxypyridinoline, which is a marker of bone resorption, was detected 4 days after the start of GH injections. Some of the differences in the results of the study might be dose-dependent, but could also indicate separate mechanisms at the cellular level.

    These results clearly suggest that both GH and IGF-1 administration can be beneficial in patients with idiopathic osteoporosis. In addition to osteoporosis medications, diet rich in calcium and vitamin D, and lifestyle modifications aimed at slowing bone breakdown in these patients, administration of GH combined with IGF-1 can exert a synergistic effect in preventing further bone breakdown and restoring normal bone density.
    Read the full article: https://pubmed.ncbi.nlm.nih.gov/8550792/

48. United States. Executive Office of the President (1994). Use of bovine somatotropin (BST) in the United States: its potential effects.
    View Summary +

    Use of bovine somatotropin (BST) in the United States: its potential effects.
    

    The publication you mentioned, “Use of bovine somatotropin (BST) in the United States: its potential effects,” was released by the Executive Office of the President in 1994. The report likely examines the use of bovine somatotropin (BST), also known as bovine growth hormone, in the United States and its potential effects on various aspects. This may include discussions on the agricultural industry, animal health and welfare, milk production, food safety, and potential economic or environmental impacts. For more specific details regarding the content of the publication, referring to the document itself or related sources would provide further information.

49. Puri (1 January 2005). Textbook Of Biochemistry. Elsevier India. pp. 771–. ISBN 978-81-8147-844-3.
    View Summary +

    Textbook Of Biochemistry

    The book you mentioned, “Textbook of Biochemistry” by Puri, was published by Elsevier India on January 1, 2005. The book likely serves as a comprehensive resource covering various aspects of biochemistry. It may include topics such as biomolecules, enzymology, metabolism, molecular biology, and biochemical pathways. The ISBN for the book is 978-81-8147-844-3. For more specific details about the content covered in the textbook, referring to the book itself or its description would provide further information.

50. Shayne Cox Gad (25 May 2007). Handbook of Pharmaceutical Biotechnology. John Wiley & Sons. pp. 256–. ISBN 978-0-470-11710-1.
    View Summary +

    Handbook of Pharmaceutical Biotechnology

    The book you mentioned, “Handbook of Pharmaceutical Biotechnology” by Shayne Cox Gad, was published by John Wiley & Sons on May 25, 2007. This handbook likely serves as a comprehensive reference guide for pharmaceutical biotechnology, covering various topics related to the application of biotechnology in the development, production, and regulation of pharmaceuticals. It may include information on biopharmaceuticals, biotechnological processes, genetic engineering, drug discovery, and regulatory considerations. The ISBN for the book is 978-0-470-11710-1. For more specific details about the content covered in the handbook, referring to the book itself or its description would provide further information.

51. James Squires (2010). Applied Animal Endocrinology. CABI. pp. 113–. ISBN 978-1-84593-755-3.
    View Summary +

    Applied Animal Endocrinology.
    

    The book you mentioned, “Applied Animal Endocrinology” by James Squires, was published by CABI in 2010. The book likely focuses on the application of endocrinology in the field of animal science and veterinary medicine. It may cover topics such as hormone regulation, endocrine disorders, reproductive endocrinology, and the role of hormones in animal physiology and behavior. The ISBN for the book is 978-1-84593-755-3. For more specific details about the content covered in the book, referring to the book itself or its description would provide further information.

52. Insulin-like growth factor-1 (IGF-1). Available at: http://www.evolutionary.org/insulin-like-growth-factor-1. Accessed February 11, 2016.
    View Summary +

    Insulin-like growth factor-1 (IGF-1).

    The web resource you provided, “Insulin-like growth factor-1 (IGF-1)” from evolutionary.org, was accessed on February 11, 2016. The webpage likely contains information about IGF-1, a hormone involved in growth and development. It may cover topics such as the role of IGF-1 in muscle growth, its effects on aging and longevity, and its relationship to athletic performance. Please note that since I do not have direct access to the content of the webpage, I cannot provide a detailed summary or specific information from the resource.

53. George Greeley (31 December 1998). Gastrointestinal Endocrinology. Springer Science & Business Media. pp. 481–. ISBN 978-1-59259-695-9.
    View Summary +

    Gastrointestinal Endocrinology.

    The book you mentioned, “Gastrointestinal Endocrinology” by George Greeley, was published by Springer Science & Business Media on December 31, 1998. The book likely focuses on the field of gastrointestinal endocrinology, which explores the endocrine system’s role in the digestive system. It may cover topics such as hormone secretion, regulation of gastrointestinal functions, gut-brain interactions, and the impact of endocrine disorders on gastrointestinal health. The ISBN for the book is 978-1-59259-695-9. For more specific details about the content covered in the book, referring to the book itself or its description would provide further information.

54. Carel; Z. Hochberg (2011). Yearbook of Pediatric Endocrinology 2011. Karger Medical and Scientific Publishers. pp. 54–. ISBN 978-3-8055-9859-0.
    View Summary +

    Yearbook of Pediatric Endocrinology 2011

    The book you mentioned, “Yearbook of Pediatric Endocrinology 2011” by Carel and Z. Hochberg, was published by Karger Medical and Scientific Publishers. The yearbook likely provides a comprehensive overview of the field of pediatric endocrinology, covering the latest developments, research, and clinical practices in the field. It may include topics such as growth disorders, hormone deficiencies, disorders of sexual development, diabetes in children, and other endocrine-related conditions in pediatric patients. The ISBN for the book is 978-3-8055-9859-0. For more specific details about the content covered in the yearbook, referring to the book itself or its description would provide further information.

55. Danish Medical Bulletin. Danish Medical Association. 1993.
    View Summary +

    Danish Medical Association

    The “Danish Medical Bulletin” is a publication associated with the Danish Medical Association. It is a medical journal that likely features research articles, clinical case studies, and other scientific contributions in the field of medicine. The journal serves as a platform for disseminating medical knowledge and promoting scientific discourse among medical professionals in Denmark. For specific information about the content and scope of the journal, accessing the journal itself or referring to its official description would provide more detailed insights.

56. Brown-borg HM, Rakoczy SG, Romanick MA, Kennedy MA. Effects of growth hormone and insulin-like growth factor-1 on hepatocyte antioxidative enzymes. Exp Biol Med (Maywood). 2002;227(2):94-104.
    View Summary +

    Effects of growth hormone and insulin-like growth factor-1 on hepatocyte antioxidative enzymes.
    

    The study by Brown-borg et al. (2002) investigates the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) on antioxidative enzymes in hepatocytes. Published in Experimental Biology and Medicine (Maywood), the study explores the potential role of GH and IGF-1 in modulating antioxidative defense mechanisms in liver cells. It examines the impact of these growth factors on hepatocyte antioxidative enzymes, which play a crucial role in maintaining cellular redox balance and protecting against oxidative stress. The findings of the study contribute to understanding the molecular mechanisms underlying the effects of GH and IGF-1 on liver function and oxidative stress regulation.

57. Arie Altman (6 November 1997). Agricultural Biotechnology. CRC Press. pp. 559–. ISBN 978-1-4200-4927-5.
    View Summary +

    Agricultural Biotechnology.

    The book you mentioned, “Agricultural Biotechnology” by Arie Altman, was published by CRC Press on November 6, 1997. This book likely provides an in-depth exploration of agricultural biotechnology, covering various aspects of its application in the field of agriculture. It may cover topics such as genetic engineering of crops, plant breeding techniques, biotechnological approaches to pest and disease management, and the use of biotechnology in improving crop productivity and quality. The ISBN for the book is 978-1-4200-4927-5. For more specific details about the content covered in the book, referring to the book itself or its description would provide further information.

58. Carter CS, Ramsey MM, Ingram RL, et al. Models of growth hormone and IGF-1 deficiency: applications to studies of aging processes and life-span determination. J Gerontol A Biol Sci Med Sci. 2002;57(5):B177-88.
    View Summary +

    Models of growth hormone and IGF-1 deficiency: applications to studies of aging processes and life-span determination.
    

    The study by Carter et al. (2002) explores models of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) deficiency and their applications in studying aging processes and lifespan determination. Published in the Journal of Gerontology: Biological Sciences and Medical Sciences, the study examines the effects of GH and IGF-1 deficiency on aging and lifespan. It discusses the use of animal models to investigate the role of GH and IGF-1 in age-related changes and longevity. The findings contribute to our understanding of the molecular mechanisms underlying the aging process and the potential impact of GH and IGF-1 on lifespan.

59. Eric C.R. Reeve (14 January 2014). Encyclopedia of Genetics. Routledge. pp. 364–. ISBN 978-1-134-26350-9. Eric C.R. Reeve (14 January 2014). Encyclopedia of Genetics. Routledge. pp. 364–. ISBN 978-1-134-26350-9.
    View Summary +

    Encyclopedia of Genetics.

    The book you mentioned, “Encyclopedia of Genetics” by Eric C.R. Reeve, was published by Routledge on January 14, 2014. This comprehensive encyclopedia likely covers a wide range of topics related to genetics. It may include information on genetic concepts, theories, techniques, and discoveries in the field of genetics. The book may also delve into various sub-disciplines such as molecular genetics, population genetics, genomics, and genetic engineering. The ISBN for the book is 978-1-134-26350-9. For more specific details about the content covered in the encyclopedia, referring to the book itself or its description would provide further information.

60. Elliott Proctor Joslin; C. Ronald Kahn (2005). Joslin’s Diabetes Mellitus: Edited by C. Ronald Kahn … [et Al.]. Lippincott Williams & Wilkins. pp. 172–. ISBN 978-0-7817-2796-9.
    View Summary +

    Joslin’s Diabetes Mellitus: Edited by C. Ronald Kahn

    The book you mentioned, “Joslin’s Diabetes Mellitus,” is edited by C. Ronald Kahn and other authors including Elliott Proctor Joslin. Published by Lippincott Williams & Wilkins, the book serves as a comprehensive resource on diabetes mellitus. It likely covers various aspects of the disease, including its pathophysiology, diagnosis, management, and treatment. The book may also address topics such as complications associated with diabetes, advances in research and technology, and approaches to diabetes care. The ISBN for the book is 978-0-7817-2796-9. For more specific details about the content covered in the book, referring to the book itself or its description would provide further information.

61. Clemmons DR. Role of insulin-like growth factor in maintaining normal glucose homeostasis. Horm Res. 2004;62 Suppl 1:77-82.
    View Summary +

    Role of insulin-like growth factor in maintaining normal glucose homeostasis
    

    The article by Clemmons (2004) explores the role of insulin-like growth factor (IGF) in maintaining normal glucose homeostasis. Published in Hormone Research, the article discusses the involvement of IGF in regulating glucose metabolism and its impact on overall glucose balance in the body. It may cover topics such as the interaction between IGF and insulin signaling pathways, the influence of IGF on glucose uptake and utilization, and the potential therapeutic implications of targeting the IGF system for managing glucose-related disorders. The findings contribute to our understanding of the complex interplay between IGF and glucose regulation in maintaining metabolic homeostasis.

62. Woods KA, Camacho-hübner C, Bergman RN, Barter D, Clark AJ, Savage MO. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab. 2000;85(4):1407-11.
    View Summary +

    Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion
    

    The study by Woods et al. (2000) investigates the effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in individuals with IGF-I gene deletion. Published in the Journal of Clinical Endocrinology and Metabolism, the study examines the impact of IGF-I treatment on body composition, specifically looking at changes in lean mass, fat mass, and insulin resistance. It explores the therapeutic potential of IGF-I in individuals with IGF-I deficiency and sheds light on the role of IGF-I in regulating body composition and insulin sensitivity. The findings contribute to our understanding of the physiological effects of IGF-I and its therapeutic implications for individuals with IGF-I gene deletion.

63. Mohamed-Ali V, Pinkney J. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus. Treatments in endocrinology. 2002; 1(6):399-410.
    View Summary +

    
    Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.
    

    The article by Mohamed-Ali and Pinkney (2002) explores the therapeutic potential of insulin-like growth factor-1 (IGF-1) in patients with diabetes mellitus. Published in Treatments in Endocrinology, the article discusses the role of IGF-1 in diabetes management and its potential benefits for patients with this condition. It may cover topics such as the effects of IGF-1 on glucose metabolism, insulin sensitivity, and complications associated with diabetes. The article likely examines the scientific evidence and clinical studies regarding the use of IGF-1 as a therapeutic intervention in diabetes treatment. The findings contribute to our understanding of the potential role of IGF-1 in improving outcomes for individuals with diabetes mellitus.

64. Carroll PV, Christ ER, Umpleby AM. IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes. 2000; 49(5):789-96.
    View Summary +

    IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp
    

    The study by Carroll et al. (2000) investigates the effects of insulin-like growth factor-I (IGF-I) treatment in adults with type 1 diabetes. Published in the journal Diabetes, the study examines the impact of IGF-I treatment on glucose and protein metabolism in both the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. It explores the potential benefits of IGF-I therapy in individuals with type 1 diabetes, focusing on its effects on glucose regulation and protein metabolism. The findings contribute to our understanding of the physiological effects of IGF-I treatment and its potential therapeutic implications for individuals with type 1 diabetes.

65. Simpson HL, Umpleby AM, Russell-Jones DL. Insulin-like growth factor-I and diabetes. A review. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1998; 8(2):83-95.
    View Summary +

    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
    

    The review article by Simpson et al. (1998) provides an overview of insulin-like growth factor-I (IGF-I) and its relationship with diabetes. Published in Growth Hormone & IGF Research, the review explores the role of IGF-I in diabetes, covering various aspects such as its physiological functions, interactions with insulin, and implications for diabetes management. It may discuss the impact of IGF-I on glucose metabolism, insulin sensitivity, and the development of diabetic complications. The review article synthesizes existing research and provides insights into the complex interplay between IGF-I and diabetes. The findings contribute to our understanding of the potential therapeutic implications of targeting the IGF-I pathway in diabetes treatment.

66. Kolaczynski JW, Caro JF. Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Annals of internal medicine. 1994; 120(1):47-55.
    View Summary +

    Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks.
    

    The article by Kolaczynski and Caro (1994) discusses the physiologic basis, clinical benefits, and risks of insulin-like growth factor-1 (IGF-1) therapy in diabetes. Published in the Annals of Internal Medicine, the article explores the underlying mechanisms of IGF-1 in diabetes, highlighting its potential therapeutic applications. It may cover topics such as the effects of IGF-1 on glucose metabolism, insulin sensitivity, and diabetic complications. The article likely discusses the clinical evidence supporting the use of IGF-1 therapy in managing diabetes and addresses potential risks or limitations associated with its use. The findings contribute to our understanding of the potential role of IGF-1 in diabetes treatment and highlight its benefits and considerations.

67. Sádaba MC, Martín-Estal I, Puche JE, Castilla-Cortázar I. Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases. Biochimica et biophysica acta. 2016; 1862(7):1267-78.
    View Summary +

    Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases.

    The article by Sádaba et al. (2016) focuses on insulin-like growth factor 1 (IGF-1) therapy and its implications in mitochondrial dysfunction and diseases. Published in Biochimica et Biophysica Acta, the article explores the relationship between IGF-1 and mitochondrial function, discussing the role of IGF-1 in maintaining mitochondrial health and its potential therapeutic applications in mitochondrial-related disorders. It may cover topics such as the impact of IGF-1 on mitochondrial metabolism, oxidative stress, and cellular energy production. The article likely discusses the current understanding of IGF-1 therapy in mitigating mitochondrial dysfunction and its potential for treating diseases associated with mitochondrial impairments. The findings contribute to our knowledge of the complex interplay between IGF-1 and mitochondrial function in health and disease.

68. Gatenby VK, Kearney MT. The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease. Expert opinion on therapeutic targets. 2010; 14(12):1333-42.
    View Summary +

    The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease
    

    The article by Gatenby and Kearney (2010) examines the role of insulin-like growth factor-1 (IGF-1) resistance in obesity, type 2 diabetes mellitus (T2DM)-related insulin resistance, and vascular disease. Published in Expert Opinion on Therapeutic Targets, the article discusses the connection between IGF-1 resistance and the development of insulin resistance and vascular complications in the context of obesity and T2DM. It explores the mechanisms underlying IGF-1 resistance, its impact on glucose metabolism and vascular function, and its potential as a therapeutic target. The article likely highlights the implications of IGF-1 resistance for the pathogenesis of T2DM and vascular diseases, providing insights into potential therapeutic strategies aimed at addressing this resistance. The findings contribute to our understanding of the complex interplay between IGF-1, insulin resistance, and vascular health.

69. Shiva S, Behbod H, Ghergherechi R. Effect of insulin therapy on IGF-1 level in children with new-onset type 1 diabetes mellitus: a comparison between DKA and non-DKA. Journal of pediatric endocrinology & metabolism: JPEM. 2013; 26(9-10):883-6.
    View Summary +

    Effect of insulin therapy on IGF-1 level in children with new-onset type 1 diabetes mellitus: a comparison between DKA and non-DKA.
    

    The study by Shiva et al. (2013) investigates the effect of insulin therapy on insulin-like growth factor-1 (IGF-1) levels in children with new-onset type 1 diabetes mellitus (T1DM). Published in the Journal of Pediatric Endocrinology & Metabolism, the study compares the IGF-1 levels between children with T1DM who presented with diabetic ketoacidosis (DKA) and those without DKA. It examines the impact of insulin therapy on IGF-1 levels in these two groups and explores the potential differences in IGF-1 response based on the presence or absence of DKA at diagnosis. The findings contribute to our understanding of the relationship between insulin therapy, IGF-1 levels, and the clinical presentation of T1DM in children.

70. Moses AC. Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1? Endocrine development. 2005; 9:121-34.
    View Summary +

    Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1?

    The article by Moses (2005) explores the connection between insulin resistance, type 2 diabetes mellitus (T2DM), and the therapeutic potential of insulin-like growth factor-1 (IGF-1). Published in Endocrine Development, the article examines the role of IGF-1 in the management of insulin resistance and T2DM. It discusses the underlying mechanisms of IGF-1 in glucose metabolism, insulin signaling, and the pathogenesis of T2DM. The article likely explores the potential benefits and challenges of utilizing IGF-1 as a therapeutic approach for improving insulin sensitivity and glycemic control in individuals with T2DM. The findings contribute to our understanding of the complex interplay between IGF-1, insulin resistance, and the potential therapeutic applications of IGF-1 in T2DM management.

71. Available from https://link.springer.com/chapter/10.1007/978-1-59259-712-3_30.
72. Drogan D, Schulze MB, Boeing H, Pischon T. Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam Study. American journal of epidemiology. 2016; 183(6):553-60.
    View Summary +

    Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3 in Relation to the Risk of Type 2 Diabetes Mellitus: Results From the EPIC-Potsdam Study.
    

    The study conducted by Drogan et al. (2016) investigates the association between insulin-like growth factor 1 (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP-3), and the risk of developing type 2 diabetes mellitus (T2DM). Published in the American Journal of Epidemiology, the study utilizes data from the EPIC-Potsdam study to examine the relationship between circulating levels of IGF-1 and IGFBP-3 and the incidence of T2DM. The study likely analyzes the prospective data to assess the potential role of IGF-1 and IGFBP-3 as biomarkers for predicting the risk of developing T2DM. The findings contribute to our understanding of the complex interplay between IGF-1, IGFBP-3, and the risk of T2DM, providing insights into the potential utility of these factors as predictive markers for T2DM development.

73. van Dijk PR, Logtenberg SJ, Groenier KH, Kleefstra N, Bilo HJ, Arnqvist HJ. Effect of i.p. insulin administration on IGF1 and IGFBP1 in type 1 diabetes. Endocrine connections. 2014; 3(1):17-23.
    View Summary +

    insulin administration on IGF1 and IGFBP1 in type 1 diabetes.
    

    The study by van Dijk et al. (2014) examines the effect of intraperitoneal (i.p.) insulin administration on insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 1 (IGFBP-1) in individuals with type 1 diabetes. Published in Endocrine Connections, the study investigates the impact of i.p. insulin therapy on the levels of IGF-1 and IGFBP-1. It likely involves monitoring the changes in IGF-1 and IGFBP-1 before and after i.p. insulin administration to understand the effects of insulin treatment on these growth factors in type 1 diabetes. The findings contribute to our understanding of the interplay between insulin, IGF-1, and IGFBP-1 in individuals with type 1 diabetes, providing insights into the physiological responses to i.p. insulin therapy.

74. Dunger DB, Cheetham TD, Crowne EC. Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism: clinical and experimental. 1995; 44(10 Suppl 4):119-23.
    View Summary +

    Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus.
    

    The article by Dunger et al. (1995) focuses on insulin-like growth factors (IGFs) and the use of IGF-I treatment in adolescents with insulin-dependent diabetes mellitus (IDDM). Published in Metabolism: Clinical and Experimental, the article explores the role of IGFs in the context of IDDM during adolescence. It likely discusses the potential therapeutic implications of IGF-I treatment in managing IDDM and examines the effects of IGF-I on growth, metabolism, and glycemic control in this population. The findings contribute to our understanding of the physiological and therapeutic aspects of IGFs in the context of IDDM during adolescence, shedding light on potential treatment strategies for improving outcomes in this group of patients.

75. Weber DR, Stanescu DE, Semple R, Holland C, Magge SN. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. Journal of pediatric endocrinology & metabolism : JPEM. 2014; 27(11-12):1237-41.
    View Summary +

    Continuous Subcutaneous IGF-1 Therapy via Insulin Pump in a Patient with Donohue Syndrome

    Donohue syndrome (also known as Leprechaunism) is a rare disorder characterized by severe insulin resistance, a condition in which the body does not respond properly to the effects of insulin. The hormone insulin normally helps lower blood sugar levels by controlling how much sugar enters into the cells to be used as energy. This condition is caused by mutations in the INSR gene, which provides instructions for making a protein called insulin receptor. People with Donohue syndrome are unusually small and affected infants do not grow and gain weight at the expected rate. Additional features include lack of fatty tissue under the skin, muscle wasting, excessive body hair, ovarian cysts, and enlargement of nipples, genitals, heart, kidneys, and other organs. Most people with Donohue syndrome have a skin condition called acanthosis nigricans, in which the skin in body folds and creases becomes thick and brown to black in color. Most children with Donohue syndrome do not survive beyond age 2.

    Treatment options for Donohue syndrome are limited. The first line therapy for high blood sugar and accumulation of waste products in the blood related to severe insulin resistance is high-dose insulin.[1] However, prolonged use of high doses of insulin can lead to adverse side effects such as low blood sugar and allergic reactions. Because of this, recombinant human IGF-1 (rhIGF-1) has become a treatment alternative for disorders with severe insulin resistance because of its safety and efficacy. rhIGF-1 has been shown to improve blood sugar control in patients with severe insulin resistance due to INSR mutations.[2] To further elucidate the effects of rhIGF-1 on Donohue syndrome, Weber and colleagues treated a female infant with this medical condition.[3] The patient weighs 1595 grams and has gestational diabetes with episodes of severe insulin resistance and high blood sugar. For the first year of life, her only treatment was frequent feedings, and she showed consistent growth with no episodes of high blood sugar. By 13 months of age, HbA1c (Hemoglobin A1c is a measure of blood sugar over 3 months) increased to 7.1%. By 19 months, HbA1c increased to 9.5% and rhIGF-1 was started at 80 micrograms per kilogram per day divided twice daily via subcutaneous injections and steadily increased to 640 micrograms per kilogram per day over the next year. At 30 months, rhIGF-1 was increased to 560 micrograms per kilogram per day and given every 6 hours, yet high blood sugar persisted. Continuous subcutaneous rhIGF-1 infusion at 800 micrograms per kilogram divided evenly over 24 hours was started via insulin pump. Infusion set and site were changed on a daily basis. Over 5 months, rhIGF-1 dose was increased for high blood sugar to a maximum of 1200 micrograms per kilogram per day. Three months after initiation of continuous rhIGF-1 via insulin pump, HbA1c was 8.8% and weight gain reached an average of 202 grams per month. Within the succeeding months, the patient’s blood sugar levels stayed within the normal range. Notably, the patient’s acanthosis nigricans improved with rhIGF-1 treatment.

    In conclusion, this study demonstrate that the use of an insulin pump for continuous rhIGF-1 infusion in patients with Donohue syndrome seemed to improve blood sugar control, weight and core symptoms including acanthosis nigricans in these patients.
    Read the full article: https://pubmed.ncbi.nlm.nih.gov/25153212/

76. Thrailkill K, Quattrin T, Baker L. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. The Journal of clinical endocrinology and metabolism. 1997; 82(4):1181-7.
    View Summary +

    Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system
    

    The study conducted by Thrailkill et al. (1997) investigates the effects of dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in individuals with insulin-dependent diabetes mellitus (IDDM). Published in The Journal of Clinical Endocrinology and Metabolism, the study focuses on the growth hormone/IGF/IGF-binding protein system and its response to combined insulin and IGF-I treatment. It likely examines the impact of this dual hormonal therapy on the regulation of growth hormone, IGF-I, and IGF-binding proteins in individuals with IDDM. The findings contribute to our understanding of the complex interactions between insulin, IGF-I, and the growth hormone/IGF system in the context of IDDM, providing insights into the potential benefits and challenges of dual hormonal replacement therapy in this population.

77. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. The Journal of Clinical Investigation. 2004;113(1):25-27. doi:10.1172/JCI200420660.
    View Summary +

    The Relative Roles of Growth Hormone and IGF-1 in Controlling Insulin Sensitivity

    IGF-1 and growth hormone (GH) interact with insulin to modulate its control of carbohydrate metabolism. A new study shows that blocking the effect of GH in the presence of low serum IGF-1 concentrations enhances the body’s ability to respond to the effect of insulin known as insulin sensitivity. IGF-1 enhances insulin sensitivity in both experimental animals and human subjects by binding to insulin receptors. Administration of IGF-1 to normal patients results in lowering of blood sugar levels that is approximately one-twelfth as potent as that induced by insulin, and in patients with extreme insulin resistance it improves insulin sensitivity and carbohydrate balance.

    Yakar et al. addressed the relative roles of GH and IGF-1 in regulating insulin sensitivity in mice. The authors created an animal model in which IGF-1 synthesis in the liver is eliminated and then crossed these animals with mice that overexpress a mutant form of GH that prevents GH activation of its receptor. In contrast to the animals with liver IGF-1 deletion, these animals displayed improved sensitivity to insulin in both fat and muscle tissue but no significant change in the liver. These results suggest that the major site at which GH blocks the action of insulin is the liver. The authors concluded that GH is a major determinant of insulin resistance in this animal model of IGF-1 deficiency. This is because in the presence of low blood levels of IGF-1, blocking GH’s action leads to a significant improvement in insulin sensitivity.

78. Friedrich N, Thuesen B, Jørgensen T, et al. The Association Between IGF-I and Insulin Resistance: A general population study in Danish adults. Diabetes Care. 2012;35(4):768-773. doi:10.2337/dc11-1833.
    View Summary +

    The Association Between IGF-I and Insulin Resistance: A general population study in Danish adults.
    

    The research conducted by Friedrich et al. (2012) investigates the association between insulin-like growth factor-I (IGF-I) and insulin resistance in the general population of Danish adults. Published in Diabetes Care, the study examines the relationship between IGF-I levels and insulin resistance, a key factor in the development of type 2 diabetes. It likely involves assessing IGF-I levels and insulin resistance markers in a large cohort of Danish adults to determine the correlation between these variables. The findings contribute to our understanding of the link between IGF-I and insulin resistance, providing insights into the potential role of IGF-I in the pathogenesis of insulin resistance and its implications for diabetes prevention and management.

    Read the full article: https://pubmed.ncbi.nlm.nih.gov/14702105/

79. Clemmons DR. Metabolic Actions of IGF-I in Normal Physiology and Diabetes. Endocrinology and Metabolism Clinics of North America. 2012;41(2):425-443. doi:10.1016/j.ecl.2012.04.017.
    View Summary +

    Metabolic Actions of IGF-I in Normal Physiology and Diabetes.

    The article authored by Clemmons (2012) explores the metabolic actions of insulin-like growth factor-I (IGF-I) in both normal physiology and diabetes. Published in the Endocrinology and Metabolism Clinics of North America, the article provides an overview of the various metabolic functions of IGF-I in both healthy individuals and those with diabetes. It likely covers topics such as the regulation of glucose metabolism, protein synthesis, lipid metabolism, and the interactions between IGF-I and insulin signaling pathways. The article aims to enhance our understanding of the role of IGF-I in metabolic regulation and its relevance to diabetes. The insights provided can contribute to the development of therapeutic strategies targeting IGF-I for the management of diabetes and related metabolic disorders.

80. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50(3):637-42.
    View Summary +

    A Polymorphism in the Gene for IGF-1 Functional Properties and Risk for Type 2 Diabetes and Myocardial Infarction

    Insulin-like growth factor 1 (IGF-1) plays a pivotal role in bone growth, cell production and survival, and metabolism. Its structural and functional resemblance with insulin as well as its blood sugar-lowering effects observed after recombinant IGF-1 administration, suggest that this hormone is involved in the regulation of normal blood sugar levels. (1) In patients with type 2 diabetes, low levels of IGF-1 in the blood are common. (2, 3) Evidence is accumulating that low levels of IGF-1 can eventually lead to complications of diabetes. Since IGF-1 may also play a role in the regulation of the heart function, various studies have also linked low IGF-1 levels and heart disease.

    Studies of the role of IGF-1 in the development of heart disease and diabetes have been hampered by the fact that circulating IGF-1 levels in the body do not necessarily reflect the local production of IGF-1 in specific tissues, such as the heart muscle and pancreas. A genetic polymorphism (presence of genetic variation within a population) in the IGF-1 gene promoter region has been identified, which may influence the production of IGF-1. (4, 5) This may open new opportunity to characterize, on a genetic basis, patients who experience low levels of IGF-1 throughout the body. Until now, studies focusing on this polymorphism in relation to the levels of IGF-1 in the body have been limited to osteoporosis and related disorders. (6-9)

    Vaessen and colleagues studied the role of a genetic polymorphism in the promoter region of the IGF-1 gene in relation to circulating IGF-1 levels and growth measured as body height, as well as the relationship of this polymorphism with type 2 diabetes and myocardial infarction. (6) The aim of the study was to investigate determinants of chronic and disabling diseases of the heart, nerves, and eyes. The relation between the IGF-1 polymorphism and body height was assessed in a population-based sample of 900 subjects, where 50 subjects were randomly selected. To assess the risk for type 2 diabetes, the researchers studied 220 patients and 596 control subjects with normal blood sugar levels. For myocardial infarction, 477 patients with evidence of the disease on electrocardiogram and 808 control subjects were studied. In this population-based study, the researchers found out that the absence of the wild-type (192-bp) allele (one of a pair of genes) of a genetic polymorphism in the regulatory region of the IGF-1 gene is significantly linked with short stature and low levels of IGF-1 in the body.

    Interestingly, the absence of this allele is also significantly associated with an increased risk for type 2 diabetes and myocardial infarction. Moreover, the relative risk for myocardial infarction is strongly increased in subjects without the 192-bp allele. This is the first study focusing on the role of IGF-1 promoter polymorphism in the development of type 2 diabetes and myocardial infarction. This study suggests that a lifetime exposure to moderate alterations in levels of IGF-1 in the body may also be relevant in terms of the risk for these diseases. In short, this study may present an opportunity to identify diabetic patients who are at high risk for heart disease and who are potential candidates for IGF- 1 therapy.

81. Simpson HL, Umpleby AM, Russell-jones DL. Insulin-like growth factor-I and diabetes. A review. Growth Horm IGF Res. 1998;8(2):83-95.
    View Summary +

    Insulin-like Growth Factor (IGF-1) in Diabetes

    The underlying rationale for using IGF-1 as a therapeutic option in diabetic patients has a strong physiological basis. IGF-1 is the same as insulin both in structure and function, specifically, stimulation of blood sugar transport into skeletal muscle cells, that’s why it is being used as a blood sugar-lowering agent in diabetes. Studies in humans have shown that post-prandial glucose test result which determines the level of blood sugar, is partly dependent upon IGF-1 concentrations and that IGF-1 administration in patients with either severe insulin resistance or type 2 diabetes led to an improved blood sugar test result. (1) This occurs primarily at the level of skeletal muscle as IGF-1 receptor deletion in skeletal muscle of mice models resulted in elevated blood sugar levels and impaired insulin action. (2)

    IGF-1 Enhances Insulin Action

    Several observations suggest that IGF-1 can enhance the action of insulin in different body tissues by stimulating PI3K activation, which is a key enzyme for regulating normal blood sugar transport within the cells. Other studies suggest that IGF-1 can improve the body’s response to insulin action by inhibiting growth hormone (GH) secretion, which can function as an insulin antagonist. (3) The same mechanism was seen in patients with type 2 diabetes who received IGF-1 treatment because GH is known to be a direct antagonist of insulin in the liver. (4)

    IGF-1 Improves Haemoglobin A1C

    Haemoglobin A1C or also known as glycosylated hemoglobin or glycohemoglobin is a blood test used to measure the average level of blood sugar in the past 2 to 3 months. This test can check how well a diabetic person controls blood sugar levels and can also be used in diagnosing diabetes. Larger clinical trials of IGF-1 administration to patients with type 1 diabetes have shown a consistent maintenance of reduced insulin requirements over 4–8-week periods and significant reductions in haemoglobin A1C. (5) However, the empiric fact remains that some diabetic patients experienced long-term control of blood sugar levels with co-administration of IGF1 and insulin. (6)

    Several large trials conducted in patients with type 2 diabetes using IGF-1 alone, significantly reduced haemoglobin A1C by 1.2%. (7) However, administration of both IGF-1 and IGFBP3 appears to be equally effective in terms of improving elevated blood sugar levels and the body’s response to insulin. Administration of this combination to 52 diabetic patients for 2 weeks significantly reduced fasting blood glucose result by 35-40% with a marked reduction in insulin requirements averaging 66%. (8) Notably different from previous studies with IGF-1 alone, this was achieved with minimal side effects.

    With these findings, it is plausible that IGF-1 can be considered as a potent blood sugar-lowering agent, even when it’s given with its binding protein IGFBP3, or with insulin. In relation to this, IGF-1 levels in diabetic patients can be a predictive marker whether the patient is responding well to treatments. Moreover, consistent IGF-1 and blood sugar monitoring while diabetic patients are under IGF-1 therapy, can help healthcare providers determine the outcome of the intervention.
    Read the full article: https://pubmed.ncbi.nlm.nih.gov/11246885/

82. Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016;14:3. Published 2016 Jan 6. doi:10.1186/s12967-015-0762-z.
    View Summary +

    Insulin-like Growth Factor-1 (IGF-1) and Metabolic Syndrome

    Metabolic syndrome (MetS) is a cluster of conditions including high blood pressure and blood sugar level, abnormal cholesterol levels, and excess body fat around the waist. Having just one of these conditions doesn’t mean you have the disease. However, any of these conditions increase your risk of having diabetes and other heart problems. If more than one of these conditions occur, your risk is even greater. Most of the disorders associated with metabolic syndrome usually have no symptoms, although a large waist circumference is a visible sign. However, in case your blood sugar shoots up, you might experience signs and symptoms of diabetes such as increased thirst and urination, dizziness, blurred vision, fatigue, and other debilitating symptoms.

    Metabolic syndrome is linked to a medical condition called insulin resistance. (1) Normally, the food that you eat is broken down into sugar (also known as glucose) by the digestive system. This sugar is needed by your cells as a source of energy for many biological processes within the body. In order for the sugar to enter the cells, they need a hormone called insulin. In people with insulin resistance, the body cannot utilize insulin effectively. This may be due to impairment in the pancreas’ ability to produce insulin, or the body simply doesn’t respond to the effects of insulin. As a result, blood sugar levels become elevated. This can eventually lead to diabetes and trigger various symptoms. Aside from insulin resistance, obesity, genetics, and hormonal decline related to aging may play a role in the development of metabolic syndrome.

    IGF-1 Levels and Metabolic Syndrome

    Consistent evidence associates IGF-1 deficiency and metabolic syndrome. (2) The anti-inflammatory actions of IGF-1 can be regarded as a crucial factor in protecting tissues from the deleterious effects of inflammatory substances in chronic disorders such as obesity. (3) In addition to this, inflammatory substances produced by fat cells in obese patients affect normal nutrition-related signaling, establishing the progression to metabolic syndrome and to type 2 diabetes. (4) Ultimately, these effects result in a blockade of IGF-1 beneficial actions. (3) Under this scenario, a correlation between lower IGF-1 levels and metabolic syndrome can be established.

    IGF-1 can Improve Insulin Resistance in Metabolic Syndrome

    IGF-1 is known to promote normal blood sugar transport in certain tissues. (5) In addition to this, IGF-1 administration has been shown to reduce blood sugar levels (6) not only in healthy individuals but also in patients with insulin resistance and type 2 diabetes. The specific mechanism by which IGF-1 lower blood sugar levels is by suppressing the process of synthesizing blood sugar in the body from non-carbohydrate sources by the liver as well as improving insulin in this organ. (7) Interestingly, additional performed studies suggested that the several mechanisms involved in blood sugar and lipid balance as well as cholesterol transport are altered in metabolic syndrome, and that IGF-1 administration can help normalize these compounds. (1) These results suggest that IGF-1 can be a therapeutic option in reversing metabolic syndrome in parallel with diet and exercise before it onsets to type 2 diabetes.

83. Zenobi PD, Jaeggi-groisman SE, Riesen WF, Røder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest. 1992;90(6):2234-41.
    View Summary +

    Insulin-like growth factor-I Improves Glucose and Lipid Metabolism in Type 2 Diabetes Mellitus

    Aside from growth stimulation, growth hormone (GH) and insulin-like growth factor 1 (IGF-1) have many different functions in the body. In the liver, GH functions to antagonize the ability of insulin by inhibiting the synthesis of glucose from non-carbohydrate sources (gluconeogenesis) and enhancing the breakdown of lipids (lipolysis), which functions to increase blood sugar or glucose levels. IGF1 can directly lower blood sugar levels by inhibiting gluconeogenesis in the kidney. Moreover, IGF-1 can also act indirectly through its receptors in the skeletal muscle, to enhance the action of insulin on blood sugar transport. In order to maintain normal blood sugar levels in the body, IGF-1 indirectly bocks the ability of GH to antagonize insulin action. IGF-1 is the same in both structure and function as insulin, and is implicated in the development of insulin resistance as well as heart disease.

    Low IGF-1 Levels and Diabetes Mellitus

    Low levels of IGF-1 in the body have been proposed to have a role in diabetes. In a recent study, Teppala and colleagues examined the blood IGF-1 levels of 5,511 participants, 387 of whom had diabetes, in order to determine the association between serum IGF-1 and diabetes in a representative sample of U.S. adults. The results of the study showed that lower blood IGF-1 levels were positively associated with diabetes in younger subjects after adjusting for several factors such as age, gender, race/ethnicity, education, lifestyle, BMI, hypertension, glomerular filtration rate, and cholesterol levels. These results indicate that low IGF-1 levels can be a predictor of diabetes in younger individuals.

    IGF-1 Administration in Diabetic Patients

    High blood sugar levels, excess levels of insulin circulating in the blood, and poor response to the action of insulin cause vascular disease (abnormal condition of the blood vessels) in type 2 diabetes mellitus. Dietary modification alone often is ineffective and oral drugs or insulin enhances the excess levels of insulin in the blood. In previous studies, recombinant human IGF-1 (rhIGF-I) has been used in Type 2 diabetes to improve the body’s response to insulin and aid in controlling the normal blood sugar levels in the body. RhIGF-I administration through the vein resulted in normalization of blood sugar levels in insulin-resistant diabetics whereas rhIGF-I infusions lowered insulin and lipid levels in healthy humans. This suggests that rhIGF-I is an effective therapeutic option in insulin-resistant states.

    To further assess the safety and efficacy of rhIGF-I, Zenobi and colleagues treated 8 type 2 diabetics on a diet received on five treatment days of subcutaneous rhIGF-I. Interestingly, rhIGF-I administration significantly increased the total IGF-I levels in the blood 5.3-fold. Also, rhIGF-I administration improved lipid levels in the blood. The magnitude of the effects of rhIGF-I administration in all the subjects correlated with the respective control levels.

    The availability of rhIGF-I used either alone or in combination with insulin, has led to various human clinical trials testing these hypotheses. In one study, Mohamed-ali and colleagues treated patients with type 1 and 2 diabetes mellitus with rhIGF-I, which resulted in significant improvement in insulin requirements and blood sugar levels. In addition to this, IGF-1 was found to have a protective effect on nerve problems, which is one of the complications of diabetes.

84. Regan FM, Williams RM, Mcdonald A, et al. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance. J Clin Endocrinol Metab. 2010;95(5):2113-22.
    View Summary +

    Long-term Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) for Severe Insulin Resistance Syndrome

    Severe insulin resistance syndrome is a condition wherein the body doesn’t respond to the effects of the hormone insulin. Normally, insulin serves a key in order for the blood sugar to enter the cells to be used as energy. In case of severe insulin resistance, the body doesn’t utilize insulin effectively, resulting in elevated blood sugar levels. Prolonged elevation of blood sugar can cause debilitating symptoms and can be life-threatening.

    Management of severe insulin resistance is a major clinical challenge in obese patients as well as those with genetic defects in the insulin receptor. Initially, excess levels of insulin circulating in the blood produces ovarian enlargement and increased male sex hormones in women, and often low blood sugar levels. However, low blood sugar gradually evolves into insulin-resistant high blood sugar when the function of the beta cells of the pancreas decline. Medical management of these complex disorders depends on early recognition of the problem and appropriate targeting of both high and low blood sugar levels.

    Long Term rhIGF-1 Administration in Severe Insulin-Resistant States

    Several studies have shown that recombinant human insulin-like growth factor 1 (rhIGF-1) can help improve survival in infants with the most severe defects in insulin receptor and also improve the function of the insulin-producing beta cells. In the past, the first line therapy for high blood sugar and accumulation of waste products in the blood related to severe insulin resistance is the administration of high-dose insulin. However, rhIGF-1 has been used as a treatment alternative to high dose insulin because prolonged use of insulin is linked with episodes of low blood sugar levels.

    Clinical trials were conducted to study patients with severe insulin-resistant states. In most of these investigations, the administration of IGF-1 was given for less than 3 months at a dose of 50-100-160 micrograms per kilogram of body weight, injected via subcutaneous route once or twice a day. However, the results of a trial of patients with severe insulin resistance who received rhIGF-1 for 1 year suggested that IGF-1 treatment may be a safe and effective long-term therapy. In children and adults with type 1 diabetes, long term administration of IGF-1 has also shown improvement in blood sugar control.

    To further elucidate the ability of treatment with rhIGF1 to improve metabolic and clinical parameters in the long-term, De kerdanet and colleagues studied the case of a four-month-old female baby with leprechaunism, a rare genetic disease resulting from mutations in the insulin receptor gene, and is characterized by severe insulin resistance, growth failure and, usually, premature death. The diagnosis of leprechaunism was confirmed based on mutations in the insulin receptor gene of the patient. The researchers analyzed the patient’s skin fibroblasts (cells in connective tissue) for response to insulin and IGF1. Cultured fibroblasts from the patient’s skin showed a decreased number of insulin receptors and were insulin-resistant. Interestingly, the results of the study showed that treatment with IGF-1/IGFBP3 (Insulin-like Growth Factor Binding Protein-3) for 8.7 years, then IGF-1 for 2 years, resulted in normalization of circulating levels of IGF-1 and IGFBP3. In addition to this, improvements in the blood sugar levels of the patient were observed. Regarding growth, the patient’s body mass index (BMI) normalized and length/height score improved. Moreover, the patient presented normal neurological development and academic achievement. In the entire duration of the study, no adverse side effects were observed.

    These results provide evidence that long term rhIGF-1 administration (more than 10 years) with and without rhIGFBP3 can help prevent fatal outcomes in patients with severe insulin resistance syndrome, and can improve growth and metabolic parameters in a safe and effective manner.

85. Cheetham TD, Holly JM, Clayton K, Cwyfan-hughes S, Dunger DB. The effects of repeated daily recombinant human insulin-like growth factor I administration in adolescents with type 1 diabetes. Diabet Med. 1995;12(10):885-92.
    View Summary +

    The Effects of Repeated Daily Recombinant Human Insulin-like Growth Factor 1 Administration in Adolescents with Type 1 Diabetes

    Several studies have shown that the levels of insulin are higher during puberty than they are during adulthood or the years preceding puberty. A decrease in insulin-stimulated blood sugar uptake in healthy adolescents compared with pre-pubertal children was demonstrated for the first time in the 1980s. Healthcare professionals should be aware of the evolution of insulin insensitivity (inability of the body to respond the effects of insulin) during puberty in children and adolescents with type 1 diabetes and appropriately adjust the dose of insulin in order to prevent any deterioration in blood sugar control.

    Recently, a large cross-sectional study of children without diabetes has shown that insulin sensitivity is lowest at age 12 to 14 years in both genders, and across ethnic groups, returning to almost pre-pubertal levels in young people above 16 years of age. Experts believe that the major hormonal changes that are associated with the onset of puberty such as the two-fold increase in the production of growth hormone and sex steroids are likely hormonal candidates for inducing insulin sensitivity in adolescents. However, while insulin sensitivity during puberty is transient, the increasing levels of sex steroids remain elevated and insulin sensitivity subsides during adulthood. Once the pubertal growth spurt is completed, the levels of growth hormone decline.

    Behavioral and Psychosocial changes during Adolescence

    In addition to the hormonal and metabolic changes during the puberty period, adolescents experience rapid behavioral changes that may impact diabetes control. Behavioral changes include being rebellious, heightened awareness of self-image and peer pressure, challenging of authority figures, establishing independence, seeking privacy and the emergence of eating disorders – all of these may be affected by the presence of a chronic illness like diabetes. Adolescents with a chronic disease are at increased risk for major depression, anxiety, and low self-esteem. The combination of depression and diabetes in adolescents has serious consequences including increased rates of suicide or suicidal tendencies, making diabetes management and self-care extremely difficult.

    Insulin-like Growth Factor 1 Administration in Adolescents with Type 1 Diabetes

    Good blood sugar control in type 1 diabetes to prevent complications may be difficult to achieve during adolescence, because of hormonal fluctuations in the production of growth hormone or insulin-like growth-factor-l (IGF-1) which can lead to lower insulin sensitivity. Recombinant human IGF-1 (rhlGF-l) given in addition to insulin therapy in type 1 diabetes, might improve blood sugar control in adolescents.

    Reduced IGF-1 has been liked to poor metabolic control and increased production of growth hormone in adolescents with type 1 diabetes. To evaluate the safety and efficacy of rhIGF-1 in these patients, Cheetham and colleagues studied a group of 6 adolescent male subjects with type 1 diabetes who were given rhIGF-1 at a dose of 40 micrograms per kilogram for 28 days via subcutaneous injections. Glycated hemoglobin (HbA1c) levels were measured throughout the study to determine blood sugar concentrations and overnight profiles were undertaken to study levels of IGF-1, insulin-like growth factor binding protein-3 (IGFBP-3), and growth hormone concentrations. Interestingly, rhIGF-1 administration was well tolerated and low blood sugar was not problematic at any stage of the study. In addition to this, rhIGF-1 led to a sustained increase in IGF-1, IGFBP-3 and mean overnight growth hormone decreased during the study. Furthermore, rhIGF-1 administration improved the levels of glycated hemoglobin in these patients, suggesting an improvement in blood sugar levels.

    The restoration of IGF-1 levels in these patients may indeed have a beneficial impact on blood sugar control. In addition to rhIGF-1 administration, a multifaceted approach that includes lifestyle and diet modifications as well as proper counseling can help adolescents with type 1 diabetes achieve good blood sugar control.

86. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004;113(1):25-7.
    View Summary +

    The Relative Roles of Insulin-like Growth Factor (IGF-1) in Controlling Insulin Sensitivity

    To understand insulin sensitivity, it is important to understand the role of insulin in the body first. Insulin is a hormone that helps transport blood sugar or glucose, into the cells as a source of energy. Since the body makes use of blood sugar for energy, insulin plays a vital role. Just think of insulin as a ”key” required by blood sugar to enter the cells. Without sufficient insulin, blood sugar cannot be transported inside the cells and remains in the bloodstream. As a result, the levels of blood sugar shoot up, which if prolonged, can lead to debilitating symptoms such as:

    1.Drowsiness
    2.Extreme thirst resulting in excessive drinking
    3.Frequent urination
    4.Heavy, difficult breathing
    5.Increased appetite resulting in excessive eating
    6.Sudden changes in vision
    7.Sudden loss of weight
    8.Sugar in urine (ants may gather in the patient’s urine)
    9.Unconsciousness
    10.Weakness and fatigue

    Insulin sensitivity describes how sensitive the body is to the effects of insulin. If a person is insulin sensitive, he or she will require smaller amounts of insulin to achieve a lower blood sugar level. Insulin sensitivity varies from person to person. People with low insulin sensitivity, also known as insulin resistance, will require larger amounts of insulin either from their own body or from injections to achieve a normal blood sugar level.

    Role of IGF-1 in Modulating Insulin Sensitivity

    IGF-1, which has the same structure and function as insulin, improves insulin sensitivity in both experimental animals and human subjects. The underlying mechanism in which IGF-1 exerts this action is by binding to insulin receptors with very low affinity. IGF-1 administration in healthy humans results in glucose lowering that is approximately one-twelfth as potent as that induced by insulin, and in patients with extreme insulin resistance, it improves insulin sensitivity and normalizes carbohydrate levels.

    Almost all human studies of IGF-1 show that, in addition to enhancing the action of insulin, IGF-1 also suppresses the secretion of growth hormone (GH). One exception is the group of subjects with GH receptor mutations who develop insulin resistance as adults. IGF-1 administration to these patients, who are unresponsive to the effects of GH, results in improvement in insulin sensitivity. Although GH counters the action of insulin the skeletal muscle, experts believe that the role of IGF-1 may still be predominant in that tissue. Inhibiting the action of GH to attain a relatively normal physiologic level rather than a GH-deficient level will be vital to further understand the role of IGF-1 in the maintenance of normal blood sugar levels. Even though IGF-1 suppresses GH section in order to improve insulin sensitivity, it is still clear how IGF-1 can be of great use in lowering elevated blood sugar levels.

    In larger clinical trials of IGF-1 administration to patients with type 1 diabetes, the results showed a consistent maintenance of reduced insulin requirements over 4–8-week periods and significant reductions in blood sugar levels. Surprisingly, the administration of both IGF-1 and IGFBP3 appears to be equally effective in terms of improving elevated blood sugar levels and insulin sensitivity. Administration of this combination to 52 diabetic patients for 2 weeks significantly reduced fasting blood glucose result by 35-40% with a marked reduction in insulin requirements averaging 66% with minimal side effects. These large body of clinical trials clearly suggest that IGF-1 can be a potent treatment in the maintenance of normal blood sugar levels especially in patients with diabetes.

87. Wang D, Zhao N, Zhu Z. Recombinant human growth hormone in treatment of diabetes: report of three cases and review of relative literature. Int J Clin Exp Med. 2015;8(5):8243-8. Published 2015 May 15.
    View Summary +

    Growth hormone: a Potential Treatment Option in Diabetes?

    Under normal conditions, insulin is the major regulator of blood glucose levels. However, human growth hormone (HGH) and insulin-like growth factor-1 (IGF-1) also play an important contributory role. Both of these hormones have potent effects on the metabolism of glucose which may be utilized in the management of diabetes. HGH has major effects on glucose metabolism. It increases the concentrations of glucose in the blood and decreases the body’s sensitivity to insulin, thus opposing the normal action of insulin. In people with diabetes, the concentrations of glucose are up to 2-3 times higher. Excessive GH secretion may be partly responsible for the ‘dawn phenomenon’ – a rise of blood glucose concentrations in the early morning before waking up.

    Insulin-like Growth Factor-1 (IGF-1) and Diabetes

    Although GH has many actions of its own, most of its actions are mediated through the generation of IGF-1. This hormone resembles the structure and function of insulin, including a rapid reduction in blood glucose levels. In people with Type 1 diabetes, the amount of insulin reaching their liver is reduced even in situations where there is intensive subcutaneous insulin treatment. As a consequence, their concentrations of IGF-1 in the blood are also reduced. Interestingly, when insulin therapy is given directly into the abdominal cavity by an implantable pump, the levels of insulin increase and there is near-normalization of IGF-1 concentrations.

    Clinical Trials of IGF-1

    When IGF-1 is given to people with Type 1 diabetes, significant improvement in blood glucose levels and a reduction in the insulin dose required to maintain normal glucose levels are observed. Similar results, together with a fat mass reduction, are seen in people with Type 2 diabetes who receive larger doses of IGF-1. Promising early clinical trials have been performed with the combination of IGF-1 and IGFBP-3, the major circulating IGF-1 binding protein. Over a 2-week period, there was a reduction in the doses of insulin and fasting blood glucose levels in patients with Type 1 and Type 2 diabetes. Notably different from previous studies with IGF-1 alone, this was achieved with minimal side effects. Low doses of IGF-1 have also been used in different rare conditions to prevent ketoacidosis (accumulation of ketones in the blood) and maintain normal blood glucose levels. Unfortunately, as IGF-1 doses increases, so is the rate of side effects.

    Conclusions

    Diabetic patients appear to have abnormalities in both HGH and IGF-1 and this contributes to both the metabolic disturbance and the susceptibility to complications. HGH may be beneficial for people with abdominal obesity who are at high risk for Type 2 diabetes. IGF-1 treatments in diabetic patients result in improved blood glucose control but its use has been limited by side effects. More recently, the combination of IGF-1 and IGFBP-3 has been shown to lower blood glucose levels without any side effects. However, further research will be needed to confirm the safety and efficacy of this compound.

88. Cathy Soto (1 January 2016). ECG: Essentials of Electrocardiography. Cengage Learning. pp. 31–. ISBN 978-1-305-68775-2.
    View Summary +

    Essentials of Electrocardiography.
    

    The book titled “ECG: Essentials of Electrocardiography” by Cathy Soto provides a comprehensive guide to understanding electrocardiography. Published by Cengage Learning, the book likely covers essential concepts and principles related to electrocardiography, including the interpretation of ECG waveforms, identification of arrhythmias, and assessment of cardiac health. It is designed to serve as a valuable resource for healthcare professionals, students, and anyone interested in mastering the fundamentals of electrocardiography. With its detailed explanations and practical examples, the book aims to enhance the reader’s knowledge and skills in interpreting ECGs, ultimately contributing to improved patient care and diagnosis of cardiac conditions.

89. Schutte AE, Volpe M, Tocci G, Conti E. Revisiting the relationship between blood pressure and insulin-like growth factor-1. Hypertension (Dallas, Tex.: 1979). 2014; 63(5):1070-7.
    View Summary +

    Insulin and Insulin‐like Growth Factor‐1 Cause Vasorelaxation in Human Vessels In vitro

    Vasorelaxation or vasodilation is the physiological mechanism of the widening of the blood vessels in the body due to the relaxation of smooth muscle tissue that they are connected to. Different stimulus in the environment such as weather and changes in physical exertion can stimulate these muscles to control both vasoconstriction (narrowing of blood vessels) and vasodilation. Widening of blood vessels actually has a number of benefits in the body. The vasodilation process allows a higher volume of blood, oxygen and other essential nutrients to flow through the vessels that have widened. More oxygen and nutrients benefit the muscles by increasing its capability of being stressed for longer periods of time and more intensively. Moreover, essential substances such as amino acids, testosterone, growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are delivered to your starving muscles, resulting in increased muscle mass, strength and regeneration. Therefore, by feeding your system more blood, oxygen and nutrients, you transport elevated amounts of important substances into your muscles necessary for various biological processes in the body.

    Nitric Oxide is the Key in Vasodilation

    Nitric oxide (NO) initiates and maintains vasodilation by:
    1.NO diffuses into smooth muscle cells after it is released from endothelial cells.
    2.Once inside the smooth muscle cells, NO binds to guanylate cyclase (GC) enzyme, resulting in GC activation.
    3.GC activation leads to the formation of cyclic guanosine monophosphate (cGMP) that is used to phosphorylate (addition of phosphate) proteins, including the smooth muscle contractile protein called myosin.
    4.The smooth muscle cell myosin relaxes, resulting in dilation of the vessel.

    Insulin and Insulin‐like Growth Factor‐1 (IGF-1) Increases Nitric Oxide

    Several studies have demonstrated IGF-1’s action in increasing NO.[2] To evaluate the vasodilatory effects of insulin and IGF‐1 and to elucidate their mechanisms of action on human vessels, Izhar and colleagues studied blood vessels taken from patients with and without noninsulin‐dependent diabetes mellitus (NIDDM).[3] The researchers harvested vascular rings of human internal mammary artery (IMA) and saphenous vein from 54 diabetic patients undergoing coronary bypass surgery and treated it with insulin and IGF-1, and were studied in vitro. Interestingly, the IMA rings from patients without NIDDM displayed greater relaxation than in saphenous vein rings treated with both insulin and IGF-1. Similar results were obtained with vessels from patients with NIDDM. Of note, vasodilation was not affected by the removal of the endothelium (produces NO) and by inhibition of the production of NO. Both insulin and IGF‐1 induced vasodilation of rings from human IMA and saphenous veins, through a mechanism involving activation of potassium channels. This mechanism remained intact in the blood vessels of patients with NIDDM.

    These results further support the role of IGF-1 in triggering vasodilation in human blood vessels. This vasodilatory effect of IGF-1 can be of great therapeutic value in managing a wide array of diseases that impairs blood circulation such as stroke, heart diseases, blood vessel diseases, high blood pressure, high blood sugar, and other fatal diseases. By restoring normal blood flow to vital organs, IGF-1 can indeed be beneficial in patients with blood circulation problems.

90. Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T. Relationship between serum insulin-like growth factor-1 levels and Alzheimer’s disease and vascular dementia. Journal of the American Geriatrics Society. 2005; 53(10):1748-53.
    View Summary +

    Relationship between serum insulin-like growth factor-1 levels and Alzheimer’s disease and vascular dementia
    

    The study titled “Relationship between serum insulin-like growth factor-1 levels and Alzheimer’s disease and vascular dementia” conducted by Watanabe et al. (2005) explored the association between insulin-like growth factor-1 (IGF-1) levels and the risk of developing Alzheimer’s disease (AD) and vascular dementia (VaD). The researchers measured serum IGF-1 levels in a group of participants and assessed their cognitive function to determine the presence of AD or VaD. The findings suggested a potential link between lower serum IGF-1 levels and an increased risk of developing AD and VaD. This study provides valuable insights into the relationship between IGF-1 and dementia, highlighting the importance of further research in this area.

91. Poehlman ET, Toth MJ, Ades PA, Rosen CJ. Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study. European journal of clinical investigation. 1997; 27(4):322-6.
    View Summary +

    Menopause-associated changes in plasma lipids, insulin-like growth factor I and blood pressure: a longitudinal study
    

    The study titled “Menopause-associated changes in plasma lipids, insulin-like growth factor I, and blood pressure: a longitudinal study” conducted by Poehlman et al. (1997) aimed to investigate the impact of menopause on various physiological factors including plasma lipids, insulin-like growth factor I (IGF-1), and blood pressure. The researchers conducted a longitudinal study, following women through the menopausal transition and assessing these parameters at multiple time points. The results indicated that menopause was associated with unfavorable changes in plasma lipids, including increased total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Additionally, there were alterations in IGF-1 levels and blood pressure measurements. These findings provide valuable insights into the physiological changes that occur during menopause and their potential implications for cardiovascular health.

92. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clinical endocrinology. 1994; 41(3):351-7.
    View Summary +

    Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin
    

    The study titled “Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin” conducted by Landin-Wilhelmsen et al. (1994) aimed to investigate the relationship between serum insulin-like growth factor I (IGF-1) levels and various factors in a random population sample. The researchers assessed IGF-1 levels in both men and women and examined their association with age, sex, smoking habits, coffee consumption, physical activity, blood pressure, and concentrations of plasma lipids, fibrinogen, parathyroid hormone, and osteocalcin. The study found significant associations between IGF-1 levels and several of these factors, indicating that IGF-1 may be influenced by multiple physiological and lifestyle factors. These findings contribute to our understanding of the factors that can affect IGF-1 levels in the general population.

93. Nolan BP, Senechal P, Waqar S, Myers J, Standley CA, Standley PR. Altered insulin-like growth factor-1 and nitric oxide sensitivities in hypertension contribute to vascular hyperplasia. American journal of hypertension. 2003; 16(5 Pt 1):393-400.
    View Summary +

    Insulin-Like Growth Factor 1 (IGF-1) Enhances the Wound Healing Process

    Wound healing is a dynamic process that involves the integrated action of several types of cells and inflammatory substances known as cytokines. In recent years, advances in technology have been made, focusing on growth factors’ ability to regenerate and repair various tissues and organs in the body. Growth factors are proteins that enhance the communication of cells. Their function depends on the receptor site they attach to. Recently, growth factors have been shown to regulate many of the activities involved in wound healing, which is a critical component of the successful resolution of a wound. Growth factors released in the traumatized or injured area promote cell migration into the wound, stimulate the growth of cells, initiate the formation of new blood vessels, and stimulate formation and remodeling of the affected area. Animal studies have shown that administration of growth factors into the injured area can accelerate the normal wound healing process. In humans, growth factors have been used successfully in treating incurable wounds related to chronic illnesses. The most intensively studied growth factors are insulin-like growth factor 1 (IGF-1), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor (TGF)-α, and TGF-β.[1]

    Keratinocyte Migration: A Critical Phase of the Wound Healing Process

    An essential feature of a healed wound is the restoration of an intact outer skin layer through wound epithelialization (formation of granulation tissue into an open wound). The directed migration of keratinocytes (cells of the outermost layer of the skin) is critical to wound epithelialization and defects in this function are associated with delayed wound healing or non-healing wounds. In order to better understand the wound healing process, you must first know the different phases of wound healing:

    1.Rapid hemostasis – this refers to the mechanism that controls the actual bleeding. Your body responds by constricting your blood vessels to prevent blood loss.
    2.Inflammation – this is your body’s way of alerting you of an existing injury. This process also helps dictate where the cells that fight inflammation and infection should be headed.
    3.Proliferation and migration – this process involves the release of several kinds of cells into the injured area to prevent further bleeding, fight infection, and to start the regeneration process.
    4.Angiogenesis – this refers to the rebuilding process where formation of new blood vessels occurs.
    5.Epithelialization – this process is also known as reepithelialization. During epithelialization, your body begins to create several layers of tissue in the injured area to offer protection and prevent fluid loss.
    6.Synthesis – this is the last step of the wound healing process wherein certain proteins form blood clots to prevent bleeding as new skin and veins are formed.

    IGF-1 Enhances Keratinocyte Migration

    Keratinocyte migration and proliferation are required for epithelialization. A number of evidence has shown that these processes are regulated by one or more growth factors. To further elucidate the effects of IGF-1 and other growth factors in wound healing, Ando and colleagues performed a direct observation of the migration path of growth factors using the phagokinetic assay on human keratinocytes.[2] Interestingly, addition of EGF to human keratinocytes in the absence of any other growth factor induced an increase in migration of 2.5-4.5 fold after overnight incubation. Moreover, the addition of an antibody completely prevented the EGF-induced migration; however, the enhancement of migration of human keratinocytes by using insulin or IGF-1 was not blocked. These results suggest that IGF-1 and insulin enhance human keratinocyte migration by a mechanism distinct from that of EGF. IGF-1’s ability to enhance this critical phase of the wound healing process can be of great therapeutic value in delayed wounds or non-healing wounds related to chronic illnesses.

94. Schut AF, Janssen JA, Deinum J. Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension. Stroke. 2003; 34(7):1623-7.
    View Summary +

    Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension.
    

    The study titled “Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension” conducted by Schut et al. (2003) aimed to investigate the association between a polymorphism in the promoter region of the insulin-like growth factor I (IGF-I) gene and measures of arterial stiffness and atherosclerosis in individuals with hypertension. The researchers examined carotid intima-media thickness (IMT) and aortic pulse wave velocity (PWV) as markers of atherosclerosis and arterial stiffness, respectively. They found that individuals with the specific polymorphism in the IGF-I gene promoter region had increased carotid IMT and aortic PWV compared to those without the polymorphism. These findings suggest that genetic variations in the IGF-I gene may contribute to the development of arterial stiffness and atherosclerosis in individuals with hypertension.

95. Cooley SM, Donnelly JC, Geary MP, Rodeck CH, Hindmarsh PC. Maternal insulin-like growth factors 1 and 2 (IGF-1, IGF-2) and IGF BP-3 and the hypertensive disorders of pregnancy. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2010; 23(7):658-61.
    View Summary +

    The Role of Growth Factors in Intestinal Regeneration and Repair in Necrotizing Enterocolitis

    Necrotizing enterocolitis(NEC) is characterized by death of the inner lining of the small or large intestine. This causes the intestine to become inflamed. Over time, this may cause a hole in thewall of the intestine, resulting in the leakage of the intestinal bacteria into the abdomen and cause widespread infection. NEC can develop in any newborn within two weeks.However, the disease is more likely to occurin premature infants, accounting for 60 to 80 percent of cases.This disease can progress very quickly and is life-threatening that’s why it is important to get treatment right away.

    What are the Symptoms of Necrotizing Enterocolitis?

    The symptoms of NEC often include the following:

    Bloody stool

    Diarrhea

    Difficulty breathing

    Discoloration of the abdomen

    Fever

    Lethargy

    Poor feeding

    Swelling or bloating of the abdomen

    Vomiting

    What Causes Necrotizing Enterocolitis?

    Although the exact cause of NEC is unknown, experts believe that insufficient amounts of oxygen during a difficult delivery can contribute to its development. When there’s inadequate oxygen or blood flow to the intestine, it can become weak. As a result, the bacteria from the food can easily damage the intestinal tissues.

    Insulin-Like Growth Factor-1 (IGF-1) Stimulates Cellular Proliferation

    IGF-1 is synthesized primarily in the liver but also in the gastrointestinal tract. This hormone is also found in the intestine of the fetus as well as in human milk, suggesting a role in the development of the intestine. IGF-1 is known to increase intestinal cell proliferation and growth. In animal models and in human studies of short bowel syndrome (malabsorption disorder), enlargement of the intestine, or inflammatory bowel disease, IGF-1 is more potent in stimulating intestinal growth than growth hormone (GH), suggesting a role in intestinal repair in NEC.In vivo evidence for the proliferative effects of IGF-1 on the intestines is derived from experimental models using both oral and parenteral route. Oral feeding of IGF-1 to neonatal pigs led to an increase in the height and weight of small intestine

    IGF-1 is Pro-Survival

    IGF-1 increases intestinal growth, in part, by inhibition of cell death or destruction. In vitro and in vivo studies demonstrate that IGF-1 administration promotes survival in smooth muscle cells of the muscularis propria (thick muscle deep in the bladder wall) of humans and mice.

    IGF-1 and Gastric Ulceration

    Recently, decreased IGF-1 level in chronically ulcerated gastric tissue has been described. When IGF-1 is administered in rat models with thermally-induced gastric injury, accelerated healing of the intestines is observed. The potential applicability of IGF-1 treatment to gastric injury is further supported by its ability to inhibit gastric acid secretion, which is an important mechanism in preventing further ulcerations in NEC.

    IGF-1 Promotes Wound Healing and Repair in the Intestinal Tract

    IGF-1 does not only stimulate proliferation and inhibition of cell death of intestinal cells, it also increases the production of collagen in these cells. Collagen plays a key role in each phase of wound healing, suggesting that IGF-1 can help repair ulcerations in NEC.

96. Available from http://erj.ersjournals.com/content/44/Suppl_58/P316.
    View Summary +

    Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension
    

    In pulmonary arterial hypertension (PAH), there is increased proliferation of pulmonary artery smooth muscle cells (PASMCs) that contribute to the development and progression of the disease. Insulin-like growth factor-1 (IGF-1) has been identified as a factor that plays a role in this process. Studies have shown that IGF-1 promotes PASMC proliferation and contributes to the remodeling of pulmonary arteries in PAH. The signaling pathways involving IGF-1 receptors and downstream molecules are activated, leading to increased cell growth and survival. Targeting the IGF-1 pathway may hold therapeutic potential for managing PAH by inhibiting PASMC proliferation and attenuating disease progression. Further research is needed to fully understand the mechanisms and explore the potential of IGF-1 as a therapeutic target in PAH.

97. Epithelial Cells—Advances in Research and Application: 2013 Edition. ScholarlyEditions. 21 June 2013. pp. 331–. ISBN 978-1-4816-8761-4.
    View Summary +

    ScholarlyEditions
    

    The citation you provided appears to be the title and publication information for a book or collection titled “Epithelial Cells—Advances in Research and Application: 2013 Edition.” It was published by ScholarlyEditions on June 21, 2013. The book likely contains a compilation of research advancements and applications related to epithelial cells. The page number and ISBN are also provided. However, without further specific information, it is challenging to provide a detailed summary or analysis of the content within the book.

98. Hemat (2004). Principles of Orthomolecularism. Urotext. pp. 408–. ISBN 978-1-903737-05-7.
    View Summary +

    Principles of Orthomolecularism
    

    The citation you provided refers to the book titled “Principles of Orthomolecularism” by Hemat, published by Urotext. It was published in 2004 and has a page count of at least 408 pages. The book likely explores the principles and concepts related to orthomolecularism, which is an approach to health and nutrition that focuses on optimizing the body’s biochemical balance through the use of vitamins, minerals, and other essential nutrients. However, without access to the specific content of the book, it is not possible to provide a detailed summary or analysis.

99. Otunctemur A, Ozbek E, Sahin S, et al. Low serum insulin-like growth factor-1 in patients with erectile dysfunction. Basic and Clinical Andrology. 2016;26:1. doi:10.1186/s12610-015-0028-x.
    View Summary +

    Low serum insulin-like growth factor-1 in patients with erectile dysfunction
    

    The article “Low serum insulin-like growth factor-1 in patients with erectile dysfunction” by Otunctemur et al. was published in Basic and Clinical Andrology in 2016. It examines the correlation between low insulin-like growth factor-1 (IGF-1) levels and erectile dysfunction. The study investigates the potential association between IGF-1 deficiency and ED. The authors explore the relationship between serum IGF-1 levels and the occurrence of ED, aiming to shed light on this connection. Further details regarding the methodology, findings, and conclusions can be found in the article, which may provide valuable insights into the topic.

100. Rajfer J. Growth Factors and Gene Therapy for Erectile Dysfunction. Reviews in Urology. 2000;2(1):34.
     View Summary +

     Growth Factors and Gene Therapy for Erectile Dysfunction.
     

     The article “Growth Factors and Gene Therapy for Erectile Dysfunction” by Rajfer was published in Reviews in Urology in 2000. It examines the potential of growth factors and gene therapy as treatment options for erectile dysfunction. The article discusses the role of growth factors in penile tissue and the use of gene therapy to deliver therapeutic genes for ED treatment. It provides an overview of advancements in this field. For further details, please refer to the article for a comprehensive understanding of the topic.

101. Sullivan ME, Thompson CS, Dashwood MR. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovascular research. 1999; 43(3):658-65.
     View Summary +

     Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease?
     

     The article “Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease?” by Sullivan et al. was published in Cardiovascular Research in 1999. It examines the connection between nitric oxide, vascular disease, and erectile dysfunction (ED). The authors explore the role of nitric oxide in penile erection and discuss how vascular health relates to the occurrence of ED. The article provides valuable insights into the vascular aspects of ED and their implications for understanding and managing the condition.

102. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism. 1997; 82(5):1472-9.
     View Summary +

     Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
     

     The article “Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women” by Khorram et al. was published in The Journal of Clinical Endocrinology and Metabolism in 1997. It investigates the effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 on the endocrine and metabolic profiles of age-advanced men and women. The study explores the potential benefits and changes associated with this hormone-releasing hormone treatment. For more detailed information, please refer to the article itself.

103. Musicki B, Palese MA, Crone JK, Burnett AL. Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection. Biology of reproduction. 2004; 70(2):282-9.
     View Summary +

     Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection.

     The article “Phosphorylated endothelial nitric oxide synthase mediates vascular endothelial growth factor-induced penile erection” by Musicki et al. was published in Biology of Reproduction in 2004. It investigates the role of phosphorylated endothelial nitric oxide synthase (eNOS) in mediating penile erection induced by vascular endothelial growth factor (VEGF). The study focuses on the signaling pathways and molecular processes involved in VEGF-induced penile erection. For more detailed information, please refer to the article itself.

104. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. The Journal of clinical endocrinology and metabolism. 1994; 78(6):1360-7.
     View Summary +

     Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age.
     

     The article titled “Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age” by Morales et al. (1994) examines the effects of a replacement dose of dehydroepiandrosterone (DHEA) in men and women as they age. The study investigates the impact of DHEA supplementation on various physiological and metabolic parameters in individuals of advancing age. The findings provide insights into the potential effects of DHEA replacement therapy on hormone levels and overall well-being in older adults. This research contributes to our understanding of the potential role of DHEA in mitigating age-related changes and promoting health in the aging population.

105. Pastuszak AW, Liu JS, Vij A. IGF-1 levels are significantly correlated with patient-reported measures of sexual function. International journal of impotence research. 2011; 23(5):220-6
     View Summary +

     IGF-1 levels are significantly correlated with patient-reported measures of sexual function. International journal of impotence research
     

     The article “IGF-1 levels are significantly correlated with patient-reported measures of sexual function” by Pastuszak et al. was published in the International Journal of Impotence Research in 2011. It examines the correlation between IGF-1 levels and patient-reported measures of sexual function. The study explores the relationship between IGF-1 and various aspects of sexual function. For more details, please refer to the article.

106. Creaney L, Hamilton B. Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 2008;42(5):314-20.
     View Summary +

     Growth factor delivery methods in the management of sports injuries: the state of play.
     

     The article “Growth factor delivery methods in the management of sports injuries: the state of play” by Creaney and Hamilton was published in the British Journal of Sports Medicine in 2008. It explores the current status of growth factor delivery methods for sports injury management. The article discusses different techniques used to administer growth factors to injured tissues. It provides an overview of the advancements, benefits, and challenges associated with growth factor delivery in sports injury treatment. For more information, please refer to the original article.

107. Provenzano PP, Alejandro-osorio AL, Grorud KW, et al. Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments. BMC Physiol. 2007;7:2.
     View Summary +

     Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments.
     

     The article “Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments” by Provenzano et al. was published in BMC Physiology in 2007. It investigates the effects of systemic administration of IGF-I on healing in collagenous extracellular matrices, specifically evaluating loaded and unloaded ligaments. The study examines the potential of IGF-I to enhance healing and regeneration in these tissues. For more information, please refer to the original article.

108. Kurtz CA, Loebig TG, Anderson DD, Demeo PJ, Campbell PG. Insulin-like growth factor I accelerates functional recovery from Achilles tendon injury in a rat model. Am J Sports Med. 1999;27(3):363-9.
     View Summary +

     IGF-1 Levels are Significantly Correlated With Patient-reported Measures of Sexual Function

     The male sexual cycle is regulated by a complex interplay between neuroendocrine, vascular and genital systems. Any dysfunction in these systems can lead to erectile dysfunction (ED). ED or also known as impotence is the inability to get and maintain an erection firm enough for sexual intercourse. Multiple studies have shown links between ED, growth hormone (GH) and insulin-like growth factor-1 (IGF-1). GH stimulates IGF-1 production while IGF-1 is known to be the main intermediary of GH action. There is a relationship between all of these hormones that has been shown to affect a man’s ability to maintain an erection.

     IGF-1 and Penile Erection

     In recent studies, it has been shown that in healthy male patients, the levels of GH increase during penile erection. (1) In patients with ED, GH levels are decreased approximately sevenfold. It has been postulated that the effects of GH in ED may be determined by IGF-1’s action in increasing nitric oxide levels. (2) Nitric oxide is considered to be a principal mediator of penile erection by increasing cGMP formation, which in turn causes relaxation of vascular smooth muscle. This leads to engorgement of the penis with blood, thereby developing an erection.

     The relationship of IGF-1 and penile erection has been described in otherwise healthy male subjects. Pastuszak and colleagues reported that IGF-1 levels correlate significantly with sexual function scores in 65 men who completed the Sexual Health Inventory for Men (SHIM) and Expanded Prostate Cancer Index Composite (EPIC) questionnaires. (1) This study was able to show a relationship between IGF-1 and validated measures of patient-reported sexual function. All subjects in this study provided a preoperative blood sample of IGF-1 and testosterone between 1 week and 2 months before scheduled surgical removal of the prostate (prostatectomy). Subjects were asked to complete the SHIM and EPIC questionnaires (questions regarding sexual function) before prostatectomy. The results of the study showed that the subjects’ IGF-1 levels were correlated with self-reported sexual function as assessed using the questionnaires.

     It is conceivable that supplementation with GH or IGF-1 can have a positive impact in ED after surgical removal of the prostate. However, there are controversies regarding IGF-1’s link to prostate cancer. In the same study, the researchers found no correlation between Gleason score (used to help evaluate the prognosis of men with prostate cancer) and IGF-1 levels. These data suggests that IGF-1 and the GH axis do not stimulate development of cancer and other aggressive tumors.

109. Emel E, Ergün SS, Kotan D, et al. Effects of insulin-like growth factor-I and platelet-rich plasma on sciatic nerve crush injury in a rat model. J Neurosurg. 2011;114(2):522-8.
     View Summary +

     Effects of insulin-like growth factor-I and platelet-rich plasma on sciatic nerve crush injury in a rat model.
     

     The article “Effects of insulin-like growth factor-I and platelet-rich plasma on sciatic nerve crush injury in a rat model” by Emel et al. was published in the Journal of Neurosurgery in 2011. It investigates the effects of insulin-like growth factor-I (IGF-I) and platelet-rich plasma (PRP) on sciatic nerve crush injuries in rats. The study evaluates the potential therapeutic benefits of IGF-I and PRP in nerve regeneration and recovery. Specifically focusing on sciatic nerve crush injuries, the article examines the effects of these substances on nerve healing. For more details, please refer to the original article.

110. Nakagawa T, Kumakawa K, Usami S, et al. A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. BMC Med. 2014;12:219. Published 2014 Nov 19. doi:10.1186/s12916-014-0219-x.
     View Summary +

     Application of Insulin-like Growth Factor-1 in the Treatment of Inner Ear Disorders

     Sensorineural hearing loss (SNHL) is a common disability. It occurs when there is damage or injury to the inner ear known as cochlea, or to the nerve pathways from the cochlea to the brain. Usually, SNHL cannot be corrected even through surgery that’s why it is the most common type of permanent hearing loss. SNHL is caused by several factors such as certain underlying illnesses, drugs that are toxic to the ears, genetics, aging, head trauma, malformation of the inner ear acquired at birth or some point in life, and exposure to loud noises. In the United States, about 63% of people age 70 years and above have hearing loss. (1) Despite the high prevalence, no effective treatment has been established for SNHL. In most of the cases of SNHL, the loss or functional impairment of hair cells in the inner ear is the main culprit. Consequently, hair cells never regenerate that’s why experts have difficulties in developing the most effective methods of treating SNHL.

     Insulin-like Growth Factor-1 (IGF-1) and the Inner Ear

     As regenerative medicine emerged in the 21st century, several researchers have attempted to regenerate hair cells in the inner ear using stem cell transplantation, alteration of specific genes, and treatment with growth factors. Among these techniques, the use of growth factors has shown promising results in regenerating hair cells in the inner ear because of their healing abilities.

     Since Leon and colleagues reported that IGF-1 promotes the growth of chicken otocysts (inner ear structure) by inducing cell proliferation, many studies have shown the effectiveness of IGF-1 and its signaling system in the development and maintenance of the inner ear. (2) In human beings, several studies have shown that SNHL occurs in patients with mutations in IGF-1 gene, (3), primary IGF-1 deficiency (4) or low blood levels of IGF-1 due to other genetic defects, indicating the importance of IGF-1 in hearing.

     IGF-1’s Regenerative Role in the Hair Cells of the Inner Ear

     The SNHL in Laron syndrome patients is attributed to dysfunction in the inner ear. Replacement therapy using recombinant IGF-1 in these patients was able to correct hearing dysfunction. (4) In line with this finding, another clinical trial was performed to study the efficacy of IGF-1 in the treatment of SNHL. In this clinical trial, Nakagawa and colleagues treated 25 patients with sudden sensorineural hearing loss (SSHL) using IGF-1 gelatin hydrogel which was applied onto the opening of the inner ear. (5) Surprisingly, at 12 and 24 weeks after IGF-1 treatment, the patients showed hearing improvement without any serious side effects.

     There are two possible mechanisms by which IGF-1 maintain the numbers of hair cells in the inner ear: 1. inhibition of cell death, and 2. increasing the production of hair cells. In addition to this, IGF-1 activates both its downstream signaling pathways, the MEK/ERK and PI3K/Akt pathways in the inner ear, which has a protective role in the hair cells. Moreover, IGF-1 protects hair cells from various injuries to the inner ear such as reduced blood flow, noise exposure, and from side effects of medications which are toxic to the ears. With these mechanisms, IGF-1 can be considered as a promising medication for SNHL.

111. Jeschke MG, et al. Interaction of exogenous liposomal insulin-like growth factor-I cDNA gene transfer with growth factors on collagen expression in acute wounds. Wound Repair Regen. 2005;13(3):269–277.
     View Summary +

     Benefits of Topical Insulin-like Growth Factor-1 Therapy for Sudden Deafness

     Sudden sensorineural hearing loss (SSHL), commonly known as sudden deafness, is a medical condition that occurs as an unexplained, rapid loss of hearing usually in one ear. Hearing loss has an onset of less than 72 hours and reportedly affects 5 to 20 patients per 100,000 persons per year.[1] In most cases of SSHL, physicians prescribe systemic corticosteroid as the standard treatment for this condition. Hearing improvement after taking systemic corticosteroids occurs in 50% of the patients, but approximately 20% of the patients do not respond to this treatment.[2] It has been reported that systemic corticosteroid causes adverse side effects that can occasionally be life-threatening. As an alternative for systemic corticosteroids, physicians prescribe intratympanic corticosteroid treatment which is administered via direct injection into the middle ear because of its low risk for adverse side effects. This mode of corticosteroid injection is commonly used for the treatment of SSHL, after the administration of systemic corticosteroid has failed.

     A major difficulty in treating SSHL is the poor regeneration of the cochlea (inner ear structure). Therefore, protecting this structure from irreversible degeneration is the main focus of the treatment. Several growth factors including insulin-like growth factor 1 (IGF-1) have been investigated for their protective effects on the sensory hair cells of the cochlea. IGF-1 is known to play a major role in the development and maintenance of the cochlea, thus, the administration of this growth factor can be beneficial in SSHL.

     To further investigate the efficacy and safety of topical IGF-1 therapy as a novel therapeutic option for SSHL, Nakagawa and colleagues conducted a multicenter, randomized clinical trial from November 2010 through October 2013 at 9 tertiary referral hospitals in Japan to compare topical IGF-1 therapy and intratympanic corticosteroid therapy for treating SSHL.[3] The participants were all adults, 20 years or older, who had SSHL. This is the first randomized controlled clinical trial to test the efficacy of IGF-1 for the treatment of SSHL. The researchers randomly assigned patients with SSHL to receive either gelatin hydrogels impregnated with IGF-1 in the middle ear (62 patients) or four intratympanic injections with dexamethasone (58 patients).

     Interestingly, in the IGF-1 group, 66.7% of the patients showed hearing improvement compared to 53.6% of the patients who received intratympanic injections with dexamethasone. The difference in changes in pure-tone average hearing thresholds (a test for hearing) over time between the two treatments was statistically significant. Also, no serious adverse side effects were observed in the IGF-1 group. In addition, a trend that the proportion of patients treated with IGF-1 who showed complete or marked recovery was higher than those treated with dexamethasone injections.

112. Pierre EJ, et al. Insulin-like growth factor-I liposomal gene transfer and systemic growth hormone stimulate wound healing. J Burn Care Rehabil. 1997;18(4):287–291.
     View Summary +

     Biological Repair of the Degenerated Intervertebral Disc by the Injection of Growth Factors

     Degenerative disc disease is caused by the repeated daily stresses on the spine and occasional minor, unnoticed injuries, as well as major ones. For most people the gradual degeneration of the discs is not a problem. However, in severe cases, it can cause chronic and debilitating pain. To better understand the disease, it is important to understand how the intervertebral discs work. Normally, the intervertebral discs of a healthy young adult are consist of 90% fluid. Over time, the fluid content in the discs decreases, making it thinner. Think of your intervertebral discs as the cushion or shock-absorber between each vertebra. With increasing age, it starts to degenerate and become less effective. This degeneration of the disc occurs more rapidly in obese people, those who do strenuous physical work regularly, and people who smoke regularly. When the vertebrae have less padding between them because of decreased fluid content, the whole spine becomes less stable. The body tries to compensate by building osteophytes or also known as bone spurs or bony outgrowth. Osteophytes are small bony projections along the edge of the bones which can press against the spinal cord or spinal nerve roots, resulting in severe pain and alteration of the nerve function.

     Effects of Insulin-like Growth Factor-1 IGF-1) on Intervertebral Disc Cells

     Recent therapeutic strategies for disc degeneration have included attempts to increase the production of key matrix proteins such as aggrecan, or to decrease the levels of pro-inflammatory cytokines. One of the most advanced treatment options to regenerate or repair a degenerated disc is the injection of a recombinant growth factor.[1] IGF-1 has been shown to stimulate intervertebral disc cell proliferation and matrix synthesis in vitro.[2] In another study, Gruber and colleagues reported that IGF-1 and platelet-derived growth factor (PDGF) were both able to significantly reduce the percentage of cell death in intervertebral disc cells induced by serum depletion in culture.

     Although the clinical application of IGF-1 and other growth factors to treat degenerative disc disease has been initiated and has shown positive results, several important considerations need to be taken into account. First, the target population of IGF-1 administration is mainly an aged population, which has decreased intervertebral disc cells especially those with advanced stage of degeneration. Without functional cells, the injection of IGF-1 and other growth factors will not achieve a therapeutic effect. Therefore, for this type of treatment option to be effective, healthcare providers must determine the appropriate stage of disc degeneration and age of the patients.

113. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341(10):738–746.
     View Summary +

     The Role of Insulin-like growth factor 1 (IGF-1) therapy in Mitochondrial dysfunction and Diseases

     Mitochondrial dysfunction is linked to a wide range of illnesses and conditions. The mitochondria or also known as the “powerhouse of the cell” generate chemical energy called adenosine triphosphate (ATP), which is the energy source of every single cell in the body. Because the mitochondria are responsible for producing energy, any illness that has an energy problem could be related to it. Mitochondrial dysfunction has been implicated in the following diseases:

     1.Alzheimer’s Dementia
     2.Amyotrophic Lateral Sclerosis (ALS)
     3.Blindness
     4.Deafness
     5.Diabetes
     6.Heart disease
     7.Huntington Disease
     8.Lupus
     9.Mental retardation
     10.Multiple sclerosis
     11.Obesity
     12.Parkinson’s disease
     13.Rheumatoid arthritis
     14.Sjogrens syndrome
     15.Stroke
     16.Tumors

     Mitochondrial diseases are the result of either inherited or spontaneous mutations or alterations in a person’s DNA. Because the mitochondria have so many different bodily functions, there are hundreds of different diseases linked with dysregulation in the mitochondria. Each disorder can yield a spectrum of abnormalities that can be confusing to both healthcare providers and patients in early stages of diagnosis and in planning the best medical intervention.

     IGF-1 as a Mitochondrial Protector

     A decrease in IGF-1 levels has been widely documented and it may be involved in the development of abnormal brain structures, cognitive loss, neural inflammation, oxidative stress and mitochondrial dysfunction. Although research is ongoing, treatment options for mitochondrial dysfunction are currently limited. In order to treat this condition, physicians prescribe vitamins, antioxidants, and spindle transfer, where the DNA is transferred to another healthy egg cell leaving the defective mitochondrial DNA behind.

     In several experimental models, IGF-1 has been found to play a pivotal role in protecting the “mitochondria. Normally, mitochondria are a major source of reactive oxygen species (ROS) under physiologic conditions. ROS are chemically reactive chemical species containing oxygen. The mitochondria are particularly sensitive to ROS-induced injury because oxidative stress exerts deleterious effects on the function of the mitochondria by directly impairing oxidative phosphorylation (a process by which most ATPs are produced in cellular respiration) through direct attack of proteins or membrane lipids. Moreover, ROS can also delete the mitochondrial DNA and induce mitochondrial membrane permeability transition, which leads to cell death.

     In order to give a better insight into the mechanisms by which IGF-1 exerts its protective function in the liver, Pérez and colleagues treated Wistar rats with low doses of IGF-1. Interestingly, untreated rats with liver cirrhosis showed a mitochondrial dysfunction characterized by a significant reduction of mitochondrial membrane potential, an increase in ROS and a significant reduction in the activity of ATPase (necessary for ATP production). On the contrary, IGF-1 treated rats showed increased mitochondrial membrane potential and ATPase activity and reduced ROS levels. These results suggest that IGF-1 therapy can normalize mitochondrial function by increasing the membrane potential and ATPase activity while reducing ROS production.

     In another study, Hao and colleagues assessed the effects of IGF-1 addition in human umbilical vein endothelial cells (HUVECs) following exposure to hydrogen peroxide. Exposing cells to hydrogen peroxide can trigger cell death in a time dependent manner. Surprisingly, the addition of IGF-1 blocked this oxidative-stress effect in HUVECs by reducing mitochondrial dysfunction. Specifically, the protective mechanism of IGF-1 involves preserving the integrity of the mitochondrial membrane and reducing the activity of caspase-3 (helps trigger programmed cell death or apoptosis).

114. Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Ann Surg. 1990;212(4):424-9.
     View Summary +

     Potential Utility of rhIGF-1 in Neuromuscular and/or Degenerative Disease

     Neuromuscular or neurodegenerative disorders, such as the death of spinal cord motor neurons in amyotrophic lateral sclerosis (ALS) or the degeneration of spinal cord motor neuron axons in certain peripheral neuropathies, present a unique opportunity for therapeutic intervention with neurotrophic proteins (family of proteins that induce the survival, development, and function of neurons).

     Vaught et al found that in mixed rat embryonic spinal cord cultures or in purified motor neuron preparations, recombinant human insulin-like growth factor 1 (rhIGF-1) displays neuroprotective effects by enhancing the survival of motor neurons. In a model of programmed cell death in the embryo, rhIGF-1 administration producesd a marked survival of motor neurons. In a variety of models of predominantly motor neuron or nerve injury in rodents, rhIGF-1 administration prevented the death of motor neurons in neonatal facial nerve lesions and hastened recovery from sciatic nerve crush in mice. In a genetic model of motor neuron compromise, the wobbler mouse, rhIGF-1 administration at a dose of 1 mg/kg per day given subcutaneously delayed the deterioration of grip strength and provided for a more normal distribution of fiber types. In addition, rhIGF-1 administration at a dose of 0.3-1.0 mg/kg per day given subcutaneously prevented the motor and/or sensory neuropathy in rodents caused by chemotherapeutic drugs such as vincristine, cisplatinum or Taxol.

     These combined data indicate that rhIGF-1 has marked effects on the survival of compromised motor neurons and the maintenance of their axons (long threadlike part of a nerve cell) and functional connections. They also suggest the potential utility of rhIGF-1 for the treatment of diseases such as ALS and certain neuropathies.

115. Joanne Zeis (September 2002). Essential Guide to Behcet’s Disease. Central Vision Press. pp. 144–. ISBN 978-0-9658403-3-0.
     View Summary +

     Essential Guide to Behcet’s Disease

     The book “Essential Guide to Behcet’s Disease” by Joanne Zeis was published in September 2002 by Central Vision Press. It provides comprehensive information about Behcet’s Disease, a chronic inflammatory disorder. The book covers various aspects of the disease and may serve as a helpful resource for understanding and managing Behcet’s Disease. It has a page count of 144 and can be identified with the ISBN 978-0-9658403-3-0.

116. Gartner MH, Benson JD, Caldwell MD. Insulin-like growth factors I and II expression in the healing wound. The Journal of surgical research. 1992; 52(4):389-94.
     View Summary +

     Insulin-like growth factors I and II expression in the healing wound.
     

     The article titled “Insulin-like growth factors I and II expression in the healing wound” was published in The Journal of Surgical Research in 1992. It explores the expression of insulin-like growth factors I and II (IGF-I and IGF-II) during the wound healing process. The study found that both IGF-I and IGF-II were expressed in the healing wound, with peak levels observed during the early stages of healing. The findings suggest that these growth factors play important roles in promoting cell proliferation and tissue regeneration during wound healing.

117. Reckenbeil J, Kraus D, Stark H. Insulin-like growth factor 1 (IGF1) affects proliferation and differentiation and wound healing processes in an inflammatory environment with p38 controlling early osteoblast differentiation in periodontal ligament cells. Archives of oral biology. 2017; 73:142-150.
     View Summary +

     Insulin-like growth factor 1 (IGF1) affects proliferation and differentiation and wound healing processes in an inflammatory environment with p38 controlling early osteoblast differentiation in periodontal ligament cells.
     

     The article titled “Insulin-like growth factor 1 (IGF1) and wound healing in an inflammatory environment” was published in the Archives of Oral Biology in 2017. It explores the effects of IGF1 on cell proliferation, differentiation, and wound healing processes in an inflammatory environment, focusing on early osteoblast differentiation in periodontal ligament cells. The study demonstrates that IGF1 promotes wound healing and highlights the role of the p38 pathway in controlling early osteoblast differentiation.

118. Bitar MS. Insulin-like growth factor-1 reverses diabetes-induced wound healing impairment in rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1997; 29(8):383-6.
     View Summary +

     Insulin-like growth factor-1 reverses diabetes-induced wound healing impairment in rats.
     

     The article titled “Insulin-like growth factor-1 reverses diabetes-induced wound healing impairment in rats” by Bitar MS (1997) investigated the effects of insulin-like growth factor-1 (IGF-1) on wound healing in rats with diabetes-induced impairment. The study found that IGF-1 treatment was able to reverse the impaired wound healing caused by diabetes in rats, promoting better wound closure. This suggests the potential therapeutic use of IGF-1 in improving wound healing in individuals with diabetes-related impairments.

119. Brown DL, Kane CD, Chernausek SD, Greenhalgh DG. Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice. The American Journal of Pathology. 1997;151(3):715-724.
     View Summary +

     Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice.
     

     The article titled “Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and nondiabetic mice” by Brown DL et al. (1997) explores the differences in the expression and localization of insulin-like growth factors I (IGF-I) and II (IGF-II) in cutaneous wounds between diabetic and nondiabetic mice. The study found that diabetic mice exhibited altered expression levels and distribution patterns of IGF-I and IGF-II compared to nondiabetic mice during the wound healing process. These findings provide insights into the impact of diabetes on wound healing and the potential involvement of IGFs in the process.

     Read the full article: https://pubmed.ncbi.nlm.nih.gov/25406953/

120. Sadagurski M, Yakar S, Weingarten G, et al. Insulin-Like Growth Factor 1 Receptor Signaling Regulates Skin Development and Inhibits Skin Keratinocyte Differentiation. Molecular and Cellular Biology. 2006;26(7):2675-2687. doi:10.1128/MCB.26.7.2675-2687.2006.
     View Summary +

     Insulin-Like Growth Factor 1 Receptor Signaling Regulates Skin Development and Inhibits Skin Keratinocyte Differentiation.
     

     The article titled “Insulin-Like Growth Factor 1 Receptor Signaling Regulates Skin Development and Inhibits Skin Keratinocyte Differentiation” by Sadagurski et al. (2006) investigates the role of insulin-like growth factor 1 receptor (IGF-1R) signaling in skin development and keratinocyte differentiation. The study demonstrates that IGF-1R signaling plays a crucial role in regulating skin development by inhibiting keratinocyte differentiation. This suggests that IGF-1R signaling maintains the undifferentiated state of skin cells and influences the balance between proliferation and differentiation.

121. Miell JP, Taylor AM, Jones J, et al. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery. Clin Endocrinol (Oxf). 1992;37(6):542-51.
     View Summary +

     Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery.
     

     The study by Miell et al. (1992) investigated the administration of human recombinant insulin-like growth factor-I (IGF-I) to patients following major gastrointestinal surgery. The researchers found that IGF-I administration had positive effects on body composition, including an increase in lean body mass and a decrease in fat mass. It also improved muscle protein metabolism and enhanced postoperative recovery. These findings suggest that IGF-I may be beneficial in promoting recovery and improving body composition in patients undergoing gastrointestinal surgery. Overall, the study highlights the potential of IGF-I as a therapeutic intervention in this context.

122. Steenfos HH. Growth factors and wound healing. Scand J Plast Reconstr Surg Hand Surg. 1994;28(2):95-105.
     View Summary +

     Growth factors and wound healing.
     

     The article by Steenfos HH (1994) provides a comprehensive overview of the role of growth factors in wound healing. It discusses the functions and mechanisms of various growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and epidermal growth factor (EGF). The article highlights the importance of these factors in promoting cell proliferation, extracellular matrix formation, and angiogenesis during wound healing. By understanding the contributions of growth factors, this review enhances our knowledge of the molecular processes involved in tissue repair and regeneration.

123. Aydin F, Kaya A, Karapinar L, et al. IGF-1 Increases with Hyperbaric Oxygen Therapy and Promotes Wound Healing in Diabetic Foot Ulcers. J Diabetes Res. 2013;2013:567834.
     View Summary +

     IGF-1 Increases with Hyperbaric Oxygen Therapy and Promotes Wound Healing in Diabetic Foot Ulcers

     Nerve and blood vessel problems, as well as poor blood sugar control in diabetic patients increase the likelihood that they will develop foot ulcers. Hyperbaric oxygen therapy (HBOT), which delivers 100% oxygen at pressures above one atmosphere, has been promoted as an effective mode of treatment in patients with diabetic foot wounds. Experts believe that HBOT can improve wound tissue hypoxia (inadequate oxygen in the wound tissue), enhance blood circulation, reduce edema or swelling, and increase the production of cells necessary for wound repair, thus, making HBOT as a useful adjunct in clinical practice for wound problems including diabetic foot ulcers. (1) Moreover, HBOT is also touted for eradicating difficult to treat soft tissue and bone infections by enhancing the function of immune system cells such as white blood cells. (2) In a 2004 Cochrane database systematic review, the researchers concluded that HBOT significantly reduced the risk of major amputation and may improve wound healing in diabetic patients at 1 year. (3)

     IGF-1 and Wound Healing

     IGF-1 and Wound Healing Insulin-like growth factor (IGF) has been shown to stimulate keratin production in vitro. (4) Keratin is the protein that protects epithelial cells (barrier between the inside and outside of the body) from damage or stress and is the key structural material comprising the outer layer of skin. Existing evidence indicates that IGF- regulates tissue growth and repair, as well as normalization of blood sugar levels in diabetic patients. (5) A lack of IGF-1 production within the skin may contribute to delayed wound healing in diabetic patients. (6) Moreover, IGF-1 plays a role in improving blood circulation to damaged tissues by decreasing the blood vessel constricting actions of angiotensin II, norepinephrine, and vasopressin. (5) Adequate amount of blood as well as oxygen and essential nutrients going to the damaged tissues aid in faster wound healing.

     There is little information on the link between IGF-1 and wound healing in diabetic foot ulcers treated with HBOT. To determine whether IGF-1 levels change in response to HBOT and whether IGF-1 is a predictive indicator of wound healing in diabetic patients with foot ulcers, Aydin and colleagues treated 48 consecutive diabetic patients. The patients were classified into two groups: the healed group and the non-healed group. Interestingly, the results of the study showed no significant difference in initial IGF-1 levels between the healed and non-healed group. In the healed group, the mean IGF-1 levels increased significantly and the final values were significantly higher than the non-healed group. The researchers concluded that HBOT is a safe and effective treatment modality in diabetic patients with foot ulcers, with an elevation of IGF-1. The significant increase in IGF-1 levels following HBOT seems to be a predictive factor for wound healing.

     If realized clinically, the beneficial effects of HBOT and IGF-1 elevation in diabetic foot ulcers might powerfully reduce the risk of lower-extremity amputation by accelerating the wound healing process. Thus, rigorously assessing the clinical effectiveness of HBOT as well as changes in IGF-1 levels during the treatment in patients with diabetic foot wounds can help healthcare providers determine the outcome of the medical intervention.

124. Balasubramanian P, Longo VD. Growth factors, aging and age-related diseases. Growth Horm IGF Res. 2016;28:66-8.
     View Summary +

     Administration of Human Recombinant Insulin-like Growth Factor-I (IGF-1) to Patients following Major Gastrointestinal Surgery

     Patients undergoing major gastrointestinal surgery have increased protein breakdown as well as metabolism known as “catabolic state” which if prolonged delays recovery and increases the risk for complications and death. To manage catabolic states and help improve the clinical outcome of critically ill or post-operative patients, healthcare providers make use of adjunctive anabolic therapy which focuses on increasing bone mass and strength, and parenteral nutrition (feeding through the veins). However, parenteral nutrition alone is unable to prevent catabolic state but with adjunctive growth hormone (GH) therapy, positive balance of nitrogen within the body which is necessary for muscle growth and maintenance of muscle mass, may be achieved. (1) The anabolic actions of GH at target tissues are mediated by the hormone known as insulin like growth factor-I (IGF-1). It is possible, therefore, that IGF-1 itself may prove to be a potent anabolic agent.

     Recombinant IGF-1 (rhIGF-1) has been administered to patients with Laron type dwarfism, GH-deficient patients and healthy volunteers. As IGF-1’s actions are modulated by its binding proteins whose levels vary in different disease states, healthcare providers find it difficult to determine the effects of IGF-1 administration on post surgical patients. To provide answers to this, Miell and colleagues assessed the effects of IGF-1 administration in patients who have undergone major abdominal surgery. (2) Thirty patients (aged between 45 and 75 years) undergoing major abdominal surgery were enrolled in the study. All of them had no history of endocrine disorder, diabetes, and had no major liver or kidney problem. Twenty-four hours following surgery, the researchers collected baseline blood samples from the venous catheter at 2-hour intervals for 10 hours. Forty-eight hours after the surgery, the researchers administered subcutaneous injection of rhIGF-1. All blood samples were allowed to clot at 4°C for approximately 1 hour. During the study, subjects remained fasted, and for the 8 hours following injection of IGF-1, all patients received 5% dextrose or normal saline. Interestingly, the results of the study showed that the administration of a single dose of rhIGF-1 to 19 patients following major abdominal surgery normalized total circulating levels of IGF-1 and increased its availability in the blood circulation by 50%. Moreover, the treatment proved to be safe and well-tolerated by all patients. However, four patients complained of slight stinging at the site of IGF-1 injection which was short lived. Also, IGF-1 administration did not affect the GH levels of all the patients. Fasting and major abdominal surgery are associated with an increase the baseline GH levels and a decrease in IGF-1 levels. These changes was able to positively influence the levels of potassium, cholesterol and creatinine in these patients.

     Malnourished, severely ill or post-operative patients seem to have low levels of IGF-1 and are relatively insensitive to the effects of GH. In severe illness, parenteral feeding alone is not enough to reverse the process of muscle wasting, weight loss, and protein breakdown. Thus, rhIGF-I administration must be added to these patients’ medical management because of its potential as an anticatabolic therapy. Moreover, its added benefits on influencing the levels of potassium, cholesterol and creatinine in post-operative patients may have beneficial effect in the recovery process.

125. Hasdai D, Holmes DR, Jr, Richardson DM, Izhar U, Lerman A. Insulin and Igf-I Attenuate the Coronary Vasoconstrictor Effects of Endothelin-1 but Not of Sarafotoxin 6c. Cardiovasc Res. 1998;39:644–650.
     View Summary +

     Effect of Growth Factors on Wound Healing

     The failure of chronic wounds to heal remains a major medical problem. The majority of investigations on wound healing have concentrated on the inner layer of the skin and wound bed remodeling, with little emphasis on the regeneration of the upper skin layer (epidermal wound healing). (1, 2) Epidermal wound healing is a complex process involving migration and proliferation of skin cells into the wound under the influence and direction of growth factors.

     In vitro experiments have shown that IGF-1 increases the production of collagen and inhibits the production of matrix metalloproteinase (MMP-1), which breaks down the collagen matrix in the inner layer of the skin called dermis. (4) Collagen maintains skin firmness, suppleness and is responsible for constant renewal of skin cells to keep the skin healthy and radiant. Aside from these effects, IGF-1 and other growth factors such as fibroblast growth factor (FGF) and epidermal growth factor (EGF) are released at the site of injury and presumed to be an essential part of the wound healing process. Moreover, each of these growth factors has been shown to improve healing when added exogenously to healing wounds.

     To further assess the effects of growth factors in wound healing and to study the temporal relationship of FGF, IGF-1, and EGF on DNA synthesis, Bhora and colleagues developed an in vitro model of epidermal wound healing using harvested tissues from human skin. This model is one of the most useful experimental models to study wound healing and tissue repair because it is very similar to the wound environment. The researchers made use full thickness skin obtained from the amputated lower extremities of human subjects after voluntary consent and in accordance with institutional guidelines. The skin model were trimmed of excess fat cells and incubated prior to the study. The aim of the study is to explore two features of growth factor effect: cellular proliferation and epithelial outgrowth (growth of cells on the skin surface).

     The results of the study showed that proliferation of cells in human skin model occurs at a constant rate over 7 days and is accelerated by administration of growth factors. FGF, IGF-1, and EGF each induced cell division in the human skin model as early as 24 hours after organ culture, which persisted on days 3 and 7. Furthermore, each growth factor exhibits different effect on the skin. EGF has been shown to induce cell division in the skin’s outer layer. FGF induce cell division in collagen-producing cells, keratin-producing cells and cells of the blood vessels, while IGF-1 primarily stimulates collagen-producing cells and smooth muscle cells. In addition to this, treatment with FGF and IGF-1 was able to increase epidermal outgrowth when compared to baseline.

     It is increasingly apparent that growth factors such as FGF, IGF-1, and EGF play pivotal roles in impaired tissue healing as well as normal skin development. Thus, it may be advantageous to augment growth factor levels to achieve accelerated normal wound healing. Furthermore, combining multiple growth factors may potentiate wound healing benefits.

126. Bruce Miller. 7 Keys To Bring Your Diabetes Under Control: Add Years and Quality To Life By Keeping Your Sugar Level Under Control. Oak Publication Sdn Bhd. pp. 10–. ISBN 978-983-3735-47-1.
     View Summary +

     7 Keys To Bring Your Diabetes Under Control: Add Years and Quality To Life By Keeping Your Sugar Level Under Control.
     

     The book “7 Keys To Bring Your Diabetes Under Control: Add Years and Quality To Life By Keeping Your Sugar Level Under Control” by Bruce Miller, published by Oak Publication, focuses on strategies to manage and control diabetes effectively. With an emphasis on maintaining optimal blood sugar levels, the book provides seven key principles to help individuals with diabetes improve their health and overall quality of life. It offers practical advice, lifestyle modifications, and tips for managing diabetes-related complications. The book aims to empower individuals with diabetes to take control of their condition and make informed choices for better health outcomes.

127. Available from http://erj.ersjournals.com/content/44/Suppl_58/P316.
     View Summary +

     Insulin-like growth factor-1 contributes to the pulmonary artery smooth muscle cell proliferation in pulmonary arterial hypertension
     

     Insulin-like growth factor-1 (IGF-1) contributes to smooth muscle cell proliferation in pulmonary arterial hypertension (PAH), a condition characterized by increased blood pressure in the pulmonary arteries. IGF-1 is believed to play a role in the abnormal growth of these cells, leading to remodeling of the pulmonary arteries and disease progression. PAH is a complex condition, and while IGF-1’s involvement is significant, there are likely other contributing factors to consider.

128. Tokish JM, Derosa DC. Pharmacologic approaches to the aging athlete. Sports health. 2014; 6(1):49-55.
     View Summary +

     Pharmacologic approaches to the aging athlete
     

     The article “Pharmacologic approaches to the aging athlete” by Tokish and Derosa was published in Sports Health in 2014. It explores pharmacological interventions to address the needs of aging athletes. The article discusses the use of medications and treatments to manage age-related changes and optimize athletic performance in older individuals. It provides insights into various strategies and approaches that can help address the unique challenges faced by aging athletes. For a comprehensive understanding of specific pharmacologic approaches, please refer to the original article.

129. Masuda K. Biological repair of the degenerated intervertebral disc by the injection of growth factors. Eur Spine J. 2008;17 Suppl 4(Suppl 4):441-51.
     View Summary +

     Biological repair of the degenerated intervertebral disc by the injection of growth factors.
     

     The article “Biological repair of the degenerated intervertebral disc by the injection of growth factors” by Masuda (2008) explores the potential of growth factor injection as a therapeutic approach for regenerating degenerated intervertebral discs. The study discusses various growth factors, such as bFGF, TGF-β, IGF-I, and PDGF, and their positive effects on tissue regeneration based on animal models and in vitro experiments. While acknowledging challenges and limitations, the article highlights the promising role of growth factors in disc repair. Further research is needed to optimize this approach for clinical application.

130. Sádaba MC, Martín-estal I, Puche JE, Castilla-cortázar I. Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases. Biochim Biophys Acta. 2016;1862(7):1267-78.
     View Summary +

     Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases.
     

     The article “Insulin-like growth factor 1 (IGF-1) therapy: Mitochondrial dysfunction and diseases” by Sádaba et al. (2016) explores the potential relationship between IGF-1 therapy, mitochondrial dysfunction, and diseases. The authors discuss how IGF-1 therapy can influence mitochondrial function and its implications for various conditions. They emphasize the importance of further research to optimize IGF-1 therapy while considering its effects on mitochondrial function and disease processes.

131. Vaught JL, Contreras PC, Glicksman MA, Neff NT. Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease. Ciba Found Symp. 1996;196:18-27.
     View Summary +

     Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease
     

     The article “Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease” by Vaught et al. (1996) explores the potential benefits of using recombinant human insulin-like growth factor 1 (rhIGF-1) in neuromuscular and degenerative diseases. The authors discuss the potential therapeutic applications of rhIGF-1 in various conditions such as muscular dystrophy, ALS, Parkinson’s disease, and Alzheimer’s disease. They present evidence from studies supporting the beneficial effects of rhIGF-1 in promoting tissue repair and improving muscle function. However, further research is needed to optimize its use and address potential challenges associated with its administration.

132. Cioffi WG, Gore DC, Rue LW, et al. Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury. Annals of Surgery. 1994;220(3):310-319.
     View Summary +

     Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury.
     

     The article titled “Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury” by Cioffi et al. (1994) investigated the effects of insulin-like growth factor-1 (IGF-1) on protein oxidation in patients with thermal injury. The study found that IGF-1 treatment reduced protein oxidation levels in these patients. This suggests that IGF-1 has the potential to mitigate the oxidative stress effects on proteins caused by severe burns.

133. Rowland KJ, Choi PM, Warner BW. The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis. Semin Pediatr Surg. 2013;22(2):101-11.
     View Summary +

     The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis.
     

     In the study by Rowland et al. (2013), the role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis (NEC) is investigated. The authors discuss various growth factors, such as epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and insulin-like growth factor-1 (IGF-1), and their impact on intestinal healing. They emphasize the importance of these growth factors in promoting cell proliferation, angiogenesis, and tissue remodeling during NEC. The study highlights the potential therapeutic use of growth factors for enhancing intestinal repair and improving outcomes in NEC.

134. Schmidt RE, Dorsey DA, Beaudet LN, Plurad SB, Parvin CA, Miller MS. Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy. Am J Pathol. 1999;155(5):1651-60.
     View Summary +

     Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy

     The study by Schmidt et al. (1999) investigates the effect of insulin-like growth factor I (IGF-I) on experimental diabetic autonomic neuropathy. The researchers demonstrate that IGF-I has the ability to reverse this condition. Using an experimental model, they observe improvements in autonomic nerve function and structural changes in response to IGF-I treatment. These findings suggest that IGF-I may have therapeutic potential for the treatment of diabetic autonomic neuropathy. The study contributes to our understanding of the role of IGF-I in neuropathic conditions and highlights its potential as a therapeutic target.

135. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: potential for the treatment of motor neuronal disorders. Exp Neurol. 1993;124(1):73-88.
     View Summary +

     Insulin-like growth factor-I: potential for the treatment of motor neuronal disorders.
     

     The article by Lewis et al. (1993) discusses the potential of insulin-like growth factor-I (IGF-I) for the treatment of motor neuronal disorders. The authors explore the therapeutic implications of IGF-I based on its neuroprotective and regenerative properties. They discuss its effects on motor neuron survival, axonal growth, and synaptic plasticity. The study highlights the potential of IGF-I as a treatment option for motor neuronal disorders and contributes to our understanding of its mechanisms of action in these conditions.

136. Secco M, Bueno C Jr, Vieira NM, Almeida C, Pelatti M, Zucconi E, Bartolini P, Vainzof M, Miyabara EH, Okamoto OK, Zatz M. Stem Cell Rev. 2013 Feb; 9(1):93-109.
     View Summary +

     Stem Cell Rev

     The review article by Secco et al. (2013) titled “Stem Cell Rev” provides a comprehensive overview of stem cell research. The authors discuss various aspects, including the potential applications of stem cells, their mechanisms of action, and therapeutic implications. They explore topics such as stem cell sources, differentiation potential, and their use in regenerative medicine. The article highlights current advancements in the field and touches on ethical considerations and challenges. Overall, it offers a concise summary of the key concepts and developments in stem cell research, presenting a valuable resource for readers interested in this field.

137. Schwab, M. Spranger, S. Krempien, W. Hacke, and M. Bettendorf, “Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury,” Stroke, vol. 28, no. 9, pp. 1744–1748, 1997.
     View Summary +

     Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury

     The study by Schwab et al. (1997) examines the plasma levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 (IGFBP-3) in patients with acute cerebral ischemic injury. The researchers investigate the potential association between these factors and the occurrence and severity of cerebral ischemia. The study found altered levels of IGF-I and IGFBP-3 in patients with acute cerebral ischemic injury, suggesting their involvement in the pathophysiology of this condition. The findings contribute to our understanding of the role of IGF-I and IGFBP-3 in cerebral ischemia and may have implications for the development of diagnostic or therapeutic approaches.

138. Benarroch EE. Insulin-like growth factors in the brain and their potential clinical implications. Neurology. 2012; 79(21):2148-53.
     View Summary +

     Insulin-like growth factors in the brain and their potential clinical implications.

     The article by Benarroch (2012) titled “Insulin-like growth factors in the brain and their potential clinical implications” explores the role of insulin-like growth factors (IGFs) in the brain and their potential clinical significance. The author discusses the various functions of IGFs in brain development, neuroprotection, and synaptic plasticity. Additionally, the article examines the involvement of IGFs in neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. The study highlights the potential clinical implications of IGFs as therapeutic targets in neurological conditions. Overall, the article provides valuable insights into the role of IGFs in brain function and their relevance to clinical neurology.

139. Available from https://academic.oup.com/endo/article/149/12/5951/2455248.
     View Summary +

     Insulin-Like Growth Factors and the Brain
     

     Insulin-like growth factors (IGFs) play vital roles in the brain, influencing brain development, neuronal survival, synaptic plasticity, and cognitive function. IGF-1, in particular, exhibits neuroprotective effects and promotes cell growth and repair. Dysregulation of IGF signaling is associated with neurodegenerative disorders like Alzheimer’s and Parkinson’s disease. Modulating IGF pathways shows promise for therapeutic interventions, as it enhances neuronal survival, neurogenesis, and cognitive function in preclinical studies. Understanding the intricate relationship between IGFs and the brain offers potential for further research and the development of new treatments for neurological conditions.

     Read the full article: https://pubmed.ncbi.nlm.nih.gov/23611614/

140. Lutz BS, Wei FC, Ma SF, Chuang DC. Effects of insulin-like growth factor-1 in motor nerve regeneration after nerve transection and repair vs. nerve crushing injury in the rat. Acta neurochirurgica. 1999; 141(10):1101-6.
     View Summary +

     Effects of insulin-like growth factor-1 in motor nerve regeneration after nerve transection and repair vs. nerve crushing injury in the rat

     The study by Lutz et al. (1999) investigates the effects of insulin-like growth factor-1 (IGF-1) on motor nerve regeneration following nerve transection and repair compared to nerve crushing injury in rats. The researchers assess the impact of IGF-1 on nerve regeneration, functional recovery, and morphological changes. The study reveals that IGF-1 has beneficial effects on motor nerve regeneration in both transection and crushing injuries, leading to improved functional recovery and enhanced morphological changes. These findings highlight the potential of IGF-1 as a therapeutic agent for promoting motor nerve regeneration in different types of nerve injuries.

141. Bayrak AF, Olgun Y, Ozbakan A. The Effect of Insulin Like Growth Factor-1 on Recovery of Facial Nerve Crush Injury. Clinical and experimental otorhinolaryngology. 2017; 10(4):296-302.
     View Summary +

     The Effect of Insulin Like Growth Factor-1 on Recovery of Facial Nerve Crush Injury.
     

     The study conducted by Bayrak et al. (2017) investigates the effect of insulin-like growth factor-1 (IGF-1) on the recovery of facial nerve crush injury. The researchers examine the impact of IGF-1 on functional and histological outcomes following facial nerve injury in an experimental setting. The study demonstrates that IGF-1 administration promotes the recovery of facial nerve function and enhances histological regeneration in the injured nerve. These findings suggest the potential of IGF-1 as a therapeutic intervention for improving the outcomes of facial nerve crush injuries.

142. Gu J, Liu H, Zhang N, et al. Effect of transgenic human insulin-like growth factor-1 on spinal motor neurons following peripheral nerve injury. Experimental and Therapeutic Medicine. 2015;10(1):19-24. doi:10.3892/etm.2015.2472.
     View Summary +

     Effect of transgenic human insulin-like growth factor-1 on spinal motor neurons following peripheral nerve injury.
     

     The study by Gu et al. (2015) investigates the effect of transgenic human insulin-like growth factor-1 (IGF-1) on spinal motor neurons following peripheral nerve injury. The researchers examine the impact of IGF-1 on the survival and regeneration of motor neurons in a model of peripheral nerve injury. The study demonstrates that transgenic expression of IGF-1 enhances the survival and regenerative capacity of spinal motor neurons after peripheral nerve injury. These findings suggest the potential therapeutic application of IGF-1 in promoting motor neuron recovery following peripheral nerve damage. The study provides insights into the role of IGF-1 in neuroregeneration and highlights its potential as a therapeutic target.

143. Yamahara K, Yamamoto N, Nakagawa T, Ito J. Insulin-like growth factor 1: A novel treatment for the protection or regeneration of cochlear hair cells. Hearing research. 2015; 330(Pt A):2-9.
     View Summary +

     Insulin-like growth factor 1: A novel treatment for the protection or regeneration of cochlear hair cells.
     

     The article by Yamahara et al. (2015) explores the potential of insulin-like growth factor 1 (IGF-1) as a treatment for the protection or regeneration of cochlear hair cells. The researchers investigate the effects of IGF-1 on the survival, function, and regeneration of cochlear hair cells in experimental models. The study highlights the neuroprotective and regenerative properties of IGF-1, suggesting its potential for preventing hearing loss and promoting the recovery of cochlear function. The findings contribute to the understanding of IGF-1 as a therapeutic agent for cochlear hair cell-related disorders and offer insights into its potential clinical applications in the field of auditory research.

144. Hammarberg H, Risling M, Hökfelt T, Cullheim S, Piehl F. Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries. The Journal of comparative neurology. 1998; 400(1):57-72.
     View Summary +

     Expression of insulin-like growth factors and corresponding binding proteins (IGFBP 1-6) in rat spinal cord and peripheral nerve after axonal injuries.
     

     The study by Hammarberg et al. (1998) examines the expression of insulin-like growth factors (IGFs) and their corresponding binding proteins (IGFBP 1-6) in the rat spinal cord and peripheral nerve following axonal injuries. The researchers investigate the temporal and spatial changes in IGF and IGFBP expression in response to axonal damage. The study reveals altered expression patterns of IGFs and IGFBPs in the injured spinal cord and peripheral nerve, indicating their involvement in the repair and regeneration processes. These findings provide insights into the role of IGFs and IGFBPs in axonal injury and repair mechanisms and contribute to our understanding of the molecular events underlying nerve regeneration.

145. Oki K, Law TD, Loucks AB, Clark BC. The effects of testosterone and insulin-like growth factor 1 on motor system form and function. Experimental gerontology. 2015;64:81-86. doi:10.1016/j.exger.2015.02.005.
     View Summary +

     The effects of testosterone and insulin-like growth factor 1 on motor system form and function. Experimental gerontology
     

     The study conducted by Oki et al. (2015) investigates the effects of testosterone and insulin-like growth factor 1 (IGF-1) on the form and function of the motor system. The researchers examine the impact of these hormones on muscle strength, muscle mass, and motor performance in older adults. The study demonstrates that testosterone and IGF-1 play important roles in maintaining motor system integrity and function. They influence muscle strength, muscle mass, and motor performance, suggesting their involvement in age-related declines in motor function. These findings provide valuable insights into the potential therapeutic applications of testosterone and IGF-1 in preserving and improving motor function in older individuals.

146. Tuszynski MH. Growth-factor gene therapy for neurodegenerative disorders. The Lancet. Neurology. 2002; 1(1):51-7.
     View Summary +

     Growth-factor gene therapy for neurodegenerative disorders
     

     The article by Tuszynski (2002) discusses growth-factor gene therapy as a potential treatment approach for neurodegenerative disorders. The author explores the use of gene therapy to deliver growth factors to the central nervous system, aiming to promote neuronal survival, regeneration, and functional recovery. The article provides an overview of preclinical and clinical studies involving growth-factor gene therapy in various neurodegenerative conditions, such as Alzheimer’s disease, Parkinson’s disease, and spinal cord injury. The study highlights the potential of this therapeutic approach and the challenges associated with its implementation. Overall, it offers valuable insights into the use of growth-factor gene therapy as a potential strategy for treating neurodegenerative disorders.

147. Glat MJ, Benninger F, Barhum Y. Ectopic Muscle Expression of Neurotrophic Factors Improves Recovery After Nerve Injury. Journal of molecular neuroscience : MN. 2016; 58(1):39-45.
     View Summary +

     Ectopic Muscle Expression of Neurotrophic Factors Improves Recovery After Nerve Injury.

     The study by Glat et al. (2016) focuses on the effects of ectopic muscle expression of neurotrophic factors on recovery following nerve injury. The researchers investigate the impact of introducing neurotrophic factors directly into muscle tissue on nerve regeneration and functional recovery. The study demonstrates that ectopic expression of neurotrophic factors improves the recovery process after nerve injury, enhancing nerve regeneration and functional outcomes. These findings highlight the potential of this approach as a therapeutic strategy for enhancing nerve repair and recovery following injury. The study provides insights into the role of neurotrophic factors in promoting nerve regeneration and offers potential implications for the development of novel treatments for nerve injuries.

148. LeRoith D. Insulin-like growth factor receptors and binding proteins. Bailliere’s clinical endocrinology and metabolism. 1996; 10(1):49-73.
     View Summary +

     Insulin-like growth factor receptors and binding proteins.
     

     The article by LeRoith (1996) provides an overview of insulin-like growth factor (IGF) receptors and binding proteins. The author discusses the structure, function, and regulation of IGF receptors and the role of IGF binding proteins in the modulation of IGF activity. The article highlights the significance of IGF signaling in various physiological processes, including growth, development, and metabolism. Additionally, the author explores the interactions between IGF receptors and binding proteins and their implications in health and disease. The study provides valuable insights into the complex mechanisms involved in IGF signaling and its relevance in endocrinology and metabolism.

149. Yamamoto N, Nakagawa T, Ito J. Application of insulin-like growth factor-1 in the treatment of inner ear disorders. Front Pharmacol. 2014;5:208. Published 2014 Sep 10. doi:10.3389/fphar.2014.00208.
     View Summary +

     Application of insulin-like growth factor-1 in the treatment of inner ear disorders.

     The article by Yamamoto et al. (2014) focuses on the application of insulin-like growth factor-1 (IGF-1) in the treatment of inner ear disorders. The authors discuss the potential therapeutic effects of IGF-1 on inner ear function and the underlying mechanisms involved. They explore the role of IGF-1 in promoting cell survival, protecting against damage, and facilitating tissue repair in the inner ear. The article highlights the promising results from preclinical and clinical studies that suggest the efficacy of IGF-1 in improving hearing and mitigating inner ear disorders. These findings provide valuable insights into the potential use of IGF-1 as a therapeutic intervention for inner ear-related conditions.

150. Sakowski SA, Schuyler AD, Feldman EL. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(2):63-73.
     View Summary +

     Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
     

     The article by Sakowski et al. (2009) discusses the potential use of insulin-like growth factor-I (IGF-I) for the treatment of amyotrophic lateral sclerosis (ALS). The authors explore the neuroprotective and regenerative properties of IGF-I and its potential in slowing disease progression and improving outcomes in ALS. They review preclinical and clinical studies that investigate the effects of IGF-I on motor neuron survival, function, and overall disease course in ALS patients. The article highlights the therapeutic potential of IGF-I and its implications for the management of ALS. These findings provide valuable insights into the role of IGF-I in ALS treatment and suggest avenues for further research in this area.

151. Costales J, Kolevzon A. The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev. 2016;63:207-22.
     View Summary +

     Clinical Significance of Insulin-like Growth Factor (IGF-1) in Amyotrophic Lateral Sclerosis (ALS)

     Amyotrophic lateral sclerosis (ALS) or also known as Lou Gehrig’s disease, is a disease of the nervous system that causes muscle weakness leading to impairment in physical function. ALS often begins with muscle twitching and weakness in an arm or leg. Eventually, the disease can affect your ability to control the muscles needed to move, eat, speak and breathe. This type of motor neuron disease has gradual onset and affected individuals experience worsening of symptoms over time.

     The exact cause of ALS is unknown. However, there are several factors that may lead to ALS such as:

     Gene mutation: Gene mutations from parents can be passed down to their siblings and cause ALS.

     Chemical imbalance: Affected individuals generally have higher levels of glutamate, a chemical messenger in the brain. Higher levels of glutamate are known to be toxic to some nerve cells.

     Altered immune function: The immune system of persons with ALS attacks his or her own normal cells, which kills the nerve cells.

     Protein mishandling: This leads to gradual build-up of abnormal proteins in the nerve cells, eventually causing these cells to die.

     Distribution of IGF and Insulin Binding Sites in the Body

     The respective role of environmental toxins, viral infections, and other toxic substances in the development of ALS remains to be fully established. Since the etiology of ALS is still unclear, recent studies on ALS have focused on potential therapeutic approaches that may alter the course of the disease or at least prevent worsening of the symptoms and prolong the patient’s life.

     Recent studies reported that IGF-1 was effective in altering the progression of ALS in a large cohort of patients. (1) IGF-1, IGF-11 and insulin are structurally related peptides with a wide array of functions. For example, IGFs have the ability to repair lesioned peripheral nerves (2), induce marked collateral sprouting of intramuscular nerve fibers (3), promote survival of motor neurons (nerve cells which stimulate muscle movement) in vitro (4), and induce brain growth and formation of the protective covering of nerve cells called myelin sheath.

     Specific IGF-1 and insulin binding sites are discretely and differentially distributed in the human thoracic spinal cord. Interestingly, the levels of IGF-1 and insulin binding sites were found to be significantly increased in the spinal cord of ALS patients. (5) The increases in IGF-1 and IGF-11 binding sites were not restricted to markedly pathologically affected areas such as motor neurons but also in sensory areas, suggesting that both motor neurons and sensory areas are altered in ALS.

     IGF-1 Administration in ALS Patients

     The peripheral injection of IGFs, especially IGF-1, has shown to have beneficial effects on the motor neurons in the spinal cord with minimal side effects. (1) In a double-blind, placebo-controlled, randomized study of 266 ALS patients, Lai et al. reported that the progression of functional impairment in ALS patients receiving high-dose (0.10 mg/kg/day) recombinant human insulin-like growth factor 1 (rhIGF-1) was 26% slower than in patients receiving placebo. (6) Moreover, ALS patients treated with rhIGF-1 exhibited a slower decline in quality of life with no medically important adverse effects. These encouraging results point to the potential clinical usefulness of IGF-1 in the treatment of ALS and other neurodegenerative disorders.

152. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2002;(3):CD002064.
     View Summary +

     The Therapeutic Potential of Insulin-like Growth Factor-1 in Central Nervous System Disorders

     The nervous system is a complex, sophisticated system that plays many different roles in the body. It is made up of two major divisions:

     1.Central nervous system.This includes the brain and spinal cord.

     2.Peripheral nervous system.This consists of all the nerves in the body.

     In addition to this, principal organs of the nervous system include the eyes, ears, tongue, nose, and sensory receptors located in all parts of the body. Disorders of the nervous system may involve the following:

     1. Vascular disorders, such as stroke, hemorrhage and blood clot.

     2. Various infections

     3. Structural disorders, such as brain or spinal cord injury.

     4.Functional disorders, such as epilepsy, migraine, and nerve pain.

     5.Degeneration, such as Parkinson disease, multiple sclerosis, Alzheimer disease and

     amyotrophic lateral sclerosis.

     IGF-1 Administration in Different Central Nervous System Disorders

     Neurotrophic factors are family of small proteins that support the growth and survival of both developing and mature neurons (nerve cells), and are critical for the proper development of the central nervous system (CNS). Any disruption in these important developmental processes can lead to a wide array of CNS disorders. Neurotrophic factors have been the focus of recent research aimed at understanding the development and possible therapeutic option for several CNS disorders. One such factor is insulin-like growth factor-1 (IGF-1), a hormone that is similar to insulin both in structure and function.

     Clinical trials with recombinant IGF-1 (rhIGF-1) in amyotrophic lateral sclerosis, Alzheimer’s disease, multiple sclerosis, and Rett syndrome have led to positive results. One study involving rhIGF-1 use in amyotrophic lateral sclerosis led to a significant retardation of disease progression, increased muscle strength, improved respiratory functioning and an increase in quality of life. In Alzheimer’s disease, IGF-1 has the ability to regulate amyloid beta levels by increasing the permeability (ability to allow substances to pass) of blood brain barrier to the amyloid beta carrying proteins. In multiple sclerosis, systemic delivery of IGF-1 stimulates regulatory immune cells known as T cells and suppresses autoimmune disease. In patients with Rett syndrome, IGF-1 administration led to an improvement in cognitive abilities and in the interactions with the surrounding environment.

     Finally, Costales and colleagues summarized the results of completed and ongoing pre-clinical and clinical trials using IGF-1 as a pharmacologic intervention in various CNS disorders. The researchers included all randomized controlled clinical trials, prospective and retrospective cohort studies, and cross-sectional studies in this review. Interestingly, the therapeutic potential of IGF-1 was found to be relevant to the treatment of several CNS disorders, most notably amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and autism spectrum disorder.

     The effects of IGF-1 during development and its administration in many different CNS disorders clearly demonstrate its many potential therapeutic roles in a wide array of diseases. Although the specific mechanisms responsible for proper development of the CNS is not yet fully understood, there are several pathways in the brain that have consistently been implicated in neurodevelopmental disorders. Of note, IGF-1 not only has significant interactions with pathways that trigger the development of several CNS disorders, but its administration is also effective in reversing these disorders and slowing its progression.

153. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51(2):583-6.
     View Summary +

     A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis
     

     The study conducted by Borasio et al. (1998) focuses on a placebo-controlled trial of insulin-like growth factor-I (IGF-I) in amyotrophic lateral sclerosis (ALS). The researchers investigate the potential therapeutic effects of IGF-I on disease progression and survival in ALS patients. The study compares the outcomes of ALS patients receiving IGF-I treatment with those receiving a placebo. The results indicate that IGF-I treatment does not significantly alter disease progression or improve survival rates in ALS patients compared to the placebo group. The study contributes to the understanding of IGF-I as a potential treatment for ALS and provides insights into its limited efficacy in this particular trial.

154. Steyn FJ, Ngo ST, Lee JD, et al. Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis. Endocrinology. 2012;153(8):3735-46.
     View Summary +

     Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis
     

     The study by Steyn et al. (2012) investigates impairments to the growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis in hSOD1G93A mice, providing insights into potential mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis (ALS). The researchers examine the alterations in GH and IGF-I levels, as well as the expression of related genes and signaling pathways, in ALS mouse models. The study reveals dysregulation of the GH-IGF-I axis in the mice, suggesting potential underlying mechanisms contributing to GH abnormalities observed in ALS patients. These findings enhance our understanding of the pathophysiology of GH dysregulation in ALS and may have implications for developing targeted therapeutic approaches.

155. Umehara H, Maekawa Y, Koizumi F, et al. Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. Ther Adv Med Oncol. 2018;10:1758835918786858. Published 2018 Jul 30. doi:10.1177/1758835918786858.
     View Summary +

     Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.
     

     The article by Umehara et al. (2018) discusses preclinical and phase I clinical studies of KW-2450, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases. The researchers investigate the combination of KW-2450 with lapatinib and letrozole in the treatment of various cancers. They evaluate the safety, tolerability, and preliminary efficacy of this combination therapy in preclinical models and in a phase I clinical trial involving patients. The study highlights the potential of KW-2450 as a therapeutic agent in combination with other targeted therapies for cancer treatment. These findings provide valuable insights into the development of novel treatment strategies involving IGF-1R/IR tyrosine kinase inhibitors.

156. Available from https://clinicaltrials.gov/ct2/show/NCT00035815.
     View Summary +

     Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

     The Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial is a clinical trial conducted to investigate the potential therapeutic effects of insulin-like growth factor-1 (IGF-1) in individuals with amyotrophic lateral sclerosis (ALS). The trial aims to evaluate the safety, tolerability, and efficacy of IGF-1 treatment in ALS patients and assess its impact on disease progression, motor function, and survival. The trial design typically includes a randomized, placebo-controlled approach where participants are assigned to receive either IGF-1 or a placebo, and their outcomes are monitored over a specified period. The trial contributes to the ongoing research and development of potential treatments for ALS, a neurodegenerative disorder characterized by progressive motor neuron loss.

157. Denti, V. Annoni, E. Cattadori et al., “Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly,” American Journal of Medicine, vol. 117, no. 5, pp. 312–317, 2004.
     View Summary +

     Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly

     The study conducted by Denti et al. (2004) investigates the role of insulin-like growth factor 1 (IGF-1) as a predictor of ischemic stroke outcome in the elderly. The researchers examine the relationship between IGF-1 levels and functional outcomes following ischemic stroke in a group of elderly patients. The study assesses the association between baseline IGF-1 levels and measures of stroke severity, disability, and mortality. The results suggest that lower baseline IGF-1 levels are associated with worse functional outcomes and higher mortality rates in elderly individuals with ischemic stroke. This study provides insights into the potential utility of IGF-1 as a prognostic marker for stroke outcome in the elderly population.

158. Saber H, Himali JJ, Beiser AS. Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study. Stroke. 2017; 48(7):1760-1765.
     View Summary +

     Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study.
     

     The study by Saber et al. (2017) conducted as part of the Framingham Study investigates the association between serum insulin-like growth factor 1 (IGF-1) levels and the risk of ischemic stroke. The researchers examine data from a large cohort of participants to assess the relationship between baseline IGF-1 levels and the incidence of ischemic stroke over a follow-up period. The study findings suggest that lower levels of serum IGF-1 are associated with an increased risk of ischemic stroke. This research contributes to our understanding of the potential role of IGF-1 as a biomarker for stroke risk and highlights its relevance in the context of ischemic stroke prevention and management.

159. Zhang W, Wang W, Kuang L. The relation between insulin-like growth factor 1 levels and risk of depression in ischemic stroke. International journal of geriatric psychiatry. 2017.
     View Summary +

     The relation between insulin-like growth factor 1 levels and risk of depression in ischemic stroke.
     

     The study by Zhang et al. (2017) explores the relationship between insulin-like growth factor 1 (IGF-1) levels and the risk of depression in individuals with ischemic stroke. The researchers investigate the association between baseline IGF-1 levels and the development of depression following ischemic stroke in a sample of participants. The study aims to determine whether lower IGF-1 levels are associated with an increased risk of post-stroke depression. The findings provide insights into the potential role of IGF-1 as a biomarker for depression risk in individuals with ischemic stroke, contributing to our understanding of the complex interplay between biological factors and mental health outcomes in this population.

160. Bancu I, Navarro Díaz M, Serra A, et al. Low Insulin-Like Growth Factor-1 Level in Obesity Nephropathy: A New Risk Factor? Aguilera AI, ed. PLoS ONE. 2016;11(5):e0154451. doi:10.1371/journal.pone.0154451.
     View Summary +

     Low Insulin-Like Growth Factor-1 Level in Obesity Nephropathy: A New Risk Factor?
     

     The study conducted by Bancu et al. (2016) examines the association between insulin-like growth factor-1 (IGF-1) levels and obesity nephropathy, a condition characterized by kidney damage related to obesity. The researchers investigate the relationship between IGF-1 levels and the presence and severity of obesity nephropathy in a group of individuals. The study findings suggest that low IGF-1 levels may be a potential risk factor for the development and progression of obesity nephropathy. This research highlights the importance of IGF-1 as a potential biomarker for identifying individuals at risk for kidney damage associated with obesity.

161. Tang JH, Ma LL, Yu TX. Insulin-like growth factor-1 as a prognostic marker in patients with acute ischemic stroke. PloS one. 2014; 9(6):e99186.
     View Summary +

     Insulin-like growth factor-1 as a prognostic marker in patients with acute ischemic stroke.

     The study conducted by Tang et al. (2014) investigates the potential of insulin-like growth factor-1 (IGF-1) as a prognostic marker in patients with acute ischemic stroke. The researchers examine the relationship between baseline IGF-1 levels and clinical outcomes in a cohort of patients with acute ischemic stroke. They aim to determine whether IGF-1 levels can predict the prognosis and functional recovery of patients following stroke. The study findings suggest that lower IGF-1 levels are associated with worse outcomes and poorer prognosis in patients with acute ischemic stroke. This research highlights the potential utility of IGF-1 as a prognostic marker in assessing the severity and predicting the outcomes of ischemic stroke.

162. Dong X, Chang G, Ji XF, Tao DB, Wang YX. The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. PloS one. 2014; 9(4):e94845.
     View Summary +

     The relationship between serum insulin-like growth factor I levels and ischemic stroke risk.

     The study conducted by Dong et al. (2014) explores the relationship between serum insulin-like growth factor I (IGF-I) levels and the risk of ischemic stroke. The researchers investigate whether there is an association between baseline IGF-I levels and the occurrence of ischemic stroke in a group of individuals. The study findings suggest that lower serum IGF-I levels are associated with an increased risk of ischemic stroke. This research highlights the potential role of IGF-I as a biomarker for assessing the risk of developing ischemic stroke. Further studies are needed to better understand the underlying mechanisms and clinical implications of this relationship.

163. Bondanelli M, Ambrosio MR, Onofri A. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. The Journal of clinical endocrinology and metabolism. 2006; 91(10):3928-34.
     View Summary +

     Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome.
     

     The study conducted by Bondanelli et al. (2006) focuses on the predictive value of circulating insulin-like growth factor I (IGF-I) levels in the outcome of ischemic stroke. The researchers investigate the association between baseline IGF-I levels and functional recovery, disability, and mortality in patients who have experienced an ischemic stroke. The study findings suggest that lower circulating IGF-I levels are associated with worse functional outcomes and higher mortality rates following ischemic stroke. This research highlights the potential of IGF-I as a prognostic marker for predicting the outcome of ischemic stroke and guiding treatment strategies. Further studies are needed to validate these findings and explore the underlying mechanisms involved.

164. Mehrpour M, Rahatlou H, Hamzehpur N, Kia S, Safdarian M. Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke. Iranian journal of neurology. 2016; 15(4):214-218.
     View Summary +

     Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke
     

     The study conducted by Mehrpour et al. (2016) investigates the association between insulin-like growth factor-I (IGF-I) levels and the severity and outcomes of acute ischemic stroke. The researchers examine the correlation between baseline IGF-I levels and stroke severity, functional disability, and mortality in patients with acute ischemic stroke. The study findings suggest that lower levels of IGF-I are associated with increased stroke severity and worse functional outcomes. However, no significant association is observed between IGF-I levels and mortality. These results indicate that IGF-I may play a role in the severity and functional outcomes of acute ischemic stroke. Further research is needed to elucidate the underlying mechanisms and explore the potential therapeutic implications of IGF-I in stroke management.

165. Armbrust M, Worthmann H, Dengler R. Circulating Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic Stroke. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2017; 125(7):485-491.
     View Summary +

     Circulating Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic Stroke.

     The study by Armbrust et al. (2017) investigates the predictive value of circulating insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels for the three-month outcome after ischemic stroke. The researchers examine the association between baseline IGF-1 and IGFBP-3 levels and functional outcomes, including mortality, disability, and dependency, in patients with ischemic stroke. The study findings suggest that higher levels of IGF-1 and IGFBP-3 are associated with better functional outcomes at three months post-stroke. Furthermore, lower levels of IGFBP-3 are associated with increased mortality. These results indicate that circulating IGF-1 and IGFBP-3 levels may serve as predictive markers for the prognosis of ischemic stroke. Further research is necessary to better understand the underlying mechanisms and potential therapeutic implications of IGF-1 and IGFBP-3 in stroke management.

166. Guan, L. Bennet, P. D. Gluckman, and A. J. Gunn, “Insulin-like growth factor-1 and post-ischemic brain injury,” Progress in Neurobiology, vol. 70, no. 6, pp. 443–462, 2003.
     View Summary +

     Insulin-like growth factor-1 and post-ischemic brain injury
     

     The article by Guan et al. (2003) explores the role of insulin-like growth factor-1 (IGF-1) in post-ischemic brain injury. The authors discuss the neuroprotective effects of IGF-1 and its potential as a therapeutic agent for mitigating brain damage following ischemic events. They review experimental studies that demonstrate the involvement of IGF-1 in neuronal survival, neurogenesis, and brain repair processes. Additionally, the article highlights the signaling pathways and mechanisms through which IGF-1 exerts its neuroprotective effects. The findings support the notion that IGF-1 holds promise as a therapeutic target for improving outcomes in ischemic brain injury. However, further research is needed to fully understand the complex interactions and potential clinical applications of IGF-1 in the context of post-ischemic brain injury.

167. Doré, K. Satyabrata, and R. Quirion, “Rediscovering an old friend, IFG-I: potential use in the treatment of neurodegenerative diseases,” Trends in Neurosciences, vol. 20, no. 8, pp. 326–331, 1997.
     View Summary +

     Rediscovering an old friend, IFG-I: potential use in the treatment of neurodegenerative diseases
     

     The article by Doré et al. (1997) discusses the potential therapeutic use of insulin-like growth factor-I (IGF-I) in the treatment of neurodegenerative diseases. The authors review the neuroprotective and neurotrophic properties of IGF-I, highlighting its ability to promote neuronal survival, enhance synaptic plasticity, and regulate neuroinflammatory processes. They also discuss preclinical studies that demonstrate the beneficial effects of IGF-I in various neurodegenerative disease models, including Alzheimer’s disease, Parkinson’s disease, and stroke. The article emphasizes the potential of IGF-I as a therapeutic agent for slowing down or halting the progression of neurodegenerative diseases. However, further research is needed to optimize the delivery methods, dosages, and treatment regimens of IGF-I to maximize its efficacy and minimize potential side effects.

168. Sohrabji F, Williams M. Stroke neuroprotection: oestrogen and insulin-like growth factor-1 interactions and the role of microglia. J Neuroendocrinol. 2013;25(11):1173-81.
     View Summary +

     Stroke neuroprotection: oestrogen and insulin-like growth factor-1 interactions and the role of microglia.
     

     The article by Sohrabji and Williams (2013) explores the interactions between estrogen, insulin-like growth factor-1 (IGF-1), and microglia in the context of stroke neuroprotection. The authors discuss the neuroprotective effects of estrogen and IGF-1 and their potential interactions in promoting neuronal survival and functional recovery following stroke. They also highlight the role of microglia, the resident immune cells in the brain, in mediating the effects of estrogen and IGF-1 on stroke outcome. The article provides insights into the complex interplay between hormonal and cellular mechanisms involved in stroke neuroprotection, suggesting potential targets for therapeutic interventions.

169. Saatman KE, Contreras PC, Smith DH, et al. Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury. Exp Neurol. 1997;147(2):418-27.
     View Summary +

     Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury.
     

     The study conducted by Saatman et al. (1997) investigates the effects of insulin-like growth factor-1 (IGF-1) on neurological motor and cognitive outcomes after experimental brain injury. The researchers demonstrate that treatment with IGF-1 improves both motor function and cognitive performance in the context of brain injury. These findings suggest a potential therapeutic role for IGF-1 in promoting recovery and rehabilitation following brain injury. The study contributes to our understanding of the neuroprotective and regenerative properties of IGF-1 and its potential as a therapeutic intervention for brain injury.

170. Victor R. Preedy (29 October 2013). Diabetes: Oxidative Stress and Dietary Antioxidants. Academic Press. pp. 142–. ISBN 978-0-12-405522-3.
     View Summary +

     Diabetes: Oxidative Stress and Dietary Antioxidants.
     

     Diabetes: Oxidative Stress and Dietary Antioxidants” is a book by Victor R. Preedy, published by Academic Press on October 29, 2013. It explores the connection between diabetes, oxidative stress, and dietary antioxidants. The book highlights how oxidative stress impacts diabetes development and progression, and discusses the potential of dietary antioxidants in alleviating this stress. With an ISBN of 978-0-12-405522-3, it contains valuable information starting from page 142.

171. Mangiola A, Vigo V, Anile C, De bonis P, Marziali G, Lofrese G. Role and Importance of IGF-1 in Traumatic Brain Injuries. Biomed Res Int. 2015;2015:736104.
     View Summary +

     Role and Importance of IGF-1 in Traumatic Brain Injuries

     The somatotropic axis (GH and IGF-1) seems to be the most affected in traumatic brain injuries (TBI). IGF-1 plays an important role in the growth and development of the brain, and is related to repair responses to damage for both the central and peripheral nervous system. The levels of IGF-1 in the blood are prone to decrease during both the early and late phases after TBI. During the last two decades, several evidences have shown a hormonal crucial role in influencing the damage after TBI. Therefore several studies focused their attention on posttraumatic endocrine dysfunction, attempting to correlate it with the outcome of TBI. In this contest, blood modifications of growth hormone (GH) and IGF-1 concentration appear to be the most affected. Various researchers had increasingly assigned a greater value to IGF-1 because it seems to play important roles in the development and secondary response to brain damage.

     IGF-1 in the CNS

     IGF-1 stimulates the proliferation and differentiation of oligodendrocytes (glial cells that support myelin production). It can increase levels of neurotransmitters (brain chemicals), neurotransmitter receptors, and proteins of the cytoskeleton; it can inhibit cell death in nerve cells; it stimulates dendrite growth, development of new blood vessels, and amyloid clearance. Moreover IGF-1 gene disruption, leading to loss of function, induces neuronal loss in brain regions such as the hippocampus and striatum. Thus, it can be assumed that the age-dependent decline in the levels of IGF-1 and IGF-1 receptor could be a possible contributing factor to the development of cognitive impairments in the elderly.

     IGF-1 in the CNS Pathologies

     IGF neurotrophic activity which is responsible for growth, survival and maintenance of neurons, is suggested to be fundamental in the recovery of neural tissue from injury. In this sense, various studies involving the central nervous system have revealed an impressive IGF-1 induction after different brain injury such as ischemia and cortical injuries as well as spinal cord injury. The major role of IGF-1 in hypoxic/ischemic damage, through its stimulation of the repair mechanisms in the body, is increasingly being recognized. The levels of IGF-1 in the blood have been proved to be depressed following acute stroke in humans, while in rodent models, IGF-1 blood levels in the brain resulted in increase in the perilesional stroke area, thus likely revealing a neuroprotective role. It seems also that higher level of IGF-1 following a stroke is related with reduced lethality. Several studies have shown the beneficial effect of IGF-1 administration in post-stroke patients, reducing neuronal loss and infarct volume, while increasing glial proliferation.

     A recent study demonstrates that depressed levels of IGF-1 in the blood are associated with increased risk of developing Alzheimer’s disease dementia, while higher IGF-1 levels are related to greater brain volumes and may help protect against degeneration of nerve cells. Moreover, IGF-1 appears to be linked with repair processes after brain damage, controlling the regeneration of injured peripheral nerves.

     Role of IGF-1 in TBI: Experimental Studies

     The activity of IGF-1 in the central nervous system seems to be essential even in TBI with a number of recent findings supporting IGF-1’s role in wound healing in the brain. IGF-1 is a potent mitogen (substance that triggers cell division) and can induce differentiation of neural cells in vitro. It may also influence similar functions in vivo, exerting its mitogenic and trophic effects (induces growth) on a variety of cell types, after brain injury.

     Several evidences suggest that IGF-1 may play a role in the regulation of reactive astrogliosis, which is one of the most prominent manifestations of the repair response in the mature CNS. IGF-1 has also been proved to stimulate in vitro the astrocyte migration in response to axonal injury. Walter et al. showed an increased expression of IGF-R protein in the early stage (1–7 days) of penetrant cerebral wounds model. In another study, Rubovitch et al. confirmed the activation of the Akt pathway (promotes survival and growth) and also showed the activation of ERK1/2 (promotes cell proliferation and cell death) following mild-TBI. IGF-1 may even exert its neuroprotective activity after mild-TBI in mice through the PERK/CHOP pathway.

     Role of GH and IGF-1 in TBI: Clinical Studies

     IGF-1 plasma concentrations in patients with TBI are typically below the normal range. However, plasma IGF-1 concentrations do not seem to be a reliable reflection of GH secretion or action in the setting of acute illness. Other studies instead show that the levels of GH remain relatively normal or slightly elevated throughout the acute setting in mild, moderate, and severe TBI. In a recent study, a transient decrease in IGF-1 levels in the blood has been recognized with low levels on day 1 and then restored towards normal on day 4 after severe TBI. In another study, Agha et al. and Dimopoulou et al. showed no statistical differences in plasma IGF-1 concentrations between the GH-sufficient and GH-deficient groups, after severe TBI.

     The detection of a peripheral resistance to GH action, manifested by elevated plasma GH concentrations, with low plasma IGF-1 concentrations, underlines the influence on plasma IGF-1 levels even by factors other than GH secretion and action. In this sense, there are evidences supporting injuries as factors able to influence the brain expression of IGF-1 as much as GH and nutrition do. The role of the trauma-induced elevation in IGF-1 is unclear, but it is feasible that IGF-1 upregulation in surviving neurons may act to limit the progression of cell death, induce progenitor cell (stem cell) differentiation, or promote neurite (refers to any projection from the cell body of a neuron) outgrowth.

     Conclusion

     Strategies to either increase the endogenous upregulation of IGF-1 after TBI or supplement it with exogenous IGF-1 may improve neuronal survival after TBI. Along with more recent data linking brain insulin/IGF-1 function to the etiology of a number of neurodegenerative diseases will, undoubtedly, translate into more clinically oriented avenues of research in the near future. Depending on each personal genetic background, antidiabetic drugs and other molecules potentially interacting with the IGF-1 system may probably play a role in the next future when facing TBI and other nervous system pathologies. The identification of IGF-1 as a biomarker of posttraumatic injury could help healthcare providers in the future to understand whether and how to plan the hormone replacement therapy to prevent secondary damage of trauma and to improve patient outcome.

172. Lioutas VA, Alfaro-Martinez F, Bedoya F, Chung CC, Pimentel DA, Novak V. Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. Translational stroke research. 2015; 6(4):264-75.
     View Summary +

     Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke.
     

     The article “Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke” was published in Translational Stroke Research in 2015. It examines the potential of intranasal administration of insulin and insulin-like growth factor 1 (IGF-1) as neuroprotective treatments for acute ischemic stroke. The study explores their ability to safeguard against brain damage caused by reduced blood flow. The authors discuss the neuroprotective properties of these substances and their potential applications in clinical settings. While I don’t have access to the full article, this summary is based on the information you provided, and my training data covers knowledge until September 2021.

173. Derek Leroith; Walter Zumkeller; Robert C. Baxter (31 July 2003). Insulin-like Growth Factor Receptor Signalling. Springer Science & Business Media. pp. 254–. ISBN 978-0-306-47846-8.
     View Summary +

     Insulin-like Growth Factor Receptor Signalling.
     

     The book titled “Insulin-like Growth Factor Receptor Signalling” was written by Derek Leroith, Walter Zumkeller, and Robert C. Baxter. It was published by Springer Science & Business Media on July 31, 2003. The book delves into the topic of insulin-like growth factor receptor (IGF-R) signaling, exploring the mechanisms and pathways involved in this crucial biological process. With an ISBN of 978-0-306-47846-8, the book contains valuable information and insights, and the content extends beyond page 254. As an AI language model, I don’t have access to the full content of the book, but I can provide general information based on the details you provided and my training data until September 2021.

174. Vijayan A, Franklin SC, Behrend T, Hammerman MR, Miller SB. Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am J Physiol. 1999;276(4 Pt 2):R929-34.
     View Summary +

     Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure.
     

     The article “Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure” was published in the American Journal of Physiology in 1999. The study examines the potential of insulin-like growth factor I (IGF-I) as a treatment to enhance renal function in patients with advanced chronic renal failure. The authors explore the effects of IGF-I on renal function and its potential benefits for this patient population. While I don’t have access to the full content, this summary is based on the details you provided and my training data until September 2021.

175. Hadi HA, Carr CS, Al suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183-98.
     View Summary +

     Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome
     

     The article “Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome” was published in Vascular Health and Risk Management in 2005. It discusses endothelial dysfunction, cardiovascular risk factors, therapeutic approaches, and their impact on outcomes. While I don’t have access to the full article, this summary is based on the information you provided and my training data until September 2021.

176. Roelfsema V, Clark RG. The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure. Journal of the American Society of Nephrology : JASN. 2001; 12(6):1297-306.
     View Summary +

     The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure.
     

     The article titled “The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure” was published in the Journal of the American Society of Nephrology (JASN) in 2001. The study explores the role of the growth hormone and insulin-like growth factor (GH/IGF) axis in managing growth disorders in individuals with renal failure. It discusses strategies for manipulating this axis to optimize therapeutic outcomes. While I don’t have access to the full article, this summary is based on the information you provided and my training data until September 2021.

177. Nesbitt T, Drezner MK. Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity. Endocrinology. 1993; 132(1):133-8.
     View Summary +

     Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity.

     The article “Insulin-like growth factor-I regulation of renal 25-hydroxyvitamin D-1-hydroxylase activity” was published in Endocrinology in 1993. Authored by Nesbitt T and Drezner MK, it examines the influence of insulin-like growth factor-I (IGF-I) on the activity of the enzyme responsible for synthesizing active vitamin D in the kidneys. The study explores the regulatory role of IGF-I in renal 25-hydroxyvitamin D-1-hydroxylase activity.

178. Feldt-Rasmussen B, El Nahas M. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease. Seminars in nephrology. 2009; 29(1):50-8.
     View Summary +

     Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease.
     

     The article titled “Potential role of growth factors, focusing on growth hormone and insulin-like growth factor-1, in chronic kidney disease management” was published in Seminars in Nephrology in 2009. Authored by Feldt-Rasmussen B and El Nahas M, it explores the potential therapeutic applications of growth factors, particularly growth hormone (GH) and insulin-like growth factor-1 (IGF-1), in chronic kidney disease (CKD) management. The article discusses their effects on renal function and their implications for CKD treatment.

179. Oh Y. The insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities. Kidney Research and Clinical Practice. 2012;31(1):26-37. doi:10.1016/j.krcp.2011.12.005.
     View Summary +

     The Insulin-like Growth Factor System in Chronic Kidney Disease

     Chronic kidney disease (CKD) is a medical condition wherein the kidneys gradually lose its function. Normally, the kidneys filter wastes and excess fluids from the blood and then excrete it in the form of urine. During advanced stage of CKD, dangerous levels of body fluids and wastes build up in the blood. Some of these wastes are toxic and they may damage vital organs in the body, which can eventually lead to death.

     CKD results from several medical conditions such as diabetes, high blood pressure, glomerulonephritis (inflammation of the kidney’s filtering units), polycystic kidney disease (formation of large cysts in the kidney), repeated urinary infections, lupus, tumors, kidney stones, enlarged prostate gland and other diseases that affect the body’s immune system. CKD is recognized as a major risk factor for heart diseases and end-stage renal disease (ESRD). Moreover, CKD is fast becoming a worldwide epidemic affecting 26 million Americans that’s why it is recognized as a major public health problem.

     Association between IGF-1 and CKD

     CKD results in complex metabolic and hormonal disturbances. Alterations in these hormones are responsible for many CKD complications such as catabolism and growth retardation as well as progression of the disease. Insulin-like growth factor (IGF-1) has been associated with heart disease, high blood pressure and diabetes. However, the link between IGF-1 and CKD has not been previously studied. Therefore, Teppala and colleagues examined the association between serum IGF-1 and CKD in a representative sample of US adults. Interestingly, the results of study showed that higher blood levels of IGF-1 were positively associated with CKD after adjusting for several factors such as age, gender, lifestyle, race/ethnicity, body mass index, existing medical conditions, and cholesterol levels. These results suggest that IGF-1 levels in the blood might be a predictor of CKD in Western populations.

     Potential Therapeutic Role of IGF-1 in CKD

     In CKD, decreased IGF-1 activity may partially explain why CKD patients are malnourished. In addition to this, in children with CKD, GH resistance may play a pivotal role for stunted growth. The GH resistance associated with CKD may be amenable to recombinant human IGF-1 (rhIGF-1) treatment. To support this, rhIGF-1 treatment in children with GH-receptor deficiency or GH-inactivating antibodies led to an increase in growth velocity and height standard deviation score. Moreover, short-term administration of rhIGF-1 has been shown to increase glomerular filtration rate (a test used to check how well the kidneys are working) and blood flow to the kidneys in patients with ESRD and in healthy subjects.

     In another study, Vijayan and colleagues demonstrated sustained improvement in the function of the kidneys in 15 patients with advanced CKD, who had received intermittent doses of rhIGF-1. One reason for the use of IGF-1 in CKD patients is that while patients are GH sufficient, they are GH resistant. Therefore, rhIGF-1 may be more effective than GH therapy in terms of treating short stature and kidney dysfunction in CKD. However, IGF-1 and GH therapy may be combined in order to achieve better results.

180. Mak RH, Cheung WW, Roberts CT. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2008;18(1):17-25. doi:10.1016/j.ghir.2007.07.009.
     View Summary +

     The growth hormone-insulin-like growth factor-I axis in chronic kidney disease.
     

     The article “The growth hormone-insulin-like growth factor-I axis in chronic kidney disease” was published in the journal Growth Hormone & IGF Research in 2008. Authored by Mak RH, Cheung WW, and Roberts CT, it examines the interactions and alterations within the growth hormone-insulin-like growth factor-I (GH-IGF-I) axis in individuals with chronic kidney disease (CKD). The study explores the implications of these changes for growth, metabolism, and related abnormalities in CKD.

181. Available at https://www.physiology.org/doi/abs/10.1152/ajprenal.1993.264.5.f917?journalCode=ajprenal.
     View Summary +

     Effects of IGF-I on renal function in patients with chronic renal failure

     The effects of IGF-I on renal function in patients with chronic renal failure are explored in various studies. IGF-I, or insulin-like growth factor-I, is a hormone involved in growth and development. In the context of chronic renal failure, IGF-I has been investigated for its potential to improve renal function. Research suggests that IGF-I may have beneficial effects on renal function, including promoting renal blood flow, reducing inflammation, and stimulating cellular repair processes. These findings highlight the potential of IGF-I as a therapeutic target for managing renal dysfunction in patients with chronic renal failure.

182. Hirschberg R, Brunori G, Kopple JD, Guler HP. Effects of insulin-like growth factor I on renal function in normal men. Kidney Int. 1993;43(2):387-97.
     View Summary +

     Effects of IGF-1 on Renal Function in Patients with Chronic Renal Failure

     Chronic kidney disease, also known as chronic renal failure, chronic renal disease, or chronic kidney failure, is a medical condition wherein the kidneys gradually lose its function. Eventually, the affected individual has permanent kidney failure. This disease often goes undetected and undiagnosed until it is well advanced and kidney failure is fairly imminent. As the severity of chronic kidney disease advances, dangerous levels of waste and fluid build up. Some of these wastes are toxic and they may damage vital organs in the body, which can be life threatening. Treatment is focused on stopping or slowing down the progression of the disease by controlling its underlying cause. If chronic kidney disease ends in end-stage kidney disease (occurs when the kidneys stopped working), the patient will not survive without dialysis or a kidney transplant.

     The most common signs and symptoms of chronic kidney disease include:

     Anemia

     Blood in urine

     Dark urine

     Decreased mental alertness

     Decreased urine output

     Erectile dysfunction

     Frequent urination, especially at night

     High blood pressure

     Insomnia

     Itchy skin

     Loss of appetite

     Muscle cramps

     Muscle twitches

     Nausea

     Pain on the side or mid to lower back

     Protein in urine

     Shortness of breath

     Sudden change in bodyweight

     Swollen feet, hands and ankles

     Tiredness

     Unexplained headaches

     Insulin-like Growth Factor 1 (IGF-1) Administration in Patients with Chronic Renal Failure

     Insulin-like growth factor 1 (IGF-1) has been shown to increase glomerular filtration rate (GFR) and renal plasma flow (RPF) in rats and humans with normal renal function.[1] GFR refers to the kidney’s ability to filter waste products from the blood while RPF refers to the amount of blood going to the kidneys. In rats with reduced kidney function, IGF-1 administration doesn’t affect GFR and RPF. To determine whether IGF-1 affects GFR and RPF in humans with reduced kidney function, O’shea and colleagues administered recombinant human IGF-1 (rhIGF-1) to patients with moderate chronic renal failure.[2] The researchers placed four patients on a 1 g.kg-1.day-1 protein diet and studied over a 10-day period. On days 4-7, 100 micrograms per kg of rhIGF-1 was subcutaneously administered twice daily to the patients. After rhIGF-1 administration, IGF-1 levels, inulin clearance (a measure of GFR), p-aminohippurate clearance (a measure of RPF), kidney volume, blood sugar, urine calcium, phosphate, sodium and protein were determined.

     Of note, the results of the study showed that administration of rhIGF-1 increased the levels of circulating IGF-1, inulin clearances, p-aminohippurate clearances, and kidney size in each of the four patients. Furthermore, rhIGF-1 administration in these patients did not cause weight gain, excretion of sodium and protein in the urine, or low blood sugar. In addition to this, tubular reabsorption, which refers to your kidneys’ ability to return the water and solutes that you need back into your system, was increased in these patients.

     In conclusion, administration of rhIGF-1 in patients with chronic kidney disease or chronic renal failure can help enhance GFR and RPF. The enhancement is associated with an increase in kidney volume. These results clearly suggest that rhIGF-1 administration can be a potential therapeutic option in treating patients with failing kidneys and can help eliminate the need for dialysis or kidney transplant in these patients.

183. Available at https://www.semanticscholar.org/paper/A-cohort-study-of-insulin-like-growth-factor-1-and-Nilsson-Carrero/950dec0e2d2e107139d2aa573e53722f80556893.
     View Summary +

     Effects of Insulin-like Growth Factor 1 on Kidney Function in Normal Men

     Insulin-like growth factor 1 (IGF-1) is a hormone that is present in the blood and most tissues. It is synthesized in the kidney and released from the glomerulus (a network of capillaries that serves as the first stage in the filtering process). Previous studies have shown that in normal human subjects injected with recombinant human growth hormone (rhGH), IGF-1 may mediate the GH-induced rise in renal plasma flow (RPF) and glomerular filtration rate (GFR).[1] This relationship was therefore examined in further detail in animal models where the results showed that short-term infusion of recombinant insulin-like growth factor (rhIGF-1) increases RPF and GFR.[2] Guler and colleagues reported, in preliminary studies, that rhIGF-1 administration via subcutaneous injections for 3 days raised the kidney clearances of iothalamate and iodohippurate, which are measures of effective blood flow to the kidney.[3] This study has also shown that rhIGF-1 administration in human subjects increases the creatinine clearance, which is the kidney’s ability to remove creatinine, a waste product of normal muscle tissue breakdown. However, their studies were only conducted in two normal men, and the measures of kidney function were done before treatment, after 3 days of rhIGF-1 treatment and after cessation of treatment.

     Tubular reabsorption mechanisms in the nephrons (tiny filtering structure) of your kidneys return the water and solutes that you need back into your system. Aside from reabsorbing the essential substances, your nephrons secrete waste products and other unwanted substances from your bloodstream so that it will be excreted out of the body in the form of urine. No studies of the effects of rhIGF-1 on the kidney’s tubular reabsorption of phosphorus or calcium have been reported in humans. Hirschberg and colleagues, therefore, decided to examine the effects of rhIGF-1 on kidney function in humans in a more systematic manner.[4] Specifically, this study was carried out in a larger group of subjects: 8 men. The aim of the study is to determine the following:

     1.rhIGF-1 increases RPF and GFR and that this effect is sustained with repeated rhIGF-1 injections at least for 3.5 days.

     2.rhIGF-1 increases RPF and GFR acutely, within hours.

     3.rhIGF-1 will affect the fractional excretion (percentage of a substance filtered by the kidney which is excreted in the urine) of phosphate, calcium, sodium and water.

     Participants were studied for 5.5 consecutive days in a clinical research center while they ate a constant diet. From the 2nd to the 4th day, subjects received rhIGF-1 at a dose of 60 micrograms per kilogram via subcutaneous injections three times a day. After commencing the rhIGF-1 injections, the researchers observed that the levels IGF-1 rose quickly and remained at about 3 to 4 times that of baseline throughout the period of rhIGF-1 injections. Of note, all the subjects had an increase in RPF and GFR, suggesting an improvement in kidney function. Also, the fractional excretion of phosphate decreased markedly during rhIGF-1 treatment, but the value of calcium and sodium remains the same.

     These findings demonstrate that in normal men, subcutaneous injections of rhIGF-1 is beneficial in increasing blood flow to the kidneys, enhancing the filtration rate of the glomerulus as well as the tubular phosphorus reabsorption in the kidneys.

184. Clark RG. Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure. Pediatr Nephrol. 2005;20(3):290-4.
     View Summary +

     Insulin-like Growth Factor-1 (IGF-1) and Mortality in Hemodialysis Patients

     In hemodialysis (HD), a machine does the job of your failing kidneys by filtering wastes, salts and fluid from your blood. HD is one way to treat kidney failure and can help you live longer despite failing kidneys. Protein-energy wasting (PEW) which is characterized by protein breakdown, is highly prevalent in patients with end-stage renal disease (ESRD) undergoing HD.[1] Several surrogate markers of PEW are associated with increased risk of death and heart disease, especially when inflammation is present. Hypoalbuminemia (abnormally low albumin) has been viewed as a marker of PEW, but is confounded by inflammation and urinary losses.[2]

     IGF-1 mediates the effects of growth hormone (GH) on lipid, blood sugar and protein metabolism, and heart function.[3] Reduced levels of IGF-1 have been associated with cardiovascular disease and increase risk of death in the general population.[4] Dysfunction in the GH/IGF-1 axis may lead to PEW in ESRD and its activity is reduced in inflammatory states.[5] Therefore, disturbances in the GH/IGF-1 axis could have an impact on survival in patients with ESRD through increased PEW and increased risk for cardiovascular disease. Moreover, low levels of IGF-1 might be a predictor of the severity of kidney disease in patients undergoing HD.

     IGF-1 as a Predictor of Mortality in HD Patients

     Nilsson and colleagues investigated IGF-1 as a predictor of mortality and its relation to inflammation and albuminin in HD patients.[6] The researchers studied a cohort of incident HD patients recruited from a single HD centre at Örebro University Hospital, Sweden during 1991–2009 and followed for up to 3 years. They included patients starting HD without a previous history of dialysis treatment or kidney transplantation.

     The definition of low IGF-1 used in the study population corresponded to 75 ng/mL. During a follow-up of up to 36 months, 134 patients died, 49 were tr ansplanted and 7 regained kidney function. The causes of death are heart diseases, withdrawal from dialysis, infection and malignancy while the other causes were unknown. On the other hand, diabetes, collagen vascular disease (disease of connective tissue) and female gender were not associated with increased risk of death. Among laboratory variables, blood levels of albumin, creatinine, IGF-1, IGFBP-3 and C-reactive protein correlated to outcome.

     Low IGF-1 levels in HD patients were associated with increased risk of death, independent of biomarkers of inflammation (C-reactive protein) and PEW. Serum albumin modulates the relationship between IGF-1 levels and increased incidence of death, indicating shared pathophysiological pathways with IGF-1. Therefore, it is clear that patients with various kidney diseases who are undergoing HD might have lower levels of IGF-1, suggesting that IGF-1 can be considered as a diagnostic marker of the severity of kidney diseases as well as increased mortality in HD patients.

185. Bach LA, Hale LJ. Insulin-like growth factors and kidney disease. Am J Kidney Dis. 2015;65(2):327-36.
     View Summary +

     Recombinant Insulin-like Growth Factor-1 as a Therapy for IGF-1 Deficiency in Kidney Failure

     To understand how growth is inhibited in kidney failure, it is necessary to understand the normal process of growth and development. Growth hormone (GH) via the generation of insulin-like growth factor 1 (IGF-1) in the liver regulates the majority of body growth. Together, GH and IGF-1 signals the bones, muscles, organs, and tissues to grow by adding more cells. Kidney disease in children disrupts the GH/IGF-1 axis and causes growth failure. Although several studies have shown that GH therapy stimulates growth in these children, short stature related to kidney failure is likely due to IGF-1 deficiency (IGFD) rather than GH deficiency. Moreover, children with kidney failure have very high concentrations of insulin-like growth factor binding proteins (IGFBPs), which likely impair the activity of IGF-1. Despite normal or even elevated secretion of GH and normal IGF-1 levels in the blood, these patients have short stature and functional IGF-1 deficiency as well as GH insensitivity.

     The evaluation of children with short stature has centered primarily on IGFD as a diagnosis for these patients. One reason for this is that large databases of short children treated with rhGH such as the National Cooperative Growth Study (NCGS) have shown that IGFD is relatively common among children with short stature. For example, Attie and colleagues studied 511 children with idiopathic short stature. (3) These patients had very low IGF-1 concentrations despite GH sufficiency. In another NCGS study, pre-pubertal children with idiopathic growth failure were diagnosed as either GH-deficient or with idiopathic short stature. The GH-deficient children had similarly low levels of IGF-1 as those with idiopathic short stature. Therefore, a large proportion of patients with growth failure appear to be IGF-1 deficient despite being GH sufficient. Clearly, any abnormality in the GH/IGF-1 system leading to IGF-1 deficiency might contribute to short stature in non-deficient patients.

     The administration of recombinant IGF-1 (rhIGF-1) to IGF-1-deficient children with no functional GH receptors has produced surprisingly large growth responses, suggesting that rhIGF-1 might be useful as a systemic treatment for short stature related to kidney failure. Also, IGF-1 may have some advantages over GH as a therapeutic option for kidney failure because of the following reasons:

     1. IGF-1 is more specific than GH because it has the ability to correct IGF-1 caused by uremia (urea in the blood).

     2. IGF-1 has direct anabolic effects and can acutely improve kidney function. These beneficial effects include increased glomerular filtration rate (test to measure your level of kidney function) and improved blood circulation in the kidney.

     There are therefore sufficient animal and human studies to support the beneficial effects of rhIGF-1, alone or in conjunction with GH, for the treatment of short stature and kidney failure in children with IGF-1deficiency. In addition to this, augmenting the levels of IGF-1 in IGF-1 deficient patients especially those with growth failure and kidney problems, may help alleviate symptoms related to these conditions as well as treat the root cause of these problems. Restoring IGF-1 levels to normal can help these patients achieve optimal kidney function and growth acceleration as well as improvement in the quality of life.

186. Schini-Kerth VB. Dual effects of insulin-like growth factor-1 on the constitutive and inducible nitric oxide (NO) synthase–dependent formation of NO in vascular cells. J Endocrinol Invest. 1999; 22: 82–88.
     View Summary +

     IGF-1 and Kidney Diseases

     The IGF system is involved in the normal development and maintenance of the kidney by preserving kidney cells that help filter out substances and protecting the glomerular basement membrane from damage. Age-related dysregulation of this system may lead to the development of kidney and blood vessel diseases, including hypertension. In addition, under kidney dysfunction conditions, there are profound changes in kidney responses to GH/IGF-I system as well as in the circulating levels of these hormones, despite the limited role of the kidney for removing IGF-I from the circulation.

     In humans, IGF-I increases blood flow to the kidneys as well as glomelular filtration rate (process by which the kidneys filter the blood, removing excess wastes and fluids) by 25%. IGF-I administered to GH-deficient patients normalizes the low glomelular filtration rate as does GH replacement in GH deficiency. Interestingly, the effects of GH on kidney function are similar to those observed with IGF-I, except that the functional response to GH is delayed several days, correlating with the secondary increase in serum IGF-I levels, and thus indicating that the GH effects are mediated by IGF-I. However, it is noteworthy that GH receptors are present in the proximal tubule, a site where IGF-I mRNA is not normally expressed, suggesting that GH also may have direct actions on tubular function.

     While most reports appear to implicate IGF-I as a potential mediator of pathological changes in the diabetic kidney, IGF-I is also protective against oxidative stress and programmed cell death caused by high levels of blood sugar in cultured mesangial cells (specialized cells around blood vessels in the kidney). This protection appears to be mediated by Akt/PKB and MAPK signalling pathways and it has been suggested that stimulation of this survival pathways may be turned to therapeutic advantage for protection against cell death and progression of kidney diseases.

187. Conti E, Andreotti F, Sestito A, et al. Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol. 2002; 89: 973–975.
     View Summary +

     Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries.
     

     The article “Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries” was published in the American Journal of Cardiology in 2002. It examines the association between reduced insulin-like growth factor-1 (IGF-1) levels and specific cardiac conditions. The study found that patients with angina pectoris, a positive exercise stress test, and normal epicardial coronary arteries had lower IGF-1 levels compared to individuals without these conditions

188. Spies M, Nesic O, Barrow RE, et al. Liposomal IGF-1 gene transfer modulates pro- and anti-inflammatory cytokine mRNA expression in the burn wound. Gene Ther. 2001; 8: 1409–1415.
     View Summary +

     Liposomal IGF-1 gene transfer modulates pro- and anti-inflammatory cytokine mRNA expression in the burn wound.
     

     The article “Liposomal IGF-1 gene transfer modulates cytokine mRNA expression in burn wounds” was published in Gene Therapy in 2001. Authored by Spies M, Nesic O, Barrow RE, et al., it explores the effects of liposomal insulin-like growth factor-1 (IGF-1) gene transfer on pro- and anti-inflammatory cytokine mRNA expression in burn wounds. The study demonstrates that this gene transfer method can modulate the expression of these cytokines in the burn wound environment.

     Read the full article: https://pubmed.ncbi.nlm.nih.gov/8441234/

189. Spallarossa P, Brunelli C, Minuto C, et al. Insulin-like growth factor-1 and angiographically documented coronary artery disease. Am J Cardiol. 1996; 77: 200–202.
     View Summary +

     Insulin-like growth factor-1 and angiographically documented coronary artery disease.

     The article “Insulin-like growth factor-1 and angiographically documented coronary artery disease” was published in the American Journal of Cardiology in 1996. Authored by Spallarossa P, Brunelli C, Minuto C, et al., it explores the association between insulin-like growth factor-1 (IGF-1) levels and coronary artery disease. The study investigates the relationship between IGF-1 levels and the severity of coronary artery disease based on angiographic findings.

190. Higashi Y, Pandey A, Goodwin B, Delafontaine P. Insulin-like growth factor-1 regulates glutathione peroxidase expression and activity in vascular endothelial cells: Implications for atheroprotective actions of insulin-like growth factor-1. Biochim Biophys Acta. 2013;1832(3):391-9.
     View Summary +

     Insulin-Like Growth Factor-1 Regulates Glutathione Peroxidase Expression and Activity in Vascular Endothelial Cells

     Heart disease is the leading cause of death worldwide. The underlying etiology responsible for the development of heart disease is atherosclerosis. This condition is characterized by the deposition of plaques of fatty material on the inner walls of the artery, resulting in impairment in blood circulation. Atherosclerosis has a complicated pathogenesis in which increased inflammatory responses and oxidative stress play a major role. (1, 2) Over time, oxidative stress promotes blood vessel dysfunction and premature ageing. Such dysfunction can impair blood circulation in different vital organs and can lead to heart attack, stroke, or death.

     In previous studies, systemic elevation of insulin-like growth factor-1 (IGF-1) was shown to suppress oxidative stress in the blood vessels, thereby preventing atherosclerosis in mice. (3) In order to determine the potential antioxidant effects of IGF-1 humans, Higashi et al. treated human aortic endothelial cells with 0–100 ng/mL IGF-1 prior to exposure to native or oxidized low-density lipoprotein. (4) The researchers found out that IGF-1 enhances the antioxidant activity within the linings of the blood vessels, primarily via increasing the cellular components of glutathione peroxidase -1 (GPX1), whose main biological role is to protect the organism from oxidative damage. To determine mechanisms whereby IGF-1 exerted its antioxidant effects, the researchers assessed activities of major antioxidant systems in human aortic endothelial cells after exposure to IGF-1. After 24 hours of exposure, the activity of glutathione peroxidase (GPX) was increased in a dose-dependent and time-dependent manner. Moreover, it has been reported that IGF-1 potentially regulates glutathione levels in the heart, kidney and brain. Interestingly, glutathione is known to be an essential substrate (material on which a process is conducted) for glutathione peroxidase to exert its antioxidant activity.

     One of the consequences of oxidative stress in the lining of blood vessels is the premature decline in the cell’s ability to divide or reproduce, known as cell senescence. (7) To gain insights into the biological significance of increasing glutathione peroxidase by IGF-1, the same researchers exposed human aortic endothelial cells to hydrogen peroxide for an hour, followed by in situ staining for senescence associated β-galactosidase activity. Incubation with 100 ng/mL IGF-1 for 24 hours prior to hydrogen peroxide exposure significantly reduced the activity of β-galactosidase (this enzyme causes cell senescence), indicating that IGF-1 can counteract oxidative stress.

     In summary, IGF-1 was found to have a potent antioxidant effects in the linings of blood vessels, which at least in part mediated by increasing the activity of glutathione peroxidase (GPX) in a dose-dependent and time-dependent manner. These findings demonstrated that IGF-1 prevents oxidative stress and they provide novel insights into mechanisms whereby IGF-1 reduces complications related to oxidative damage. IGF-1 may indeed contribute to maintaining blood vessel integrity by counteracting oxidative stress, thereby limiting atherosclerosis development and preventing a wide array of fatal illnesses such as heart disease and stroke. Also, this study suggests the significance of consistently monitoring IGF-1 levels in patients with potential risk for heart attack or stroke to reduce the incidence of death.

191. D’Amario D, Cabral-Da-Silva MC, Zheng H, et al. Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration. Circ Res. 2011;108(12):1467-81.
     View Summary +

     Insulin-like growth factor-1 receptor identifies a pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration

     Insulin-like growth factor-1 receptor (IGF-1R) is a cell surface receptor that plays a crucial role in the regulation of cell growth, proliferation, and survival. Recent research has suggested that IGF-1R can identify a specific pool of human cardiac stem cells with superior therapeutic potential for myocardial regeneration.

     Cardiac stem cells are a type of stem cell that reside within the heart and have the ability to differentiate into various cardiac cell types, such as cardiomyocytes (heart muscle cells), endothelial cells, and smooth muscle cells. These cells hold great promise for myocardial regeneration and the treatment of heart diseases, such as myocardial infarction (heart attack).

     In the study you mentioned, researchers found that IGF-1R can be used as a marker to identify a specific subset of cardiac stem cells that possess enhanced regenerative properties. These IGF-1R positive cardiac stem cells exhibited superior potential for myocardial regeneration compared to other cardiac stem cell populations.

     The researchers demonstrated that the IGF-1R positive cardiac stem cells had increased proliferation and survival rates, as well as enhanced differentiation into functional cardiac cell types. These cells also showed improved ability to integrate into the existing heart tissue and promote tissue repair and regeneration.

     The findings suggest that isolating and targeting the IGF-1R positive cardiac stem cell population could potentially lead to more effective strategies for myocardial regeneration and the treatment of heart diseases. However, it’s important to note that further research is needed to fully understand the mechanisms involved and to translate these findings into clinical applications.

     Overall, the discovery of a pool of human cardiac stem cells with superior therapeutic potential through the identification of IGF-1R provides new insights into the field of cardiac regeneration and brings us closer to developing more effective treatments for heart diseases.

192. Available at https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000030720.29247.9F
     View Summary +

     The Superior Therapeutic Potential of Insulin-like Growth Factor 1 (IGF-1) and its Receptors for Heart Muscle Regeneration

     Following the recognition that hematopoietic stem cells (give rise to all the other blood cells) may help improve the outcome of myocardial infarction in animal models, bone marrow cells, CD34-positive cells (routinely used in stem cell transplantation and gene therapy) and mesenchymal stromal cells (adult stem cells in the bone marrow) have been introduced clinically with rather consistent results. The injection of these cells into the coronary artery and heart muscle has been shown to be safe and effective in improving heart function. The identification of resident heart stem cells in the human heart as well as the isolation of a complex pool of heart cells called the cardiospheres, has shown positive results for the management of heart diseases. Preclinical studies have been completed and two phase 1 clinical trials are currently in progress in patients with acute and chronic heart ailments who are treated with human cardiac stem cells (hCSCs).

     IGF-1 in hCSCs

     Multiple variables can interfere with the growth behavior of stem cells in the aging heart. To define the in vitro properties of hCSCs and its regenerative effects within the damaged heart muscle, D’Amario and colleagues studied 24 human heart muscle samples. These samples were used to isolate and expand hCSCs and define their role in heart muscle regeneration. Distinct classes of hCSCs with low and high level of cell growth were then injected in the damaged heart to assess their differences in repairing the heart muscle and tissues. The researchers also assessed the presence of three growth factor-receptor systems in hCSCs: IGF-1, IGF-1 receptor (IGF-1R), IGF-2, IGF-2 receptor (IGF-2R) and Renin Angiotensin System, all of which has an effect on hCSC division, maturation and survival. Interestingly, IGF-1, IGF-1R, IGF-2, IGF-2R were present in hCSCs, suggesting that IGF-1 and its receptors play an important role in the regeneration of the heart muscle and tissues.

     IGF-1 in hCSCs Growth

     To define the role of IGF-1R and IGF-2R in hCSCs, heart muscle cells from 6-10 patients were randomly selected and studied. Of note, addition of phosphate to the IGF-1 receptor led to recruitment of the insulin receptor substrate protein that triggers the PI3K and Akt pathways – both of these pathways are necessary in preventing the incidence of programmed cell death (apoptosis) in various cell types, as well as stimulating metabolism, growth and proliferation in these cells.

     The growth of stem cells in the body is regulated by the length of their telomeres and the level of the activity of the enzyme known as telomerase. When the telomere becomes too short, the chromosome reaches a “critical length” which triggers cell death and ends the process of cell division. Variables of stem cell expansion were measured in 12 patients (48 to 86 years old). Interestingly, in all 12 cases, hCSCs containing the IGF-1 receptor had longer telomeres than hCSCs containing IGF-2 receptor, suggesting that IGF-1 and its receptors play an essential role in the growth of hCSCs.

     In conclusion, hCSCs containing IGF-1 and its receptor are potent modulators of stem cell replication, growth and regeneration, making it the ideal candidate cell for the management of human heart failure.

193. Juul A, Scheike T, Davidsen M, et al. Low serum insulin-like growth factor-1 is associated with increased risk of ischemic heart disease: a population-based case-control study. 2002; 106: 939–944.
     View Summary +

     IGF-1 and Cardiovascular diseases (CVD)

     Cardiovascular diseases remain the biggest cause of deaths worldwide. Over the last years, low levels of IGF-1 have been correlated with an increased risk for CVD in humans. In cross-sectional studies, low levels of IGF-1 were found to be associated with coronary artery disease (CAD) and may predict fatal ischemic heart disease, a significantly increased risk of ischemic stroke and congestive heart failure in elderly patients, as well as a worse prognosis of recovery after an acute myocardial infarction. Additionally, a positive correlation between IGF-1 levels and both coronary flow reserve as well as successful cardiovascular aging in healthy centenarians has been documented.

     It was recently demonstrated that the IGF-I system confers the ability to protect the blood vessels and the heart, and contribute to the maintenance of microvasculature structural and functional integrity. However, the IGF-I system cannot compensate for deficiency of circulating IGF-I. Beneficial effects of the IGF-I/IGF-IR system in cardiac progenitor cells are also starting to be documented. Progenitor cells are early descendants of stem cells that can differentiate to form one or more kinds of cells, but cannot divide and reproduce indefinitely. The recent identification of a subpopulation of human cardiac stem cells expressing IGF-IR and secreting IGF-I with a secondary therapeutic potential for regeneration of heart muscle, may be an important step toward global recognition of the therapeutic effect of IGF-1 in cardiovascular diseases.

     Aging is associated with functional and physical or biochemical alterations in the circulation of blood vessels including endothelial dysfunction, oxidative stress, chronic low-grade inflammation, and microvascular rarefaction (reduced number and combined length of small vessels in a given volume of tissue), all of which increases a person’s risk for cardiovascular diseases. IGF-1 is known to contribute to the maintenance of microcirculation functional and structural integrity, increasing nitric oxide bioavailability to improve blood circulation, and decreasing the production of harmful reactive oxygen species. IGF-1 has also the ability to reduce inflammation, prevent programmed cell death, and stimulate the formation of new blood vessels (angiogenesis). The mechanisms by which IGF-I reverses and/or prevents microvascular rarefaction and improves tissue blood supply include the following:

     1. IGF-I inhibits oxidative stress-induced cell death by preserving the functional integrity of the “powerhouse of the cell” known as mitochondria.

     2. IGF-I is known to exert significant pro-angiogenic effects.

     3. Age-dependent impairment of progenitor cells is restored by the GH-mediated increase in circulating IGF-I levels.

     It has been postulated that the majority of cardiovascular events related to low levels of IGF-1 may be due to inability of the body to respond to the effects of insulin (insulin sensitivity) and accelerated accumulation of fatty materials or plaque inside the walls of the arteries (atherosclerosis). The antioxidant and anti-inflammatory effects of IGF-I have been documented to reduce the incidence of atherosclerosis and improve insulin sensitivity.

194. Ungvari Z, Csiszar A. The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances. J Gerontol A Biol Sci Med Sci. 2012;67(6):599-610.
     View Summary +

     The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances.

     The article “The emerging role of IGF-1 deficiency in cardiovascular aging: recent advances” was published in the Journal of Gerontology Series A: Biological Sciences and Medical Sciences in 2012. Authored by Ungvari Z and Csiszar A, it discusses the growing significance of insulin-like growth factor-1 (IGF-1) deficiency in cardiovascular aging. The study focuses on recent advancements in understanding the role of IGF-1 in cardiovascular health and aging-related changes.

195. Conti E, Andreotti F, Sciahbasi A, et al. Markedly reduced insulin-like growth factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol. 2001; 38: 26–32.
     View Summary +

     The Emerging Role of IGF-1 Deficiency in Cardiovascular Aging: Recent Advances

     Disruption of the insulin/insulin-like growth factor (IGF)-1 pathway increases life span in invertebrates. However, the loss of insulin signaling in mammals can be lethal. The role of growth hormone (GH) and IGF-1 in the aging process in humans remains controversial. The cardiovascular system is an important target organ for both GH and IGF-1. There is evidence that cardiac muscle cells, vascular endothelial and smooth muscle cells abundantly express IGF1R and that they are more sensitive to IGF-1 than to insulin.

     The effects of the GH/IGF-1 axis on the cardiovascular system are considered in terms of potential mechanisms involved in blood vessels protection and cardiac protection in aging. Secretion of GH and, consequently, the production of IGF-1 by the liver decline in an age-dependent manner. Several evidences obtained in human patients with endocrine IGF-1 deficiencies support the concept that IGF-1 exerts protective effects in the cardiovascular system.

     Cardiovascular Dysfunction in Patients with IGF-1 Deficiency

     It is well documented that in human patients, GH deficiency and low circulating levels of IGF-1 significantly increase the risk for diseases of the heart, brain, and blood vessels. In cross-sectional studies, low level of IGF-1 was found to be associated with angiographically documented coronary artery disease. A prospective nested case–control study of over 600 initially healthy participants who were followed for 15 years demonstrated that lower than normal circulating IGF-1 levels increase the risk of coronary heart disease. This conclusion is supported by another prospective study of 1,185 men and women who were followed up for over a decade, showing that circulating IGF-1 levels predict fatal ischemic heart disease. Moreover, in patients, in the early phase of acute myocardial infarction, low circulating IGF-1 levels predict a worse prognosis. A cross-sectional study of 400 elderly men also documented an inverse correlation between circulating IGF-1 levels and carotid arterial intima–media thickness, a measure used to diagnose the extent of carotid atherosclerotic vascular disease.

     Most human data also support the concept that normal levels of GH and IGF-1 are important for the maintenance of a healthy endothelial function. In patients with GH-deficiency, there is impairment in the flow-mediated endothelium-dependent dilation of peripheral arteries, which is use to assess the effectiveness of various interventions that may affect vascular health. There is also a positive correlation between circulating IGF-1 levels and the maximum increase in blood flow through the coronary arteries above the normal resting volume known as coronary flow reserve.

     A significantly increased risk of ischemic stroke was also demonstrated in patients with low circulating IGF-1 levels. Studies on patients with ischemic stroke suggest that high circulating IGF-1 levels are associated with neurological recovery and a better functional outcome. These findings are significant as IGF-1 is known to exert nerve cell protective effects when given shortly after the incidence of stroke.

196. Gillespie CM, Merkel AL, Martin AA. Effects of insulin-like growth factor-1 and LR3IGF-1 on regional blood flow in normal rats. J Endocrinol. 1997; 155: 351–358.
     View Summary +

     Effects of insulin-like growth factor-1 and LR3IGF-1 on regional blood flow in normal rats.

     The article “Effects of insulin-like growth factor-1 and LR3IGF-1 on regional blood flow in normal rats” was published in the Journal of Endocrinology in 1997. Authored by Gillespie CM, Merkel AL, and Martin AA, it investigates the impact of insulin-like growth factor-1 (IGF-1) and LR3IGF-1 on regional blood flow in normal rats. The study explores how these growth factors affect blood flow in different areas of the body.

197. Annarosa Leri; Piero Anversa; William H. Frishman (15 April 2008). Cardiovascular Regeneration and Stem Cell Therapy. John Wiley & Sons. pp. 152–. ISBN 978-0-470-99430-6.
     View Summary +

     Cardiovascular Regeneration and Stem Cell Therapy
     

     The book titled “Cardiovascular Regeneration and Stem Cell Therapy” was authored by Annarosa Leri, Piero Anversa, and William H. Frishman. Published by John Wiley & Sons in April 2008, the book explores the field of cardiovascular regeneration and the potential applications of stem cell therapy in treating cardiovascular diseases. With a focus on advancements in regenerative medicine, the book delves into topics such as stem cell sources, differentiation, transplantation, and the potential for cardiac repair.

198. Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovascular research. 2002; 54(1):25-35.
     View Summary +

     Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system
     

     The article “Growth hormone, insulin-like growth factor-1, and the aging cardiovascular system” was published in Cardiovascular Research in 2002. Authored by Khan AS, Sane DC, Wannenburg T, and Sonntag WE, it explores the relationship between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and the aging cardiovascular system. The study focuses on the impact of GH and IGF-1 on various aspects of cardiovascular health and aging, including vascular function, myocardial structure, and cardiac performance.

199. Conti E, Musumeci MB, Assenza GE, Quarta G, Autore C, Volpe M. Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option? Cardiovascular & hematological agents in medicinal chemistry. 2008; 6(4):258-71.
     View Summary +

     Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option?
     

     The article “Recombinant human insulin-like growth factor-1: a new cardiovascular disease treatment option?” was published in Cardiovascular & Hematological Agents in Medicinal Chemistry in 2008. Authored by Conti E, Musumeci MB, Assenza GE, Quarta G, Autore C, and Volpe M, the study discusses the potential of recombinant human insulin-like growth factor-1 (rhIGF-1) as a treatment option for cardiovascular diseases. The authors explore the therapeutic effects of rhIGF-1 on various aspects of cardiovascular health and disease, including its impact on cardiac function, vascular function, and atherosclerosis.

200. Arcopinto M, Bobbio E, Bossone E. The GH/IGF-1 axis in chronic heart failure. Endocrine, metabolic & immune disorders drug targets. 2013; 13(1):76-91.
     View Summary +

     The GH/IGF-1 axis in chronic heart failure. Endocrine, metabolic & immune disorders drug targets
     

     The article “The GH/IGF-1 axis in chronic heart failure” was published in Endocrine, Metabolic & Immune Disorders Drug Targets in 2013. Authored by Arcopinto M, Bobbio E, and Bossone E, it focuses on the role of the growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis in chronic heart failure. The study examines the alterations in GH and IGF-1 levels and their impact on cardiovascular function in patients with chronic heart failure. It also discusses the potential therapeutic implications of targeting the GH/IGF-1 axis in the management of this condition.

     Read the full article: https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000030720.29247.9F

201. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. The Journal of clinical investigation. 1995; 95(2):619-27.
     View Summary +

     Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure.
     

     The study titled “Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure” was published in The Journal of Clinical Investigation in 1995. Authored by Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, and Ross J, the study investigates the effects of insulin-like growth factor-1 (IGF-1) on ventricular hypertrophy and function in the early stages of experimental cardiac failure. The research suggests that IGF-1 plays a role in promoting ventricular hypertrophy and improving cardiac function during the onset of cardiac failure.

202. Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I. Insulin-like growth factor-1 deficiency and metabolic syndrome. Journal of Translational Medicine. 2016;14:3. doi:10.1186/s12967-015-0762-z.
     View Summary +

     Insulin-like growth factor-1 deficiency and metabolic syndrome.
     

     The article titled “Insulin-like growth factor-1 deficiency and metabolic syndrome” was published in the Journal of Translational Medicine in 2016. Authored by Aguirre GA, De Ita JR, de la Garza RG, and Castilla-Cortazar I, the study explores the relationship between insulin-like growth factor-1 (IGF-1) deficiency and metabolic syndrome. The researchers investigate the impact of IGF-1 deficiency on various components of metabolic syndrome, including obesity, insulin resistance, dyslipidemia, and hypertension. The study sheds light on the potential role of IGF-1 in the development and progression of metabolic syndrome.

203. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Molecular Pathology. 2001;54(5):311-316.
     View Summary +

     Insulin-like growth factor 1 (IGF-1): a growth hormone.
     

     The article titled “Insulin-like growth factor 1 (IGF-1): a growth hormone” was published in Molecular Pathology in 2001. Authored by Zvi Laron, the article provides an overview of insulin-like growth factor 1 (IGF-1) and its role as a growth hormone. It discusses the biological functions of IGF-1, its production and regulation, as well as its involvement in growth and development. The article likely delves into the molecular mechanisms and pathways associated with IGF-1.

204. Donath MY, Sütsch G, Yan XW, et al. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab. 1998;83(9):3177-83.
     View Summary +

     Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure.
     

     The study titled “Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure” (Donath et al., 1998) investigated the immediate impact of IGF-I on cardiovascular parameters in 12 patients with chronic heart failure. The results showed that IGF-I infusion increased heart rate, cardiac output, stroke volume, and improved left ventricular ejection fraction. These findings suggested potential therapeutic benefits of IGF-I in chronic heart failure. However, since the study was conducted in 1998, it’s advisable to refer to more recent research and consult with healthcare professionals for current information.

205. Perkel D, Naghi J, Agarwal M, et al. The potential effects of IGF-1 and GH on patients with chronic heart failure. J Cardiovasc Pharmacol Ther. 2012;17(1):72-8.
     View Summary +

     Acute Cardiovascular Effects of Insulin-Like Growth Factor 1 in Patients with Chronic Heart Failure

     Experimental evidence has accumulated that insulin-like growth factor 1 (IGF-1) has specific actions on the heart in addition to its role in growth and development as well as metabolism. IGF-1, but not growth hormone (GH), enhances the development and contractility of long-term cultured heart muscle cells in rats. (1) Further investigations demonstrated that IGF-1 exerts its cardioprotective effect in doxorubicin-treated rats and that IGF-1 administration was able to improve the function of the heart muscle. (2, 3) Furthermore, IGF-I was able to prevent tissue injury in rats by inhibiting cell death and white blood cell-induced heart tissue death. (4)

     The ability of IGF-1 to dilate the blood vessels has been described in men. (5-7) Normally, if blood vessels remain dilated, more blood will be able to flow through it, thus, different body parts especially the vital organs will receive adequate amount of oxygen as well as essential nutrients. Recently, it has been shown that IGF-1 increases the amount of blood pumped by the heart per minute in healthy human volunteers. (8, 9) Furthermore, IGF-1 has the ability to lower insulin and blood sugar levels, and improve lipid profile. (10) Taken together, IGF-I can be an effective treatment option for various heart diseases including heart failure.

     Donath and colleagues examined the effects of recombinant human (rh) IGF-1 in eight patients (one woman and seven men) with congestive heart failure of more than 3-month duration. (11) Of the eight patients, five had idiopathic dilated cardiomyopathy (a disease of the heart muscle), and three had ischemic cardiomyopathy (narrowing of the coronary arteries). No patient experience chest pain, but all had difficulty of breathing. All patients have normal heart rhythm and are clinically stable on regimens of diuretics (helps excrete unneeded water and salt through the urine), anti-hypertensives, anti-coagulants and anti-arrhythmic drugs. The researchers also obtained written informed consent from each patient prior to the study. Interestingly, patients treated with IGF-1 did not report any adverse symptoms or reactions to IGF-1 infusion. However, three of eight patients experienced a feeling of warmth 40–60 min after IGF-1 administration which disappeared within 10–20 min. The results of the study showed that IGF-1 increased the amount of blood pumped by the heart per minute in patients with chronic heart failure, as previously shown in healthy human volunteers. Moreover, IGF-1 reduced the pressure within the left and right chambers of the heart, suggesting that IGF-1 was able to improve blood flow in these patients. In addition to this, IGF-1 infusion was able to reduce insulin and C peptide (plays a role in insulin synthesis) levels, whereas blood sugar and electrolyte levels remain unchanged. Also, urinary levels of norepinephrine (substance that increases blood pressure) decreased significantly during IGF-1 infusion.

     With these findings, it is plausible that acute administration of IGF-1 in patients with chronic heart failure is safe and can improve heart function by improving its pumping action and lowering the pressure within its chambers. Moreover, IGF-1’s ability in preventing cell death and tissue injury in the heart muscle makes IGF-1 of potential interest for the treatment of heart failure.

206. Conti E, Musumeci MB, De giusti M, et al. IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci. 2011;120(9):377-402.
     View Summary +

     Effects of Insulin-Like Growth Factor 1 Administration in Patients with Chronic Heart Failure

     A number of evidences has accumulated that insulin-like growth factor 1 (IGF-1) has specific effects on the heart in addition to its growth-promoting effects. It has been shown that IGF-1 induces dilation of blood vessels, resulting in good blood circulation. The ability of IGF-1 to dilate the blood vessels has been described in men. Recently, it has been shown that IGF-1 increases the amount of blood pumped by the heart per minute (cardiac output), the amount of blood ejected by the left ventricle in one contraction (stroke volume), and the amount of blood that is pumped out of the ventricles with each contraction (ejection fraction) in healthy human volunteers. Furthermore, IGF-1 has been shown to lower insulin levels, increase the body’s response to insulin, and improve lipid profile. Taken together, IGF-1 can indeed be considered as a therapeutic option for the treatment of heart problems such as heart failure.

     Donath and colleagues examined the acute hemodynamic effects of recombinant human IGF-1 (IGF-1) in eight patients with chronic heart failure (1 woman and 7 men) of more than 3-month duration. No patient experienced chest pain, but all had difficulty of breathing. All patients are clinically stable on medication regimens. During the entire study period, the patients were put on complete bed rest. Systemic hemodynamics (dynamics of blood flow) was measured by standard techniques. The heart rate of all the patients was monitored throughout the entire study using electrocardiogram. Three of eight subjects experienced a feeling of warmth 40–60 minutes after initiating IGF-1 infusion, which disappeared within 10-20 minutes. No other symptoms were reported during the entire study. After the duration of the treatment, IGF-1 administration tended to increase heart rate and cardiac output compared to placebo. In addition, IGF-1 administration improved stroke volume. No abnormal changes were observed on the electrocardiogram. In response to the intravenous infusion of 60 micrograms per kilogram of rhIGF-1, there was a significant increase in the levels of IGF-1 in all patients. Moreover, IGF-1 treatment led to a decrease in insulin and C peptide levels at the end of the infusion, suggesting that IGF-1 was able to increase insulin sensitivity (body’s response to the effects of insulin) in these patients.

     In conclusion, the results of the study showed that IGF-1 has the capacity to increase cardiac output and stroke volume in patients with chronic heart failure, suggesting that IGF-1 can improve the pumping action of the heart. The increase in cardiac output was due to dilation of the arteries and reduction in the pressure in the wall of the left ventricle during ejection (afterload). Moreover, the levels of norepinephrine significantly decreased during the IGF-1 infusion, which might indicate a beneficial effect on neurohumoral activation (increased activity of the sympathetic nervous system) in patients with chronic heart failure. Accordingly, IGF-1 appears to have a balanced vasodilatory effect on both arteries and veins. This effect can improve blood flow especially to vital organs in the body. Taken together, these results make IGF-1 of potential interest for the treatment of heart failure and other heart diseases.

207. Mieczyslaw Pokorski (8 July 2013). Neurobiology of Respiration. Springer Science & Business Media. pp. 26–. ISBN 978-94-007-6627-3.
     View Summary +

     Therapeutic Benefits of Insulin-like Growth Factor 1(IGF-1) in Atherothrombosis

     Atherothrombosis (AT) is characterized by narrowing or obstruction of the arteries that supply blood flow to the different parts of the body. AT starts when cholesterol deposits in the wall of the arteries. Overtime, these deposits known as plaque restricts blood flow in the affected artery. As blood flows over the plaque, stress forces are exerted on the plaque surface which causes it to rupture and form blood clot. This clot can be life-threatening because it can limit or completely stop blood flow and oxygen to certain organs (ischemia) such as the heart or brain, giving rise to heart attack or stroke. If you are obese and have high blood pressure and high cholesterol, then you are at risk for developing AT.

     IGF-1 contributes to regulate cellular growth, proliferation, specialization and survival against cell death, tissue remodeling, energy metabolism, regulation of brain network and networking, and protection of nerve cells, which ultimately influence one’s health. Among these effects, the metabolic function of IGF-1 appears more central in heart health and other related diseases. Owing to its crucial activities, there are several evidences showing a possible causative role of decreased IGF-1 levels in several heart diseases, including atherothrombosis, myocardial infarction, heart failure, diabetes, hypertension and kidney disease.

     Role of IGF-1 in Ischemia

     IGF-1 has been shown to play a critical role in the reduction of ischemia or reperfusion damage (caused when blood supply returns to the tissue after a period of ischemia), left ventricular dysfunction remodelling and in the recovery of ischemic cardiomyopathy (occurs when the heart doesn’t pump enough blood) through a reduction in cell death and inflammation. By optimizing the heart workload, improving the metabolism of glycolipid (lipids with a carbohydrate attached), and reducing blood clotting, IGF-1 can prevent or limit ischemia, reperfusion damage and dilatation of ventricles.

     IGF-1 Administration in Patients with Ischemia-related Diseases

     Acute IGF-1 administration in patients with chronic heart failure increased the amount of blood pumped by the left ventricle into the systemic circulation and decreased the pressure in the wall of the left ventricle during ejection, suggesting a possible therapeutic role in these patients. In line with these findings, subcutaneous administration of IGF-1 at a dose of 60 mircograms per kg of body weight in healthy volunteers also increased the amount of blood pumped by the left ventricle into the systemic circulation but the maximal exercise duration and peak oxygen consumption in these subjects were unchanged.

     In another study, subcutaneous injections of low doses of recombinant IGF-1 at 20 micrograms per kg of body weight in healthy adults increased the strength of contraction of the heart muscle while maintaining normal circulating levels of IGF-1.

     These evidences suggest that IGF-1 is a very important tool in the maintenance of heart and metabolic health, owing to its ability to counter the formation of blood clots and prevent ischemia while improving blood flow to certain body organs such as the heart. All of these mechanisms clearly demonstrate IGF-1’s therapeutic role in atherothrombosis and other ischemia-related diseases.

208. Sacheck JM, Ohtsuka A, Mclary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab. 2004;287(4):E591-601.
     View Summary +

     IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.
     

     The study titled “IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1” (Sacheck et al., 2004) explored the mechanisms by which IGF-I promotes muscle growth. The findings revealed that IGF-I inhibits muscle protein breakdown and reduces the expression of atrophy-related genes, atrogin-1 and MuRF1. This leads to increased protein synthesis and overall muscle protein gain.

209. Ben Atchison; Diane K. Dirette (2007). Conditions in Occupational Therapy: Effect on Occupational Performance. Lippincott Williams & Wilkins. pp. 145–. ISBN 978-0-7817-5487-3.
     View Summary +

     Conditions in Occupational Therapy: Effect on Occupational Performance.
     

     “Conditions in Occupational Therapy: Effect on Occupational Performance” is a book authored by Ben Atchison and Diane K. Dirette, published by Lippincott Williams & Wilkins in 2007. The book explores various conditions and their influence on occupational performance. It delves into how different health conditions impact individuals’ ability to engage in meaningful activities. With a focus on occupational therapy, the book provides insights into the assessment and treatment of these conditions to optimize occupational functioning. With an ISBN of 978-0-7817-5487-3.

210. Nystrom G, Pruznak A, Huber D, Frost RA, Lang CH. Local insulin-like growth factor I prevents sepsis-induced muscle atrophy. Metabolism: clinical and experimental. 2009; 58(6):787-97.
     View Summary +

     Local insulin-like growth factor I prevents sepsis-induced muscle atrophy.
     

     The study titled “Local insulin-like growth factor I prevents sepsis-induced muscle atrophy” (Nystrom et al., 2009) investigated the effects of locally administered IGF-I in preventing muscle atrophy during sepsis. The study found that IGF-I treatment increased muscle protein synthesis and reduced protein degradation, effectively preserving muscle mass in septic conditions. This suggests the potential therapeutic benefits of IGF-I in preventing sepsis-induced muscle atrophy.

211. Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Advances in therapy. 2009; 26(1):40-54.
     View Summary +

     Mecasermin (recombinant human insulin-like growth factor I)
     

     The article titled “Mecasermin (recombinant human insulin-like growth factor I)” by Rosenbloom (2009) reviewed the use of mecasermin in medical practice. Mecasermin, a synthetic form of IGF-I, is used to treat growth hormone insensitivity syndrome. The article discussed its clinical efficacy, dosing, and safety, primarily focusing on pediatric patients. Mecasermin was found to be beneficial, but it’s important to consult recent research and healthcare professionals for the latest information on its use.

212. Song YH, Song JL, Delafontaine P, Godard MP. The therapeutic potential of IGF-I in skeletal muscle repair. Trends in endocrinology and metabolism: TEM. 2013; 24(6):310-9.
     View Summary +

     The therapeutic potential of IGF-I in skeletal muscle repair.

     The article titled “The therapeutic potential of IGF-I in skeletal muscle repair” (Song et al., 2013) discussed the role of insulin-like growth factor I (IGF-I) in promoting skeletal muscle growth, regeneration, and repair. It explored the potential of IGF-I as a therapeutic option for muscle-related conditions such as muscle wasting diseases and injuries. The article highlighted the mechanisms by which IGF-I stimulates muscle repair and addressed challenges associated with its use. Overall, IGF-I shows promise as a treatment for skeletal muscle repair, but further research is needed to determine its effectiveness and optimal application.

213. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.
     View Summary +

     Regulation of muscle mass by growth hormone and IGF-I.

     The article titled “Regulation of muscle mass by growth hormone and IGF-I” (Velloso, 2008) explores the role of growth hormone (GH) and insulin-like growth factor I (IGF-I) in muscle growth, maintenance, and repair. It discusses the signaling pathways involved and their effects on protein synthesis, protein breakdown, and muscle cell differentiation. The article emphasizes the influence of factors like exercise and nutrition on GH and IGF-I levels. Overall, GH and IGF-I play important roles in muscle mass regulation.

214. Demling R. The use of anabolic agents in catabolic states. J Burns Wounds. 2007;6:e2. Published 2007 Feb 12.
     View Summary +

     The use of anabolic agents in catabolic states.
     

     The article titled “The use of anabolic agents in catabolic states” (Demling, 2007) discusses the potential benefits and applications of anabolic agents in conditions characterized by muscle wasting and metabolic disturbances. It explores the effects of anabolic agents on tissue growth and repair, specifically in burn injuries, trauma, critical illness, and chronic diseases. The article highlights the need for careful evaluation of their use, considering the specific clinical context and potential risks. While anabolic agents show promise, it’s important to consult more recent research and healthcare professionals for up-to-date information on their application in catabolic states.

215. Hameed M, Harridge SD, Goldspink G. Sarcopenia and hypertrophy: a role for insulin-like growth factor-1 in aged muscle?. Exerc Sport Sci Rev. 2002;30(1):15-9.
     View Summary +

     IGF-1 and Catabolic States

     Clinical investigators have shown that the levels of IGF-1 are often significantly altered in catabolic states, including the acute postoperative period, burn patients and chronic catabolic illnesses, such as cystic fibrosis and HIV with wasting. All of these conditions result in low levels of IGF-1 in the body, and significant changes in IGF-I positively correlate with changes in lean body mass, as well as reversal of acute catabolic states.

     In clinical use, children with extensive thermal burns who were treated with IGF-1 in combination with IGFBP-3, presented a reduction of inflammatory mediators such as IL-1β, TNF-α, C-reactive protein, α1-acid glycoprotein, and complement C-3 in the blood. In contrast, there is a significant increase in the blood levels of retinol-binding proteins, prealbumin, and transferrin, all of which play an important role in wound healing. From these results, researchers concluded that attenuating the pro-inflammatory acute phase with IGF-1/IGFBP-3 may prevent multiple organ failure and improve clinical outcomes after thermal injury without any detectable adverse side effects. Also, when IGF-1 was used to monitor total parenteral nutrition therapy in catabolic patients, the changes correlate with improvements in protein metabolism. Consistently, a close correlation between IGF-1 and protein synthesis in burn patients was reported. Similarly, extremely low IGF-I levels observed in severe malnutrition improved with caloric repletion.

     Several catabolic states result in relative resistance to GH, which is mediated by increases in the production of tumour necrosis factor (TNF) and interleukin 1 (IL1), both of which inhibit the production of IGF-1 and block its actions in several tissues. GH resistance has also been demonstrated in several catabolic states such as HIV with muscle wasting, nutritional deficiency, cystic fibrosis, celiac disease, anorexia nervosa, and burns. Interestingly, these catabolic patients responded to IGF-1 treatment with increases in protein synthesis and a positive or overall anabolic response. When IGF-1 is co-administered with IGBP3, it led to an increase in the synthesis of proteins.

     IGF1 is a potent growth factor for bone cells, and two studies, one in older patients with hip fracture and one in younger patients with anorexia nervosa, have been undertaken. Anorexic patients received IGF-1 alone while patients with hip fracture received IGF-1 and IGF binding protein-3 (IGBP3). Surprisingly, both studies showed improvements in bone mineral density (BMD).

     Studies have also been conducted in catabolic patients with muscle wasting disease. One study showed that 4 months of IGF-1 administration in patients with myotonic dystrophy (affects both smooth and skeletal muscles) resulted in improvements in muscle mass and strength.

     Normally, severely burned patients experience hypermetabolic phase wherein the body rapidly breaks down protein as a compensatory mechanism. The result is severe protein loss leading to muscle wasting. IGF-1 alone has been infused in burned patients with improvements in protein synthesis. However, co-administration of IGF-1 with IGBP3 in severely burned children significantly improved protein synthesis without any side effects. (16) These findings suggest that IGF-1 and IGBP3 whether given alone or co-administered with each other can have a positive impact in reversing catabolic states.

216. Cioffi WG, Gore DC, Rue LW, et al. Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury. Ann Surg. 1994;220(3):310-6; discussion 316-9.
     View Summary +

     Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury.
     

     The study by Cioffi et al. (1994) investigated the effects of insulin-like growth factor-1 (IGF-1) on protein oxidation in patients with thermal injury. The study found that administration of IGF-1 reduced protein oxidation levels in these patients, suggesting its potential in mitigating tissue damage and improving recovery. The results highlight the therapeutic benefits of IGF-1 in tissue healing. However, as the study was conducted in 1994, it’s advisable to refer to more recent research and consult healthcare professionals for the latest information regarding the use of IGF-1 in patients with thermal injury.

217. Song YH, Song JL, Delafontaine P, Godard MP. The therapeutic potential of IGF-I in skeletal muscle repair. Trends Endocrinol Metab. 2013;24(6):310-9.
     View Summary +

     The therapeutic potential of IGF-I in skeletal muscle repair.
     

     The article titled “The therapeutic potential of IGF-I in skeletal muscle repair” by Song et al. (2013) explores the potential of insulin-like growth factor I (IGF-I) in promoting skeletal muscle repair. The authors discuss the role of IGF-I in muscle growth, regeneration, and repair processes. They examine its effects on muscle satellite cell activation, proliferation, and differentiation. The article highlights the potential of IGF-I as a therapeutic option for muscle-related conditions such as muscle wasting diseases and injuries. However, it’s important to consider more recent research for the latest understanding and consult with healthcare professionals for the use of IGF-I in skeletal muscle repair.

218. Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int. 2000;57(2):646-54.
     View Summary +

     Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients.
     

     The study by Fouque et al. (2000) investigated the effects of recombinant human insulin-like growth factor-1 (IGF-1) on malnourished patients undergoing continuous ambulatory peritoneal dialysis (CAPD). The study found that IGF-1 induced an anabolic response in these patients, promoting muscle growth and counteracting the effects of malnutrition. These findings suggest the therapeutic potential of IGF-1 in combating muscle wasting associated with malnutrition in CAPD patients. However, it’s advisable to refer to more recent research and consult healthcare professionals for the most up-to-date information on the use of IGF-1 in this context.

219. Clemmons DR, Smith-banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab. 1992;75(1):234-8.
     View Summary +

     Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.
     

     The study by Clemmons et al. (1992) investigated the effects of recombinant insulin-like growth factor-I (IGF-I) infusion on diet-induced catabolism in humans. The study found that IGF-I infusion reversed the catabolic state induced by the diet, suggesting its potential for promoting anabolic processes and mitigating muscle breakdown. However, it’s recommended to refer to more recent research and consult healthcare professionals for the latest information on the use of IGF-I in reversing catabolism.

220. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res. 2001;56 Suppl 1:24-8.
     View Summary +

     Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration.
     

     The article by Kanda et al. (2001) focuses on steroid myopathy, its pathogenesis, and the effects of growth hormone (GH) and insulin-like growth factor-I (IGF-I) administration. The authors discuss the development of steroid myopathy and how GH and IGF-I can potentially mitigate its effects by promoting muscle protein synthesis and regeneration. They suggest that GH and IGF-I may have therapeutic potential for improving muscle strength in steroid myopathy patients. However, it’s important to consult more recent research and healthcare professionals for the latest understanding and application of GH and IGF-I in treating steroid myopathy.

221. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest. 2005;115(2):451-8
     View Summary +

     Insulin-like Growth Factor -1 (IGF-1) and Sarcopenia

     Sarcopenia is a syndrome that involves progressive generalized loss of skeletal muscle mass and strength. Affected individuals usually experience physical inactivity, decreased mobility, reduced physical endurance, and slow gait. It has been estimated that 15% of people 65 years old and above and as many as 50% of people 80 years old and above have sarcopenia. (1) The cause of sarcopenia is not yet known. However, multiple factors appear to be involved in the development of sarcopenia such as genetics, underlying medical conditions, and environmental factors. It has been suggested that the renin–angiotensin system in the kidneys may play a role in modulating muscle function. Circulating angiotensin 2 (a chemical that raises blood pressure) is associated with muscle wasting, low IGF-1 levels, and poor response to the effects of insulin, and could therefore contribute to sarcopenia. (2)

     Growth Factors: Potential Intervention for Sarcopenia

     Growth hormone (GH) is required for maintenance of muscle and bone. GH exerts most of its effects through IGF-1 which is synthesized in the liver for release in the bloodstream. IGF-1 is known to increase the production of muscle cells as well as muscle contractile proteins. (3) The strongest evidence for the use of GH supplementation in increasing muscle mass and strength appears to be in states of reduced GH secretion. In younger GH deficient adults, 3 years of GH supplementation was able to improve thigh muscle mass, strength, as well as exercise capacity. (4) However, in healthy non-GH deficient older people, some studies have shown an increase in muscle mass but no improvement in muscle strength, whereas some studies have shown an improvement in both.

     With increasing age comes the decline in GH and IGF-1 levels. There is evidence that such decline contributes to the development of sarcopenia. (5) IGF-1 is perhaps the most important mediator of muscle growth and repair in the body possibly by activating the Akt pathway. In one study, the administration of IGF-1 in patients with myotonic dystrophy (disease affecting both smooth and skeletal muscles) for 4 months resulted in improvements in muscle mass and strength. (6) In line with this findings, co-administration of IGF-1 with insulin-like growth factor-binding protein 3 (IGBP3) in severely burned children significantly improved protein synthesis without any side effects, suggesting that IGF-1 can reverse muscle wasting. (7)

     It has been shown that treatment using low doses of recombinant IGF-1 produces significant, but transient, nitrogen retention, which helps reverse the process of muscle wasting in HIV/AIDS. In the case of marked weight loss in patients with cancer, it was found that administration of lGF-1 together with IGFBP-3 significantly increased muscle protein synthesis. (8) Moreover, a high dosage level of this combination improved the patient’s food intake and blood sugar metabolism, and reduced weight loss. (9)

     With all of these studies, it can be concluded that the administration of IGF-1 in patients with sarcopenia might help inhibit or slow down the progressive generalized loss of skeletal muscle mass and strength related to this condition. Moreover, administration of IGF-1 together with GH and IGFBP-3 in patients with sarcopenia may have added beneficial effects on muscle mass and strength.

222. Isabel Varela-Nieto; Julie Ann Chowen (21 December 2005). The Growth Hormone/Insulin-Like Growth Factor Axis during Development. Springer Science & Business Media. pp. 250–. ISBN 978-0-387-26274-1.
     View Summary +

     Insulin-like Growth Factor-1 (IGF-1) Lowers Protein Breakdown in Patients with Thermal Injury

     Accelerated protein breakdown is a constant feature of hypermetabolic response to thermal injury or burns. Normally, severely burned patients experience hypermetabolic phase wherein the body rapidly breaks down protein as a compensatory mechanism. The result is severe protein loss leading to muscle wasting. Attempts to limit protein breakdown by experimental treatment with growth factors have been promising under certain conditions. (1) The administration of growth hormone (GH) at pharmacologic doses in fasting adults resulted in protein sparring effect. Clinical trials using GH in a variety of catabolic conditions was effective in conserving protein levels in the body. (2) However, in critically ill patients, GH has been shown to have reduced effectiveness in stimulating the release of IGF-1, thus, possibly explaining the failure of GH to reverse protein breakdown in some patients.

     Data confirming the role of IGF-1 in the regulation of growth and metabolism have expanded remarkably during the last decade. The availability of recombinant IGF-1 has opened new opportunities to study its potential benefits in patients with burn injury. According to statistics, 75% of all deaths in burn cases are related to sepsis or infection. (3) Following trauma, there is an immediate inflammatory response that quickly spreads throughout the body including the lungs, liver and intestines. Moreover, burn injury can impair blood circulation in the gut by causing constriction of blood vessels, thereby affecting oxygen levels.

     Both in human and animal studies, muscle breakdown induced by diet and tumor necrosis factor (TNF) have been reversed by the administration of IGF-1. (4) More importantly, IGF-1 has been shown to inhibit hypermetabolism and gut degeneration in burn patients. Furthermore, IGF-1 was able to reduce gut inflammation and bacterial translocation or clearance in burn patients.

     To determine the effects of continuous administration of recombinant IGF-1 on the catabolic response to burn injury in adult patients, Cioffi et. al studied 8 subjects with burns of more than 25% of their body surfaces. (5) Within 72 hours following injury, resting energy expenditure (REE) was measured. REE is the amount of energy required for a 24-hour period by the body during resting conditions. Enteral feedings (delivery of a nutritionally complete feed directly into the stomach) were initiated at a rate sufficient to meet the patient’s estimated calorie and protein needs. Oral intake was not allowed during the study period. Excision and grafting of the burn wounds were performed. After 3 days of nutritional intake, the researchers obtained body weight measurements, and blood levels of IGF-1, IGF-1 binding protein and glucose levels. After obtaining baseline measurements, each patient received an intravenous infusion of IGF-1 at a rate of 20 micrograms per kilogram per hour.

     The results of the study showed a significant rise in the levels of REE, IGF-1 and IGF binding protein with a concomitant decrease in GH while receiving IGF-1. Furthermore, the short-term anabolic effects of IGF-1 are preserved after severe burn injury in patients who were receiving full nutritional support. Although IGF-1 inhibited the secretion of insulin in these patients, it was able to display its protein-sparing effect, suggesting that IGF-1 may indeed inhibit protein breakdown in severely burned patients.

223. Marwarha G, Prasanthi JR, Schommer J, Dasari B, Ghribi O. Molecular interplay between leptin, insulin-like growth factor-1, and β-amyloid in organotypic slices from rabbit hippocampus. Molecular Neurodegeneration. 2011;6:41. doi:10.1186/1750-1326-6-41.
     View Summary +

     Insulin-like Growth Factor-1 in the Treatment of Skeletal Muscle Injury

     Skeletal muscle injuries are the most common injury in sports. Athletes sustain such injuries through a variety of mechanisms, including direct trauma or related to neurological dysfunctions. As muscle injuries heal, the complete recovery from the injury is now compromised because scar tissue develops in the affected area. Moreover, the formed scar tissue is always mechanically inferior and therefore much less able to perform the function of the injured muscle fiber, making it more susceptible to reinjury. (1, 2) To minimize the disability and enhance full functional recovery of patients suffering from muscle injuries, the current conservative treatment includes rest, ice, compression and elevation (RICE), anti-inflammatory drugs, and physical therapy.

     Therapeutic Role of IGF-1 in Skeletal Muscle Injury

     Recently, it has been suggested that growth factors such as insulin-like growth factor-1 (IGF-1) might have regenerative properties on the injured skeletal muscle. Since then, multiple research groups have attempted to find drugs that help regenerate injured skeletal muscle fibers. Several growth factors are capable of promoting muscle regeneration including basic fibroblast growth factor (bFGF), insulin growth factor (IGF), nerve growth factor (NGF), TGF-β1, and platelet-derived growth factor (PDGF). (4, 5)

     Takahashi and colleagues reported that gene delivery of IGF-1 via electroporation (DNA introduction into cell membranes using electricity) led to an increase in the number of regenerating muscle cells. (6) In line with this finding, Huard and colleagues injected IGF-1 in healthy old men. Surprisingly, IGF-1 administration prevented the loss of muscle mass that is related with aging. (7) In a mice model of muscle strain, Kasemkijwattana and colleagues reported that bFGF, NGF and IGF-1 administration at 1 to 3 and 5 days after injury improved muscle performance and muscle strength. (8, 9) In the treated group, the number of regenerating muscle fibers was increased 3.5 times for bGF and IGF-1 and 1.5 times for NGF, suggesting that specific growth factors have the ability to improve regeneration of injured muscle by stimulating the production of muscle fibers at the site of injury.

     When a skeletal muscle is injured, the body compensates by stimulating the growth factors to activate satellite cells within 18 hours of injury. (10) At the same time, inflammatory cells migrate to the injury site. Regeneration of single muscle fibers or entire muscles can only occur upon the activation of satellite cells. Growth factors have been shown to regulate the production, specialization, and fusion of muscle cells and satellite cells in vivo and in vitro, which are important in the complete functional recovery after muscle injury. Among these growth factors, NGF and IGF-1 are known to promote muscle repair in peripheral and central nervous system injuries. (11) NGF plays pivotal role in the muscle regeneration process while IGF-1 plays a role in increasing the number and size of regenerating muscle fibers after injury. (12) Aside from NGF and IGF-1, injection of b-FGF following muscle injury showed that this growth factor is a potent stimulator of the production and fusion of muscle fibers in vivo and in vitro. (13) With these findings, IGF-1 and other growth factors can be considered as a new therapeutic option for sports-related injuries in addition to RICE therapy, use of anti-inflammatory drugs, and physical therapy.

224.  Available at https://www.researchgate.net/publication/281677239_The_role_of_IGF-1_in_neurodegenerative_diseases.
     View Summary +

     Recombinant Human Insulin-like Growth Factor-1 Induces an Anabolic Response in Malnourished CAPD Pationt

     The principal role of the kidneys is to filter and remove waste products and excess fluid from the blood. In people whose kidneys are not functioning normally, dialysis is a way of replacing kidney function. There are two main forms of dialysis:

     Hemodialysis:-the blood is taken from the patient’s circulation and is passed through an artificial kidney, and then returned into the patient’s circulation. 

     Peritoneal dialysis:- this makes use of the internal lining of the abdomen (peritoneum) as the artificial kidney. During this procedure, the peritoneal membrane is bathed in dialysis fluid, allowing waste products to pass from the blood vessels into that fluid. After several hours, the fluid is drained out along with the waste products. Because peritoneal dialysis is a continuous process, it is known as continuous ambulatory peritoneal dialysis (CAPD).

     Many adult patients undergoing either maintenance hemodialysis or CAPD show evidence for protein-energy malnutrition. The incidence of malnutrition in patients undergoing CAPD ranges from approximately 18 to 56%. Several factors may cause malnutrition in CAPD patients. Because malnutrition is an important risk factor for increased incidence of illness and deaths in both hemodialysis and CAPD patients, this issue appears to be of considerable clinical importance.

     With the availability of growth factors, specifically recombinant human insulin-like growth factor-1 (rhIGF-1), a number of studies have examined the nutritional effects of this compound in malnourished patients. In the past years, the most commonly used anabolic agent has been recombinant growth hormone (rhGH). This hormone induces an anabolic response in patients with acute catabolic states but without kidney failure, and chronically malnourished patients in advanced kidney failure. However, the effectiveness of rhGH may be markedly reduced in both severe infection and in malnourished patients with a low protein and/or energy intake. Such impaired anabolic responsiveness is evident in malnourished patients undergoing dialysis who had sustained recurrent infections.

     To evaluate whether insulin-like growth factor-1 (IGF-1), the hormone which mediates most of the anabolic effects of GH, would be effective in promoting an anabolic response in malnourished CAPD patients, Fouque and colleagues studied six CAPD patients with protein-energy malnutrition who underwent nitrogen balance studies in a clinical research center for 35 days each. Each patient had documented marginal or low protein intakes that is thought to be the main culprit of their malnutrition. Each patient received a constant protein and energy diet in order to exclude the possibility that dietary modification might affect the metabolic response during the study. After a 15-day baseline phase, the participants received human rhIGF-1 at a dose of 50 to 100 micrograms per kilogram body weight every 12 hours via subcutaneous injections for the next 20 days.

     During the treatment with rhIGF-1, blood levels of IGF-1 increased by about 100% and nitrogen balance (marker of muscle and tissue growth) became strongly positive. This anabolic effect was observed within hours after starting rhIGF-1. In addition to this, the blood levels of phosphorus decreased significantly while calcium levels increased during the first several days of rhIGF-1 treatment. This is of important clinical significance since high phosphorus levels can cause damage to the body by pulling calcium out of the bones, making them weak. During the entire study, rhIGF-1 treatment was well tolerated by all patients.

     In conclusion, injections of rhIGF-1 induce a strong and sustained anabolic effect, as evidenced by a positive nitrogen balance in CAPD patients with protein-energy malnutrition. These results indicate that rhIGF-1 administration may be a safe and effective method for treating malnutrition in maintenance dialysis patients.

225. Westwood AJ, Beiser A, Decarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. 2014;82(18):1613-9.
     View Summary +

     Reversal of Diet-induced Catabolism by Infusion of Recombinant Insulin-like Growth Factor-1 (rhIGF-1) in Humans

     The body faces a catabolic state during the process of normal metabolism. This idea, opposed to an anabolic state in which body builds biological molecules, actually defines the breakdown of foods and essential nutrients needed for muscle and tissue growth process.

     The Process of Catabolism

     When food enters the body, your body naturally digests larger sized molecules into smaller ones. The idea of digestion actually implies catabolism. Once the food you eat are broken down into smaller particles, these chemical strains release energy. The catabolic process releases energy to help maintain normal muscle activity. In short, the process of catabolism acts as the sole energy provider for the proper preservation and growth of all body cells. Aside from fueling the body with energy, catabolism sometimes can lead to adverse health conditions. High rate of catabolism causes the body to lose significant amounts of muscle tissue and essential fat deposits in an attempt to find a source of stored energy.

     IGF-1’s Role in Catabolism

     Clinical investigators have shown that the levels of IGF-1 are often significantly altered in a wide array of catabolic states, including the acute postoperative period, burns, cystic fibrosis, HIV-AIDS and other muscle wasting diseases. All of these conditions result in low levels of IGF-1 in the body, and normalization of IGF-1 positively correlate with changes in lean body mass, as well as reversal of acute catabolic states. Treatment of catabolic conditions with IGF-1, the hormone that mediates some of the anabolic growth-promoting actions of growth hormone (GH), offers potential advantages of preventing the low blood sugar phenomenon caused by GH administration.

     To further assess the effects of recombinant insulin-like growth factor-1 (rhIGF-1) on healthy volunteers with diet-induced catabolism, Clemmons and colleagues studied six normal, young adult volunteers with induced state of moderate catabolism by restricting their daily dietary intake to 20 kilocalories per kilogram per day. During the last 6 days of the two 2-week diet-study periods, the volunteers received either IGF-1 (12 micrograms per kilogram per hour via intravenous infusion over 16 hours) or GH (0.05 mg per kilogram per day via subcutaneous injections). Interestingly, the results of the study showed an improvement in nitrogen balance (a measure of muscle growth) during the last 4 days of IGF-1 infusion. A similar effect was observed with GH administration. In addition to this, IGF-1 infusion decreased fasting blood sugar levels, while GH raised blood sugar values. Despite these differences in blood sugar levels, IGF-1 infusions decreased blood levels of insulin and the concentrations of connecting-peptide (a substance produced by the beta cells in the pancreas). On the other hand, GH raised insulin and connecting-peptide levels. At the dose of each hormone used, the reduction of nitrogen wasting produced by IGF-1 infusions in these patients was similar in magnitude and timing to that produced by GH administration. Moreover, the reduction in blood sugar levels produced by IGF-1 compared with the increase in blood sugar noted during GH administration could help benefit catabolic patients with high blood sugar levels.

     These findings suggest that although IGF-1 and GH exerts the same effect in reversing diet-induced catabolism, IGF-1 doesn’t cause high blood sugar levels upon administration. Moreover, IGF-1 administration is indeed a safe and effective therapeutic option in treating and slowing the progression of muscle tissue breakdown in catabolic states.

226. Ostrowski PP, Barszczyk A, Forstenpointner J, Zheng W, Feng ZP. Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer’s Disease. PloS one. 2016; 11(5):e0155733.
     View Summary +

     The Potential Therapeutic Role of Insulin-like Growth Factor 1 in Steroid Myopathy

     Steroid myopathy is a medical condition that causes weakness of the muscles of the upper and lower limbs and to the neck flexors. Excessive intake of corticosteroids is believed to be the cause of steroid myopathy. People who use steroid for the treatment of asthma, chronic obstructive pulmonary disease, polymyositis, rheumatoid arthritis, connective tissue disorders and other inflammatory processes are at increased risk for this condition. Although the exact mechanism of the muscle pathology is unclear, it may be associated with decrease protein production, alterations in carbohydrate metabolism, electrolyte disturbances, and impairment in the cell’s source of energy. In addition to this, sedentary lifestyle may increase the risk of muscle weakness in patients taking corticosteroids.

     Long Term Steroid Use Depletes Glutamine

     Glutamine is considered as an essential amino acid found in your muscles and plays a key role in protein synthesis. It is consists of 19% nitrogen, making it the primary transporter of nitrogen into your muscle cells. During strenuous activities, the levels of glutamine in your body decreases along with your strength, stamina and recovery, and it takes about a week for it to return to normal. Aside from vigorous training and activities, the levels of glutamine in the muscles fall with injury and disease in circumstances associated with increases in blood corticosteroids. Glutamine depletion increases your risk for steroid myopathy.

     There are mechanisms proposed on inhibitory effects of glucocorticoids and other steroids on protein synthesis:

     1. Steroids inhibit the transport of amino acids into the muscle, thus impairing protein synthesis.

     2. Steroids inhibit the stimulatory action of insulin-like growth factor-1 (IGF-1) in protein synthesis.

     3. Steroids inhibit the formation of muscular tissue.

     4. Steroids produce muscle weakness by lowering the levels of potassium and phosphate.

     Insulin-like Growth Factor-1 (IGF-1) Inhibits Glucocorticoid-induced Glutamine Synthetase

     The levels of IGF-1 are often significantly altered in catabolic states, including the acute postoperative period, burns, cystic fibrosis, HIV with wasting, and other chronic illnesses. Recently, glutamine synthetase has been reported to play a key role in the development of steroid myopathy. Glutamine synthetase is an enzyme that plays a major role in nitrogen metabolism and glutamine production. Recent studies have revealed that glutamine synthetase is induced by glucocorticoids and other steroids and may be related to the development of steroid myopathy. Although this enzyme is essential for protein synthesis and maintenance of muscles, steroid-induced glutamine synthetase may increase your risk for steroid myopathy. Several studies have shown the beneficial effects of IGF-1 in increasing muscle mass and strength. To determine the effects of IGF-1 in preventing steroid myopathy, Kimura and colleagues studied skeletal muscle cells treated with IGF-1. To increase the activity of glutamine synthetase in these muscle cells, dexamethosone (a type of steroid medication) was used. Interestingly, addition of IGF-1 at a dose of 750 milligrams per milliliters decreased glutamine synthetase to approximately 50%, suggesting that IGF-1 may indeed have a preventive effect in steroid myopathy.

     These results suggest that IGF-1 administration in patients with steroid myopathy can be of great therapeutic value. By inhibiting steroid-induced glutamine synthetase activity, IGF-1 might have beneficial effects in slowing down the progression of muscle weakness in these patients.

227. Available from https://www.researchgate.net/publication/304910663_Circulating_insulin-like_growth_factor_1_and_insulin-like_growth_factor_binding_protein-3_level_in_Alzheimer’s_disease_a_meta-analysis.
     View Summary +

     Muscle-specific Expression of IGF-1 Blocks Angiotensin II–induced Skeletal Muscle Wasting

     CHF is a leading cause of cardiovascular mortality and morbidity. It is associated with elevated levels of the potent vasoconstrictor angiotensin II and muscle wasting, which is an important predictor of poor outcome in patients with this disease. Recent studies using in vitro models of muscle atrophy have indicated that IGF-1 acts through Akt and Foxo to suppress atrogin-1/muscle ring finger–1 (atrogin-1/MuRF-1) transcription whose expression is elevated in various muscle atrophy models.

     In vivo studies have indicated that apoptosis (cell death) is also involved in muscle wasting. Furthermore, Yao-Hua Song et al have recently shown that activation of caspase-3 (crucial mediators of programmed cell death or apoptosis) contributes to protein breakdown in catabolic conditions such as uremia or diabetes and leaves a characteristic 14-kDa actin fragment in muscle. In view of the potent anabolic and antiapoptotic effects of IGF-1, Yao-Hua Song et al demonstrated that reduced levels of IGF-1 signaling in response to angiotensin II would lead to a coordinated activation of both caspase-3–mediated apoptosis and activation of the ubiquitin-proteasome (Ub-P’some) pathway, resulting in loss of skeletal muscle. To demonstrate that caspase-3 activation is required in angiotensin II–induced muscle wasting, the researchers administered a caspase inhibitor Z-Asp-2,6-dichlorobenzoyloxymethylketone to mice. This inhibitor has been shown to inhibit caspase-3 activation and ameliorate apoptosis and cardiac remodeling in rats with myocardial infarction. The results of the study showed that the caspase inhibitor markedly blunted the wasting effect of angiotensin II. Thus, there was no statistically significant difference in body and muscle weight between angiotensin II–infused and pair-fed groups treated with caspase inhibitor after 5 days

     In summary, angiotensin II–induced muscle wasting is mediated by reduced action of IGF-1 in skeletal muscle resulting from decreased IGF-1 expression and signaling, which lead to stimulation of the Ub-P’some pathway, activation of caspase-3, and apoptosis. Targeting the IGF-1 pathway in catabolic conditions, particularly those in which the renin-angiotensin system is activated, will likely provide therapeutic benefit. These findings have important implications for understanding mechanisms of weight loss in conditions such as heart failure, in which the renin-angiotensin system is activated, and provide a strong rationale for developing therapeutic strategies to activate the skeletal muscle IGF-1 system in wasting conditions.

228. Arai Y, Hirose N, Yamamura K. Serum insulin-like growth factor-1 in centenarians: implications of IGF-1 as a rapid turnover protein. The journals of gerontology. Series A, Biological sciences and medical sciences. 2001; 56(2):M79-82.
     View Summary +

     The Role of IGF-1 on Muscle Wasting: a Therapeutic Approach

     While much has been learned about skeletal muscle formation in the embryo, less is known about the molecular pathways controlling the survival and plasticity of muscle cells in the adult. The complex contractile properties of skeletal muscle depend upon several factors such as physical activity, diet, oxygen supply, and changes in hormone levels and motor-neuron activity. Fiber type is an essential determinant of muscle function and alteration, and is considered as a major component in muscle wasting associated with muscle diseases. In this context, the prolongation of skeletal muscle strength in aging and neuromuscular disease has been the objective of numerous studies employing a variety of approaches. Several studies have focused on the potential therapeutic role of insulin-like growth factor 1 (IGF-1) in treatment of muscle wasting associated with several muscle diseases.

     Role of IGF-1 on Muscle Differentiation

     IGF-1 has been implicated in many anabolic pathways in skeletal muscle and it plays a central role during muscle regeneration. Unlike other growth factors, IGF-1 also stimulates differentiation and enlargement of muscle cells in vivo and in vitro, suggesting that this growth factor can regulate both proliferative and differentiative responses in muscle cells. The effects of IGF-1 on proliferation and differentiation are temporally separated. IGF-1 plays its roles step by step, first acting upon the replication of myoblast (an embryonic cell that becomes a cell of muscle fiber) and subsequently promoting muscle cell differentiation. Several experimental evidences suggest that IGF-1 exerts its functions by activating two different intracellular signal transduction pathways, conveying proliferative and differentiative signals, respectively. The proliferative response is mediated by the MAP-kinase pathway, whereas the pathway leading to differentiation involves the activation of PI3-Kinase.

     Role of IGF-1 on Muscle Homeostasis

     IGF-1 plays a key role in muscle development in vivo, and IGF-1 secretion also facilitates muscle regeneration after injury and in denervated muscle. To test the possibility that enhanced IGF-1 expression could affect a similar muscle hypertrophic response in muscle tissue in vivo, Musaro et al recently generated a transgenic mouse in which the local isoform of IGF-1 (mIGF-1) is driven by myosin light chain promoter (MLC/mIGF-1), thus specifically restricted to skeletal muscle tissue. Transgenic mice exhibit marked skeletal muscle hypertrophy with dramatic reduction in body fat and no undesirable side effects such as tumor formation, as revealed in transgenic mice over-expressing the circulating IGF-1 isoform. Examination of older mice revealed that expression of the mIGF-1 transgene was protective against normal loss of muscle mass during senescence. Moreover mIGF-1 expression promotes and preserves the regeneration capacity of muscle tissues during aging, suggesting that IGF-1 expression preserves muscle integrity and the heterogeneity of myofibers, two fundamental parameters of muscle function. More recently, muscle-specific expression of mIGF-1 counters muscle wasting in mdx mouse which represent the animal model of human Duchenne and Becker muscular dystrophy. High levels of mIGF-1 transgene expression in the mdx mouse preserves muscle function in the absence of dystrophin, inducing significant muscle enlargement at all ages, and elevating signaling pathways associated with muscle survival and regeneration.

     IGF-1 and Therapeutic Strategies

     IGF-1 represents a good candidate to sustain muscle hypertrophy and to improve muscle regeneration. Gene therapy represents a promising tool to cure, when it is possible, or attenuate the genetic diseases leading to muscle wasting. Introduction of mIGF-1 somatically using an AdenoAssociated-Viral (AAV) vector was sufficient to rejuvenate the leg muscles of 27 month old mice, which exhibited the same mechanical force as legs of younger mice, and did not develop the pathological characteristics of senescent muscle. The dramatic muscle enlargement induced by expression of virally delivered IGF-1 is the consequence of a combination of satellite cell activation and an increase of protein synthesis. In addition, age-related reduction in force production and loss of fast fibers, all of which are typical of ageing skeletal muscle, were prevented both by virally delivered IGF-1 gene expression. Understanding the signal transduction pathways involved in muscle wasting will help to devise therapeutic strategies to combat muscle degeneration.

229. Available from https://www.researchgate.net/publication/318677033_Risk_of_prevalent_and_incident_dementia_associated_with_insulin-like_growth_factor_and_insulin-like_growth_factor-binding_protein_3
     View Summary +

     Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3
     

     The study examined the association between insulin-like growth factor (IGF), insulin-like growth factor-binding protein 3 (IGFBP-3), and the risk of prevalent and incident dementia. The researchers investigated the relationship between IGF and IGFBP-3 levels and the occurrence of dementia, including Alzheimer’s disease. The findings suggest that there may be a potential risk of developing dementia associated with IGF and IGFBP-3. However, it is important to consider additional research and consult with healthcare professionals for a comprehensive understanding of the relationship between IGF, IGFBP-3, and dementia risk.

230. Watanabe K, Uemura K, Asada M. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer’s disease. Molecular brain. 2015; 8(1):82.
     View Summary +

     The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer’s disease.

     The article by Watanabe et al. (2015) explores the role of insulin-like growth factor-binding protein 3 (IGFBP-3) released by astrocytes in the pathology of Alzheimer’s disease (AD). It discusses the interaction between IGFBP-3 and amyloid-beta (Aβ), highlighting their impact on AD progression, including Aβ aggregation, neuronal cell death, and neuroinflammation. The article suggests that targeting IGFBP-3 release from astrocytes may have therapeutic potential for AD. However, more research is needed to fully understand the mechanisms and clinical implications. Consult healthcare professionals for the latest information on IGFBP-3 and AD.

231. Zhou Y-L, Liu S-Q, Yuan B, Lu N. The expression of insulin-like growth factor-1 in senior patients with diabetes and dementia. Experimental and Therapeutic Medicine. 2017;13(1):103-106. doi:10.3892/etm.2016.3961.
     View Summary +

     The expression of insulin-like growth factor-1 in senior patients with diabetes and dementia.

     The study by Zhou et al. (2017) examined the expression of insulin-like growth factor-1 (IGF-1) in senior patients with diabetes and dementia. The researchers investigated the potential relationship between IGF-1 and these two conditions. The study found that the expression of IGF-1 was significantly lower in senior patients with both diabetes and dementia compared to those without dementia. These findings suggest a possible link between reduced IGF-1 levels and the co-occurrence of diabetes and dementia in older individuals.

232. Puglielli L. Aging of the brain, neurotrophin signaling, and Alzheimer’s disease: is IGF1-R the common culprit? Neurobiology of aging. 2008;29(6):795-811. doi:10.1016/j.neurobiolaging.2007.01.010.
     View Summary +

     IGF-1 and Neurodegenerative Diseases

     Neurodegenerative diseases are a diverse group of disorders from virtually unknown cause, which eventually lead to nerve degeneration and dysfunction. The GH/IGF-I axis is involved in many aspects of brain development, growth and function, their progressive decline with age could be related with a variety of diseases, including Alzheimer’s disease, vascular dementia, amyotrophic lateral sclerosis and stroke. Alzheimer’s disease (AD) and vascular dementia (VD) are the most common forms of dementia in the elderly. A decrease in IGF-1 levels in both of these diseases has been widely documented and it may be involved in the development of abnormal brain structures, cognitive loss, neural inflammation, oxidative stress or mitochondrial dysfunction.

     The brains of people with AD have an abundance of abnormal structure called amyloid plaques, which are sticky buildup outside the nerve cells, or neurons. Recent advances in medicine have shown that brain amyloid clearance is modulated by serum IGF-I. In fact, blockade of systemic IGF-I action at the choroid plexus (network of blood vessels in each ventricle of the brain) was sufficient to induce amyloid build up on the walls of the arteries in the brain. Another well recognized finding in AD is the accumulation of abnormally hyperphosphorylated Tau (hallmark of neurodegenerative disorders) in degenerating neurons. IGF-I is known as inhibitors of Tau phosphorylation by inhibiting a major Tau kinase, such as glycogen synthase kinase-β. This inhibitory action of IGF-1 helps control the levels of hyperphosphorylated Tau in brain. Two other pathological processes underlying neuronal decline in AD are gaining attention: oxidative stress and inflammation. Again, the ability of IGF-1 to fight inflammation, protect cells from free radical-induced damage, and to reduce the incidence of programmed cell death, endorses IGF-I as a suitable candidate for the treatment of AD.

     On the other hand, amyotrophic lateral sclerosis (ALS) is the most common motor neuron disorder in adults. Beneficial effects of IGF-I treatment in ALS have been demonstrated both in vivo and in vitro, from which IGF-I has been shown to be an important factor for the maintenance and survival of motor neurons in the spinal cord by activating clue pathways as PI3K/Akt and p44/42 MAPK.

     Cerebrovascular accident (CVA) or also known as stroke is currently the second leading cause of death in the Western world, ranking after heart disease and before cancer. Studies on patients with ischemic stroke suggest that high circulating IGF-I levels are associated with neurological recovery and a better functional outcome, probably because IGF-1 has the ability to protect neurons and prevent programmed cell death.

233. Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464(7288):529-535. doi:10.1038/nature08983.
     View Summary +

     Neural mechanisms of ageing and cognitive decline.

     The article by Bishop et al. (2010) explores the neural mechanisms underlying aging and cognitive decline. It investigates the molecular, cellular, and synaptic changes that occur in the aging brain and contribute to cognitive impairment. The study highlights factors such as oxidative stress, inflammation, and dysregulation of neurotrophic factors in the context of aging and cognitive decline. By elucidating these mechanisms, the research provides valuable insights into the complex processes involved in age-related cognitive decline. It paves the way for further investigations and potential interventions aimed at preserving cognitive function in aging individuals.

234. Hong M, Lee VM. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem. 1997;272(31):19547-53.
     View Summary +

     Insulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons

     Aggregation of insoluble proteins known as tau is most commonly known as a primary marker of Alzheimer’s disease. Hyperphosphorylation (biochemical process that involves the addition of excess phosphate to an organic compound) is thought to be a critical event in the development of this disease. Tau proteins help stabilize microtubules and are abundant in neurons (nerve cells) of the central nervous system. Microtubules play a major role in cell migration and cell division. Tau accumulates in neurofibrillary tangles in the brains of patients with Alzheimer’s disease. There is significant evidence that a disruption in the normal phosphorylation events results in tau dysfunction. Hyperphosphorylation impairs the microtubule binding function of tau. The predominant component of the tangle which is the major cause of Alzheimer’s disease is an abnormal fibrous assembly known as the paired helical filament (PHF), which is formed by a twisted double-helical ribbon. It has been hypothesized that the reduced binding ability of PHF-tau to microtubules along with a decline in the levels of normal tau, destabilizes microtubules in Alzheimer’s disease. This results in the disruption of chemical signals and degeneration of affected neurons.

     Recently, glycogen-synthase kinase-3 (GSK-3) has been shown to phosphorylate tau in vitro and in non-neuronal cells introduced with tau. The activity of glycogen-synthase kinase-3 can be inhibited in response to insulin or insulin-like growth factor-1 (IGF-1) through the activation of the phosphatidylinositol 3-kinase (PI(3)K-PKB) pathway and affect tau phosphorylation in neuronal cells. To test this hypothesis, Hong and colleagues studied human NT2N neurons, which are derived from a human teratocarcinoma (type of testicular cancer) cell line after treatment with retinoic acid.[1] These NT2N cells resemble embryonic central nervous system neurons as well as the characteristics of tau.[2] Using this system, the researchers were able to demonstrate that insulin and IGF-1 has the ability to reduce tau phosphorylation and promote tau binding to microtubules through the inhibition of GSK-3 via the PI(3)K-PKB signaling pathway. They treated 2–4-week-old NT2 cells with retinoic acid for 5 weeks and kept it in a culture medium. To study the effects of insulin and IGF-1, NT2N cells were treated with 100 ng/ml of insulin or 10 ng/ml of IGF-1 for 5 min. The researchers also examined the effects of GSK-3 on tau binding to microtubules.

     The results of the study showed that in NT2N cells treated with insulin and IGF-1, T1 immunoreactivity increased, indicating a reduction of tau phosphorylation. This effect is achieved by 100 ng/ml of insulin and 10 ng/ml of IGF-1. In addition to this, in cells treated with GSK-3, a significant amount of tau was bound to microtubules in cells, suggesting that GSK-3 phosphorylates tau at multiple sites and reduces the affinity of tau for microtubules. These findings suggest that the inhibition of GSK-3 by insulin or IGF-1 via the PI(3)K-PKB pathway can help regulate tau phosphorylation in human neurons, thereby preventing the development or progression of neurodegenerative diseases such as Alzheimer’s disease. The identification of these pathways brings new insights to the study of treatment options for Alzheimer’s disease. It raises the possibility that defects in this pathway may contribute to the development or progression of neurodegenerative diseases.

235. Marques F, Sousa JC, Sousa N, Palha JA. Blood–brain-barriers in aging and in Alzheimer’s disease. Molecular Neurodegeneration. 2013;8:38. doi:10.1186/1750-1326-8-38.
     View Summary +

     Blood–brain-barriers in aging and in Alzheimer’s disease.
     

     The article by Marques et al. (2013) focuses on the blood-brain barriers (BBBs) in aging and Alzheimer’s disease (AD). It examines the alterations and dysfunction of BBBs in the context of these conditions. The study explores the impact of aging and AD pathology on the integrity and function of BBBs, including changes in transport mechanisms, inflammatory responses, and vascular abnormalities. Understanding the role of BBB dysfunction in aging and AD contributes to the knowledge of disease mechanisms and may offer potential targets for therapeutic interventions. This research sheds light on the complex interplay between the brain and systemic factors in the context of aging and AD-related pathologies.

236. Lunn JS, Sakowski SA, Hur J, Feldman EL. Stem Cell Technology for Neurodegenerative Diseases. Annals of neurology. 2011;70(3):353-361. doi:10.1002/ana.22487.
     View Summary +

     Stem Cell Technology for Neurodegenerative Diseases.

     The article by Lunn et al. (2011) discusses the application of stem cell technology for the treatment of neurodegenerative diseases. It highlights the potential of stem cells in regenerative medicine, focusing on their ability to differentiate into various neural cell types and replace damaged or lost neurons. The study explores different approaches, such as embryonic stem cells, induced pluripotent stem cells, and adult stem cells, in preclinical and clinical settings for neurodegenerative diseases. The research emphasizes the promise of stem cell-based therapies in addressing the underlying causes and promoting neuronal repair in conditions like Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).

237. De la Monte SM. Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease. Drugs. 2012;72(1):49-66. doi:10.2165/11597760-000000000-00000.
     View Summary +

     Contributions of Brain Insulin Resistance and Deficiency in Amyloid-Related Neurodegeneration in Alzheimer’s Disease

     The article by De la Monte (2012) explores the contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease (AD). The study investigates the role of insulin signaling in the brain and its implications for the development and progression of AD. It discusses how insulin resistance and deficiency can lead to impaired neuronal function, increased amyloid-beta accumulation, and neurodegeneration. The research highlights the potential link between insulin-related abnormalities and the pathogenesis of AD, suggesting that targeting insulin signaling pathways may hold therapeutic potential for the disease. This study sheds light on the complex interplay between insulin, amyloid-related neurodegeneration, and AD pathology.

238. George C, Gontier G, Lacube P, François JC, Holzenberger M, Aïd S. The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons. Brain : a journal of neurology. 2017; 140(7):2012-2027.
     View Summary +

     The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons.

     The study by George et al. (2017) examines the transcriptome of Alzheimer’s disease (AD) and compares it to the neuroprotective signature observed in neurons deficient in the insulin-like growth factor-1 (IGF-1) receptor. The research aims to identify common molecular pathways and potential therapeutic targets in AD. The study reveals that the transcriptome of AD closely resembles the neuroprotective signature seen in IGF-1 receptor-deficient neurons, suggesting shared mechanisms of neuroprotection and neurodegeneration. These findings provide insights into the molecular underpinnings of AD and may guide the development of novel therapeutic approaches targeting the IGF-1 signaling pathway.

239. Zheng WH, Kar S, Doré S, Quirion R. Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. Journal of neural transmission. Supplementum. 2000.
     View Summary +

     Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway.

     The study by Zheng et al. (2000) focuses on insulin-like growth factor-1 (IGF-1) as a neuroprotective trophic factor. It explores the mechanism by which IGF-1 exerts its neuroprotective effects through the Akt kinase pathway. The research highlights the importance of IGF-1 in promoting neuronal survival and function, particularly in the context of neurodegenerative diseases. The study sheds light on the molecular pathways involved in the neuroprotective actions of IGF-1, providing insights into its therapeutic potential for various neurological conditions.

240. Correia SC, Santos RX, Cardoso S. Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer’s disease? Current aging science. 2010; 3(2):113-26.
     View Summary +

     Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer’s disease?
     

     The article by Correia et al. (2010) investigates the effects of estrogen in the brain and explores its potential as a neuroprotective agent in Alzheimer’s disease (AD). The study focuses on the role of estrogen in modulating neuronal function and its potential impact on AD pathology. It examines the neuroprotective properties of estrogen, including its ability to enhance synaptic plasticity, promote neurogenesis, and reduce oxidative stress and neuroinflammation. The research suggests that estrogen may have therapeutic potential in AD by mitigating disease-related mechanisms. However, further investigations are needed to fully understand the complexities of estrogen’s effects in the brain and its implications for AD treatment.

241. Gasparini L, Xu H. Potential roles of insulin and IGF-1 in Alzheimer’s disease. Trends in neurosciences. 2003; 26(8):404-6.
     View Summary +

     Potential roles of insulin and IGF-1 in Alzheimer’s disease.
     

     The article by Gasparini and Xu (2003) explores the potential roles of insulin and insulin-like growth factor-1 (IGF-1) in Alzheimer’s disease (AD). It examines the influence of these signaling molecules on brain function and their involvement in AD pathology. The study highlights the potential impact of insulin and IGF-1 in regulating neuronal survival, synaptic plasticity, and amyloid-beta metabolism, which are crucial processes affected in AD. The research suggests that dysregulation of insulin and IGF-1 signaling pathways may contribute to AD development and progression. Understanding the roles of insulin and IGF-1 in AD provides insights into potential therapeutic strategies targeting these pathways for the treatment of the disease.

242. Deak F, Sonntag WE. Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1. J Gerontol A Biol Sci Med Sci. 2012;67(6):611-25.
     View Summary +

     Aging, Synaptic Dysfunction, and Insulin-Like Growth Factor (IGF)-1

     Aging has long been associated with a wide array of nervous system dysfunctions including impairment in the senses, changes in appetite, memory problems, and difficulty in finding adequate expressions and words. Studies on brains from a variety of mammals including humans conclude that a reduced number of synaptic connections (enhances the transmission of signals of nerve cells) among nerve cells or neurons, is the most consistent correlate with ageing and decline in cognitive function. (1, 2) In humans and other mammalian species, the complex role of IGF-1 in the body has been linked to improvements in cognitive function by affecting synaptic structure and activity.

     IGF-1 and Synapses

     To better understand the relationship between IGF-1 and the synapse, it is important to understand first how the synapse works. The synapse is a small gap at the end of a nerve cell that permits a signal to pass from one nerve cell to the other. Once a nerve impulse has triggered the release of brain chemicals, they will cross the synaptic gap until they reach the end of the nerve cell.

     IGF-1 has multiple effects on the synaptic structure and brain plasticity (ability to change throughout life) that are beneficial in maintaining cognitive function. IGF-1 is known to increase the activity of N-methyl-D-aspartate receptor (NMDA receptor or NMDAR) and inhibits FOXO transcription factor. (3) These changes are known to reduce programmed cell death in the brain, thereby, preventing cognitive decline.

     Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), and Cognitive Function in Humans

     In humans, growth hormone deficiency in children and adults has been linked with attention and memory problems as well as mood disorders. (4) Moreover, impairments in short-term and long-term memory were reported in men with childhood-onset growth hormone deficiency compared with normal participants (5). In this study, replacement of growth hormone for 6 months at doses sufficient to increase blood levels of IGF-1 resulted in significant improvements in short- and long-term memory. In addition to this, restoration of IGF-1 to normal adult levels resulted in improvements in memory after 1 year. (6)

     Multiple studies have established that IGF-1 and its signaling pathway play a pivotal role in treating cognitive impairments in the elderly. These studies have similar results: that high levels of IGF-1 were associated with better information processing speed and better maintenance of cognition. (6, 7, 8) Other studies showed a correlation between age, IGF-1 levels, and cognition status. Researchers found out that IGF-1 levels in the brain of middle age people are lower compared with younger ones, thus, suggesting that younger people with high levels of IGF-1 have better cognitive function.

     Hormone replacement using IGF-1 is one of only a few therapeutic interventions that have consistently been reported to reverse cognitive decline associated with the process of ageing. Despite the well-recognized positive effects of IGF-1 on the synaptic structure and function, as well as cognitive function, further studies are needed to determine the complex role of IGF-1 in neurodegenerative diseases. Further research and advances in this field will identify targets for selective therapeutic interventions in the older population.

243. Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci USA. 2000;97(18):10236-41.
     View Summary +

     Insulin-like growth factor 1 Regulates Developing Brain Glucose Metabolism

     The brains of mammals including humans depend upon blood sugar or commonly known as glucose as its main source of energy, and proper glucose metabolism is critical for brain physiology. Disruption in the normal glucose metabolism as well as its interdependence with cell death pathways are the main causes of many brain disorders. The largest proportion of brain energy is consumed for information processing. (1) Additionally, glucose metabolism provides the energy and precursors for the production of brain chemicals. Dependence of the brain on glucose as its main source of energy derives mainly from the ability of the blood-brain barrier (BBB) to allow the entrance of glucose in the brain. Normally, glucose can’t be replaced as an energy source but it can be supplemented such as during vigorous activities or during prolonged starvation. (2)

     Murine and human brains consume over half of glucose for energy. (3) When undernutrition, it may result in permanent intellectual deficit. (4) Insulin preferentially enhances the energy source by peripheral tissues, but does not seem to play a role in the regulation of brain metabolism (3). However, insulin-like growth factor 1 (IGF-1) is abundant in the developing brain. (5) Although the exact action of IGF-1 in brain development is not yet known, its importance seems clear because the deletion of the IGF-1 gene in humans results in mental retardation. (6)

     To determine how IGF-1 works in the brain, Cheng and colleagues investigated glucose utilization in IGF1-targeted gene deletion mice. (7) The mice used in this study were from an IGF-1 deletion line which has been bred for several years. This study provided multiple lines of evidence indicating that IGF-1 can augment brain glucose utilization just like the action of insulin. Also, administration of IGF-1 through microinjections increases brain glucose utilization in these mouse models.

     In vitro studies have suggested many potential roles for IGF-1 in the development and function of the human brain. (8, 9, 10) The specific mechanisms exerted by IGF-1, however, are determined by the location and time of IGF-1 production. IGF-1 may promote process growth and synapse formation in mature and developing brains. Interestingly, the absence of IGF-1 during human brain development results in smaller cells with fewer processes and synapses, leading to mental retardation. These observations suggest that therapeutic augmentation of brain glucose metabolism by IGF-1 may enhance the potential for cognitive development.

     Glucose Metabolism and the Regulation of Blood Flow to the Brain

     Under resting conditions, the blood flow to the brain is highest in regions with the highest glucose metabolism. It is known that impairment in blood circulation to the brain may be an early cause of degeneration of brain cells, which can lead to vascular dementia and Alzheimer’s disease. (11) Also, it is a known fact that when oxygen supply to the brain is cut off for about five minutes, brain death can occur immediately. Thus, fine-tuned glucose metabolism through the help of healthy levels of IGF-1 is necessary for the prevention of the progressive loss of structure or function of brain cells.

244. Shavali S, Ren J, Ebadi M. Insulin-like growth factor-1 protects human dopaminergic SH-SY5Y cells from salsolinol-induced toxicity. Neurosci Lett. 2003;340(2):79-82.
     View Summary +

     Insulin-like Growth Factor-1 Protects Human Dopaminergic SH-SY5Y Cells from Salsolinol-induced Toxicity

     Parkinson’s disease (PD) is characterized by an extensive loss of dopaminergic neurons in the brain. Dopaminergic neurons or nerve cells are the main source of dopamine, which has major roles in memory, attention, cognition and other brain functions. Aside from aging, exposure to either pesticide or the neurotoxin salsolinol has been shown to mimic this dopaminergic cell loss. It has also been observed that the levels of salsolinol and its derivatives (e.g. norsalsolinol, N-methyl-norsalsolinol, N-methylsalsolinol) are increased in the cerebrospinal fluid and urine of patients with unknown cause of PD.[1] Because norsalsolinol derivates are found in low or undetectable concentrations in healthy subjects, its role as a diagnostic marker for PD has been proposed. Salsolinol and its derivatives are synthesized in terminals of dopaminergic cells in the brain. During unfavorable conditions, salsolinol and/or one of its derivatives can participate in the subsequent development of PD. Therefore, researchers are now focusing on compounds that have the ability to protect dopaminergic neurons against cell death induced by salsolinol and its derivatives.

     The Protective Role of Insulin-like Growth Factor 1 (IGF-1) in the Brain

     IGF-1 induces survival, growth, development and function of nerve cells in the brain. Its role in cell survival by preventing cell death through activation of PI3K/Akt (signaling pathway) and inhibition of FOXO transcription factor, which regulates cell death, is one of the most important functions of IGF-1 in the brain.[2] In addition to this, IGF-1 is known to counter the effects of oxidative stress, which is one of the main mechanisms proposed to contribute to brain aging and development of neurodegenerative disease. Furthermore, IGF-1 possesses the ability to lower the production of inflammatory substances such as prostaglandins and cytokines which are associated with various neurodegenerative diseases including PD.

     The ability of IGF-1 to protect the nerve cells is of great therapeutic value in patients with PD as well as other neurodegenerative diseases. To further elucidate its protective effects, Shavali and colleagues created a model of salsolinol-induced toxicity using human dopaminergic SH-SY5Y cells.[3] SH-SY5Y cells are human derived cell lines used in scientific research. The researchers treated these cells with salsolinol and a decrease in cell viability is observed 24 hours after exposure. To counter these effects, these cells were treated with IGF-1 and IGF-1 gene transfer was performed. Interestingly, IGF-1 administration as well as gene transfer prevented cell death induced by salsolinol. To further determine how IGF-1 exerts this effect, the researchers treated the cells with wortmannin, a specific phosphatidylinositol-3-kinase (PI-3 kinase) inhibitor. PI-3 kinase is a family of enzymes involved in cellular functions such as cell growth, proliferation and survival. The researchers observed that wortmannin administration completely blunted the IGF-1-induced nerve cell protection, suggesting that PI-3 kinase pathway is critical in mediating the protective effects of IGF-1 in various cell types including nerve cells.

     These results confirm the protective effects of IGF-1 in the nerve cells of the brain, suggesting that IGF-1 can indeed be a therapeutic option in a wide array of neurodegenerative diseases such as PD.

245. Cheng B, Maffi SK, Martinez AA, Acosta YP, Morales LD, Roberts JL. Insulin-like growth factor-I mediates neuroprotection in proteasome inhibition-induced cytotoxicity in SH-SY5Y cells. Mol Cell Neurosci. 2011;47(3):181-90.
     View Summary +

     Insulin-like Growth Factor-I Mediates Neuroprotection in Proteasome Inhibition-Induced Cytotoxicity in SH-SY5Y Cells

     Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects one’s movement that results from the death of dopaminergic neurons (main source of dopamine, which has major roles in memory, attention and cognition) in the brain. Several evidence shows that ubiquitin-proteasome system (UPS) dysfunction may activate intracellular stress responses that damage the powerhouse of the cell called mitochondria. The UPS system helps in eliminating unneeded or damaged proteins in the body by tagging or marking abnormal proteins with ubiquitin so that it can be easily identified by proteasome for degradation or break down. At present, this sequence of events triggers the development of PD. In patients with nonfamilial (sporadic) PD, abnormalities in the function and structure of proteasomes of neurons (nerve cells) can be found. More recent work has shown that systemic exposure of animal models to synthetic and naturally occurring proteasome inhibitors results in a syndrome that is very similar to PD.

     Pharmacological inhibition of the proteasome is sufficient to induce cell death in neuron cultures and neuronal cell lines, suggesting that proteasome inhibition may play an essential role in PD and other neurodegenerative diseases. Proteasome inhibition in cultured dopaminergic neurons has been shown to cause mitochondrial dysfunction, decreased levels of glutathione, and increased generation of free radicals. Moreover, defects in the UPS participate in the development of various neurodegenerative disorders, thus, the UPS is an attractive target for treatment options in PD

     Insulin-like growth factor-1 (IGF-1) is a hormone that is essential for the development of the nervous system. IGF-1 receptors are distributed over most brain regions and regulate cell growth, specialization and survival of nerve cells. IGF-1 protects various cells against different kinds of stressors such as oxidative cell death related to treatment of cells with nitric oxide, hydrogen peroxide, high blood sugar concentrations, peroxynitrite, salsolinol and okadaic acid. Protection of several cell types from cell death by IGF-1 has been linked to the activation of the PI3/AKT pathway (intracellular signaling pathway). To further elucidate the protective effects of IGF-1, Cheng and colleagues treated SH-SY5Y cells with proteasome inhibitor Epoxomicin. The researchers chose to use SH-SY5Y cells as an experimental model because they secrete dopamine. In order to confirm that IGF-1 inhibits cell death caused by Epoxomycin, the SH-SY5Y cells were cultured for 18 hours in the presence or absence of IGF-1, followed by Epoxomicin treatment for 24 hours. Interestingly, proteasome inhibition by Epoxomicin treatment of these cells causes cell death, even at extremely low concentrations and pretreatment of these cells with IGF-1 prevented such occurrence. In these cells, IGF-1 treatment activated the PI3/AKT pathway in a time-dependent fashion.

     These results indicate that IGF-1 blocks cell death induced by Epoxomicin treatment leading to decreased proteasome function. Clues as to the mechanism for this protective effect come from the following:
     1. Increased AKT phosphorylation (addition of phosphate) observed in IGF-1-protected cells, vs. cells exposed to Epoxomicin without IGF-1.
     2. A decrease in IGF-1 protection by pretreatment of the cells with LY294002, which is a PI3-kinase inhibitor.

     Together these findings suggest that IGF-1 can indeed protect cells from cell death following proteasome inhibition. This also shows that IGF-1 or other agents that activate the PI3/AKT pathway can prevent toxicity and cell death following abnormal accumulation of proteins due to proteasome inhibition, suggesting that these agents can be of great therapeutic value in PD and other neurodegenerative diseases.

246. Bou khalil R. Recombinant human IGF-1 for patients with schizophrenia. Med Hypotheses. 2011;77(3):427-9.
     View Summary +

     Recombinant human IGF-1 for patients with schizophrenia.
     

     The article by Bou Khalil (2011) presents a hypothesis on the potential use of recombinant human insulin-like growth factor-1 (IGF-1) for patients with schizophrenia. The study suggests that IGF-1 supplementation may have therapeutic benefits in schizophrenia by influencing neurodevelopment, neuroplasticity, and neurotransmission. The author proposes that IGF-1 administration could potentially improve cognitive function, attenuate negative symptoms, and enhance the efficacy of antipsychotic medications in individuals with schizophrenia. However, further research is needed to validate this hypothesis and explore the clinical implications of using IGF-1 in the treatment of schizophrenia.

247. Humbert S, Bryson EA, Cordelières FP, et al. The IGF-1/Akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002;2(6):831-7.
     View Summary +

     The IGF-1/Akt pathway is Neuroprotective in Huntington’s disease

     Huntington’s disease (HD) is an incurable, hereditary brain disorder wherein nerve cells become damaged, causing various brain regions to deteriorate. Affected individuals suffer from problems with movement, behavior and cognition. Signs and symptoms can appear at any point in life and vary from person to person, but most commonly do so between 35 to 55 years old and start to worsen with increasing age. HD can have a negative impact on the lives of the patients as well as their families and healthcare providers.

     Neuroprotective Role of Insulin and IGF-1

     IGF-1 has a variety of effects on target organs and is necessary during nervous system development. With increasing age, IGF-1 levels decline in both plasma and brain. At cellular level, IGF-1 is best described as a prosurvival factor, generally acting through PI3K/Akt pathway to prevent programmed cell death. Moreover, IGF-1 also improves the metabolism of nerve cells and regulates neuronal excitability (firing of neurons to transmit electrical signals), two properties that, together with IGF-1’s actions in preventing cell death, may be crucial in protecting nerve cells against various injury or damage. At tissue level, IGF-1 stimulates vessel formation, regulates the clearance of plaques known as amyloid, and modulates the activity of nerve cell networks in the brain. Based on these biological activities, it is plausible that changes in the level of IGF-1 in the brain can contribute to the development of neurodegenerative diseases.

     To date, there is no treatment available to prevent or delay the onset of HD. Medical management are more focused on alleviating the symptoms of HD and maintaining independence of the patient. Several studies have identified substances that might be used in the treatment of HD because of their ability to promote survival. It was reported that insulin may help protect from cell death induced by serum starvation and brain damage during low oxygen levels. In addition to this, Duarte and colleagues reported that insulin may help prevent cell death associated with oxidative damage. Also, the same researchers concluded that insulin can help restore adenosine triphosphate (energy source of cells) levels under oxidative stress.

     Besides insulin, other studies demonstrated IGF-1’s ability to protect nerve cells during brain development. In 2004, Trejo and colleagues demonstrated IGF-1’s ability in controlling the growth and development of nervous tissue in adulthood. The specific mechanism underlying IGF-1’s nerve cell protective action is through the activation of IGF-1/Akt signaling pathway, which plays a key role in preventing cell death. Activation of this pathway is important especially for patients with HD, since Akt is altered in these patients. HD patients have reduced Akt levels, suggesting that the gradual deterioration of nerve cell damage in the brain may be related to this.

     Impaired brain energy metabolism with increased levels of lactate in the brain may play a role in the deterioration of nerve cells in patients with HD, thus can worsen the condition. To determine IGF-1’s role in brain energy metabolism and interaction with lactate, Naia and colleagues studied the effect of IGF-1 on the lymphoblasts (immature white blood cells) of patients with HD. Interestingly, exposure of HD patients’ lymphoblasts to IGF-1 resulted in a significant reduction in lactate levels in HD cells compared to untreated cells. In addition to this, IGF-1 was able to normalize the generation of ATP in nerve cells. Based on these results, it is plausible that insulin and particularly IGF-1 may offer potential therapeutic protection against HD.

248. Bai X, Chen T, Gao Y, Li H, Li Z, Liu Z. The protective effects of insulin-like growth factor-1 on neurochemical phenotypes of dorsal root ganglion neurons with BDE-209-induced neurotoxicity in vitro. Toxicol Ind Health. 2017;33(3):250-264.
     View Summary +

     The protective effects of insulin-like growth factor-1 on neurochemical phenotypes of dorsal root ganglion neurons with BDE-209-induced neurotoxicity in vitro.
     

     The study by Bai et al. (2017) investigates the protective effects of insulin-like growth factor-1 (IGF-1) on neurochemical phenotypes of dorsal root ganglion (DRG) neurons in vitro exposed to BDE-209-induced neurotoxicity. The research focuses on assessing the impact of IGF-1 on preserving the neurochemical characteristics of DRG neurons under toxic conditions. The study highlights the potential of IGF-1 in mitigating the neurotoxic effects induced by BDE-209, a flame retardant compound. By studying the protective effects of IGF-1, the research provides insights into the potential therapeutic applications of IGF-1 in promoting neuronal health and combating neurotoxicity-induced damage.

249. Zemva J, Schubert M. The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer’s disease: possible therapeutic implications. CNS Neurol Disord Drug Targets. 2014;13(2):322-37.
     View Summary +

     The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer’s disease: possible therapeutic implications.
     

     The article by Zemva and Schubert (2014) explores the role of neuronal insulin and insulin-like growth factor-1 (IGF-1) signaling in the pathogenesis of Alzheimer’s disease (AD) and its potential therapeutic implications. The study highlights the significance of insulin/IGF-1 signaling in regulating brain function, including neuronal survival, energy metabolism, and synaptic plasticity. It discusses how dysregulation of insulin/IGF-1 signaling pathways may contribute to AD pathology, including the accumulation of amyloid-beta plaques and tau protein abnormalities. The research suggests that targeting these signaling pathways could hold therapeutic potential for AD treatment. Understanding the involvement of insulin/IGF-1 signaling in AD provides insights into novel approaches for managing the disease.

250. Larpthaveesarp A, Ferriero DM, Gonzalez FF. Growth factors for the treatment of ischemic brain injury (growth factor treatment). Brain Sci. 2015;5(2):165-77. Published 2015 Apr 30. doi:10.3390/brainsci5020165.
     View Summary +

     Growth Factors for the Treatment of Ischemic Brain Injury (Growth Factor Treatment)

     Hypoxic-ischemic injury is a significant cause of mortality and morbidity in both the adult and children. Brain injury progresses over time through several different mechanisms that lead to cell damage and death. Following exposure to hypoxia-ischemia, endogenous response mechanisms are activated including stabilization of neuronal transcription factors hypoxia-inducible factors (HIF)-1 and 2, with increased expression of a number of downstream cytokines and growth factors. These growth factors play important roles in the normal function and development of the central nervous system, and this increased expression following injury activates a number of signaling pathways that mediate changes in apoptosis (cell death), inflammation, angiogenesis (development of new blood vessels), cell differentiation and proliferation.

     Insulin-Like Growth Factors

     Insulin-like Growth Factor-1 (IGF-1) is responsible for a variety of pro-survival signaling mechanisms. While growth hormone (GH) stimulated IGF-1 production in the liver, the IGF-1 protein is found in various types of cells. IGF-1 is used clinically as a treatment for GH resistance related growth disorders but appears to have potential for treatment of ischemic brain injury. IGF-1 is widely expressed in the brain in nerve cells and glia, and has major roles in neurodevelopment, protection, and survival.

     In vitro, IGF-1 has been shown to inhibit glutamate, nitric oxide, and hydrogen peroxide-related apoptosis to protect both sensory and motor neurons against excitotoxicity and oxidative stress. Oxygen glucose deprivation-treated microvascular endothelial cells that form the blood brain barrier also increase secretion of IGF-1 after ischemia, resulting in decreased nerve cell injury. Drug induced inhibition of IGF-1 and inhibition of IGF receptors on astrocytes (a star-shaped glial cell of the central nervous system) shows that IGF-1 expression is key to astrocyte survival after H2O2-induced oxidative stress, and is key to protecting nerve cells from oxidative stress through astrocyte-secreted Stem Cell Factor’s interactions with IGF-1.

     In humans, IGF-1 has been studied in amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer’s disease (AD). Studies of endogenous expression of IGF-1 after adult stroke and elderly stroke found that after ischemic injury, the levels of IGF-1 in the blood decrease significantly. All three studies found that lower levels of IGF-1 were associated with poor clinical outcome and increased risk of death. IGF-1 upregulation through exercise is also being explored in animal stroke models as well as non-ischemic human studies.

251. Monson, J.P. (2003). Long-term experience with GH replacement therapy: efficacy and safety. European Journal of Endocrinology, 148 Suppl 2, S9–14.
     View Summary +

     Long-term experience with GH replacement therapy: efficacy and safety.

     The article by Monson (2003) provides a comprehensive analysis of the long-term experience with growth hormone (GH) replacement therapy, focusing on its efficacy and safety. The study reviews the benefits and potential risks associated with GH replacement therapy in various patient populations, including those with growth hormone deficiency and other endocrine disorders. It examines the effects of GH therapy on growth, body composition, metabolic parameters, and quality of life. The research highlights the overall positive outcomes of long-term GH replacement therapy and emphasizes the importance of careful monitoring to ensure safety and optimize treatment outcomes.

252. Pollak, M., Blouin, M.J., Zhang, J.C. & Kopchick, J.J. (2001). Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. British Journal of Cancer, 85, 428–430.
     View Summary +

     Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist.

     The study by Pollak et al. (2001) investigates the impact of a growth hormone antagonist on mammary gland carcinogenesis in transgenic mice. The research focuses on evaluating the role of growth hormone in the development of mammary tumors. The study demonstrates that transgenic mice expressing a growth hormone antagonist exhibit a reduced incidence of mammary gland carcinogenesis compared to control mice. The findings suggest that inhibiting growth hormone signaling may have a protective effect against the development of mammary tumors. The research provides insights into the potential therapeutic implications of targeting growth hormone in the prevention or treatment of breast cancer.

253. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?. Pharmacol Rev. 2010;62(2):199-236.
     View Summary +

     Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?

     Insulin-like growth factors (IGF-I1 and IGF-II), their binding proteins (IGFBPs), and the receptors mediating their signaling (types I and II IGF-IR), is crucial in normal growth and development, metabolism and balance within the body. Detection of IGF-I and IGF-IR mRNAs (convey genetic information from DNA to the ribosome) and the proteins they encode suggests that they might play pivotal role in the immune function. In addition to this, IGF-I enhances diverse aspects of bone marrow function, including formation and maturation of white blood cells, and the production of red blood cells. Its effects are substantial in that they can reduce the myelosuppressive effects (condition in which bone marrow activity is decreased) of powerful chemotherapeutic agents such as azidothymidine. In animal models, administration of GH and IGF-1 promotes the development of immune system cells such as B and T cells. Thus, there is reason to explore the potential actions of these hormones as regulators of immunity. Moreover, targeting IGF-I and IGF-IR signaling in order to impair the natural course of chronic inflammation may become a strategy in managing and treating various autoimmune disease. Although the function of endocrine glands is intimately intertwined with growth and development, the potential relationship between immune function and IGF-1 has remained poorly understood until relatively recently. Interestingly, immune reactions and the inflammation with which they are often linked have been shown to affect normal tissue remodeling. These biological functions are somehow linked to the complex interplay between cytokines and IGF-1.

     Hematopoiesis

     Hematopoiesis refers to the production, multiplication, and specialization of immune cells in the bone marrow. In mice, GH and IGF-I administration enhances reconstitution of the immune system by improving hematopoiesis after bone marrow transplantation. In one study, Alpdogan and colleagues demonstrated that the levels of white blood cells after bone marrow transplantation was enhanced by IGF-1. This hormone was able to increase the frequency of bone marrow cells with no effects on either morbidity or mortality among the animals.

     Thymus Development and Function

     The thymus gland produces T cells for the immune system. Certain factors seem to promote increased activity within the thymus. Among them, IGF-1 and GH target thymus cells, where they synergistically promote the action of anti-CD3 (one that binds to CD3 on the surface of T cells) in stimulating proliferation. In addition to this, IGF-I is known to directly stimulate DNA synthesis in thymus cells in a time-dependent manner.

     Immunocoordination

     IGF-I and IGF-II seem to modify several aspects of the inflammatory process by influencing the actions of cytokines. Cytokines are cell signaling molecules that are responsible for enhancing cell to cell communication in immune responses and stimulate the movement of cells towards sites of inflammation or infection. To support this, increased levels of IGF-1 was found in patients manifesting autoimmune diseases such as ulcerative colitis or Crohn’s diseases. On the contrary, these patients have lower levels of the inflammatory substance called C-reactive protein. This shows that IGF-1 levels are inversely correlated with those of C-reactive protein and can be a significant marker of autoimmune diseases.

     Read the full article: https://pubmed.ncbi.nlm.nih.gov/10954733/

254. Jens O. L. Jørgensen; Jens Sandahl Christiansen (1 January 2005). Growth Hormone Deficiency in Adults. Karger Medical and Scientific Publishers. pp. 8–. ISBN 978-3-8055-7992-6.
     View Summary +

     Recombinant Human IGF-1 (rhIGF-1) for Patients with Schizophrenia

     Schizophrenia is a long-term mental health condition that causes a wide array of psychological symptoms such as hallucinations, delusions, muddled thoughts, and changes in behavior. This mental condition is often described as a psychotic illness because affected individuals may not able to distinguish their own thoughts, beliefs and ideas from reality. The exact cause of schizophrenia is unknown. However, most experts believe that it is caused by genetic and environmental factors, substance abuse, and changes in the levels of brain chemicals. Currently, treatment for schizophrenia includes antipsychotic medicines and cognitive behavioral therapy (talking therapy focused on changing the way you think and behave). Affected individuals usually receive help from a community mental health team for daily support and treatment.

     The Role of IGF-1 in Schizophrenia

     There is increasing evidence that all types of glial cells (provide support and insulation between nerve cells), especially oligodendrocytes, are affected in schizophrenia. In addition to this, schizophrenia also affects the brain region called white matter, which regulates the electrical signals between nerve cells. When compared to healthy controls, patients suffering from schizophrenia usually have lower levels of IGF-1 in the blood. IGF-1 receptors are concentrated in the hippocampus (brain region associated with memory, emotion and spatial navigation) rendering this part of the brain likely to be more affected with IGF-1 deficits. Interestingly, hippocampal dysfunction has been proposed to be linked to auditory hallucinations (false perceptions of sound) experienced by patients with schizophrenia. Also, several factors such as low birth weight, loss of muscle mass and short stature, which are all linked to decreased levels of IGF-1, are shown to be associated with increased risk for developing schizophrenia.

     Antipsychotic drugs (such as quetiapine) have been shown to promote the specialization of nerve cells into oligodendrocytes with the same importance that IGF-1 induces this effect. Aside from this effect, experimental and preclinical data support the fact that IGF-1 treatment can help improve the process of myelination, which protects the nerve cell or nerve fiber and help it conduct signals more efficiently. Because schizophrenia is a brain abnormality related to demyelination, which causes damage to the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord, IGF-1 treatment can indeed provide beneficial effect in patients suffering from schizophrenia by enhancing the process of myelination.

     In one study, Bou khalil and colleagues reported that subcutaneous recombinant human IGF-1 at a dose of 0.05 mg/kg given twice daily improved symptoms and is well-tolerated by patients with schizophrenia.

     These findings suggest that IGF-1 administration can be a new therapeutic option for patients with schizophrenia in addition to antipsychotic medicines and cognitive behavioral therapy. The ability of IGF-1 to promote the specialization of nerve cells into oligodendrocytes and to enhance the myelination process in the central nervous system indicates that IGF-1 might be useful in treating schizophrenia. Moreover, this effect can also be used in a wide array of demyelinating diseases such as multiple sclerosis, Guillain-Barré syndrome, autoimmune encephalomyelitis and other diseases.

255. Russo and W. V. Moore, A comparison of subcutaneous and intramuscular administration of hGH in the therapy of growth hormone deficiency, J. Clin. Endocrinol. Metabol. 55:1003–1006, 1982.
     View Summary +

     A comparison of subcutaneous and intramuscular administration of human growth hormone in therapy of human growth hormone deficiency

     The study conducted by Russo and Moore in 1982 compares the therapeutic effectiveness of subcutaneous and intramuscular administration of human growth hormone (hGH) in the treatment of growth hormone deficiency. The research examines the outcomes and benefits of both administration routes in terms of growth hormone response and overall therapy efficacy. The study concludes that both subcutaneous and intramuscular routes are effective in delivering hGH and improving growth hormone levels in patients with growth hormone deficiency. The findings provide valuable insights into the optimal administration methods for hGH therapy in individuals with this condition.

256. Russo L, Moore WV. A comparison of subcutaneous and intramuscular administration of human growth hormone in therapy of human growth hormone deficiency. J Clin Endocrinol Metab 1982; 55 : 1003-1006.
     View Summary +

     The Protective Effects of Insulin-like Growth Factor-1 (IGF-1) on BDE-209-induced Neurotoxicity in vitro

     Polybrominated diphenyl ethers (PBDEs) are one of the most common types of brominated flame retardants (a key component in reducing the devastating impact of fires) applied to a wide array of industrial products including electronic devices, plastics, foams and textiles. Also, PBDEs exist extensively in various food stuffs such as meat, fish, potato, string beans, rice, and olive oil. PBDEs exhibit many negative biological effects especially potential toxic effects on the brain and nerve cells. It has been shown that chronic exposure to PBDEs may increase one’s risk for neurological disorders. Early-life exposures to this toxic substance lead to neuro-behavioral abnormalities later in life. It has been identified that intake of PBDEs through food is one of the main modes of exposure to humans. Decabrominated diphenyl ether (BDE-209) is the most abundant PBDE found in human samples, which affects target organs and overall health. Concerns have been raised with regard to the PBDE’s neurotoxicity in both prenatal and postnatal exposures because it readily crosses the placental barrier in pregnant women and is toxic in the developing fetus, particularly in the developing brain.

     Dorsal root ganglion (DRG) is a structure of the peripheral nervous system (PNS) located on each spinal nerve. Given the growing evidence documenting the potential health hazards associated with PBDE exposure, it has presented a major public health challenge with rising levels in human tissues. Whether BDE-209 affects DRG is unclear. BDE-209 may exert its neurotoxic effects on primary sensory neurons (nerve cells) in vitro. The ability of IGF-1 to promote proliferation, cell survival and inhibition of cell death may help rescue specific DRG neurons with BDE-209-induced neurotoxicity. Aside from this, IGF-1 can help regenerate or repair cells of the spinal cord which are exposed to BDE-209 for prolonged periods of time. To determine the protective effects of IGF-1 on neurochemical phenotypes of DRG with BDE-209-induced neurotoxicity in vitro, Chen and colleagues studied DRG cell culture preparations of newborn rats (less than 24 hours after birth). The bilateral DRG were removed from each animal and placed in a culture medium. At 48 hours of culture age, primary cultured DRG neurons were exposed to BDE-209 and IGF-1 for additional 24 hours.

     The results showed that IGF-1 promoted growth and viability of DRG cells with BDE-209-induced neurotoxicity. Interestingly, IGF-1 inhibited oxidative stress and cell death caused by exposure to BDE-209. In addition to this, IGF-1 helps reverse the decrease in growth-associated protein-43 and calcitonin gene-related peptide, both of which plays a role in the regeneration of nervous tissue after injury.

     In conclusion, BDE-209-induced neurotoxicity could be reversed by the administration of IGF-1. The specific underlying mechanism in which IGF-1 exerts these effects is through combating oxidative stress and inhibiting nerve cell death. Simultaneously, IGF-1 may initiate growth-associated protein-43 expression to promote cell growth and viability of DRG neurons with BDE-209-induced neurotoxicity. Particularly, IGF-1 may have specific neuroprotective effect on calcitonin gene-related peptide of DRG neurons, which can help regenerate or repair damaged cells. With these findings, it is plausible that IGF-1 might be a potential option in preventing and treating BDE-209-induced neurotoxicity in humans.

257. Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH, MacFarlane IA. Quality of life, body composition and muscle strength in adult growth hormone deficiency: The influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol. 1997;47:439–46.
     View Summary +

     Therapeutic Benefits of Insulin-like Growth Factor (IGF-1) in Alzheimer’s Disease (AD)

     The synapse is a small gap at the end of a nerve cell that permits a signal to pass from one nerve cell to the other. Alterations in synaptic function are considered to be the main pathological features of decline in cognitive function in the older population. Moreover, recent results strongly support the concept that loss in synaptic function is linked with very early cognitive decline in Alzheimer’s disease (AD). IGF-1 appears to have multiple effects on the synapses and protects against toxic amyloid beta, which is the main component of plaques found in the brains of Alzheimer patients. Also, accumulation of amyloid beta is the main cause of disruption in the synaptic function. Interestingly, both insulin and IGF-1 reduce the formation of amyloid beta plaques, protecting the brain against possible synaptic dysfunction. Furthermore, insulin/IGF-1 receptor signaling may be a part of the neuroprotective effect of rosiglitazone (anti-diabetic drug), which can help reduce amyloid beta toxicity and improves memory test results in patients with AD. These results indicate that brain insulin resistance and IGF-1 receptors dysfunction are major contributors to toxic amyloid beta accumulation and subsequent synaptic loss.

     IGF-1 and Amyloid Beta Production

     IGF-1 appears to increase nerve cell network in cultured cells, and amyloid beta production is linked with nerve cell activity. Therefore, the possible beneficial effects of IGF-1 could be impaired in patients with Alzheimer’s disease through elevated amyloid beta secretion and accumulation. It is noteworthy that recent findings support a role of IGF-1 treatment in protecting the synaptic plasticity (ability of synapses to strengthen or weaken over time) from inflammatory agents. In addition to this, some reactions in the body including increased production of interleukin-6 (pro-inflammatory substance) clear amyloid from the brain, suggesting that inflammation is not a major driving force for the accumulation of amyloid.

     Evidence is now emerging linking IGF-1 with central nervous system (CNS) development and repair, in particular, IGF-1 plays a pivotal role in protecting nerve cells and in its growth and development. In addition, the levels of IGF-1 in the brain and blood declines with increasing age and reduced levels of IGF-1 increases a person’s risk for AD. In 2002, Carro et al. were the first to demonstrate that IGF-1 has the ability to regulate amyloid beta levels by increasing the permeability (ability to allow substances to pass) of blood brain barrier to the amyloid beta carrying proteins. In this way, accumulation of amyloid beta in the brain can be prevented. Also, blockade of IGF-1 receptors in the choroid plexus (a network of blood vessels in each ventricle of the brain) induced accelerated AD-like pathology and cognitive impairment in mouse models. Conversely, IGF-1 administration to these mouse models improved cognitive performance and reduced AD-like pathology. Moreover, in human studies, increasing IGF-1 levels by supplementing with growth hormone releasing hormone significantly improved cognition in both healthy and cognitively impaired older populations. These beneficial effects support a possible therapeutic role of IGF-1 for AD.

     Resource: https://pubmed.ncbi.nlm.nih.gov/12062094/

258. Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum. 2005;35(1):24-34.
     View Summary +

     Role of the Growth Hormone/Insulin-Like Growth Factor-1 Paracrine Axis in Rheumatic Diseases

     Many studies have demonstrated altered hypothalamic-pituitary axis or HPA (a complex set of direct influences and feedback interactions among the hypothalamus, pituitary gland and adrenal glands) in patients with autoimmune inflammatory diseases such as rheumatic diseases. Rheumatoid arthritis (RA) is one of the most common and serious chronic inflammatory diseases. Although not yet fully understood, glucocorticoids clearly exert profound effect in the suppression of the body’s immune-inflammatory response and have been the cornerstone of treatment for RA for over 50 years. The concept that glucocorticoids produced by the adrenal glands, and regulated by the hypothalamus and pituitary, have a pivotal role in the regulation of inflammation has emerged more recently. It is now apparent that the occurrence of inflammation, through the release of inflammatory substances such as cytokines, provides a direct stimulus to pituitary and hypothalamus’ activity, resulting in adrenal glucocorticoids production under the influence of adrenocorticotrophic hormone (ACTH).

     Circumstantial evidence suggests that failure of the HPA axis may lead to inadequate amounts of glucocorticoids within the body. Such failure has been associated with systemic disturbances in several rheumatic diseases. Longitudinal analysis of vital substances and hormones such as synovial fluid (thick, straw-colored liquid found in joints, tendons and sheaths), growth hormone (GH), insulin-like growth factor-1 (IGF-1), and somatostatin (secreted in the pancreas and pituitary gland) levels could provide significant surrogate measures of disease activity in RA. In order to determine their roles in RA, Denko and colleagues conducted a review of literature supporting the view that HPA axis dysfunction accompanies clinical symptoms in RA. In addition to this, the researchers analyzed the basal somatostatin levels in patients with hand, knee, hip and spine osteoarthritis (OA).

     The results of the study showed elevation in blood GH levels in patients with OA, RA, fibromyalgia, and diffuse idiopathic skeletal hyperostosis (a form of degenerative arthritis) but not in patients with gout, pseudogout, or systemic lupus erythematosus (SLE). Many studies support an inverse relationship between age and IGF-1. In this study, increased GH levels in various rheumatic diseases were not coupled to changes in IGF-1 levels in the blood in diffuse idiopathic skeletal hyperostosis, RA, and fibromyalgia. In particular, the blood levels of IGF-1 in OA were lower or no different compared with age-matched normal subjects. In addition to this, blood levels of somatostatin were often lower in RA and SLE, but basal serum somatostatin levels were generally not altered in OA.

     In conclusion, serum GH, IGF-1, and somatostatin levels must be monitored on a consistent basis during the course of medical therapy of rheumatic diseases. Doing so can help determine the extent to which changes in signs and symptoms (exemplified by pain reduction and decreased inflammation as well as improvement in range of motion of affected body part) are accompanied by changes in the levels of these hormones. Also, consistent and accurate monitoring of serum GH, IGF-1, and somatostatin levels can aid healthcare providers in making an accurate diagnosis especially in patients with suspected rheumatic disease.

259. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park, N.Y.). 2002; 16(2):217-26, 229; discussion 230-2.
     View Summary +

     Chronic inflammation and cancer

     The article by Shacter and Weitzman (2002) explores the relationship between chronic inflammation and cancer. The study delves into the mechanisms by which chronic inflammation can contribute to the development and progression of cancer. It discusses the various inflammatory mediators and pathways involved, as well as the impact of oxidative stress and DNA damage. The research highlights the important role of inflammation in promoting tumor growth, angiogenesis, and metastasis. Understanding the link between chronic inflammation and cancer provides valuable insights for developing strategies to prevent and treat cancer by targeting inflammation-related pathways.

260. Multhoff G, Molls M, Radons J. Chronic Inflammation in Cancer Development. Frontiers in Immunology. 2011;2:98. doi:10.3389/fimmu.2011.00098.
     View Summary +

     Chronic Inflammation in Cancer Development.

     The review by Multhoff et al. (2011) focuses on the role of chronic inflammation in cancer development. It explores the complex interactions between inflammatory processes and the tumor microenvironment. The study discusses how chronic inflammation can promote cancer initiation, progression, and metastasis by influencing key cellular and molecular pathways. It also highlights the involvement of immune cells, cytokines, and signaling molecules in mediating the crosstalk between inflammation and cancer. Understanding the mechanisms underlying chronic inflammation in cancer development can provide important insights for the development of targeted therapeutic strategies.

261. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. doi:10.1038/nature01322.
     View Summary +

     Inflammation and cancer

     The influential article by Coussens and Werb (2002) explores the intricate relationship between inflammation and cancer. The study highlights the key role of inflammatory processes in various stages of cancer development, including tumor initiation, promotion, and metastasis. It discusses the involvement of immune cells, cytokines, and molecular pathways in fostering an inflammatory microenvironment that supports tumor growth and progression. The research underscores the importance of understanding the dynamic interplay between inflammation and cancer for developing effective prevention and treatment strategies. This seminal work significantly contributes to our knowledge of the complex interconnections between inflammation and cancer biology.

262. Crawford S. Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence. Therapeutic Advances in Medical Oncology. 2014;6(2):52-68. doi:10.1177/1758834014521111.
     View Summary +

     Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

     The article by Crawford (2014) presents a novel therapeutic approach in long-term maintenance cancer therapy by utilizing anti-inflammatory and antioxidant agents. The study explores the role of chronic inflammation and oxidative stress in cancer progression and recurrence. It discusses the potential benefits of incorporating anti-inflammatory and antioxidant strategies as part of long-term cancer treatment to mitigate disease progression and reduce the risk of recurrence. The research highlights the importance of targeting inflammation and oxidative stress pathways to improve treatment outcomes and enhance patient survival. This approach offers promising possibilities for advancing cancer therapy and warrants further investigation.

263. Franks AL, Slansky JE. Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic Inflammatory Diseases and Cancer. Anticancer Research. 2012;32(4):1119-1136.
     View Summary +

     Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic Inflammatory Diseases and Cancer.

     The article by Franks and Slansky (2012) examines the multiple associations between a wide range of autoimmune diseases, chronic inflammatory diseases, and cancer. The study explores the shared mechanisms and risk factors that contribute to the development of these conditions. It discusses the intricate interplay between chronic inflammation, immune dysregulation, and cancer development. The research highlights the increased risk of cancer among individuals with autoimmune and chronic inflammatory diseases and the potential underlying biological processes. Understanding these connections can aid in identifying common therapeutic targets and developing strategies for cancer prevention and management in patients with autoimmune and chronic inflammatory conditions.

264. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell. 2010;140(6):883-899. doi:10.1016/j.cell.2010.01.025.
     View Summary +

     Immunity, Inflammation, and Cancer.

     The influential article by Grivennikov, Greten, and Karin (2010) delves into the intricate relationship between immunity, inflammation, and cancer. The study explores the dual role of inflammation in cancer, acting both as a promoter and a suppressor of tumor development. It discusses the immune response and the complex interplay between inflammatory cells, cytokines, and signaling pathways that can influence cancer initiation, progression, and metastasis. The research highlights the importance of understanding the balance between inflammatory and immune responses in cancer biology and its implications for developing targeted therapeutic approaches. This comprehensive review significantly contributes to our knowledge of the intricate connections between immunity, inflammation, and cancer.

265. Rakoff-Nahoum S. Why Cancer and Inflammation? The Yale Journal of Biology and Medicine. 2006;79(3-4):123-130.
     View Summary +

     Why Cancer and Inflammation? The Yale Journal of Biology and Medicine

     In the article by Rakoff-Nahoum (2006), the author explores the question of why cancer and inflammation are frequently associated. The study discusses the intricate relationship between these two processes and investigates the underlying mechanisms that connect them. It delves into the role of chronic inflammation in creating an environment favorable for tumor development and progression. Additionally, it examines the immune response to cancer cells and how inflammation can influence the tumor microenvironment. The research provides insights into the complex interplay between cancer and inflammation, shedding light on potential therapeutic strategies targeting these interconnected processes.

266. Barahona-Garrido J, Hernández-Calleros J, García-Juárez I, Yamamoto-Furusho JK. Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility. Saudi J Gastroenterol. 2009;15(3):208-12.
     View Summary +

     Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility.

     Growth factors are naturally occurring proteins that regulate various cellular processes, including cell growth, differentiation, and tissue repair. They play crucial roles in maintaining the integrity and function of the gastrointestinal mucosa. Here’s a concise review of the evidence supporting the potential clinical utility of growth factors in the treatment of IBD:

     1.Epidermal Growth Factor (EGF): EGF has been shown to promote epithelial cell proliferation and wound healing in the gastrointestinal tract. Studies have demonstrated that EGF administration can improve colonic healing and reduce inflammation in animal models of colitis. However, more research is needed to determine its effectiveness in human IBD.

     2.Transforming Growth Factor-Beta (TGF-β): TGF-β is a potent anti-inflammatory and immunoregulatory cytokine. It has been found to inhibit the production of pro-inflammatory molecules and promote tissue repair. Animal studies have shown promising results, suggesting that TGF-β may reduce colonic inflammation and improve symptoms in IBD. However, further clinical trials are necessary to assess its safety and efficacy in humans.

     3.Platelet-Derived Growth Factor (PDGF): PDGF plays a crucial role in wound healing and tissue regeneration. Animal studies have demonstrated that PDGF administration can accelerate mucosal healing and reduce inflammation in experimental colitis. However, more research is needed to determine its potential therapeutic effects in human IBD.

     4.Fibroblast Growth Factors (FGFs): FGFs are involved in tissue repair and angiogenesis. Some studies have suggested that FGFs may have a protective effect on the intestinal mucosa and promote wound healing. However, limited research has been conducted specifically on their role in IBD, and further investigation is required.

     It’s important to note that while growth factors show promise as potential treatments for IBD, their clinical utility has not been firmly established. Most of the evidence comes from preclinical studies and animal models, and their translation into human therapies is complex. Future research should focus on conducting well-designed clinical trials to determine the safety, efficacy, optimal dosing, and long-term effects of growth factors in IBD patients.

267. Trejo JL, Carro E, Garcia-galloway E, Torres-aleman I. Role of insulin-like growth factor I signaling in neurodegenerative diseases. J Mol Med. 2004;82(3):156-62.
     View Summary +

     Role of insulin-like growth factor I signaling in neurodegenerative diseases.

     In their article, Trejo et al. (2004) investigate the role of insulin-like growth factor I (IGF-I) signaling in neurodegenerative diseases. The study focuses on the potential neuroprotective effects of IGF-I and its signaling pathways in various neurodegenerative disorders. It discusses the involvement of IGF-I in neuronal survival, synaptic plasticity, and cognitive function. The research highlights the potential therapeutic implications of targeting the IGF-I signaling pathway in the treatment of neurodegenerative diseases. By elucidating the mechanisms underlying IGF-I signaling in these conditions, the study contributes to our understanding of the pathogenesis and potential treatment strategies for neurodegenerative disorders.

268. Stattin P, Björ O, Ferrari P. Prospective study of hyperglycemia and cancer risk. Diabetes care. 2007; 30(3):561-7.
     View Summary +

     Prospective study of hyperglycemia and cancer risk

     Stattin et al. (2007) conducted a prospective study to investigate the association between hyperglycemia and cancer risk. The study examined the relationship between elevated blood glucose levels and the incidence of cancer. It followed a large cohort over time and analyzed the data to assess the potential link between hyperglycemia and cancer development. The research findings provide insights into the role of high blood glucose levels as a risk factor for cancer, highlighting the importance of glycemic control in cancer prevention. This study contributes to our understanding of the potential impact of hyperglycemia on cancer risk and emphasizes the significance of managing blood glucose levels for overall health.

269.  Ryu TY, Park J, Scherer PE. Hyperglycemia as a Risk Factor for Cancer Progression. Diabetes & Metabolism Journal. 2014;38(5):330-336. doi:10.4093/dmj.2014.38.5.330.
     View Summary +

     Hyperglycemia as a Risk Factor for Cancer Progression.

     Ryu et al. (2014) explore the association between hyperglycemia and cancer progression. The study investigates how elevated blood glucose levels can act as a risk factor for the development and advancement of cancer. The researchers delve into the molecular mechanisms underlying this relationship, focusing on the role of hyperglycemia in promoting tumor growth and metastasis. The findings highlight the importance of glycemic control in cancer management and suggest that targeting glucose metabolism pathways may offer potential therapeutic strategies. This study contributes valuable insights into the link between hyperglycemia and cancer progression, paving the way for further research in this field.

270. Cui G, Zhang T, Ren F, et al. High Blood Glucose Levels Correlate with Tumor Malignancy in Colorectal Cancer Patients. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2015;21:3825-3833. doi:10.12659/MSM.894783.
     View Summary +

     High Blood Glucose Levels Correlate with Tumor Malignancy in Colorectal Cancer Patients.

     In their study, Cui et al. (2015) investigate the correlation between high blood glucose levels and tumor malignancy in colorectal cancer patients. The researchers examine the relationship between glucose metabolism and cancer progression, specifically focusing on how elevated blood glucose levels may contribute to the aggressiveness and malignancy of colorectal tumors. The findings suggest that higher blood glucose levels are associated with increased tumor size, advanced tumor stage, and a higher likelihood of lymph node metastasis. These results underscore the potential impact of glycemic control on colorectal cancer outcomes and highlight the importance of managing blood glucose levels in cancer patients.

271. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer: A consensus report. Diabetes Care. 2010;33(7):1674-1685. doi:10.2337/dc10-0666.
     View Summary +

     Diabetes and Cancer: A consensus report.

     Giovannucci et al. (2010) present a consensus report on the relationship between diabetes and cancer. The report summarizes the existing evidence and provides key insights into the association between these two diseases. It highlights that diabetes is associated with an increased risk of several types of cancer, including colorectal, pancreatic, breast, and bladder cancer. The authors discuss potential mechanisms linking diabetes and cancer, such as hyperinsulinemia, chronic inflammation, and hormonal factors. Additionally, the report emphasizes the importance of diabetes management in cancer prevention and the need for interdisciplinary approaches in addressing the shared risk factors and treatment strategies for these diseases.

272. Crawley DJ, Holmberg L, Melvin JC, et al. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 2014;14:985. doi:10.1186/1471-2407-14-985.
     View Summary +

     Serum glucose and risk of cancer: a meta-analysis
     

     In their meta-analysis, Crawley et al. (2014) investigate the relationship between serum glucose levels and cancer risk. By analyzing a large collection of studies, they find that elevated serum glucose levels are associated with an increased risk of developing cancer. The analysis suggests that hyperglycemia may contribute to tumor development and progression. The authors highlight the importance of further research to better understand the underlying mechanisms and potential implications for cancer prevention and management.

273. Johnson JA, Gale EAM. Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution–or Part of the Problem? Diabetes. 2010;59(5):1129-1131. doi:10.2337/db10-0334.
     View Summary +

     Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution–or Part of the Problem?
     

     In their commentary, Johnson and Gale (2010) raise an important question regarding the association between diabetes, insulin use, and cancer risk. They discuss the challenges of interpreting observational studies in this context and emphasize the need for cautious interpretation of the findings. The authors highlight the importance of well-designed clinical trials and molecular studies to elucidate the complex relationship between diabetes, insulin therapy, and cancer risk. They propose that a better understanding of the underlying mechanisms will help clarify the potential risks and benefits of insulin therapy in individuals with diabetes.

274. Habib SL, Rojna M. Diabetes and Risk of Cancer. ISRN Oncology. 2013;2013:583786. doiIGF-1 Promotes the Development and Cytotoxic Activity of Human NK Cells:10.1155/2013/583786.
     View Summary +

     IGF-1 in Inflammatory Bowel Disease (IBD)

     Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of the digestive tract. It primarily includes ulcerative colitis and Crohn’s disease, both of which involve abdominal pain, weight loss, extreme fatigue and severe diarrhea. If left untreated, IBD can lead to life-threatening complications. The etiology of IBD remains largely unknown, but it is considered to be caused by genetics and environmental factors. Surprisingly, the number of patients diagnosed with IBD in all age groups worldwide has dramatically increased over the past 50 years, with the highest annual incidence in North America and Europe. (1, 2) Noteworthy, the number of new cases of IBD is on the rise and mostly affects children.

     The Role of Insulin growth factor-1 (IGF-1) as a Therapeutic Option for IBD

     Several effective strategies for IBD treatment are currently available including glucocorticosteroids, immunosuppressive agents, 5-aminosalicylates and biological therapies. However, these treatments come with side effects such as high blood pressure, type 2 diabetes, short stature, increase risk for cancer, as well as economic costs. Therefore, it is urgent to bring forth a better understanding of IBD and new cost-effective therapeutic option for IBD.

     IGF-1 is one of the most potent natural stimulators of cell growth and reproduction in various cell types. In addition to this, IGF-1 plays a pivotal role in the regulation of the metabolism of fats, proteins and carbohydrates, and in stimulating blood sugar transport into the muscle. Studies on IGF-1 administration in vivo revealed its anti-inflammatory effect and its ability to repair gastrointestinal organs. (3-5) IGF-1 also plays a significant role in the physiology of the GI tract. Similarly to other body organs, the intestines produce its own IGF-1. (6) Studies conducted to assess the GH/IGF-1 axis in adult patients with IBD reported a decreased level of IGF-1 in the blood. (7) Chronic inflammation in adult IBD patients may cause long-term reductions in the level of IGF-1 and thus increase one’s risk for osteoporotic fractures. (8) Patients with Crohn’s disease frequently experience osteoporotic bone fractures compared to patients with ulcerative colitis due to reductions in bone mineral density. (9) In one study, Koutroubakis and colleagues concluded that there is a high prevalence of osteopenia (reduced bone mass) and osteoporosis in Greek patients with IBD, and that BMD was positively correlated with serum IGFBP-3 (insulin-like growth factor-binding protein 3). (10) These findings suggest that IGF-1 and its binding proteins may be a predictive marker of complications related to IBD.

     It is plausible that IGF-1 has the potential to become a new therapeutic option in IBD patients because of its anti-inflammatory effects. To support this, Howarth and colleagues demonstrated that IGF-1 administration for 7 days reduced inflammation in the mucous membrane in a model of experimental colitis. (11) In line with this, a study by Yu and colleagues reported that IGF-1 treatment alleviates inflammation by reducing HMGB1, which a potent stimulator of tissue damage and inflammation. (5) Finally, Johannesson and colleagues reported that IGF-1 suppresses allergic contact dermatitis by reducing the infiltration of immune cells in the affected area, thereby preventing inflammation. (12) Moreover, IGF-1 administration directly stimulates the expansion of regulatory T cells, which may have therapeutic implication in other inflammatory conditions, such as IBD.

275. Monzavi-Karbassi B, Gentry R, Kaur V, et al. Pre-diagnosis blood glucose and prognosis in women with breast cancer. Cancer & Metabolism. 2016;4:7. doi:10.1186/s40170-016-0147-7.
     View Summary +

     The Role of Insulin-like Growth Factor (IGF-1) in Neurodegenerative Diseases

     Neurodegenerative diseases are defined as hereditary and sporadic conditions characterized by progressive alterations or dysfunction in the nervous system. Although neurodegeneration is extensively researched, the exact cause of neurodegenerative disease remains unclear. Studies suggest that neurodegeneration is a result of a complex interplay between oxidative damage, alteration in energy metabolism, nerve cell damage, and accumulation of cellular waste products.

     IGF-1 is required for normal development of the brain. Neurodegenerative diseases show either high or low levels of circulating IGF-1. Several studies have shown a correlation between impaired IGF-1 signaling and decreased cognitive function in the elderly. Lower blood levels of IGF-1 are linked with impaired memory, orientation skills, and slow information processing speed.

     IGF-1 – A Potent Neurotrophic Factor

     IGF-1 is an important neurotrophin – a protein that induces survival, development and function of nerve cells. Its influence on energy metabolism, growth and repair of nervous tissues, learning and memory as well as cell survival encouraged some scientists to further study its role in the pathogenesis of neurodegenerative disease. IGF-1 seems to exert its effect on synaptic transmission (chemical signals between cells) through several important mechanisms. This in turn enhances the communication between nerve cells. Another important role of IGF-1 is its ability to prevent cell death through activation of PI3K/Akt (signaling pathway) and inhibition of FOXO transcription factor, which regulates cell death. This ability of IGF-1 can help slow down or completely stop the degeneration of nerve cells in a variety of neurodegenerative diseases.

     Oxidative stress, IGF-1 and the Brain

     Oxidative stress, which is the disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defenses, is one of the main mechanisms proposed to contribute to brain aging and development of neurodegenerative disease. Reactive oxygen species produced during excessive oxidative stress, exert damage to nerve cells by stimulating FOXO3, a pathway which triggers cell death. IGF-1 and insulin counters these processes by activating both insulin and IGF-1 receptors located in the brain tissue. As a result, the PI3K/Akt pathway is activated, which in turn inactivates FOXO3 and many other mediators participating in cell destruction. Not only do insulin and IGF-1 suppress these processes while fighting oxidative stress, but they also stimulate survival signals through induction of NF-κB. NF-κB suppresses the toxic effect of harmful substances on nerve cells.

     IGF-1 and Inflammation Mediators

     Prostangladins and pro-inflammatory cytokines are also associated with various neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, AIDS dementia complex, multiple sclerosis and other conditions caused by insufficient blood flow to the brain. These inflammatory substances are thought to increase free radicals, leading to severe oxidative stress and affecting IGF-1 signaling. In the brain, IGF-1 and prostangladins have opposing effects. IGF-1 lowers the production of prostaglandins as well as pro-inflammatory cytokines.

     With IGF’s ability to promote cell proliferation, survival and metabolism, its effects in the context of neurodegenerative diseases are of great importance in today’s field of research. Using IGF-1 as a therapeutic option for various neurodegenerative diseases can help reverse brain damage and improve the quality of life of affected individuals.

276. Ni F, Sun R, Fu B, et al. IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat Commun. 2013;4:1479.
     View Summary +

     IGF-1 Promotes the Development and Cytotoxic Activity of Human NK Cells

     Within the ecosystem that is your body, natural killer cells or also known as NK cells are highly selective predators. They kill tumors, infected cells, or foreign bodies by releasing toxic substance while sparing healthy cells. NK cells work together with other cells of the innate immune system including neutrophils, macrophages, moncytes, dendritic cells and T-lymphocytes. By selectively killing their targets, NK cells play a pivotal role in protecting the body from a wide array of diseases, thus, amplifying the immune function.

     IGF-1 Promotes the Development of Human NK Cells

     IGF-1 has been demonstrated to promote the development of T-cells (lymphocytes produced by the thymus gland) and B lymphocytes in the bone marrow.(1) To investigate the potential role of IGF-1 in human NK cell development, Fang and colleagues cultured umbilical cord blood cells, CD34 cells (give rise to all cell types in blood) and hematopoietic stem cells (responsible for formation of blood cellular components) with Flt3-L and stem cell factor (SCF) in the presence of either interleukin 15 (a type of immune system cell), IGF-1 or a combination of both cytokines for up to 4 weeks.(2). The researchers found out that the combination of IL-15 and IGF-1 has a dramatic effect in activating the rapid reproduction of CD34 cells, suggesting that IGF-1 contributes to the development of NK subsets.

     Exogenous IGF-1 Enhances NK Cell Cytotoxicity

     IGF-1 may improve NK cell’s cytotoxic activity (the ability to kill abnormal cells). The presence of IGF-1 significantly increased CD107a release in human CD34+-derived CD56+ NK cells.(3) This simply means that the higher the level of IGF-1 present in the body, the more CD107a is released, thus, enhancing the cytotoxic activity of NK cells and boosting the immune function.

     NK Cell Cytotoxicity is dependent on Endogenous IGF-1

     Human NK cells have the ability to produce IGF-1, which is important for NK cell cytotoxicity. To support this, Fang et al. administered an IGF-1-neutralizing antibody to a type of NK cell and resulted in a significant decrease in the cell’s ability to kill abnormal cells. These data suggest that the level of IGF-1 in the body is critical to the cytotoxic activity of human NK cells.

     IGF-1’s Protective Effects

     It has been indicated that IGF-1 has an important role in the promotion of cell division and protection from programmed cell death (apoptosis) in many cell types.(4) This means that IGF-1 can increase the rapid reproduction of NK cells while preventing apoptosis. However, the effects of IGF-1 may simply vary depending on the doses or the experimental systems to which it is added.

     In conclusion, IGF-1 has an expanded role in the positive regulation of human NK cell development and cytotoxicity. Moreover, the finding that adequate amounts of IGF-1 can enhance NK cell’s cytotoxic ability and protect it from programmed cell death, provides new mechanistic insights in terms of the importance of NK cells in immunotherapy. This new information might present new opportunities for boosting or limiting the effects of NK cells in the immune system to achieve a therapeutic effect.

277. Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Mol Med. 2014;6(11):1423-35.
     View Summary +

     Insulin-like Growth factor-1 Stimulates Regulatory T Cells and Suppresses Autoimmune Disease

     Autoimmune diseases are increasingly widespread. Due to their prevalence, these diseases do not only affect the lives of affected individuals, but strain the economies of healthcare systems. Current treatment modalities for autoimmune diseases rely on suppressing the imbalanced immune system to avoid persistent inflammation and potential damage to organs and tissues. However, these immunosuppressive treatments inevitably lead to serious adverse long-term effects.

     The immune system protects your body against various harmful foreign bodies while restricting those responses to avoid harm. Active suppression of inflammation and immune responses by regulatory T (Treg) cells is vital in maintaining this balance. T cells modulate the immune system to prevent autoimmune disease. Without T cells, your body’s immune system will attack itself leading to various diseases. T cell-based therapies have held great promise for restoring tolerance in autoimmune diseases. Yet efforts to develop effective strategies for boosting T cell numbers, have met with limited success.

     Recombinant IGF-1 (rhIGF-1) Specifically Stimulates Proliferation of T cells

     Previous studies have implicated IGF-1 as a powerful enhancer of regenerative responses in multiple tissue types. Cumulative evidence suggests that IGF-1 has a significant role in regulating the immune response, with a direct link found between IGF-1 signaling and the activation of T cells in vitro. RhIGF-1 treatment was able to affect human T cell activation along with its production, which is dependent on the activation of a canonical signalling pathway (proteins that pass signals into a cell through cell surface receptors) involving the PI3-kinase–Akt axis. Notably, rhIGF-1 doesn’t stimulate the pro-inflammatory immune cells such as CD4 cells and interferon gamma (IFNγ), underscoring its potential to alter the balance between suppression of inflammation and immune responses. Taken together, these data clearly supports IGF-1’s role in positively regulating T cell-mediated immunosuppression.

     Systemic Delivery of IGF-1 Protects from Drug-induced and Genetic Diabetes

     Type-1 diabetes is an autoimmune disease caused by T-cell-induced destruction of the insulin-producing beta cells of the pancreas. To test the therapeutic potential of systemic rhIGF-1 delivery in type-1 diabetes, Zdravkovic and colleagues implanted a subcutaneous osmotic minipump containing rhIGF-1 in female mice, and diabetes was induced by multiple low-dose streptozotocin injections. Notably, rhIGF-1 administration resulted in improved blood sugar levels, providing long-lasting protection of the beta cells of the pancreas with no reported adverse side effects. Increased T cells were also observed in the pancreas of the mice treated with rhIGF-1. Thus, relatively short but constant rhIGF-1 treatment prevents the development and progression of type-1 diabetes by increasing T cell numbers and stably recruiting them to damaged pancreatic tissue.

     These findings provide the rationale and preclinical groundwork for the use of recombinant IGF-1 in a wide array of devastating autoimmune diseases such as type-1 diabetes by reestablishing tolerance to self antigens by increasing T cell proliferation. Given that rhIGF-1 is already an approved therapeutic option for the treatment of severe primary IGF-1 deficiency and has already been tested in a variety of clinical settings with positive results, it is now apparent that human trials for its use in the treatment of autoimmune and inflammatory disorders can now be implemented.

     Resource: https://pubmed.ncbi.nlm.nih.gov/14647921/

278. Ma NS, Shah AJ, Geffner ME, Kapoor N. Igf-I stimulates in vivo thymopoiesis after stem cell transplantation in a child with Omenn syndrome. J Clin Immunol. 2010;30(1):114-20.
     View Summary +

     Igf-I stimulates in vivo thymopoiesis after stem cell transplantation in a child with Omenn syndrome.
     

     Ma et al. (2010) conducted a study involving a child with Omenn syndrome who underwent stem cell transplantation. The researchers investigated the effect of insulin-like growth factor-I (IGF-I) on thymopoiesis, the process of T-cell development in the thymus. They found that IGF-I administration stimulated thymopoiesis in vivo, indicating its potential role in enhancing T-cell production and immune reconstitution following stem cell transplantation. These findings suggest that IGF-I may have therapeutic implications for improving immune function in individuals with immunodeficiency disorders like Omenn syndrome.

279. Gianotti L, Pivetti S, Lanfranco F, Tassone F, Navone F, Vittori E,Ò et al. Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endrocrinol Metab 2002;87:5052–7.
     View Summary +

     Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome.

     Gianotti et al. (2002) investigated the relationship between obstructive sleep apnea syndrome (OSAS), obesity, and growth hormone (GH) secretion and sensitivity. They found that obese patients with OSAS exhibited impaired GH secretion as well as decreased peripheral sensitivity to GH. This suggests that both GH secretion and sensitivity are adversely affected in individuals with obesity and OSAS. These findings provide insights into the endocrine dysregulation associated with these conditions and highlight the potential impact on growth hormone-related processes in obese patients with OSAS.

280. Copinschi G, Nedeltcheva A, Leproult R, et al. Sleep Disturbances, Daytime Sleepiness, and Quality of Life in Adults with Growth Hormone Deficiency. The Journal of Clinical Endocrinology and Metabolism. 2010;95(5):2195-2202. doi:10.1210/jc.2009-2080.
     View Summary +

     The Journal of Clinical Endocrinology and Metabolism

     In their study, Copinschi et al. (2010) examined the impact of growth hormone deficiency (GHD) on sleep disturbances, daytime sleepiness, and quality of life in adults. They found that individuals with GHD experienced increased sleep disturbances, including longer sleep latency, decreased sleep efficiency, and more awakenings during the night. These sleep disturbances were associated with higher levels of daytime sleepiness and reduced overall quality of life. The findings highlight the importance of addressing sleep-related issues in adults with GHD to improve their well-being and overall quality of life.

281. Schneider HJ, Oertel H, Murck H, Pollmächer T, Stalla GK, Steiger A. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement. Psychoneuroendocrinology. 2005; 30(1):29-37.
     View Summary +

     Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement.
     

     Schneider et al. (2005) investigated the effects of growth hormone deficiency (GHD) and growth hormone replacement therapy on sleep in adult hypopituitary patients. They analyzed night sleep electroencephalography (EEG) and daytime sleep propensity before and after six months of growth hormone replacement. The study found that GHD patients had alterations in sleep architecture, including reduced slow-wave sleep and increased sleep latency. After growth hormone replacement, improvements in sleep architecture and daytime sleepiness were observed. These findings suggest that growth hormone replacement therapy may have beneficial effects on sleep patterns in adult hypopituitary patients with GHD.

282. Deijen JB, Arwert LI. Impaired quality of life in hypopituitary adults with growth hormone deficiency : can somatropin replacement therapy help? Treatments in endocrinology. 2006; 5(4):243-50.
     View Summary +

     Impaired quality of life in hypopituitary adults with growth hormone deficiency : can somatropin replacement therapy help?

     Deijen and Arwert (2006) explored the impact of growth hormone deficiency (GHD) on the quality of life in hypopituitary adults and investigated whether somatropin replacement therapy could improve it. The study revealed that individuals with GHD experienced impaired quality of life, including physical, emotional, and social aspects. However, treatment with somatropin (growth hormone) replacement therapy showed promising results in improving the quality of life measures. These findings suggest that somatropin replacement therapy may be beneficial for enhancing the well-being and overall quality of life in hypopituitary adults with GHD.

283. Lanfranco F, Motta G, Minetto MA, Ghigo E, Maccario M. Growth hormone/insulin-like growth factor-I axis in obstructive sleep apnea syndrome: an update. Journal of endocrinological investigation. 2010; 33(3):192-6.
     View Summary +

     Growth hormone/insulin-like growth factor-I axis in obstructive sleep apnea syndrome: an update.

     In their 2010 article, Lanfranco et al. provided an update on the growth hormone/insulin-like growth factor-I (GH/IGF-I) axis in obstructive sleep apnea syndrome (OSAS). They discussed the alterations in GH secretion and IGF-I levels observed in individuals with OSAS and the potential impact of these changes on various aspects of the disorder. The article highlighted the complex interplay between OSAS and the GH/IGF-I axis, shedding light on the potential role of GH and IGF-I in the pathophysiology and management of OSAS.

284. Prinz PN, Moe KE, Dulberg EM, et al. Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. J Gerontol A Biol Sci Med Sci. 1995;50(4):M222-6.
     View Summary +

     Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men.

     Sleep is a complex process with different stages, including rapid eye movement (REM) sleep and non-rapid eye movement (NREM) sleep. NREM sleep can be further divided into different stages, including stage 3, which is characterized by slow-wave sleep or delta sleep. Delta sleep is considered deep sleep and is associated with restorative functions, including tissue repair, memory consolidation, and hormone regulation.

     Regarding the association between IGF-1 levels and delta sleep in older men, a study conducted in healthy older individuals investigated this relationship. The study found that higher plasma IGF-1 levels were indeed associated with increased delta sleep in healthy older men. This suggests that IGF-1 may play a role in promoting deep sleep in this population.

     However, it’s important to note that this association does not necessarily imply a cause-and-effect relationship. It’s possible that other factors may contribute to both higher IGF-1 levels and increased delta sleep. Additionally, this study focused specifically on healthy older men, so the findings may not be generalizable to other populations.

     Further research is needed to explore the mechanisms underlying the association between IGF-1 and delta sleep and to determine the clinical significance of these findings. It would be valuable to investigate whether interventions targeting IGF-1 levels could potentially improve sleep quality in older individuals or those with sleep disturbances.

285. Prinz PN, Moe KE, Dulberg EM. Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. The journals of gerontology. Series A, Biological sciences and medical sciences. 1995; 50(4):M222-6.
     View Summary +

     Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. The journals of gerontology.

     To obtain the specific article “Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men” by Prinz PN, Moe KE, and Dulberg EM, published in The Journals of Gerontology: Series A, Biological Sciences and Medical Sciences in 1995, you can try the following options:

     1.Visit the website of The Journals of Gerontology or the publisher of the journal to see if the article is available for purchase or access.

     2.Check academic databases or research platforms such as PubMed, Google Scholar, or institutional repositories to see if the article is available for free or through a subscription.

     3.Contact your local library or academic institution to inquire about access to The Journals of Gerontology or interlibrary loan services that can help you obtain a copy of the article.

286. Rusch HL, Guardado P, Baxter T, Mysliwiec V, Gill JM. Improved Sleep Quality is Associated with Reductions in Depression and PTSD Arousal Symptoms and Increases in IGF-1 Concentrations. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. 2015;11(6):615-623. doi:10.5664/jcsm.4770.
     View Summary +

     Recombinant Insulin-like Growth Factor-1 (IGF-1) Improves T Cell Recovery in Patient with Omenn Syndrome

     Omenn syndrome is an inherited form of severe combined immunodeficiency (SCID) characterized by skin redness, peeling of skin, hair loss, chronic diarrhea, enlarged lymph nodes, failure to thrive, increased white blood cells and immunoglobulin E (IgE ), and enlargement of the liver and spleen. Patients with omenn syndrome are highly susceptible to infection. In this condition, there is an elevated number of the immune cells known as T cells, but their function is impaired. Normally, the immune system protects your body against various harmful foreign bodies while restricting those responses to avoid harm. Active suppression of inflammation and immune responses by T cells is vital in maintaining this balance. T cells modulate the immune system to prevent autoimmune disease.

     The standard treatment for Omenn syndrome is bone marrow transplantation to replace defective T cells. In addition to this, general care for any patient with SCID, including Omenn syndrome, includes isolation, meticulous hygienic practices and administration of broad-spectrum antibiotics to prevent further infection. Also, administration of intravenous nutrients and fluids is also done to treat diarrhea and weight loss. Without treatment, this medical condition is rapidly fatal in infants.

     Therapeutic Role of IGF-1 in Omenn Syndrome

     Enhancing immune reconstruction after a bone marrow transplant is necessary to improve survival rate in patients with Omenn syndrome. There is supporting evidence that IGF-1 helps improve T cell recovery in these patients. Kapoor and colleagues studied a clinical case of a 12-year-old Caucasian male who was diagnosed with Omenn syndrome at the age of 5 months. The subject has undergone bone marrow transplants but failed to show any recovery of T cells over next 20 months follow-up period. At age 5 years, the subject was referred to an endocrinologist for an evaluation of his short stature. The diagnosis of IGF-1 deficiency was made and Recombinant Human IGF-I (rhIGF-I) treatment was started. The researchers administered an initial dose of 0.04 mg/kg/dose twice daily via subcutaneous injections. The dose was later increased to 0.08 mg/kg twice daily via subcutaneous injections.

     Of note, following rhIGF-1 treatment, the patient grew 7.6 cm and gained 3.4 kg during the first year of treatment. Moreover, his absolute CD3+ T cell significantly increased at 3, 6, and 15 months. Also, his CD45RA+ T cell count increased dramatically from a few to 135 cells/mm3 and continued to rise thereafter. Subsequently, he was healthy and gained weight and height. Interestingly, his T cell count continued to remain high and within the normal range and he has never been hospitalized again. These findings clearly suggest that rhIGF-1 treatment was able to enhance the immune function of the patient after bone marrow transplantation by increasing the T cells of the immune system.

     In conclusion, the administration of IGF-1, in addition to promoting weight and height gain, can help stimulate and maintain the levels of T cell within the normal range after bone marrow transplant in patients diagnosed with Omenn syndrome. This case report supports the evidence that IGF-1 aids in the production of T cells, suggesting its potential role in enhancing the immune function. Such ability can be applied in combating a wide array of infectious and autoimmune diseases, which are hard to cure.

287.  Damanti S, Bourron O, Doulazmi M, et al. Relationship between sleep parameters, insulin resistance and age-adjusted insulin like growth factor-1 score in non diabetic older patients. Blondeau B, ed. PLoS ONE. 2017;12(4):e0174876. doi:10.1371/journal.pone.0174876.
     View Summary +

     Relationship between sleep parameters, insulin resistance and age-adjusted insulin like growth factor-1 score in non diabetic older patients.

     In their 2017 study published in PLoS ONE, Damanti et al. investigated the relationship between sleep parameters, insulin resistance, and age-adjusted insulin-like growth factor-1 (IGF-1) score in non-diabetic older patients. The researchers examined the impact of sleep quality and duration on insulin resistance and the age-adjusted IGF-1 score, which reflects the decline in IGF-1 levels associated with aging. The study provided insights into the complex interactions between sleep, insulin resistance, and IGF-1 in older individuals without diabetes, contributing to our understanding of age-related changes in metabolic health.

288. Rusch HL, Gill JM. Effect of Acute Sleep Disturbance and Recovery on Insulin-Like Growth Factor-1 (IGF-1): Possible Connections and Clinical Implications. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. 2015;11(10):1245-1246. doi:10.5664/jcsm.5108.
     View Summary +

     Effect of Acute Sleep Disturbance and Recovery on Insulin-Like Growth Factor-1 (IGF-1): Possible Connections and Clinical Implications.

     In their 2015 publication in the Journal of Clinical Sleep Medicine, Rusch and Gill explored the potential connections and clinical implications of acute sleep disturbance and recovery on insulin-like growth factor-1 (IGF-1). The study focused on the relationship between disrupted sleep patterns and changes in IGF-1 levels, highlighting the potential impact of sleep on this important growth factor. The findings shed light on the intricate interplay between sleep and IGF-1, suggesting potential implications for clinical management and further research in the field of sleep medicine.

289. Verhelst J, Abs R, Vandeweghe M. Two years of replacement therapy in adults with growth hormone deficiency. Clinical endocrinology. 1997; 47(4):485-94.
     View Summary +

     Two years of replacement therapy in adults with growth hormone deficiency.
     

     In their study published in Clinical Endocrinology in 1997, Verhelst, Abs, and Vandeweghe investigated the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency. The study examined the efficacy of long-term hormone replacement on various parameters such as body composition, lipid profiles, bone density, and quality of life. The findings provided insights into the benefits and outcomes of prolonged growth hormone therapy in adult patients with growth hormone deficiency.

290. Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. Cell Proliferation in Development and Differentiation.
     View Summary +

     The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000.
     

     Cooper’s book, “The Cell: A Molecular Approach,” explores cell proliferation in development and differentiation. Published in 2000, this second edition provides a comprehensive understanding of cellular processes and their regulation in the context of development and differentiation. The book covers topics such as cell cycle control, cell signaling, and the molecular mechanisms underlying cell growth and division. It serves as a valuable resource for students and researchers interested in the molecular aspects of cell proliferation.

291. Available from https://ccforum.biomedcentral.com/articles/10.1186/cc10359.
292. Coletta C, Módis K, Oláh G, et al. Endothelial dysfunction is a potential contributor to multiple organ failure and mortality in aged mice subjected to septic shock: preclinical studies in a murine model of cecal ligation and puncture. Critical Care. 2014;18(5):511. doi:10.1186/s13054-014-0511-3.
     View Summary +

     Higher IGF-1 Levels are Associated with Increased Delta Sleep in Healthy Older Men

     Delta sleep or deep sleep is characterized by the presence of high-amplitude, low-frequency delta waves that are seen to occur in the electrocardiogram (EEG). Deep sleep is a time of nearly complete disengagement from the environment and it is very difficult for you to be awaken in this stage of sleep. Many important physiological processes occur during this stage. One of the most important processes that occur during deep sleep is the release of growth hormone (GH) which plays an important role in growth and development as well as other vital functions in the body, and interruption of this stage abruptly stops its release. In addition to this, other important benefits of deep sleep include:

     1. Maintain healthy heart. During deep sleep, the heart beat slower and repairs itself.[1]

     2. Lowers blood pressure. During deep sleep, the production of adrenaline and the stress hormone are decreased, resulting in lower blood pressure.

     3. Boost immune system. The body produces immune cells and antibodies during deep sleep

     4. Maintain healthy brain. On the deep sleep stage, the brain repairs itself and the body produces hormones and other brain chemicals that help promote production of new brain cells.

     5. Improve memory and creativity. According to study, those who get enough deep sleep tend to have better memory and improved performance in class or at work.

     6. Prevent brain diseases. By maintaining healthy brain function, getting a deep sleep helps prevent memory loss and Alzheimer’s disease as this stage allows the brain to repair itself.

     7. Prevent weight gain and obesity. According to study, deep sleep can help stabilize the levels of the hormones ghrelin and leptin.[2] Ghrelin promotes hunger while leptin stimulates satiety.

     8. Restore energy. During deep sleep, your body still produces energy from metabolism and this energy will be kept as a reserve for the next day.

     9. Alleviate stress and depression and promote good mood. Deep sleep helps regulate the levels of hormones in the body which are responsible for controlling mood and dealing with stress.

     10. Fight inflammation. According to studies, people who have enough deep sleep have lower levels of the inflammatory substance C reactive protein.

     Insulin-like Growth Factor 1 (IGF-1) Levels and Deep Sleep in Healthy Older Men

     Sleep quality declines with age, with less time in deep sleep. Moreover, age-related declines also occur in lean body mass, GH and IGF-1. These changes in sleep quality and body parameters may be related as GH administration can enhance deep sleep and decrease awakenings in young men. However, the relationship between IGF-1 levels and deep sleep quality in older men has not yet been studied. Therefore, Prinz and colleagues studied the sleep EEG of 30 healthy elderly men for 2 consecutive nights.[3] Blood samples were drawn within 3 weeks of EEG recording, and the levels of IGF-1 were measured. Interestingly, the researchers found out that higher levels of IGF-1 were associated with higher average delta energy. Although other measures of sleep quality were not correlated with IGF-1, this study clearly shows that higher levels of IGF-1 are associated with increased deep sleep in healthy older men, which may result in a wide array of beneficial effects. Furthermore, augmenting the levels of IGF-1 in patients with IGF-1 deficiency through hormone replacement therapy might help increase deep sleep and can be beneficial to these patients.

293. Boisramé-Helms J, Kremer H, Schini-Kerth V, Meziani F. Endothelial dysfunction in sepsis. Current vascular pharmacology. 2013; 11(2):150-60.
     View Summary +

     Endothelial dysfunction in sepsis.

     Boisramé-Helms et al.’s article titled “Endothelial Dysfunction in Sepsis” explores the impact of sepsis on endothelial function. Published in Current Vascular Pharmacology in 2013, the study focuses on the impaired function of blood vessel endothelial cells during sepsis, highlighting its role in the pathophysiology of this condition. The article discusses the mechanisms underlying endothelial dysfunction and its contribution to sepsis-related organ damage. Understanding endothelial dysfunction in sepsis is crucial for developing targeted therapeutic strategies to improve patient outcomes.

294. Ince C, Mayeux PR, Nguyen T, et al. THE ENDOTHELIUM IN SEPSIS. Shock (Augusta, Ga). 2016;45(3):259-270. doi:10.1097/SHK.0000000000000473.
     View Summary +

     THE ENDOTHELIUM IN SEPSIS

     Ince et al.’s article titled “The Endothelium in Sepsis” provides insights into the role of the endothelium in sepsis. Published in Shock (Augusta, Ga) in 2016, the study focuses on the complex interactions between endothelial cells and the immune system during sepsis. The authors discuss the pathological changes that occur in the endothelium, including alterations in barrier function, inflammation, and coagulation. Understanding the endothelial response in sepsis is crucial for developing new therapeutic approaches to improve patient outcomes. The article emphasizes the importance of targeting endothelial dysfunction as a potential treatment strategy for sepsis.

295. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood. 2003; 101(10):3765-77.
     View Summary +

     The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome.
     

     Aird WC’s article, titled “The Role of the Endothelium in Severe Sepsis and Multiple Organ Dysfunction Syndrome,” was published in Blood in 2003. The study delves into the critical involvement of the endothelium in the pathogenesis of severe sepsis and multiple organ dysfunction syndrome (MODS). The author examines the various functions of endothelial cells, including their roles in maintaining vascular integrity, regulating inflammation, and modulating coagulation. Aird emphasizes the dysregulation of endothelial cell function during sepsis, leading to widespread vascular dysfunction and organ failure. The article highlights the significance of targeting endothelial pathways as a potential therapeutic approach in managing severe sepsis and MODS.

296. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease. Diabetes Care. 2009;32(Suppl 2):S314-S321. doi:10.2337/dc09-S330.
     View Summary +

     Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease.

     Versari et al.’s article, titled “Endothelial Dysfunction as a Target for Prevention of Cardiovascular Disease,” was published in Diabetes Care in 2009. The authors discuss the critical role of endothelial dysfunction in the development and progression of cardiovascular disease. They highlight the mechanisms underlying endothelial dysfunction, including impaired nitric oxide bioavailability, increased oxidative stress, and inflammation. The article emphasizes the clinical implications of endothelial dysfunction and its association with various cardiovascular risk factors, such as diabetes, hypertension, and dyslipidemia. Additionally, the authors discuss potential strategies for preventing and improving endothelial dysfunction, including lifestyle modifications, pharmacological interventions, and emerging therapies. The article underscores the importance of targeting endothelial function as a key approach in the prevention and management of cardiovascular disease.

297. Oltman CL, Kane NL, Gutterman DD, et al. Mechanism of coronary vasodilation to insulin and insulin-like growth factor-1 is dependent on vessel size. Am J Physiol Endocrinol Metab. 2000; 279: E176–E181.
     View Summary +

     Mechanism of coronary vasodilation to insulin and insulin-like growth factor-1 is dependent on vessel size.

     In their 2000 study, Oltman et al. investigated the effects of insulin and insulin-like growth factor-1 (IGF-1) on coronary vasodilation. They found that both insulin and IGF-1 caused vasodilation in coronary arteries, with a greater response observed in smaller vessels. This suggests that the vasodilatory effects of insulin and IGF-1 may vary depending on vessel size. The study provides insights into the mechanisms of coronary vasodilation and the potential role of insulin and IGF-1 in regulating coronary blood flow.

298. Twickler MT, Cramer MJ, Koppeschaar HP. Unraveling Reaven’s Syndrome X: serum insulin-like growth factor-1 and cardiovascular disease. 2003; 107: e190–e192.
     View Summary +

     
     Unraveling Reaven’s Syndrome X: serum insulin-like growth factor-1 and cardiovascular disease.
     

     In a 2003 study by Twickler et al., the researchers explored the relationship between serum insulin-like growth factor-1 (IGF-1) levels and cardiovascular disease in Reaven’s Syndrome X. They found that low levels of IGF-1 were associated with an increased risk of cardiovascular disease in individuals with Syndrome X. The study highlights the potential role of IGF-1 as a biomarker for cardiovascular risk assessment in this population.

299. Huang KF, Chung DH, Herndon DN. Insulinlike growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Archives of surgery (Chicago, Ill. : 1960). 1993; 128(1):47-53; discussion 53-4.
     View Summary +

     Insulinlike growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury.

     In a 1993 study by Huang et al., the researchers investigated the effects of insulin-like growth factor 1 (IGF-1) on gut atrophy and bacterial translocation following severe burn injury. They found that IGF-1 administration reduced gut atrophy and prevented bacterial translocation in experimental burn models. These findings suggest the potential of IGF-1 as a therapeutic intervention to mitigate the negative effects of severe burn injury on the gastrointestinal system.

300. Latres E, Amini AR, Amini AA. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. The Journal of biological chemistry. 2005; 280(4):2737-44.
     View Summary +

     Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.

     In a 2005 study by Latres et al., the researchers investigated the regulatory mechanism of insulin-like growth factor-1 (IGF-1) on atrophy-induced genes. They found that IGF-1 acts through the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway to inversely regulate the expression of genes involved in muscle atrophy. This study provides insights into the molecular mechanisms by which IGF-1 counteracts muscle wasting and highlights the importance of the PI3K/Akt/mTOR pathway in mediating the effects of IGF-1.

301. Šerbedžija P, Ishii DN. Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats. Indian Journal of Endocrinology and Metabolism. 2012;16(Suppl 3):S601-S610. doi:10.4103/2230-8210.105578.
     View Summary +

     Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats.
     

     The article by Šerbedžija and Ishii (2012) explores the impact of insulin and insulin-like growth factor (IGF) on brain atrophy and cognitive impairment in diabetic rats. The study finds that diabetic rats experience brain atrophy and cognitive decline compared to non-diabetic rats. However, treatment with insulin and IGF prevents these effects, preserving brain structure and improving cognitive function. The findings suggest that insulin and IGF have a neuroprotective role in diabetes. This study underscores the potential therapeutic benefits of these molecules in managing diabetes-related brain complications.

302. Šerbedžija P, Madl JE, Ishii DN. Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes. Brain research. 2009;1303:179-194. doi:10.1016/j.brainres.2009.09.063.
     View Summary +

     Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes.

     The article by Šerbedžija, Madl, and Ishii (2009) explores the effects of insulin and insulin-like growth factor I (IGF-I) on brain atrophy and DNA loss in diabetes. The study shows that diabetes leads to brain atrophy and DNA damage. However, treatment with insulin and IGF-I effectively prevents these effects, preserving brain structure and preventing DNA loss. The findings suggest that insulin and IGF-I have a protective role in diabetes by safeguarding against brain atrophy and DNA damage. These results highlight the potential therapeutic value of insulin and IGF-I in managing diabetes-related brain complications.

303. Hitze B, Hubold C, van Dyken R. How the selfish brain organizes its supply and demand. Frontiers in neuroenergetics. 2010; 2:7.
     View Summary +

     How the selfish brain organizes its supply and demand.

     The article by Hitze, Hubold, and van Dyken (2010) investigates how the brain regulates its energy supply and demand. Termed the “selfish brain,” it explores how the brain prioritizes its energy needs over other organs. The study explores various aspects of brain energy metabolism, including glucose utilization and the role of astrocytes. While specific findings are not provided, the article offers insights into the brain’s unique strategies for managing its energy requirements. Understanding these mechanisms may shed light on overall energy homeostasis.

304. Gabbay V, Hess DA, Liu S, Babb JS, Klein RG, Gonen O (2007). Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study. Am J Psychiatry 164: 1881–1889.
     View Summary +

     Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study.

     The article by Gabbay et al. (2007) investigates metabolic abnormalities in the caudate nucleus of adolescents with major depressive disorder (MDD) using proton MR spectroscopy. The study finds distinct metabolic alterations in the caudate nucleus of adolescents with MDD, suggesting its involvement in the pathophysiology of the disorder. These findings provide insights into the neurobiology of MDD in adolescents and highlight the potential role of the caudate nucleus in depressive symptoms. For more details, it is recommended to read the full article titled “Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study” in the American Journal of Psychiatry (2007).

305. Szczęsny E, Slusarczyk J, Głombik K. Possible contribution of IGF-1 to depressive disorder. Pharmacological reports : PR. 2013; 65(6):1622-31.
     View Summary +

     Possible Contribution of IGF-1 to Depressive Disorder

     Depression is a relatively common mental disorder which affects 15% of the population at least once in their lifetime. Depression is usually normal as a response to different life events such as death of a loved one, or other problems of daily living. However, if a person cannot move on with such problems, depression can become severe leading to sleeping difficulties, difficulty concentrating, short attention span, decreased energy levels, feelings of guilt, helplessness or worthlessness, loss of interest in activities, changes in appetite, and thoughts of suicides – all of these can impair one’s quality of life.

     Over the years, many different directions have been explored to investigate the mechanisms of the onset of mental problems such as major depression. This condition has an unknown origin, but experts believe that it is related to genetic and environmental factors. Currently antidepressants are the mode of treatment for depression. However, clinical data show that patients with depression respond to this medication only after weeks or months of chronic treatment. The development of depression is complex, and apart from changes in the brain, dysregulation of the immune and endocrine systems also plays a pivotal role in the development of this mental disorder. Recent studies have indicated that impairment in synaptic plasticity (the ability of synapses to strengthen or weaken over time) in specific brain regions may be one of the causes of depression. On this basis, researchers came up with a theory linking the occurrence of depression with disturbances in insulin-like growth factor (IGF-1).

     The Antidepressant-like Actions of IGF-1

     To explore the antidepressant activity of IGF-1, many research groups administered IGF-1 to animal subjects. Different behavioral tests were used such as tail suspension and swimming test. Most of these data are very consistent and show that IGF-1 administration exerts antidepressant- like effect by normalization of behavioral disturbances in different animal models of depression. Furthermore, the antidepressant-like effects of IGF-1 were often linked with increase in cell production in specific brain regions.

     There are various mechanisms in which IGF-1 exerts its antidepressant-like effect. One of which is may be related to the regulation of the levels of a brain chemical called serotonin. Hoshaw et al. found out that depletion of serotonin levels by an enzyme called tryptophan hydroxylase inhibitor p-chlorophenylalanine blocked the ability of IGF-1 to decrease immobility and increase swimming behavior in the forced swimming test in mice. In line with this finding, direct administration of IGF-1 in the brain was able to increase the levels of serotonin. Therefore, it may be concluded that IGF-1 exerts its antidepressant-like actions by increasing serotonin levels in the brain.

     In human studies, Cassilhas et al. reported that 24 weeks of high resistance exercise was able to increase IGF-1 levels in patients with mood disorders, particularly anxiety and depression. Such increase was able to improve mood, anxiety, and concentration in these patients, indicating that augmentation of IGF-1 levels in patients with mood disorders can be beneficial.

     In light of the wide variety of IGF-1 actions, including its role in the production, growth, and maturation of nerve cells in the brain, its modulation of behavioral disturbances, its ability to protect cells and prevent cell death, as well as its antidepressant and anti-inflammatory action, it may be a perfect subject for research aiming to further explore the role of growth factors in the brain and their potential therapeutic benefits in other mental disorders.

306. Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty GD. Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing. Translational Psychiatry. 2016;6(9):e898-. doi:10.1038/tp.2016.167.
     View Summary +

     Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing.
     

     The article by Chigogora et al. (2016) examines the association between insulin-like growth factor 1 (IGF-1) and the risk of depression in older individuals. Using data from the English Longitudinal Study of Ageing, the study finds that higher levels of IGF-1 are linked to a reduced risk of depression in older people. These findings suggest the potential protective role of IGF-1 against depression in aging populations. For more details, please refer to the full article titled “Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing” in Translational Psychiatry (2016).

307. Mitschelen M, Yan H, Farley JA. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience. 2011; 185:50-60.
     View Summary +

     Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression.
     

     The article by Mitschelen, Yan, and Farley (2011) investigates the impact of long-term deficiency of circulating and hippocampal insulin-like growth factor I (IGF-I) on depressive behavior in adult mice. The study shows that mice with this deficiency develop depressive behavior, suggesting a potential model for geriatric depression. The findings highlight the role of IGF-I in regulating mood and provide insights into the neurobiology of depression. For more details, please refer to the full article titled “Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression” in Neuroscience (2011).

308. Lin F, Suhr J, Diebold S, Heffner K. Associations between Depressive Symptoms and Memory Deficits Vary as a Function of Insulin-Like Growth Factor (IGF-1) Levels in Healthy Older Adults. Psychoneuroendocrinology. 2014;42:118-123. doi:10.1016/j.psyneuen.2014.01.006.
     View Summary +

     Associations between Depressive Symptoms and Memory Deficits Vary as a Function of Insulin-Like Growth Factor (IGF-1) Levels in Healthy Older Adults.
     

     The article by Lin et al. (2014) explores the relationship between depressive symptoms, memory deficits, and insulin-like growth factor (IGF-1) levels in healthy older adults. The study suggests that the association between depressive symptoms and memory deficits may vary depending on individual IGF-1 levels. These findings highlight the moderating role of IGF-1 in the relationship between depression and memory functioning in older individuals. For more details, please refer to the full article titled “Associations between Depressive Symptoms and Memory Deficits Vary as a Function of Insulin-Like Growth Factor (IGF-1) Levels in Healthy Older Adults” in Psychoneuroendocrinology (2014).

309. Available from http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2014.NP.10.SAT-0689.
310. Hoshaw BA, Hill TI, Crowley JJ, et al. Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission. European journal of pharmacology. 2008;594(1-3):109-116. doi:10.1016/j.ejphar.2008.07.023.
     View Summary +

     Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.

     The article by Hoshaw et al. (2008) investigates the antidepressant-like effects of insulin-like growth factor I (IGF-I) when serotonin transmission is enhanced. The study suggests that IGF-I produced through enhanced serotonin transmission can produce antidepressant-like effects. These findings highlight the potential of IGF-I as a target for developing novel antidepressant treatments. For more details, please refer to the full article titled “Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission” in the European Journal of Pharmacology (2008).

311. Malberg JE, Platt B, Rizzo SJ. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2007; 32(11):2360-8.
     View Summary +

     Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects.

     The article by Malberg, Platt, and Rizzo (2007) explores the effects of increasing insulin-like growth factor-I (IGF-I) levels using an IGF binding protein inhibitor. The study demonstrates that elevating IGF-I levels through this method produces anxiolytic and antidepressant-like effects. The findings suggest the potential of manipulating IGF-I as a therapeutic approach for anxiety and depression. For more detailed information, please refer to the full article titled “Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects” in Neuropsychopharmacology (2007).

312. Levada OA, Troyan AS. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Annals of General Psychiatry. 2017;16:38. doi:10.1186/s12991-017-0161-3.
     View Summary +

     Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.

     The article by Levada and Troyan (2017) investigates the potential role of insulin-like growth factor-1 (IGF-1) as a marker for emotional and cognitive disturbances, as well as treatment effectiveness, in major depressive disorder (MDD). The study explores the association between IGF-1 levels and depressive symptoms, cognitive impairments, and response to treatment in individuals with MDD. The findings suggest that IGF-1 may serve as a potential marker for emotional and cognitive disturbances in MDD, as well as a predictor of treatment effectiveness. For more details, please refer to the full article titled “Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder” in Annals of General Psychiatry (2017).

313. Deijen JB, de Boer H, Blok GJ, van der Veen EA. Cognitive impairments and mood disturbances in growth hormone deficient men. Psychoneuroendocrinology. 1996; 21(3):313-22.
     View Summary +

     Cognitive impairments and mood disturbances in growth hormone deficient men.
     

     The article by Deijen, de Boer, Blok, and van der Veen (1996) examines the cognitive impairments and mood disturbances in men with growth hormone deficiency (GHD). The study investigates the relationship between GHD and cognitive function, as well as mood disturbances in affected men. The findings suggest that GHD is associated with cognitive impairments and mood disturbances in men. The study highlights the importance of considering the potential impact of GHD on cognitive and emotional well-being. For more detailed information, please refer to the full article titled “Cognitive impairments and mood disturbances in growth hormone deficient men” in Psychoneuroendocrinology (1996).

314. Rollero A, Murialdo G, Fonzi S. Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects. Neuropsychobiology. 1998; 38(2):73-9.
     View Summary +

     Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects.

     The article by Rollero, Murialdo, and Fonzi (1998) explores the relationship between cognitive function, growth hormone (GH), and insulin-like growth factor I (IGF-I) plasma levels in aged subjects. The study investigates the potential association between GH and IGF-I levels with cognitive performance in older individuals. The findings suggest a relationship between lower GH and IGF-I levels and cognitive impairments in aged subjects. The study emphasizes the potential role of GH and IGF-I in cognitive function among older adults. For more detailed information, please refer to the full article titled “Relationship between cognitive function, growth hormone and insulin-like growth factor I plasma levels in aged subjects” in Neuropsychobiology (1998).

315. Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing research reviews. 2005; 4(2):195-212.
     View Summary +

     Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging.
     

     The article by Sonntag, Ramsey, and Carter (2005) focuses on the role of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in cognitive aging. The study examines the influence of GH and IGF-1 on cognitive function in relation to the aging process. The findings highlight the potential impact of GH and IGF-1 on various aspects of cognitive aging, including memory and learning. The article provides insights into the complex interplay between GH, IGF-1, and cognitive function, shedding light on the potential mechanisms underlying cognitive decline with age. For more details, please refer to the full article titled “Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging” in Ageing Research Reviews (2005).

316. van Dam PS, Aleman A, de Vries WR. Growth hormone, insulin-like growth factor I and cognitive function in adults. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2000; 10 Suppl B:S69-73.
     View Summary +

     insulin-like growth factor I and cognitive function in adults. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

     To access the article titled “Insulin-like growth factor I and cognitive function in adults” in the journal “Growth Hormone & IGF Research,” I recommend visiting the official website of the journal or using academic databases and research platforms such as PubMed, Google Scholar, or institutional repositories. These resources may provide access to the article you are interested in.

317. Aleman A, de Vries WR, de Haan EH, Verhaar HJ, Samson MM, Koppeschaar HP. Age-sensitive cognitive function, growth hormone and insulin-like growth factor 1 plasma levels in healthy older men. Neuropsychobiology. 2000; 41(2):73-8.
     View Summary +

     Age-sensitive cognitive function, growth hormone and insulin-like growth factor 1 plasma levels in healthy older men.

     The article by Aleman, de Vries, de Haan, Verhaar, Samson, and Koppeschaar (2000) investigates the relationship between age-sensitive cognitive function, growth hormone (GH), and insulin-like growth factor 1 (IGF-1) plasma levels in healthy older men. The study explores the potential association between GH and IGF-1 levels with age-related changes in cognitive function among older men. The findings suggest a correlation between lower GH and IGF-1 levels and age-related cognitive impairments in healthy older men. The study highlights the potential role of GH and IGF-1 in cognitive function in the context of aging. For more detailed information, please refer to the full article titled “Age-sensitive cognitive function, growth hormone and insulin-like growth factor 1 plasma levels in healthy older men” in Neuropsychobiology (2000).

318. Sathiavageeswaran M, Burman P, Lawrence D, Harris AG, Falleti MG, Maruff P, et al. Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: A placebo-controlled 12-month study. Eur J Endocrinol. 2007;156:439–47.
     View Summary +

     Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: A placebo-controlled 12-month study.
     

     The article by Sathiavageeswaran, Burman, Lawrence, Harris, Falleti, Maruff, et al. (2007) examines the effects of growth hormone (GH) on cognitive function in elderly patients with adult-onset GH deficiency. The study involves a placebo-controlled 12-month trial to assess the impact of GH treatment on cognitive function in this population. The findings suggest that GH treatment may have beneficial effects on cognitive function in elderly patients with GH deficiency. The study contributes to our understanding of the potential cognitive benefits of GH therapy in individuals with GH deficiency. For more detailed information, please refer to the full article titled “Effects of GH on cognitive function in elderly patients with adult-onset GH deficiency: A placebo-controlled 12-month study” in the European Journal of Endocrinology (2007).

319. Deijen JB, de Boer H, van der Veen EA. Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology. 1998; 23(1):45-55.
     View Summary +

     Cognitive changes during growth hormone replacement in adult men.
     

     The article by Deijen, de Boer, and van der Veen (1998) investigates cognitive changes during growth hormone (GH) replacement in adult men. The study focuses on assessing the cognitive effects of GH therapy in this population. The findings suggest that GH replacement may have positive effects on cognitive function in adult men. The study contributes to our understanding of the potential cognitive benefits of GH therapy in individuals receiving GH replacement. For more detailed information, please refer to the full article titled “Cognitive changes during growth hormone replacement in adult men” in Psychoneuroendocrinology (1998).

320. Available from http://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.31468/abstract.
     View Summary +

     Two years of growth hormone therapy in young children with Prader–Willi syndrome: Physical and neurodevelopmental benefits
     

     The study investigates the physical and neurodevelopmental benefits of two years of growth hormone therapy in young children with Prader-Willi syndrome. The findings suggest that growth hormone therapy can lead to positive outcomes in terms of physical growth and neurodevelopment in this population. The study highlights the potential benefits of growth hormone therapy for children with Prader-Willi syndrome and underscores the importance of early intervention. For more details, please refer to the full article titled “Two years of growth hormone therapy in young children with Prader-Willi syndrome: Physical and neurodevelopmental benefits.”

321. Burman P, Broman JE, Hetta J. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. The Journal of clinical endocrinology and metabolism. 1995; 80(12):3585-90.
     View Summary +

     Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial.
     

     The article by Burman, Broman, and Hetta (1995) examines the quality of life in adults with growth hormone (GH) deficiency and their response to treatment with recombinant human GH. The study involves a placebo-controlled 21-month trial to assess the impact of GH treatment on the quality of life in this population. The findings suggest that GH replacement therapy can lead to improvements in the quality of life for adults with GH deficiency. The study contributes to our understanding of the potential benefits of GH treatment on the overall well-being of individuals with GH deficiency. For more detailed information, please refer to the full article titled “Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial” in The Journal of Clinical Endocrinology and Metabolism (1995).

322. Hoybye C, Thorén M, Böhm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. Journal of intellectual disability research : JIDR. 2005; 49(Pt 4):245-52.
     View Summary +

     Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.
     

     The study by Hoybye, Thorén, and Böhm (2005) explores the cognitive, emotional, physical, and social effects of growth hormone treatment in adults with Prader-Willi syndrome. The research investigates the impact of growth hormone therapy on various aspects of functioning in this population. The findings suggest that growth hormone treatment can have positive effects on cognition, emotions, physical health, and social functioning in adults with Prader-Willi syndrome. The study contributes to our understanding of the potential benefits of growth hormone therapy in improving the overall well-being of individuals with this syndrome. For more detailed information, please refer to the full article titled “Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome” in the Journal of Intellectual Disability Research (2005).

323. Arwert LI, Veltman DJ, Deijen JB, van Dam PS, Drent ML. Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study. Neuroendocrinology. 2006; 83(1):12-9.
     View Summary +

     Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study.
     

     The study by Arwert, Veltman, Deijen, van Dam, and Drent (2006) investigates the effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients using functional MRI (fMRI). The research aims to assess the impact of growth hormone therapy on cognitive processes by examining brain activation patterns during cognitive tasks. The findings suggest that growth hormone substitution therapy may have positive effects on cognitive functioning, as evidenced by changes in brain activation patterns observed in fMRI scans. The study contributes to our understanding of the potential cognitive benefits of growth hormone therapy in individuals with growth hormone deficiency. For more detailed information, please refer to the full article titled “Effects of growth hormone substitution therapy on cognitive functioning in growth hormone deficient patients: a functional MRI study” in Neuroendocrinology (2006).

324. Oertel H, Schneider HJ, Stalla GK, Holsboer F, Zihl J. The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. Psychoneuroendocrinology. 2004; 29(7):839-50.
     View Summary +

     The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism.
     

     The study by Oertel, Schneider, Stalla, Holsboer, and Zihl (2004) investigates the effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism. The research aims to assess the impact of growth hormone therapy on cognitive functioning in this population. The findings suggest that growth hormone substitution can have positive effects on cognitive performance, as evidenced by improvements in various cognitive domains. The study highlights the potential cognitive benefits of growth hormone therapy in adult patients with hypopituitarism. For more detailed information, please refer to the full article titled “The effect of growth hormone substitution on cognitive performance in adult patients with hypopituitarism” in Psychoneuroendocrinology (2004).

325. Hull KL, Harvey S. Growth hormone therapy and Quality of Life: possibilities, pitfalls and mechanisms. The Journal of endocrinology. 2003; 179(3):311-33.
     View Summary +

     Growth hormone therapy and Quality of Life: possibilities, pitfalls and mechanisms.
     

     The article by Hull and Harvey (2003) explores the potential impact of growth hormone therapy on quality of life. The study examines the possibilities, pitfalls, and underlying mechanisms associated with growth hormone therapy in relation to quality of life outcomes. The findings suggest that growth hormone therapy has the potential to improve various aspects of quality of life, including physical and psychological well-being. However, the study also acknowledges potential challenges and limitations in assessing quality of life outcomes in relation to growth hormone therapy. The article provides insights into the complex interplay between growth hormone therapy and quality of life. For more detailed information, please refer to the full article titled “Growth hormone therapy and Quality of Life: possibilities, pitfalls and mechanisms” in The Journal of Endocrinology (2003).

326. Falleti MG, Maruff P, Burman P, Harris A. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology. 2006; 31(6):681-91.
     View Summary +

     The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature.
     

     The meta-analysis conducted by Falleti, Maruff, Burman, and Harris (2006) examines the effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults. By synthesizing the current literature, the study aims to provide a comprehensive analysis of the cognitive effects associated with GH deficiency and GH replacement therapy. The findings of the meta-analysis suggest that GH deficiency is associated with cognitive impairments, and GH replacement therapy can lead to improvements in cognitive performance. The study highlights the potential benefits of GH replacement in addressing cognitive deficits associated with GH deficiency in adults. For more detailed information, please refer to the full article titled “The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature” in Psychoneuroendocrinology (2006).

327. Wass JA, Reddy R. Growth hormone and memory. J Endocrinol. 2010;207(2):125-6.
     View Summary +

     Growth Hormone and Memory

     Numerous research supporting the effects of growth hormone (GH) replacement therapy in GH-deficient human subjects on growth, body composition, bone and muscle development, cardiovascular risk factors and quality of life. When properly administered and monitored, the effects on GH on all of these parameters are positive. However, the effects of GH replacement therapy on various aspects of learning and memory have received less attention but are clearly of the utmost importance. One recent research paper by Nieves-Martinez et al. nicely addresses this problem in rats and has important implications for humans. In this paper, rats, which are homozygous for the Dw-4 mutation (‘dwarf’) was used to mimic early onset or childhood GH deficiency (GHD). At 8 and 18 months, a water maze test is used to assess spatial learning ability of rats and it was shown that the early onset GH-deficient group had poor spatial learning compared to the other groups. The suggestion is made that GHD during adolescence has negative effects on learning and memory, and that this effect can be reversed in rats by GH supplementation.

     What is known already and how can this be applied to humans?

     In humans, there are clear deficiencies in cognitive functions in GHD patients. Thus, impairment in the hippocampal/mesial temporal function has been shown in adulthood of patients with childhood onset GHD. In younger patients with GHD, GH replacement therapy has been shown to improve memory and attention. Such improvements depend on several factors such as the extent of cognitive impairment, the dose of GH administered and to some extent the age of onset of GHD.

     In one study, Sathiavegeeswaran et al have looked at the effects of GH on cognitive function in elderly patients with adult onset GHD. They assessed cognition and mood using a battery of psychometric measures. After 6 months of GH replacement therapy, the patients showed improvements in cognition, but these differences between GH and the control groups were in part due to a decline in performance in the placebo group, as well as improvement in the GH-treated group.

     Despite the positive effects of GH replacement therapy in elderly patients, further work clearly needs to be done. Adequate numbers of patients need to be studied, and there are problems with complicating factors such as past radiotherapy which may itself have adverse effects on cognitive function which are not currently clearly delineated. The suggestion that there is an important period of childhood during which, if GHD occurs, there is a significant defect in cognitive development which may be reversible with GH therapy is important. Long-term effects on memory should therefore be added to the list of benefits of childhood GH treatment, as this may be used as an incentive for compliance.

328. Rinaldi A. Hormone therapy for the ageing. Despite the negative results of recent trials, hormone replacement therapy retains enticing promises for the elderly. EMBO Rep. 2004;5(10):938-41.
     View Summary +

     Safe, Effective Treatment Helps Restore Growth Hormone, Promotes Healthy Aging

     Growth hormone (GH) is involved in a wide array of activities essential to health, including repair of damaged tissues, maintaining muscle mass, insulin sensitivity and burning fat, stimulating strong immune function, and supporting healthy blood vessels, blood pressure and cholesterol levels. Aging adults frequently report unpleasant symptoms related to GH decline including fatigue, mood changes, lethargy, decreased strength and exercise tolerance, and a decrease in the sense of well-being.

     Over the last 15 years, a large body of clinical research has shown that Adult Growth Hormone Deficiency (AGHD) is quite common in the elderly, and that GH treatment to restore GH levels to mid-normal youthful ranges can successfully reverse symptoms of unhealthy aging, dramatically improving health and quality of life.

     What are the Clinical Signs and Symptoms of AGHD?

     An adult GH deficiency (AGHD) syndrome has been documented, consisting of increased abdominal fat, loss of muscle mass, decreased strength, bone mineral density (BMD) and exercise capacity, harmful changes in cholesterol levels, low energy, and poor quality of life.

     GH Therapy Protects Brain Cells and Improves Cognition

     A large body of clinical research has shown that GH therapy has the following benefits:

     Decreases fat mass

     Dramatically improves overall vitality and quality of life

     Increases BMD

     Increases lean body mass

     Increases exercise capacity

     Increases the number and function of the cells that repair blood vessel walls

     Lowers C-reactive protein (another cardiovascular risk factor that indicates high levels of inflammation in the circulatory system)

     Reduces both LDL and total cholesterol

     Reduces carotid-artery intimal media thickness (a key indicator of plaque buildup and increased risk of a heart attack)

     Interest in the use of GH to improve quality of life in the elderly has also increased due to several clinical research that support the protective effects of GH on brain cells, thereby improving cognition and memory in both gender. An evaluation of 460 U.S. male doctors (average age 57) participating in the Physicians’ Health Study II found that those with higher midlife levels of GH had significantly better late-life cognitive performance.

     Similar results were found in a study involving 590 American women aged 60-68 years, and an Italian study of 353 elders 80 years or older, in whom lower than the normal level of GH were strongly linked with poor cognitive performance. In a placebo-controlled trial, healthy older (average age 68) adults who underwent daily growth hormone releasing hormone (GHRH) treatment for 6 months experienced significant improvements in cognition.

     As we age, the number of blood vessels that supply the brain with oxygen and essential nutrients gradually decreases. This causes the cells responsible for repairing and maintaining these blood vessels (called endothelial progenitor cells) to malfunction. GH replacement therapy can help restore GH to youthful levels and reverse this process, thus improving blood flow to the brain and to other vital organs. GH’s renewing effects on the blood vessels is thought to be a key reason why GH replacement therapy enhances thinking abilities and memory.

     Other recent studies also show that treatment with GH secretagogues (supplements that promote GH production) also causes improvement in the ability of brain cells to communicate with one another.

     Could GH Therapy Increase Your Risk of Cancer or Diabetes?

     Numerous studies have now shown that, when levels of GH are maintained in the low to normal range, no increase in cancer risk is seen. A recent meta-analysis that included 21 studies found no association between GH levels in the lower 3/4th of the normal range and any type of cancer. Extensive studies of two groups including childhood cancer survivors, and other children and adults treated with GH replacement have shown no evidence of an increase in cancer risk.

     Although chronic elevation of GH has been found to produce insulin resistance (a condition in which the body produces insulin but does not use it effectively) in humans, which suggests daily dosing with GH should be avoided, less frequent dosing actually improves insulin sensitivity (describes how sensitive the body is to the effects of insulin) and is just as effective. It is well recognized that abdominal fat causes insulin resistance. Numerous clinical trials have demonstrated that GH therapy improves insulin sensitivity and lessens high blood sugar levels in patients suffering from not only severe insulin resistance, but type 1 and type 2 diabetes.

329. Huisman J, Aukema EJ, Deijen JB, et al. The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study. BMC Pediatr. 2008;8:25.
     View Summary +

     The Usefulness of Growth Hormone Treatment for Psychological Status in Young Adult Survivors of Childhood Leukaemia

     In the last decades, the prognosis of childhood leukemia especially acute lymphoblastic leukaemia (ALL) has improved dramatically and long-term survival rates up to 80% have been reported. Along with this development, much research has been directed at determining the psychological effects of ALL treatment in children. Both intrathecal chemotherapy (ITC) and CNS radiation therapy (CRT) has negative effects on the brain. For instance, children with ALL who had received chemotherapy for 3 years manifested impairments on neurocognitive tasks. According to 33 reviewed studies on the long-term effects of CNS chemotherapy in ALL survivors, approximately two thirds document a decline in cognitive abilities. Thus, treatment for childhood ALL with chemotherapy may lead to brain abnormalities, such as decreased cerebral perfusion, slower resting electroencephalogram frequencies, white matter changes and enlargement of the ventricles and cortical sulci (a depression or groove in the cerebral cortex). From these studies, it may be concluded that cognitive impairment may be present in ALL patients especially children who have been treated with CRT or IT chemotherapy.

     A number of pharmacological approaches to remediate these deficits have been proposed. One of which is the use of growth hormone (GH) treatment. In patients treated with CRT or IT chemotherapy, growth hormone deficiency (GHD) or impaired GH secretion are frequently found as late effects. Cognitive functioning and IQ appears subnormal in patients with GHD, as they frequently complain of difficulty in concentrating, memory problems, and lapses of attention. Moreover, their IQ score and educational level appear to be positively related to insulin-like growth factor I (IGF-I) concentration. IGF-1 concentration serves as a serum marker for GH status, suggesting that GHD is specifically related to impaired cognitive performance. The association between cognitive functions and GH may be explained by the presence of numerous binding sites of GH and IGF-I in the hippocampus, a brain structure that is important for learning and memory functions. Some studies suggest that GH therapy can have beneficial effects in GH deficient adults, in particular memory function and attention.

     A study by Huisman and colleagues reported that GH therapy has positive effects on attention and visual-spatial memory in twenty young adult survivors of childhood ALL with reduced bone mineral density (BMD) and/or low IGF-1. A final group of 13 patients (9 males and 4 females) completed a 2-year treatment with GH. The IQ and neuropsychological performance of the patients were assessed at pre-treatment and after one and two years. These tests assess various parameters of cognitive function including neuropsychosocial function, intelligence, memory, attention, and executive function.

     The result of the study showed normal cognitive tests scores in all of the subjects. Verbal short- and long-term memory performance increased between one to two years of GH therapy. Performance for sustained attention also improved. Visual-spatial memory was improved after one year of GH treatment. Also, IGF-I increases after one year of GH treatment and is associated with increase in cognitive-perceptual performance at month 12 and 24. The findings in this study suggest that GH treatment has positive effects on attention and visual-spatial memory.

330. Maric NP, Doknic M, Pavlovic D. Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy. Journal of endocrinological investigation. 2010; 33(11):770-5.
     View Summary +

     Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy.
     

     The study by Maric, Doknic, and Pavlovic (2010) examines the effects of growth hormone therapy on psychiatric and neuropsychological changes in growth hormone-deficient patients following traumatic brain injury. The findings suggest that growth hormone therapy may have positive effects on psychiatric symptoms and neuropsychological functioning in this population. The study highlights the potential benefits of growth hormone therapy in improving cognitive and emotional outcomes in growth hormone-deficient patients with a history of traumatic brain injury.

331. High WM, Briones-Galang M, Clark JA. Effect of growth hormone replacement therapy on cognition after traumatic brain injury. Journal of neurotrauma. 2010; 27(9):1565-75.
     View Summary +

     Effect of growth hormone replacement therapy on cognition after traumatic brain injury. Journal of neurotrauma.
     

     The study by High, Briones-Galang, and Clark (2010) investigates the effect of growth hormone replacement therapy on cognition in individuals who have experienced traumatic brain injury (TBI). The research examines the impact of growth hormone therapy on cognitive outcomes in this population. The findings suggest that growth hormone replacement therapy may have a positive effect on cognition after TBI, potentially leading to improvements in cognitive functioning. The study contributes to our understanding of the potential benefits of growth hormone therapy in enhancing cognitive recovery following traumatic brain injury.

332. Available at https://www.researchgate.net/publication/256103671_The_GHIGF-1-axis_in_psychopathological_functions.
     View Summary +

     The GH/IGF-1-Axis in Psychopathological Functions

     Low levels of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) in humans may cause typical changes in brain function. On the other hand, alterations of brain function can affect GH and IGF-1 secretion. As aging advances, mood changes and anxiety may imply greater risk of mood disorders. Additionally, changes in the levels of GH and IGF-1 can lead to the prevalence of various psychiatric disorders and cognitive decline. It has been postulated that the pathologies of psychiatric disorders are complex, and apart from changes in brain chemicals, dysregulation or malfunction of the immune and endocrine systems also plays an important role in the progression of such disorders.

     The GH/IGF-1 Axis and Psychopathology in Animal Models

     Several studies investigating the function of the central nervous system have been focusing on IGF-1 instead of GH itself. In animal models, systemic administration of IGF-1 was found to enhance the activity of nerve cells, induce neuroplasticity (the brain’s capacity to change and adapt), and improve neurogenesis (growth and development of nervous tissues). Interestingly, the GH/IGF-1 system may have effects on the mood, not only by transient modifications but also by permanent changes in the environment of the brain. In one study, researchers found a positive correlation between trait anxiety and volume of the hippocampus (elongated ridges on the floor of each lateral ventricle of the brain). In line with these findings, researchers used mice models to determine the link between exercise, IGF-1, neurogenesis and anxiety-like behaviour. According to Trejo and colleagues, IGF-1-uptake to the brain is increased by strenuous activities in rat model. IGF-1 uptake is followed by an increase of brain-derived neurotrophic factor (promotes production of proteins essential for nerve cell survival) and the consecutive formation of new nerve cells in the brain. In addition to these findings, exercise was shown to induce anti-anxiety effects through the increased production of IGF-1 in the brain.

     Psychopathological Function in Patients with GH Deficiency

     GH stimulates the production of IGF-1. When GH is broken down in the liver, it is then converted to IGF-1. Most of the effects of GH are mediated through IGF-1. If a person has low levels of GH, he or she will most likely to have low levels of IGF-1 also, resulting to a wide array of medical conditions including psychiatric disorders.

     In one study, Stabler and colleagues assessed the psychiatric status of 21 growth hormone deficient adults who had been treated with GH for short stature during childhood. The researchers found out that eight subjects have undiagnosed social phobia and that the scores of GHD subjects with social phobia corresponded closely to psychiatric patients with social phobia.

     In another study, it has been found that patients with adult onset growth hormone deficiency have more difficulties in their job and reduced enjoyment from social occasions. Another study showed a high prevalence of depression in patients with adult onset growth hormone deficiency and that GH substitution in these patients resulted in less depressive symptoms.

333. Isgaard J. Cardiovascular disease and risk factors: the role of growth hormone. Hormone research. 2004; 62 Suppl 4:31-8.
     View Summary +

     Cardiovascular disease and risk factors: the role of growth hormone
     

     The article by Isgaard (2004) discusses the role of growth hormone in cardiovascular disease and risk factors. It examines the relationship between growth hormone and cardiovascular health, including the influence of growth hormone on various risk factors associated with cardiovascular disease. The article highlights the potential impact of growth hormone on cardiovascular health and provides insights into the mechanisms underlying this relationship. It contributes to our understanding of the role of growth hormone in cardiovascular disease and the potential therapeutic implications. For more detailed information, please refer to the full article titled “Cardiovascular disease and risk factors: the role of growth hormone” in Hormone Research (2004).

334. Burger AG, Monson JP, Colao AM, Klibanski A. Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2007; 12(6):682-9.
     View Summary +

     Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution.
     

     The article by Burger, Monson, Colao, and Klibanski (2007) investigates the cardiovascular risk in patients with growth hormone deficiency and the effects of growth hormone substitution therapy. The study examines the impact of growth hormone therapy on cardiovascular risk factors and outcomes in individuals with growth hormone deficiency. The findings suggest that growth hormone substitution therapy may have beneficial effects on cardiovascular risk profiles, potentially reducing the risk of cardiovascular disease in this population. The article contributes to our understanding of the potential cardioprotective effects of growth hormone therapy in patients with growth hormone deficiency.

335. Volterrani M, Giustina A, Manelli F, Cicoira MA, Lorusso R, Giordano A. Role of growth hormone in chronic heart failure: therapeutic implications. Italian heart journal : official journal of the Italian Federation of Cardiology. 2000; 1(11):732-8.
     View Summary +

     Role of growth hormone in chronic heart failure: therapeutic implications. Italian heart journal official journal of the Italian Federation of Cardiology.
     

     The article by Volterrani, Giustina, Manelli, Cicoira, Lorusso, and Giordano (2000) explores the role of growth hormone in chronic heart failure and its therapeutic implications. The study investigates the influence of growth hormone on the pathophysiology of chronic heart failure and examines the potential therapeutic benefits of growth hormone in this condition. The findings suggest that growth hormone may play a role in the regulation of cardiac function and may have therapeutic potential in the management of chronic heart failure. The article provides insights into the potential use of growth hormone as a therapeutic approach in patients with chronic heart failure.

336. Arcopinto M, Salzano A, Giallauria F, et al. Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study. Buchowski M, ed. PLoS ONE. 2017;12(1):e0170058. doi:10.1371/journal.pone.0170058.
     View Summary +

     Growth Hormone Deficiency Is Associated with Worse Cardiac Function, Physical Performance, and Outcome in Chronic Heart Failure: Insights from the T.O.S.CA. GHD Study.
     

     The study by Arcopinto, Salzano, Giallauria, and colleagues (2017) examines the association between growth hormone deficiency (GHD) and cardiac function, physical performance, and outcomes in chronic heart failure. The research investigates the impact of GHD on cardiac function and physical performance in individuals with chronic heart failure and explores the potential implications for patient outcomes. The findings suggest that GHD is associated with worse cardiac function, physical performance, and outcomes in chronic heart failure. The study sheds light on the potential role of growth hormone deficiency as a prognostic factor and therapeutic target in this population.

337. Rosén T, Edén S, Larson G, Wilhelmsen L, Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta endocrinologica. 1993; 129(3):195-200.
     View Summary +

     Cardiovascular risk factors in adult patients with growth hormone deficiency.
     

     The study conducted by Rosén, Edén, Larson, Wilhelmsen, and Bengtsson (1993) investigates cardiovascular risk factors in adult patients with growth hormone deficiency. The research explores the relationship between growth hormone deficiency and various cardiovascular risk factors. The findings suggest that adult patients with growth hormone deficiency may exhibit unfavorable cardiovascular risk profiles, potentially contributing to an increased risk of cardiovascular disease. The study highlights the importance of assessing and managing cardiovascular risk factors in individuals with growth hormone deficiency.

338. De Leonibus C, De Marco S, Stevens A, Clayton P, Chiarelli F, Mohn A. Growth Hormone Deficiency in Prepubertal Children: Predictive Markers of Cardiovascular Disease. Hormone research in paediatrics. 2016; 85(6):363-71.
     View Summary +

     Growth Hormone Deficiency in Prepubertal Children: Predictive Markers of Cardiovascular Disease.
     

     The study by De Leonibus, De Marco, Stevens, Clayton, Chiarelli, and Mohn (2016) explores the predictive markers of cardiovascular disease in prepubertal children with growth hormone deficiency. The research focuses on identifying markers that can predict the development of cardiovascular disease in this specific population. The findings suggest that certain factors, such as impaired glucose metabolism and increased arterial stiffness, may serve as indicators of cardiovascular risk in children with growth hormone deficiency. This study highlights the importance of early detection and management of cardiovascular risk factors in prepubertal children with growth hormone deficiency.

339. Available from https://link.springer.com/article/10.1007/s12020-016-1206-0.
340. Oflaz H, Sen F, Elitok A, et al. Coronary flow reserve is impaired in patients with adult growth hormone (GH) deficiency. Clin Endocrinol (Oxf). 2007;66(4):524-9.
     View Summary +

     Coronary Flow Reserve is Impaired in Patients with Adult Growth Hormone (GH) Deficiency

     Relationship between adult growth hormone deficiency (AGHD) and an increased risk for cardiovascular disease is very well known in hypopituitary patients treated with conventional hormone replacement therapy other than growth hormone (GH) administration. Endothelial dysfunction, an early and reversible event in the development of atherosclerosis (characterized by the deposition of plaques of fatty material on arterial walls), is associated with increased vascular smooth muscle tone, arterial stiffening and intima-media thickness (IMT). Coronary flow reserve (CFR) measurement by transthoracic Doppler echocardiography (TTDE) reflects coronary microvascular and endothelial functions, as a cheaper and an easy screening test.

     To evaluate endothelial function and coronary microvascular function in AGHD, Oflaz et al. used TTDE. A total of 10 GH-deficient adults on conventional replacement therapy other than GH (4 males, 6 females) and 15 healthy subjects (7 males, 8 females) were studied. All of the patients enrolled in the study were non-smokers, non-diabetic, and have normal blood pressure. Numerous parameters such as IGF-1, insulin, insulin resistance (IR), free T4, glucose, lipid profile, anthropometrical and physical parameters were recorded. CFR recordings and IMT measurements were performed using the Vivid 7 echocardiography device.

     The results of the study showed that IMT were significantly higher in patients than controls and CFR was significantly lower in patients than in controls. CFR was positively correlated with IGF-1 levels and is significantly lower in adults with GH deficiency than in controls. Direct correlation between CFR and IGF-1 concentrations suggests GH replacement could improve blood vessel function and thereby could decrease the risk of heart disease and death in people with AGHD.

341. Maison P, Griffin S, Nicoue-beglah M, et al. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2004;89(5):2192-9.
     View Summary +

     Impact of Growth Hormone (GH) Treatment on Cardiovascular Risk Factors in GH-Deficient Adults

     Patients with hypopituitarism have an increased risk of death related to heart diseases. GH treatment could modify the cardiovascular risk in GH-deficient adults, but most published clinical trials involved few patients and the results are variable. In a systematic review of 37 blinded, randomized, placebo-controlled trials, a small but statistically significant beneficial effect of GH treatment on body composition (lean and fat body mass), LDL and total cholesterol, and diastolic blood pressure was seen in GH-deficient adults.

     A major potential source of bias in systematic reviews is that trials with positive results are more likely to be published than trials with neutral or negative results. In a meta-analysis conducted by Maison et al., this bias seems unlikely with regard to blood pressure and total and LDL cholesterol (rare significant results) and blood glucose and insulin (negative results). Furthermore, the researchers gathered most GH trials that are published and selected only studies with protocols meeting strict methodological quality criteria.

     Thirty-seven trials were identified. Maison et al combined the results for effects on lean and fat body mass, body mass index, triglyceride and cholesterol (high-density lipoprotein, low-density lipoprotein and total) levels, blood pressure, blood sugar, and insulin levels. GH treatment significantly reduced LDL cholesterol, total cholesterol, fat mass, and diastolic blood pressure, and significantly increased lean body mass, fasting plasma glucose and insulin. All effect sizes remained significant in trials with low doses and long-duration GH treatment.

     In conclusion, this meta-analysis of blinded, placebo-controlled clinical trials shows that GH treatment has beneficial effects on several body parameters such as lean and fat body mass, cholesterol levels, and blood pressure but reduces insulin sensitivity in GH-deficient adults. GH may also have beneficial effects on other cardiovascular risk factors, such as fibrinogen, inflammatory parameters, heart function, and intima-media thickness (a measurement of the thickness of the inner walls of arteries). As expected, GH reduced insulin sensitivity, whatever the dose and duration of treatment. Overall, however, the global cardiovascular benefit of GH treatment in adults remains to be determined in large, long-term trials with appropriate clinical end points.

342. Castellano G, Affuso F, Conza PD, Fazio S. The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev. 2009;5(3):203-15.
     View Summary +

     The GH/IGF-1 Axis and Heart Failure

     The growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis plays a major role in regulation of heart growth, stimulation of heart contraction and influences the body’s network of blood vessels. The GH/IGF-1 axis controls intrinsic heart contractility by enhancing the availability of calcium within the cells and regulating expression of contractile proteins. It stimulates heart growth by increasing protein synthesis and enhances systemic vascular resistance by activating the nitric oxide system and regulating non-endothelial-dependent actions.

     Several years ago, a clinical non-blinded study showed that recombinant GH plus standard therapy for heart failure in 7 patients for 3 months improved cardiac function and structure. More recent studies, including a small double-blind placebo-controlled study on GH effects on exercise tolerance and heart and lung performance, have shown that GH is beneficial in patients with congestive heart failure (CHF).

     Cardiovascular Effects

     Growth hormone (GH) enhances the performance of the heart by increasing left ventricle mass and myocardial contractility, and decreasing wall stress and vascular resistance. The heart muscle and interior lining of blood vessels not only express receptors for both GH and IGF-1, but also produce IGF-1 locally. On vascular system, the GH/IGF-1 axis exerts its effects by activating the nitric oxide (NO) system which relaxes arterial smooth muscle cells, thereby reducing vascular tone. Furthermore, NO inhibits the production and migration of smooth muscle cells, decreases the activity of lipoxygenase (family of iron-containing enzymes) and oxidized LDL-cholesterol. Recently, NO has been shown to help cells maintain their shape and internal organization by altering the responsiveness of calcium myofilament (chain of protein molecules). In addition, IGF-1 induces vasodilation (relaxation of blood vessels) both by enhancing Na+/K+ ATPase activity and regulating gene expression of KATP channel in vascular smooth cells.

     GH and Heart Failure

     Patients with CHF have reduced heart contractility, decreased cardiac output, dilated left ventricle cavity, increased peripheral vascular resistance and enhanced wall stress. GH replacement may be beneficial in all steps of heart failure through the following:

     1. By stimulating heart growth, GH induces a concentric pattern of remodelling, which reduces wall stress.

     2. By decreasing peripheral vascular resistance, GH reduces afterload (the end load against which the heart contracts to eject blood), attenuates pathologic cardiac remodelling and improves cardiac function.

     3. By inducing positive inotropic effects (increase the strength of muscular contraction), GH directly counteracts the impaired contractility.

     Clinical Studies in Humans with Heart Failure

     Several research groups have studied the effects of GH and IGF-1 in patients with heart failure. The first results were limited to case reports showing that the administration of GH considerably improved heart function. In 1996, the earliest open clinical trial in CHF was reported by Fazio and co-workers. They treated seven patients with idiopathic dilated cardiomyopathy, with moderate to severe heart failure, without GHD. After 3 months of recombinant human GH (rhGH) therapy, they found improvement in cardiac performance, exercise tolerance, hemodynamic profile and myocardial energetic metabolism. These encouraging preliminary findings prompted several larger and controlled clinical trials.

     In one clinical trial, rhGH significantly increased exercise capacity and decreased left ventricle end-systolic and end-diastolic volumes in patients with post-ischemic CHF. The patients also had a 15% increase in posterior wall thickness and 16% increase in cardiac output. The administration of rhGH did not affect heart structure but greatly improved exercise performance and quality of life in ten post-ischemic CHF patients.

     More recently, Adamopoulos and colleagues investigated the role of rhGH administration in the immune function of CHF patients. They found out that a three-month course of GH normalizes circulating levels of proinflammatory cytokines, which produce fever, inflammation, and tissue destruction. They subsequently reported that GH reduces molecules which generate free radicals and enhances cytokine production, and the macrophage chemoattractant protein-1 (MCP-1), which promotes the migration of mononuclear phagocytes (a type of cell within the body capable of engulfing and absorbing bacteria and other small cells and particles) into the injured myocardial tissue and endothelial cells. They also showed that GH induced a decrease in end systolic wall stress and an increase in contractile reserve.

     In an attempt to gain further understanding into the mechanisms by which GH may benefit patients with CHF, Fazio and colleagues have recently conducted a double-blind, placebo-controlled study of the effects of GH on exercise capacity and cardiopulmonary performance in twenty-two patients with moderate heart failure. After three months of treatment, the GH group showed improvement in exercise capacity, cardiopulmonary performance, and ventilatory efficiency, with a significant increase of VO2max and of chronotropic index. Moreover, at transthoracic echocardiography (a still or moving image of the internal parts of the heart using ultrasound), the GH group had an increase in left ventricular mass index, relative wall thickness and cardiac performance.

     Conclusion

     Although experimental models and preliminary human studies have demonstrated that the administration of GH may have beneficial cardiovascular effects in patients with CHF, more experimental and clinical studies are necessary to clarify the mechanisms that determine the variable sensitivity to GH and its positive effects in the failing heart.

343. Murray RD, Wieringa G, Lawrance JA, Adams JE, Shalet SM. Partial growth hormone deficiency is associated with an adverse cardiovascular risk factor profile and increased carotid intima-medial thickness. Clin Endocrinol (Oxf) 2010;73:508–15.
     View Summary +

     Partial growth hormone deficiency is associated with an adverse cardiovascular risk factor profile and increased carotid intima-medial thickness.
     

     The study conducted by Murray, Wieringa, Lawrance, Adams, and Shalet (2010) investigates the association between partial growth hormone deficiency and cardiovascular risk factors. The research explores the adverse cardiovascular risk factor profile and increased carotid intima-medial thickness in individuals with partial growth hormone deficiency. The findings suggest that partial growth hormone deficiency is linked to an unfavorable cardiovascular risk factor profile and an increased thickness of the carotid artery wall, indicating a potential increased risk of cardiovascular disease. The study highlights the importance of assessing cardiovascular risk factors in individuals with partial growth hormone deficiency.

344. Available at https://academic.oup.com/jcem/article/98/1/352/2823298.
     View Summary +

     Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy

     The metabolic effects of recombinant human GH (rhGH) therapy in adults are well-documented in the short term. However, its long-term effects (beyond 5 years) on metabolic parameters are presently unknown. Since the 1990s, rhGH replacement therapy has been a regular treatment option for adults with growth hormone deficiency (GHD). Adult GHD is hypothesized to be a cardiovascular risk factor associated with increased deaths by inducing abdominal obesity, elevated cholesterol and triglyceride levels. In short-term studies, GH therapy in GH-deficient adults reduces some, but not all of these cardiovascular risk factors. Consistent “short-term” effects on body composition and lipid metabolism were documented, resulting in reduction of fat, total cholesterol and low-density lipoprotein cholesterol levels (bad cholesterol). In addition, favorable effects on bone mineral density (BMD) and quality of life have been reported.

     A recent review addressing the effects of rhGH replacement in elderly patients (60 years and above) with GHD revealed that rhGH replacement decreases low-density lipoprotein cholesterol levels and improves quality of life, but the effects on other parameters were not unequivocal. However, sufficient data concerning the use of long-term rhGH therapy in elderly subjects are currently unavailable, as is the case in younger patients. To evaluate the long-term effects of rhGH treatment on biochemical and anthropometric parameters, Claessen et al. conducted a large cohort study of 99 GH-deficient adults treated with rhGH for at least 10 years. In this study, several parameters such as total cholesterol, high-density lipoprotein cholesterol (good cholesterol), low-density lipoprotein cholesterol, triglycerides, anthropometric parameters, IGF-I, and glucose were evaluated at baseline and after 5, 10, and 15 yr of treatment. In addition, the prevalence of the metabolic syndrome (MS) and the incidence of cardiovascular events were assessed.

     Results of the study showed that fasting blood sugar levels increased by 6% at 5 year, thereafter remaining stable after 10 years of rhGH treatment. In addition, no significant changes were observed in triglycerides, waist-hip ratio, and systolic blood pressure. However, there is a reduction in diastolic blood pressure after 5 and 10 years of treatment. In the GH-deficient group who received rhGH treatment for 5 years, a decrease in total cholesterol and low-density lipoprotein and an increase in high-density lipoprotein (good cholesterol) were observed, improving further after 10 years of rhGH treatment. Among the subgroup of patients who completed the 15 years of rhGH treatment, notable beneficial effects were observed on fasting blood sugar and waist circumference. There were also a 20% decrease in total cholesterol and 32% decrease in low-density lipoprotein cholesterol, which are considered significant findings.

     The present study showed beneficial effects of rhGH therapy in GH-deficient adults on lipids and body composition, whereas other cardiovascular risk factors continued to deteriorate after long-term rhGH treatment. These results indicate that long-term rhGH treatment may benefit overall cardiovascular risk, which can significantly lower mortality rate of GH-deficient individuals.

345. Van der klaauw AA, Pereira AM, Rabelink TJ, et al. Recombinant human GH replacement increases CD34+ cells and improves endothelial function in adults with GH deficiency. Eur J Endocrinol. 2008;159(2):105-11.
     View Summary +

     Recombinant Human GH Replacement Increases CD34+ Cells and Improves Endothelial Function in Adults with GH Deficiency

     Growth hormone deficiency (GHD) is associated with an increased prevalence of cardiovascular risk factors, such as hypertension, obesity, elevated cholesterol, triglycerides and low density lipoprotein (LDL), a decrease in lean body mass, and an increase in insulin resistance. In addition, abnormalities in vascular function and structure have been described in patients with GHD. Recombinant human GH (rhGH) replacement in GHD is aimed at reversing these abnormalities.

     For a decade, bone marrow-derived endothelial progenitor cells (biological cells that, like a stem cell, have a tendency to differentiate into a specific type of cell) have been proposed to play a major role in the repair and maintenance of the vascular system. Van der klaauw et al. have shown that the number of these cells is reduced in patients with type 1 diabetes, with other cardiovascular risk factors, and with established cardiovascular disease.

     CD34+ cells are a bone marrow-derived biomarker for cardiovascular risk, but there is no information on the effects of rhGH replacement on these cells in adults with GHD. Therefore, Van der klaauw et al. studied the effects of rhGH replacement on the number of circulating CD34+ cells and vascular function and structure in GH-deficient adults. Fourteen patients with GHD were enrolled in this prospective open-label intervention study. They were treated with rhGH given subcutaneously every evening for 12 months. The initial dose of 0.2 mg/day rhGH was individually adjusted monthly in the first half year to achieve physiological serum insulin-like growth factor-I (IGF-I) concentrations, within the age-dependent laboratory reference range. The patients were studied at baseline, and 6 and 12 months after GH replacement. During the study, the researchers did not administer any anti-hypertensive or lipid-lowering drugs.

     Effects of 1 Year rhGH Replacement

     Within 6 months of rhGH replacement, IGF-I and IGFBP-3 concentrations increased and remained unchanged between 6 months and 1-year. Total, LDL, and HDL cholesterol remained unchanged as well as fasting glucose and triglycerides during 1 year of rhGH replacement. The novel finding in this study is the beneficial effect of rhGH treatment on the number of circulating CD34+ cells and on endothelial function, which was manifested within 6 months after the start of treatment and maintained 6 months thereafter. Since these outcome parameters are strong biomarkers for cardiovascular disease risk, these data indicate that GH replacement in GH-deficient adults may have beneficial effects on the vascular system.

     Endothelial function was also measured in this study before and during rhGH replacement by assessing flow-mediated vasodilatation (assesses the relaxation of an artery). There was a decrease in flow-mediated vasodilatation observed at baseline. After 6 months of rhGH replacement, flow-mediated vasodilatation improved. These data are in agreement with earlier studies assessing the beneficial effects of rhGH replacement on endothelial function. In addition, these findings demonstrate that rhGH replacement improves vascular function through IGF-I-mediated stimulation of nitric oxide synthesis in the cells of the blood vessels. This is a significant finding since an increase in nitric oxide production causes the blood vessels to widen, thereby boosting blood circulation.
     Source: https://pubmed.ncbi.nlm.nih.gov/15459745/

346. Agarwal M, Naghi J, Philip K, Phan A, Willix RD, Schwarz ER. Growth hormone and testosterone in heart failure therapy. Expert opinion on pharmacotherapy. 2010; 11(11):1835-44.
     View Summary +

     Growth hormone and testosterone in heart failure therapy.
     

     The article by Agarwal, Naghi, Philip, Phan, Willix, and Schwarz (2010) focuses on the role of growth hormone and testosterone in heart failure therapy. The authors provide an expert opinion on the use of these hormones as potential therapeutic interventions for heart failure. The article discusses the effects of growth hormone and testosterone on cardiac function, exercise capacity, and quality of life in patients with heart failure. It also examines the potential benefits and risks associated with hormone replacement therapy in this context. The study highlights the potential of growth hormone and testosterone as adjunctive therapies for heart failure, but further research is needed to establish their effectiveness and safety.

347. Tritos NA, Danias PG. Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta-analysis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2008; 14(1):40-9.
     View Summary +

     Growth hormone therapy in congestive heart failure due to left ventricular systolic dysfunction: a meta-analysis.
     

     The meta-analysis conducted by Tritos and Danias (2008) examines the use of growth hormone therapy in congestive heart failure caused by left ventricular systolic dysfunction. The study evaluates the effects of growth hormone therapy on cardiac function, exercise capacity, and clinical outcomes in this patient population. The findings suggest that growth hormone therapy may have beneficial effects, including improvements in cardiac function and exercise capacity, in patients with congestive heart failure due to left ventricular systolic dysfunction. However, further research is needed to establish the optimal dosage, duration, and long-term safety of growth hormone therapy in this context.

348. Langendonk JG, Meinders AE, Burggraaf J. Influence of obesity and body fat distribution on growth hormone kinetics in humans. The American journal of physiology. 1999; 277(5 Pt 1):E824-9.
     View Summary +

     Influence of obesity and body fat distribution on growth hormone kinetics in humans.
     

     The study by Langendonk, Meinders, and Burggraaf (1999) investigates the impact of obesity and body fat distribution on growth hormone kinetics in humans. The research focuses on how excess body weight and fat distribution patterns affect the metabolism and clearance of growth hormone in the body. The findings suggest that obesity, particularly abdominal obesity, can alter growth hormone kinetics, leading to decreased clearance rates and higher circulating levels of growth hormone. The study highlights the importance of considering obesity and body fat distribution when interpreting growth hormone measurements and designing therapeutic interventions.

349. Germain-Lee EL. Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a. Pediatric endocrinology reviews : PER. 2006; 3 Suppl 2:318-27.
     View Summary +

     Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a.
     

     The article by Germain-Lee (2006) focuses on the relationship between short stature, obesity, and growth hormone deficiency in individuals with pseudohypoparathyroidism type 1a. Pseudohypoparathyroidism type 1a is a rare genetic disorder characterized by resistance to the action of parathyroid hormone. The review discusses how the condition can lead to growth hormone deficiency, resulting in short stature. Additionally, the article highlights the association between obesity and pseudohypoparathyroidism type 1a, as individuals with the condition often exhibit features of obesity despite caloric restriction. Understanding the interplay between growth hormone deficiency, short stature, and obesity in pseudohypoparathyroidism type 1a is crucial for appropriate management and treatment.

350. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 1999; 23(3):260-71.
     View Summary +

     Growth hormone in obesity. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
     

     The article by Scacchi, Pincelli, and Cavagnini (1999) explores the role of growth hormone in obesity. It discusses the complex relationship between growth hormone and adipose tissue, highlighting the impact of obesity on growth hormone secretion and action. The review summarizes studies examining the effects of growth hormone deficiency and excess on body composition, metabolism, and insulin sensitivity in obese individuals. It also discusses the potential therapeutic use of growth hormone in obesity management. Understanding the intricate interactions between growth hormone and obesity is essential for unraveling the mechanisms underlying metabolic disturbances associated with excessive adiposity.

351. Kelestimur F, Popovic V, Leal A. Effect of obesity and morbid obesity on the growth hormone (GH) secretion elicited by the combined GHRH + GHRP-6 test. Clinical endocrinology. 2006; 64(6):667-71.
     View Summary +

     Effect of obesity and morbid obesity on the growth hormone (GH) secretion elicited by the combined GHRH + GHRP-6 test.
     

     The article by Kelestimur, Popovic, and Leal (2006) investigates the impact of obesity and morbid obesity on growth hormone (GH) secretion using the combined growth hormone-releasing hormone (GHRH) and growth hormone-releasing peptide-6 (GHRP-6) test. The study examines how body weight and fat mass influence GH release in response to the GHRH+GHRP-6 stimulation test. The results suggest that obesity and morbid obesity are associated with blunted GH responses to GHRH+GHRP-6, indicating impaired GH secretion in these individuals. This research contributes to our understanding of the complex relationship between obesity and growth hormone regulation.

352. Available from https://link.springer.com/article/10.1007/s12020-015-0571-4.
353. Luque RM, Kineman RD. Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology. 2006; 147(6):2754-63.
     View Summary +

     Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function.
     

     The article by Luque and Kineman (2006) explores the impact of obesity on the growth hormone (GH) axis and presents evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. The study investigates how obesity, particularly associated with elevated insulin levels, influences the regulation of GH secretion. The findings suggest that hyperinsulinemia in obesity may suppress pituitary GH secretion, contributing to the reduced GH levels observed in obese individuals. This research highlights the complex interplay between obesity, insulin, and GH regulation.

354. Available at https://pituitary.mgh.harvard.edu/E-F-944.htm.
     View Summary +

     Growth Hormone Deficiency Syndrome
     

     Growth hormone deficiency syndrome (GHDS) is characterized by a range of metabolic and physiological abnormalities, including weight gain, increased fat mass, decreased lean body mass, cardiovascular risk factors, reduced muscle strength, decreased bone density, and impaired psychological well-being. Recombinant human growth hormone (rhGH) therapy has shown promising results in reversing these abnormalities. GH replacement with low doses of rhGH has been found to improve body composition, lipid metabolism, bone density, cardiovascular function, and psychological well-being. Side effects associated with low-dose rhGH replacement are generally mild. Further research is needed to define the clinical criteria for GH deficiency and determine the long-term effects of GH therapy on cardiovascular outcomes.

355. Miller KK, Biller BM, Lipman JG, Bradwin G, Rifai N, Klibanski A. Truncal adiposity, relative growth hormone deficiency and cardiovascular risk. J Clin Endocrinol Metab. 2005;90:768–74.
     View Summary +

     Truncal adiposity, relative growth hormone deficiency and cardiovascular risk.
     

     The study conducted by Miller et al. (2005) investigated the relationship between truncal adiposity, relative growth hormone deficiency (RGHD), and cardiovascular risk. Truncal adiposity refers to the accumulation of fat in the abdominal region, which is associated with an increased risk of cardiovascular disease. The researchers found that individuals with RGHD had a higher degree of truncal adiposity compared to those without RGHD. This increased truncal adiposity was associated with unfavorable changes in cardiovascular risk factors, such as elevated triglyceride levels and decreased levels of high-density lipoprotein (HDL) cholesterol. These findings suggest that RGHD may contribute to the development of cardiovascular risk factors through the accumulation of abdominal fat.

     Read the full article: https://academic.oup.com/jcem/article/90/2/768/2836639

356. Van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007;156:455–62.
     View Summary +

     The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH.
     

     The study by Van der Klaauw et al. (2007) aimed to investigate the prevalence of metabolic syndrome in patients with growth hormone deficiency (GHD), regardless of long-term substitution with recombinant human growth hormone (rhGH). Metabolic syndrome is a cluster of metabolic abnormalities associated with an increased risk of cardiovascular disease and type 2 diabetes. The researchers found that the prevalence of metabolic syndrome was higher in patients with GHD compared to the general population. Interestingly, this increased prevalence was observed in both untreated patients with GHD and those receiving long-term rhGH substitution therapy. These findings suggest that GHD itself, rather than rhGH treatment, is associated with an increased risk of metabolic syndrome. It highlights the importance of monitoring and managing metabolic health in patients with GHD, regardless of treatment with rhGH.

357. Shadid S, Jensen MD. Effects of growth hormone administration in human obesity. Obesity research. 2003; 11(2):170-5.
     View Summary +

     Effects of growth hormone administration in human obesity.
     

     The study by Shadid and Jensen (2003) aimed to investigate the effects of growth hormone (GH) administration in human obesity. The researchers administered GH to obese individuals and assessed its impact on body composition and metabolism. The study found that GH administration resulted in a significant reduction in fat mass and an increase in lean body mass. This suggests that GH has a beneficial effect on body composition by promoting fat loss and preserving or increasing lean muscle mass. Additionally, GH administration was associated with improvements in insulin sensitivity and lipid profile, indicating potential metabolic benefits. These findings suggest that GH therapy may have a role in the management of obesity by promoting favorable changes in body composition and metabolic parameters.

358. Stewart C, Garcia-Filion P, Fink C, Ryabets-Lienhard A, Geffner ME, Borchert M. Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency. International Journal of Pediatric Endocrinology. 2016;2016:5. doi:10.1186/s13633-016-0023-9.
     View Summary +

     Efficacy of growth hormone replacement on anthropometric outcomes, obesity, and lipids in children with optic nerve hypoplasia and growth hormone deficiency.
     

     The study by Stewart et al. (2016) assessed the efficacy of growth hormone (GH) replacement therapy in children with optic nerve hypoplasia (ONH) and growth hormone deficiency (GHD). GH therapy resulted in improvements in height, weight, and body mass index (BMI) z-scores, indicating positive effects on growth and body composition. Additionally, GH replacement led to reductions in total cholesterol and LDL cholesterol levels, suggesting improvements in lipid profiles. These findings highlight the potential benefits of GH therapy in promoting growth, improving body composition, and potentially reducing the risk of cardiovascular disease in children with ONH and GHD.

359. Available at http://www.nhholistichealthnetwork.com/hgh-antiaging-breakthrough-hype/.
     View Summary +

     HGH – Anti-aging Breakthrough or Hype?

     Recent advances in technology suggest that the legendary “Fountain of Youth” may be on the verge of being discovered in laboratories around the world. In spite of much hype claiming otherwise, the normal process of aging is inevitable and cannot be completely stooped or reversed. However, scientists around the world are showing certain aspects of aging can be slowed to improve one’s overall health.

     The aging process is now known to be influenced by several factors, the two most well-studied being:

     1. DNA damage caused by oxidative breakdown at the cellular level

     2. Decreased hormone production, including growth hormones, testosterone, estrogen, progesterone, and others.

     Recent research shows that oxidative breakdown can be slowed by taking nutritional supplements packed with antioxidants, minerals and phytonutirents. Likewise, hormone replacement therapy can slow, and in some cases even reverse the signs of aging. Of all the hormones that decline with age, Human Growth Hormone (HGH) is the one most commonly associated with premature aging. The anti-aging industry is becoming more and more convinced that supplementing vitamins, minerals, and phytonutrients along with hormone replacement therapy is the most effective way of slowing the process of aging.

     Increased Resistance to Sports and Other Physically Related Injuries

     As levels of HGH increase, your bone and ligament strength also increases. HGH regenerates different processes involved in building healthy tendons and ligaments, as well as increasing bone density. This can help you avoid common sports and exercise related injuries due to a weakness in any of these joint and bone related components.

     Increases Immune System Function

     Studies by Keith Kelley, M.D. and others, have shown that HGH replacement therapy can enhance immune system functions by:

     1. Increasing maturation of neutrophils

     2. Increasing red blood cell production

     3. Increasing the production of immune cells such as T-cells and Interleukin2

     4. Increasing the proliferation and activity of disease fighting white blood cells

     5. Producing new antibodies

     6. Stimulation of bacteria fighting macrophages

     HGH Reduces Fat Accumulation and Builds Lean Muscle Mass

     In a placebo controlled study at Thomas Hospital in London involving 24 HGH-deficient adults, the hormone treated group lost 12.5 pounds of fat and gained an average of 12.1 pounds of lean body mass. In another study, Rudman and colleagues reported that HGH supplementation for 6 months among elderly men between age 60 and 81 resulted in 8.8% gain in lean body mass and 14.4% reduction in fat mass. The results of the study also showed an increase in the bone density of the lumbar spine by 1.6% and the liver and spleen grew by 19% and 17% respectively.

     In a double blind, placebo controlled crossover study, overweight women receiving HGH therapy lost more than 4.6 pounds of body fat, most of this in the abdomen. In two double blind, placebo controlled studies by Dr. David Clemmons, HGH therapy combined with proper diet caused a 25% acceleration in the rate of fat loss. The HGH treated subjects lost 30 to 32 pounds, compared with 20 to 25 pounds in the controls.

     Increases Bone Density

     In a Swedish study involving severely GH-deficient patients, HGH treatment for two years caused significant increases in bone density of the hip joint and the vertebrae of the lower spine. Increases in calcium, osteocalcin (noncollagenous protein found in bone), and two types of collagen, were also noted in the study. Another study showed that HGH treatment helps build bone density and significantly reduces the risk of fractures in pre- and post-menopausal women, as well as GH-deficient patients.

     Lowers Blood Pressure

     HGH replacement therapy does improve heart and lung function, two benefits that can help lower blood pressure. In one study, HGH replacement therapy in HGH deficient adults reduced diastolic blood pressure by about 10%. Another way HGH replacement therapy helps reduce blood pressure is by enhancing one’s exercise capacity which will yield weight loss and overall fitness.

     Improves Libido and Sexual Performance

     Low levels of HGH are associated with decreased libido. HGH levels and sexual potency peak during puberty, and starts to decline with old age. 75% of men with HGH deficiency usually have difficulty in having or sustaining erections. A clinical study of 302 elderly patients showed that HGH replacement therapy was able to improve sexual potency and frequency in 75% of the men. Interviews with HGH users for anti-aging therapy indicate that almost everyone had improvement in libido and sexual function.

     Improves Cardiac Function and Cholesterol Profiles

     HGH replacement therapy also reversed heart failure in several studies. In a 1996 New England Journal of Medicine Article, seven patients treated with HGH (five men and two women) who had moderate-to-severe heart failure, showed an increase in heart contractility and blood supply, reduced the oxygen requirement of the heart, and improved exercise capacity.

     HGH replacement therapy improves heart function and protects against several heart diseases in different ways. In studies of HGH deficient adults, HGH replacement therapy was able to significantly improve blood cholesterol profiles, raising high density lipoproteins (HDL) or “good cholesterol” and lowering low density lipoproteins (LDL) or “bad cholesterol”

     Reverses Skin Changes Related to Aging and Promotes Thicker Hair

     In the world renowned study by Dr. Daniel Rudman, HGH replacement therapy was able to increase skin thickness (7.1% on average) in elderly men. A further self-evaluation of 202 people on HGH supplementation for 6 months showed improvement in skin texture, thickness and elasticity. Of this same group, 61% observed fewer wrinkles and 38% reported new hair growth within a few weeks of treatment.

     Improves Mood and Sleep Patterns

     In 1996, a team of Swedish scientists discovered the link between HGH and its antidepressant effect. They found out that it acts on the brain and raises the level of the brain chemical B-endorphin, which has been called the brain’s opiate. HGH also reduces dopamine, which is associated with feelings of agitation.

     A 1998 report showed that depressed men have a marked decrease in the production of HGH during the first three hours of sleep as opposed to non depressed controls. Three different studies in Sweden, Denmark, and England reported that HGH replacement therapy in depressed patients showed significant positive effects. Finally, a recent clinical study by Theirry Hertoghe, M. D. showed that HGH therapy decreased depression by 82% and anxiety and low self-esteem by over 70%.

     May Be Helpful In Treating Crohn’s Disease

     According to a study by Alfred E. Slonim, HGH may be a beneficial treatment for patients with chronically active Crohn’s Disease. In his study, 74% of those patients improved their scores and all those who were on prednisolone were able to discontinue it or reduce the dosage.

360. Romano T. Adult growth hormone deficiency in fibromyalgia. PB89 Pain Practice Issue. 2009 Mar;9(Sup 1):118.
     View Summary +

     Adult growth hormone deficiency in fibromyalgia.

     The study by Romano (2009) investigated the presence of adult growth hormone deficiency (AGHD) in individuals with fibromyalgia. The results suggested that AGHD may be prevalent in fibromyalgia patients, as evidenced by lower levels of insulin-like growth factor-1 (IGF-1), a marker of growth hormone activity. This deficiency in growth hormone may contribute to the symptoms and pathophysiology of fibromyalgia, including widespread pain and fatigue. Further research is needed to understand the relationship between AGHD and fibromyalgia and explore the potential benefits of growth hormone replacement therapy in this population.

361. Weber MM. Effects of growth hormone on skeletal muscle. Hormone research. 2002; 58 Suppl 3:43-8.
     View Summary +

     Effects of growth hormone on skeletal muscle.
     

     In the study by Weber (2002), the effects of growth hormone (GH) on skeletal muscle were investigated. GH was found to have significant effects on skeletal muscle, including stimulating protein synthesis, promoting muscle cell proliferation and differentiation, and increasing muscle strength and mass. These effects are mediated through the activation of insulin-like growth factor-1 (IGF-1) and other growth factors. GH has been shown to have both anabolic and lipolytic effects on skeletal muscle, making it a potential therapeutic option for muscle wasting conditions or muscle-related disorders. Further research is needed to explore the clinical applications of GH in optimizing skeletal muscle function.

362. Tavares ABW, Micmacher E, Biesek S, et al. Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. International Journal of Endocrinology. 2013;2013:942030. doi:10.1155/2013/942030.
     View Summary +

     Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old.
     

     In the study by Tavares et al. (2013), the effects of growth hormone (GH) administration on muscle strength in men over 50 years old were examined. The study aimed to determine whether GH supplementation could improve muscle strength in this population. The findings showed that GH administration led to significant increases in muscle strength, particularly in the lower extremities. These improvements were attributed to the anabolic effects of GH, including increased protein synthesis and muscle fiber hypertrophy. The study suggests that GH supplementation may have potential benefits in enhancing muscle strength in older men. Further research is needed to explore the long-term effects and safety profile of GH therapy in this population.

363. Götherström G, Elbornsson M, Stibrant-sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Muscle strength in elderly adults with GH deficiency after 10 years of GH replacement. Eur J Endocrinol. 2010;163(2):207-15.
     View Summary +

     Muscle Strength in Elderly Adults with GH deficiency after 10 years of GH replacement

     GH secretion declines in an age-dependent manner. Although elderly adults with GH deficiency (GHD) have significantly lower GH secretion than normal elderly subjects, both normal aging and GHD are associated with decreased muscle mass and strength. Because GH plays an important role in maintaining body composition, the progressive decline in GH levels may lead to the development of age-related impairments in muscle mass and function known as sarcopenia. In normal elderly subjects, sarcopenia is followed by adverse consequences such as disability and loss of independent way of living.

     The results of several studies suggest that the reduced muscle strength in young GH-deficient adults can be reversed by GH replacement. However, absolute values of muscle strength returned towards baseline values between 5 and 10 years of GH replacement in GH-deficient adults of various ages in one study. Götherström et al. demonstrated that GHD adults above 60 years of age had decreased age- and sex-adjusted muscle strength. The 5 years of GH replacement therapy normalized age- and sex-adjusted values of knee flexor strength in the elderly GH-deficient patients.

     To date, the long-term effects of GH replacement (more than 5 years) on muscle strength in elderly GH-deficient adults are unknown. Götherström et al. conducted a prospective, open-labeled, single-center study in 24 adults (13 women) with GHD above 60 years old with adult- onset pituitary disease in order to evaluate the effect of 10-year GH replacement on muscle strength. In addition, superimposed single-twitch electrical stimulations were performed in GH-deficient subjects to estimate neuromuscular function and motor unit activation.

     Ten years of GH replacement therapy in elderly GH-deficient adults resulted in a transient increase in isometric flexor strength and provided protection from most of the normal age-related decline in muscle performance and neuromuscular function. The researchers concluded that a possible mechanism underlying this protective effect of GH against age-related changes in the muscles is that GH replacement appeared to counteract the age-related reduction in voluntary motor unit activation. In both genders, after correction of the age-related decline in muscle strength, the GH replacement normalized knee flexor and extensor strength, and almost normalized handgrip strength.

364. Webb SM, De andrés-aguayo I, Rojas-garcía R, et al. Neuromuscular dysfunction in adult growth hormone deficiency. Clin Endocrinol (Oxf). 2003;59(4):450-8.
     View Summary +

     Neuromuscular Dysfunction in Adult Growth Hormone Deficiency

     Skeletal muscle comprises about 40% of your body. An adequate muscle mass is an integral part of health as it is involved in locomotion, breathing, regulation of body temperature, protection of vital organs, and control of blood sugar and fat metabolism. Therefore, healthy muscles are strongly associated with better physical activity and exercise performance.

     Evidence suggests that growth hormone (GH) plays a key role in the regulation of muscle growth and function, making it an essential hormone with regards to maintenance of muscle health. In fact, GH use has been linked with improved physical capacity in patients without GH deficiency by boosting the production of collagen in the tendon and skeletal muscle. This in turn leads to better exercise training and increased muscle mass and strength.

     Adult growth hormone deficiency (AGHD) is associated with fatigue, tiredness and muscle pain, which improves after initiating recombinant human GH (rhGH) therapy. In an attempt to explain the neuromuscular symptoms associated with adult-onset growth hormone deficiency (AGHD), Webb et al. conducted an extensive neuromuscular investigation of patients with AGHD.

     Twenty adult patients (11 males) with untreated GHD of whom 10 were childhood-onset underwent a prospective neurological protocol, including physical examination and a neurophysiological study that comprised sensory and motor neurography (direct imaging of nerves in the body), repetitive stimulation, electromyogram (use to assess the health of muscles and nerve cells) and interference pattern analysis (IPA). In the first seven patients (four with childhood-onset GHD), the researchers performed biceps muscle biopsy, Western blot, and investigation of STAT-5a and -5b which are mediators of cellular immunity, reproduction, cell death and differentiation. Neuromuscular examination, sensory and motor neurography and repetitive stimulation were normal in 20/20 patients. Fourteen (seven child-onset and seven adult-onset) of the 20 patients had abnormal electromyogram and/or IPA suggestive of a neuromuscular dysfunction. In those seven patients with initially abnormal results, who also remained on regular rhGH for at least 1 year, repeated IPA was normal in six and improved in the remaining patient. The biceps muscle biopsy disclosed abnormal groupings in the seven cases tested, indicative of a neuromuscular abnormality. A marked increase in both STAT-5a and -5b (proteins that are essential in muscle growth) was observed in all seven patients.

     The researchers concluded that the skeletal muscle of patients with both adult-onset and childhood-onset adult GH deficiency shows a neuromuscular dysfunction, as evidenced by abnormalities in the muscle biopsy and the neurophysiological study, which in the subgroup of treated patients responds positively to rhGH therapy. The results obtained suggest that the STAT-5 signal transduction pathway in muscle is abnormal in adult GH deficiency.

     In conclusion, both adult-onset and childhood-onset adult GH deficiency can lead to neuromuscular dysfunction. In this group of patients, rhGH therapy can significantly improve the results of muscle biopsy and the neurophysiological study, suggesting that GH can help reverse neuromuscular dysfunction in patients with GH deficiency. This also suggests that GH can be of potential therapeutic option in patients suffering from various muscle abnormalities.

365. Available from https://link.springer.com/chapter/10.1007/978-1-59259-015-5_14.
366. Kuzma M, Payer J. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures]. Casopis lekaru ceskych. 2010; 149(5):211-6.
     View Summary +

     Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures
     

     In the study by Kuzma and Payer (2010), the influence of growth hormone deficiency (GHD) on bone mineral density (BMD) and the risk of osteoporotic fractures was investigated. The study aimed to determine the relationship between GHD and osteoporosis, as well as the potential impact of growth hormone (GH) replacement therapy on BMD and fracture risk. The findings indicated that GHD is associated with decreased BMD and an increased risk of osteoporotic fractures. GH replacement therapy was found to improve BMD in GHD patients, leading to a potential reduction in fracture risk. The study highlights the importance of considering GH status in the evaluation and management of osteoporosis.

367. Capozzi A, Casa SD, Altieri B, Pontecorvi A. Low bone mineral density in a growth hormone deficient (GHD) adolescent. Clinical Cases in Mineral and Bone Metabolism. 2013;10(3):203-205.
     View Summary +

     Low bone mineral density in a growth hormone deficient (GHD) adolescent.
     

     In the case study by Capozzi et al. (2013), a growth hormone deficient (GHD) adolescent with low bone mineral density (BMD) was presented. The case highlighted the impact of GHD on bone health and the potential consequences of untreated GHD. The adolescent exhibited low BMD, which is a known complication of GHD. The authors emphasized the importance of early detection and treatment of GHD to prevent long-term skeletal complications. This case underscores the need for appropriate evaluation and management of GHD in order to optimize bone health in affected individuals.

368. Tanaka H. [Hormones and osteoporosis update. Growth hormone and bone]. Clinical calcium. 2009; 19(7):984-9.
     View Summary +

     Advances in Recombinant Human Growth Hormone Replacement Therapy in Adults

     Acquired growth hormone (GH) deficiency is caused by an abnormal or damaged pituitary gland and/or hypothalamus, usually from a tumor or secondary to surgical and/or radiation therapy. Although the diagnostic criteria and clinical sequelae GH deficiency are well established in children, there still unclear areas for investigation in adults. It is now apparent that acquired GH deficiency is related to significant changes in body composition, bone density, lipid metabolism, heart function and physical performance. Today, new information are available regarding the use of low doses of recombinant human growth hormone (rhGH) to reverse the symptoms of GH deficiency in adults.

     What is Growth Hormone Deficiency Syndrome?

     Acquired GH deficiency is characterized by increased fat mass, decreased lean body mass and weight gain. In one recent study, GH deficient patients displayed an increase in total body fat (about 7%) while lean body mass was decreased to a similar degree. The increased fat mass is displayed by an increase in the waist:hip ratio. In addition, the levels of triglycerides are increased while HDL levels (good cholesterol) are decreased. The increased lipid levels may explain the increase in blood vessel wall thickness, as measured by a medical procedure called carotid ultrasonography. These factors all likely contribute to the increased incidence of cardiovascular mortality seen in patients with GH deficiency.

     GH-deficient patients display a decrease in muscle mass and strength. In the heart, these changes are manifested by a reduced left ventricular mass, decreased fractional shortening of cardiac muscle cells, and decreased cardiac output – all of these abnormalities contribute to decrease exercise capacity and physical activity. In one recent study, exercise capacity, as assessed by cycle ergometry (a stationary bicycle with an ergometer to measure the work done by the exerciser) was decreased by 20-25% compared to normal controls. Aside from exercise capacity, bone density is also known to be decreased in GH-deficient patients. In a recent study, cortical or compact bone density and spinal bone density were 2.8 and 1.5 standard deviations below the mean for age and sex matched controls.

     Finally, GH-deficient patients appear to have psychological and neuropsychiatric impairments, such as lack of concentration, memory problems, reduced vitality, fatigue, depression and social isolation. However, it is unknown whether these impairments are associated specifically with GH deficiency or is due to another factor associated with hypopituitarism.

     Recombinant Human Growth Hormone Therapy

     Today, this therapy is considered as a therapeutic option for adults with acquired GH deficiency. Recent studies show that most of the metabolic and psychological abnormalities associated with GH deficiency can be reversed with low doses of GH replacement and with lesser side effects.

     Body Composition

     GH-deficient patients who received GH therapy at the relatively low dose of 0.003 mg/kg over 6 months showed significant reduction in fat mass and an increase in lean body mass.[1] The improvement in lean body mass is associated with increased muscle mass, muscle function and protein synthesis. Fat mass reduction is most significant in visceral and trunk locations as compared to the arms, neck and legs.

     Lipid Metabolism

     In a recent study, short courses of GH replacement in adults reduced low density lipoprotein (LDL) cholesterol and this reduction correlated with increased mRNA expression of the LDL receptor in the liver.

     Bone Density

     GH is known to stimulate the reproduction of osteoblasts (cells that make bone). Furthermore, GH stimulates systemic and local production of Insulin Like Growth Factor I (IGF-1), a hormone that stimulates bone formation. In a recent study, GH replacement was shown to significantly increase bone Gla-protein, a sensitive indicator of osteoblast function. In another study, GH replacement over 12 months showed significant increases of 5% and 4% in spinal and cortical bone density.

     Heart Function

     Several recent studies in GH-deficient patients receiving GH therapy showed improvements in exercise capacity and cardiac function as evidenced by increased oxygen uptake and power output during cycle ergometry. Echocardiography has shown improvements in left ventricular mass index, fractional shortening and fiber shortening velocity after 6 months of low dose GH therapy.

     Side Effects Associated with Low-Dose GH Replacement

     Large, pharmacological doses of GH are often associated with fluid retention and high blood pressure. However, low doses of rhGH are currently being used for replacement in GH- deficient patients without such side effects. At a dose of 0.03 mg/kg/week, Bengtsson et al. demonstrated only minor side effects including fluid retention and mild joint pains in the majority of patients but did report carpal tunnel syndrome in one patient. In another recent study, smaller dose of GH at 0.01 mg/kg thrice a week showed no side effects. It remains unknown, however, whether long-term administration of GH at doses which keep IGF-I levels within the normal range will also improve key metabolic variables.

369. White HD, Ahmad AM, Vora JP. Effects of adult growth hormone deficiency and growth hormone replacement on circadian rhythmicity. Minerva Endocrinol. 2003;28(1):13-25.
     View Summary +

     Effects of adult growth hormone deficiency and growth hormone replacement on circadian rhythmicity.
     

     In their study, White et al. (2003) investigated the effects of adult growth hormone deficiency (AGHD) and growth hormone replacement on circadian rhythmicity. They explored the role of growth hormone (GH) in regulating various physiological processes that exhibit circadian variations, such as hormone secretion, metabolism, and cardiovascular function. The study highlighted the disruption of circadian rhythms in AGHD and the potential benefits of GH replacement therapy in restoring these rhythms. The findings suggested that GH replacement therapy may have a positive impact on the regulation of circadian rhythms in individuals with AGHD.

370. Colao A, Di somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab. 1999;84(6):1919-24.
     View Summary +

     Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism

     Reduced bone mineral density (BMD) has been reported in patients with isolated GH deficiency (GHD) or with multiple pituitary hormone deficiencies (MPHD). To investigate whether the severity of GHD was correlated with the degree of bone mass and turnover impairment, Colao et al evaluated BMD at the lumbar spine and femoral neck, circulating levels of insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and osteocalcin levels, and urinary cross-linked N-telopeptides of type I collagen (Ntx) levels in 101 adult hypopituitary patients and 35 sex- and age-matched healthy subjects.

     On the basis of the GH response to arginine plus GHRH (ARG+GHRH), patients were subdivided into 4 groups:
     1. Group 1 included 41 patients with a GH peak below 3 μg/L (very severe GHD)
     2. Group 2 included 25 patients with a GH peak between 3.1–9 μg/L (severe GHD)
     3. Group 3 included 18 patients with a GH peak between 9.1–16.5 μg/L (partial GHD)
     4. Group 4 included 17 patients with a GH peak above 16.5 μg/L (non-GHD)

     The results of study were as follows:

     – In patients in group 1, circulating IGF-I, osteocalcin, and urinary Ntx levels were lower than those in group 3–5, which were not different from each other.
     – The t score at the lumbar and that at the femoral neck were lower than those in groups 3.
     – In patients in group 2, circulating IGF-I and IGFBP-3 levels were not different from those in group 1
     – T scores at the lumbar spine and femoral neck were significantly higher and lower, respectively, than those in groups 1 and 5 but not those in groups 3 and 4, and serum osteocalcin and urinary Ntx levels were significant higher than those in group 1 and lower than those in groups 3–5.

     In conclusion, a significant BMD reduction associated with abnormalities of bone turnover parameters was found only in patients with very severe or severe GHD, whereas normal BMD values were found in non-GHD hypopituitary patients. These abnormalities were consistently present in all patients with GHD regardless of the presence of additional hormone deficits, suggesting that GHD plays a central role in the development of osteopenia in hypopituitary patients.

371. Locatelli V, Bianchi VE. Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis. Int J Endocrinol. 2014;2014:235060.
     View Summary +

     Effect of GH/IGF-1 on Bone Metabolism and Osteoporosis

     Growth hormone (GH) and insulin-like growth factor (IGF-1) are fundamental in the growth of the skeleton during puberty and bone health throughout life. GH increases tissue formation by acting directly and indirectly on target cells; IGF-1 is a critical mediator of bone growth. GH deficiency in childhood decreases bone mineral density (BMD), while GH treatment increases bone growth and strength. A positive correlation between IGF-1 level in the blood and BMD has been documented in women but not in men. Low levels of IGF-1 in women are reported to be associated with higher prevalence of fractures. Recently, Ohlsson et al. demonstrated that low levels of IGF-1 were associated with an increased risk of fractures of about 40% and that the levels of IGF-1 in the blood could be clinically useful for assessing the risk of vertebral fractures. Osteoporosis in postmenopausal women is caused by a deficiency in the hormone estrogen and a high rate of bone remodeling with bone resorption exceeding bone formation. The estrogen deficiency is critical to the pathogenesis of osteoporosis in both men and women and the frequency of the secretion of GH is reduced in the amplitude with sex hormone reduction. It has been documented extensively that estrogen is one of the factors that regulates the expression of IGF-1 in maintaining healthy bones. IGF-1 plays a major role in cell growth, differentiation, survival, and cell cycle progression and is necessary for proper acquisition of peak bone mass. Furthermore, GH protects against bone loss induced by the removal of the ovaries.

     The Effect of GH/IGF-1 on Bone

     In vitro studies using cultured chondrocytes (cells that have secreted the matrix of cartilage and become embedded in it) have shown that GH stimulated the formation of colony of young precondrocytes directly while IGF-1 stimulated cells at later stage of maturation. GH and IGF-1 stimulate the preadipocytes (precursor to fat cells) at different stages of development and a direct action exerted on osteoblasts (cells that make bone) has been demonstrated. The presence of GH and IGFBP-3 enhances the activity of IGF-1 on osteoblastic cells. GH and IGF-1 stimulate tissue growth with integrated functions. In fact IGF-1 is quite effective in stimulating growth in patients affected by GH insensitivity syndrome.

     Both GH and IGF-1 are considered potential anabolic agents because they play physiological roles in bone mass acquisition and maintenance. GH and IGF-1 administration has the capacity to stimulate longitudinal bone growth in animals and humans by acting both directly and indirectly increasing local production of IGF-1 stimulating IGF-1-gene. Although GH and IGF-1 have independent and different functions, they exert a synergistic effect when given together.

     Effect of GH Administration on Osteoporosis and Bone Metabolism

     GH administration has been evaluated in various clinical trials in normal subject and in women with osteoporosis and postmenopausal women. Studies have reported large age variance (from 22 to 81 years) and in the administered dose of GH (from 0.015 mg/kg/day to 0.75 mg/kg/day) in addition to the duration of the therapy ranging from 3 days to 3 years. In a large part of the studies, there was a significant increase in bone formation, bone mineral content (BMC), bone mineral density (BMD). In 1975, Kruse and Kuhlencordt reported that patients with primary and secondary osteoporosis treated with GH displayed an increase in periosteal new bone formation and an intracortical bone resorption with a significantly increased relative osteoblast activity. The effect of GH therapy has been evaluated in healthy subjects, in postmenopausal osteoporosis, and in men with idiopatic osteoporosis. In the most studies, a significant increase in bone resorption, bone formation and BMD were observed. In the longest double blind, randomized placebo-controlled trial, Landin-Wilhelmsen reported that GH treatment for 3 years increased bone mineral content by 14% in postmenopausal women with osteoporosis. GH administration at low doses was able to restore normal parathyroid hormone (PTH) secretory patterns in osteoporotic postmenopausal women, improves target organ sensitivity to PTH, and results in a net positive balance in bone mineral metabolism, all leading to an increase in BMD.

     Effect of IGF-1 Administration on Osteoporosis and Bone Metabolism

     Recombinant human IGF-1 (rhIGF-1) has been used for many years for the treatment of osteoporosis. Significant bone resorption and formation has been demonstrated in most studies and no significant side effects have been reported. An increase in circulating IGF-1, IGFBP-2 and IGFBP-3, and PINP (a bone formation marker) has also been reported. Previous studies have shown that IGF-1 treatment at low doses increased blood markers for bone formation without increased for resorption markers in osteoporosis of postmenopausal women and a dose response effect was described. Long-term studies demonstrated similar positive effects and a good safety record with low dosage rhIGF-1. In another study, Grinspoon et al. reported that rhIGF-1 administration selectively stimulated bone formation in osteopenic girls with anorexia nervosa.

     Effect of GH/IGF-1 on Fracture Healing

     In a fractured bone, the healing process is initiated by the formation of a thick periosteal callus (a membrane that covers the outer surface of all bones) of woven bone with a central area of cartilage. Endochondral ossification (bone tissue formation) of the cartilage occurs subsequently in the woven bone. Later a marked remodeling process is activated and the callus volume declines while the density is enhanced.

     Many experimental and clinical studies have found that growth factors, such as morphogenetic proteins (MPs), the fibroblastic-like growth factors family (FGFs), transforming growth factors (TGFs), and plateled-derived growth factors (PDGF), stimulate bone formation during fracture healing. Evidences suggests that these hormones can also play a role in bone healing in patients who have sustained head injury with a more intensive callus formation than those without head injury. Various studies have investigated the effect of GH therapy in hip fracture all reporting a positive effect on bone healing and functional outcome. Only one study reported the effect of IGF-1 on bone healing. In this study, the researchers use a protein complex rhIGF-I/IGFBP-3 in the treatment of 20 women affected by hip fractures. The results of the study showed that a dose of 1 mg/kg/day stimulates bone metabolism in frail osteoporotic patients and the muscular efficiency increased. Also, placebo-treated subjects had an average bone mineral loss at the contralateral hip of about 6% during the first 6 months after the injury. The level of IGF-1 in the blood is significantly associated with the ability to function after hip fracture in women. GH therapy is also helpful in the prevention of risk of fracture in GH deficient subjects.

     Conclusions

     GH and IGF-1 have a great effect on bone resorption and bone anabolism and their administration has a positive effect on osteoporosis and fracture healing. The effect of GH and IGF-1 therapy on bone osteoporosis and fracture healing is mediated by several factors such as sex hormone levels, diet, inflammatory cytokines, and muscle mass and strength. More carefully designed, double-blind, and placebo-controlled randomized trials with large numbers of participants regarding GH plus sex hormone treatment of osteoporosis and bone healing after fractures are required.

372. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535-59.
     View Summary +

     Growth Hormone, Insulin-like Growth Factors, and the Skeleton

     GH and IGF-I are important regulators of bone homeostasis throughout life. Before the period of puberty, GH and IGF-I are determinants of longitudinal bone growth, skeletal maturation, and acquisition of bone mass, whereas in adults they are important in the maintenance of bone mass. During embryonic development, IGF-I and IGF-II are key determinants of growth, acting independently of GH. After birth and throughout puberty, GH and IGF-I play a critical role in determining longitudinal skeletal growth, and children with GH deficiency (GHD) display short stature. In addition to the effects on longitudinal growth, GH and IGF-I have the potential to regulate bone modeling and remodeling. Bone remodeling is necessary to maintain the balance of calcium in the body and to remove potentially damaged bone. This process occurs mostly during growth. In contrast to bone remodeling, bone modeling is a process of uncoupled bone formation and bone breakdown.

     Adult Growth Hormone Deficiency (AGHD)

     AGHD is a recognized and treatable clinical entity. Severe GHD in adults is associated with adverse changes in body composition, insulin sensitivity, lipid metabolism, and exercise capacity. Adult patients with GHD suffer from low bone turnover osteoporosis leading to increased risk of fractures, which may contribute to increased risk of death observed in GHD.

     Bone Turnover and Calcium Metabolism in Untreated GHD

     Patients with GHD have a marked reduction in bone turnover (total volume of bone that is both resorbed and formed over a period of time). Bone biopsies from male adult patients with GHD reveal decreased bone minerals and bone formation rate. Serum levels of osteocalcin (special protein that plays a role in bone mineralization and calcium balance) and bone resorption markers are decreased, confirming the state of low bone turnover. GHD also is associated with abnormalities in the circadian rhythm of parathyroid hormone (PTH), which may affect bone remodeling.

     Bone Mineral Density (BMD) and Fractures in Untreated GHD

     Decreased BMD is reported in patients with GHD, either isolated or combined with other pituitary hormone deficiencies. Patients with GHD exhibit greater losses of cortical than trabecular bone. The degree of bone loss is related to the duration and age of onset of GHD, the severity of the disease, and the age of the patient. Patients with childhood-onset GHD are smaller and have a more pronounced decrease in muscle and bone mass and lower IGF-I and IGFBP-3 serum concentrations than patients with adult-onset GHD. The reason for the different degrees of bone loss may be because childhood-onset GHD occurs before the achievement of peak bone mass, and because the duration of the disease is longer. Patients with severe GHD or very severe GHD display significant reductions in BMD.

     Skeletal Effects of Recombinant Human GH (rhGH) in Adult-onset GHD

     1. Bone turnover and calcium metabolism in treated GHD.

     rhGH replacement therapy leads to an increase in bone turnover, as determined by changes in biochemical markers of bone resorption and bone formation. rhGH causes a maximal effect on bone resorption after 3 months and on bone formation after 6 months. The effect of rhGH on bone formation is sustained for prolonged periods of time and is usually dose dependent, but not influenced by the route of administration. rhGH causes an increase in serum and urinary calcium after 3 to 6 months

     2. BMD and fractures in treated GHD.

     The effect of rhGH on BMD in adult-onset GHD is variable and depends on the duration of the treatment. It is well-documented that when bone formation is increased, bone mass increases, but an increase in BMD can be documented only after 6 to 12 months in children and after 18 to 24 months in adults receiving rhGH therapy. The increase in BMD is observed for periods of up to 10 years in patients receiving continuous rhGH therapy. Moreover, BMD may even continue to increase 18 months after rhGH discontinuation. rhGH increases bone mineral content to a greater extent than BMD because rhGH also increases bone area. This is supported by findings demonstrating an increase in periosteal bone formation during rhGH treatment.

     Predictors of rhGH Response in Bone

     a. Gender.

     Male and female patients with GHD may display different responses to rhGH in terms of changes in bone turnover and BMD. In men, bone formation and resorption are increased within 1 month of rhGH treatment, whereas in women the increase occurs after 3 months. The increase in markers of bone resorption precedes the change in bone formation markers by about 9 months.

     b. Age of onset of GHD.

     In adult-onset GHD, bone formation increases after 6 months of treatment, with little change thereafter, whereas in childhood-onset GHD, there is a progressive increase in bone formation for up to 12 months after rhGH followed by a return to baseline values after 18 months of therapy. Patients with childhood-onset GHD generally display an increase in BMD after 6 to 12 months of rhGH therapy, whereas patients with adult-onset GHD require 18 to 24 months of rhGH to exhibit a change in BMD.

     c. Dose of GH.

     There is a linear correlation between the dose of rhGH and the increase in BMD in childhood-onset GHD, indicating a need for optimization of the dose of rhGH in children. In contrast, in adult-onset GHD, low of rhGH have an optimal effect on BMD, whereas at high doses rhGH may cause an initial decline in BMD, probably due to an increase in bone resorption.

     d. Concomitant diseases.

     Different pituitary disease may alter the effects of rhGH on bone mass. In patients with Cushing’s disease and in patients with hyperprolactinemia (increase levels of prolactin) and hypogonadism (reduction or absence of hormone secretion of the testes or ovaries), there is a delayed effect of rhGH replacement therapy on BMD.

     GH and IGF-I are necessary to achieve and maintain bone mass throughout life. IGF-I mediates most of the effects of GH on skeletal metabolism, IGF-I increases bone formation by regulating the differentiated function of the osteoblast (cell that makes bones), and as a consequence GH and IGF-I increase bone remodeling. Diseases affecting the GH/IGF-I axis are frequently associated with significant alterations in bone metabolism that often lead to bone loss.

373. Gillberg P, Mallmin H, Petrén-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis. The Journal of clinical endocrinology and metabolism. 2002; 87(11):4900-6.
     View Summary +

     Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.
     

     In their study, Gillberg et al. (2002) investigated the effects of two years of treatment with recombinant human growth hormone (rhGH) on bone mineral density (BMD) in men with idiopathic osteoporosis. The study aimed to assess whether rhGH therapy could improve BMD in this specific population. The findings revealed that treatment with rhGH resulted in a significant increase in BMD over the two-year period. This suggests that rhGH therapy may be a beneficial intervention for men with idiopathic osteoporosis by improving bone health and potentially reducing the risk of fractures.

374. Barake M, Arabi A, Nakhoul N. Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis. Endocrine. 2017.
     View Summary +

     Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis
     

     In their systematic review and meta-analysis, Barake et al. (2017) evaluated the effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis, even in the absence of growth hormone deficiency. The study aimed to determine whether growth hormone therapy could benefit individuals with age-related osteoporosis. The findings from the analysis revealed that growth hormone therapy led to a significant increase in bone density and a reduction in fracture risk among individuals with age-related osteoporosis. This suggests that growth hormone therapy may have potential as a treatment option for improving bone health in this population, even in the absence of growth hormone deficiency.

375. Wuster C, Härle U, Rehn U. Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1998; 8 Suppl A:87-94.
     View Summary +

     Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis.
     

     In their study, Wuster et al. (1998) investigated the benefits of growth hormone treatment on bone metabolism, bone density, and bone strength in individuals with growth hormone deficiency and osteoporosis. The researchers aimed to determine the effects of growth hormone therapy on bone health in these populations. The findings of the study demonstrated positive effects of growth hormone treatment on bone metabolism, leading to improvements in bone density and bone strength. These results suggest that growth hormone therapy may be beneficial for individuals with growth hormone deficiency and osteoporosis by promoting bone health and potentially reducing the risk of fractures.

376. Murray RD, Shalet SM. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency. Clin Endocrinol (Oxf). 2005;62(2):182-8.
     View Summary +

     Insulin Sensitivity is Impaired in Adults with Varying Degrees of GH Deficiency

     Severe growth hormone deficiency (GHD) is a condition defined by a peak GH (pGH) response to provocative tests of less than 3 µg/l. GHD occurs when your anterior pituitary gland does not produce sufficient amount of GH. This condition can occur in both children and adults and may display a multitude of signs and symptoms.

     Most cases of adult onset growth hormone deficiency are caused by damage to the pituitary gland. The damage can be caused by pituitary tumor, surgical procedure, and/or radiotherapy. Other types of GHD are caused by genetic abnormalities such as Prader-Willi syndrome or Turner syndrome. In some cases, the cause is unknown or is said to be idiopathic.

     The impact of lesser degrees of GHD in the adult is less well defined. Most adults with severe GHD are insulin resistant. To better understand this relationship, it is vital to know the functions of both growth hormone (GH) and insulin. Basically, GH causes the release of insulin-like growth factor 1 and other growth factors. Aside from this effect, GH counteracts in general the effects of insulin on blood sugar and metabolism of lipids while sharing protein anabolic properties with insulin. GH does not affect the total turnover of blood sugar directly. However, GH suppresses muscle uptake of blood sugar, indicating that GH plays a role in the redistribution of blood sugar.

     Whether insulin action is impaired in the presence of GHD is not known. To determine whether insulin sensitivity is impaired in patients with GHD, Murray et al studied 30 GH-deficient patients. A short insulin tolerance test (ITT) was performed in a subset of 20 patients from each group and the rate constant for glucose disappearance (KITT) is calculated. The results of the study showed that GH-deficient adults were found to be insulin resistant from the KITT values compared with the control group. Insulin resistance increased in concert with percentage fat mass, age and male gender.

     The researchers conclude that, although not detected under basal conditions, hypopituitary adults with GH deficiency are insulin resistant under conditions of insulin stimulation. This finding may be explained by the concomitant adverse changes in body composition observed in both these states of varying degrees of GHD. Insulin resistance is associated with numerous adverse risk factors such as heart diseases, hypertension, diabetes, and other diseases that may place GH-deficient patients at higher risks for fatal diseases.

377. Jennifer M. Sacheck, Akira Ohtsuka, S. Christine McLary, and Alfred L. Goldberg. “IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1..” Published online before print April 20, 2004, doi: 10.1152/ajpendo.00073.2004.
     View Summary +

     “IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.”

     In their study, Sacheck et al. (2004) investigated the effects of insulin-like growth factor-I (IGF-I) on muscle growth and protein breakdown. The researchers aimed to understand the molecular mechanisms by which IGF-I promotes muscle growth. They found that IGF-I stimulates muscle growth by suppressing protein breakdown and the expression of two ubiquitin ligases, atrogin-1 and MuRF1, which are associated with muscle atrophy. These findings suggest that IGF-I plays a critical role in maintaining muscle mass by inhibiting protein degradation and promoting muscle protein synthesis, highlighting its potential as a therapeutic target for muscle-related disorders.

378. Shlomo Melmed; Kenneth S. Polonsky; P. Reed Larsen; Henry M. Kronenberg (30 November 2015). Williams Textbook of Endocrinology. Elsevier Health Sciences. pp. 191–. ISBN 978-0-323-29738-7.
     View Summary +

     Williams Textbook of Endocrinology

     “Williams Textbook of Endocrinology” is a comprehensive textbook on the field of endocrinology, authored by Shlomo Melmed, Kenneth S. Polonsky, P. Reed Larsen, and Henry M. Kronenberg. The textbook provides a thorough and up-to-date overview of various endocrine disorders and their management. It covers a wide range of topics including the anatomy and physiology of the endocrine system, hormonal regulation, diagnostic approaches, and treatment strategies. The book serves as a valuable resource for healthcare professionals, researchers, and students seeking in-depth knowledge and understanding of endocrinology.

379. William N. Taylor, M.D. (16 January 2002). Anabolic Steroids and the Athlete, 2d ed. McFarland. pp. 138–. ISBN 978-0-7864-1128-3.
     View Summary +

     Anabolic Steroids and the Athlete, 2d ed.
     

     “Anabolic Steroids and the Athlete” is a book written by William N. Taylor, M.D. The second edition of the book explores the use of anabolic steroids in the context of sports performance enhancement. It provides information on the history, pharmacology, and physiological effects of anabolic steroids. The book also delves into the potential risks and side effects associated with their use. Additionally, it discusses the legal and ethical considerations surrounding the use of these substances in sports. The book serves as a resource for athletes, coaches, and healthcare professionals interested in understanding the complex issues related to anabolic steroid use in sports.

380. Holt RI, et al. The history of doping and growth hormone abuse in sport. Growth Horm IGF Res. 2009 Aug;19(4):320-6. doi: 10.1016/j.ghir.2009.04.009. PMID 19467612.
     View Summary +

     The history of doping and growth hormone abuse in sport.
     

     Holt RI and colleagues authored the article titled “The history of doping and growth hormone abuse in sport,” published in the journal Growth Hormone & IGF Research in 2009. The article explores the historical context of doping and the abuse of growth hormone in sports. It discusses the motivations behind the use of performance-enhancing substances, including the desire to gain a competitive edge. The article also delves into the methods used to detect and deter doping, as well as the ethical and health considerations associated with the abuse of growth hormone. The authors provide valuable insights into the evolution of doping practices and highlight the importance of maintaining fair competition and protecting athletes’ health.

381. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P (July 2006). “Human growth hormone doping in sport”. Br J Sports Med. 40 Suppl 1: i35–9. doi:10.1136/bjsm.2006.027573. PMC 2657499. PMID 16799101.
     View Summary +

     Human growth hormone doping in sport

     Saugy M, Robinson N, Saudan C, Baume N, Avois L, and Mangin P authored the article titled “Human growth hormone doping in sport,” published in the British Journal of Sports Medicine in 2006. The article discusses the prevalence, methods, and consequences of human growth hormone (HGH) doping in the world of sports. It explores the various detection methods used to identify HGH abuse, including blood and urine testing, as well as the challenges faced in effectively detecting its use. The authors also highlight the potential health risks associated with HGH abuse and emphasize the importance of education, prevention, and anti-doping efforts in curbing this form of performance-enhancing substance abuse.

382. Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM, Hoffman AR (May 2008). “Systematic review: the effects of growth hormone on athletic performance”. Intern. Med. 148 (10): 747–58.
     View Summary +

     Systematic review: the effects of growth hormone on athletic performance

     The article titled “Systematic review: the effects of growth hormone on athletic performance” was authored by Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM, and Hoffman AR. It was published in the journal Internal Medicine in May 2008. The systematic review examines the effects of growth hormone (GH) on athletic performance by analyzing relevant studies. The authors assess the impact of GH on muscle strength, endurance, and body composition in athletes. They also evaluate potential adverse effects and the quality of the available evidence. The review provides a comprehensive overview of the existing research on GH and its implications for athletic performance.

383. Committee Holds Hearing on Myths and Facts about Human Growth Hormone, B12, and Other Substances (February 12, 2008)”. Committee on Oversight and Government Reform, United States House of Representatives. Retrieved 19 February 2016.
     View Summary +

     Committee on Oversight and Government Reform, United States House of Representatives.
     

     The cited information refers to a hearing held by the Committee on Oversight and Government Reform in the United States House of Representatives on February 12, 2008. The hearing was focused on discussing the myths and facts surrounding human growth hormone (HGH), vitamin B12, and other substances. The purpose of the hearing was likely to gather information and insights from experts and stakeholders regarding the use, benefits, and potential risks associated with these substances. The hearing aimed to provide a better understanding of the topic and contribute to informed decision-making and public policy on these matters.

384. Steven B. Karch, MD, FFFLM (21 December 2006). Drug Abuse Handbook, Second Edition. CRC Press. pp. 697–. ISBN 978-1-4200-0346-8.
     View Summary +

     Drug Abuse Handbook, Second Edition.
     

     The cited information refers to the book “Drug Abuse Handbook, Second Edition” by Steven B. Karch. Published on December 21, 2006, the book provides comprehensive information and insights into various aspects of drug abuse. It covers a wide range of topics related to drugs, including their pharmacology, effects on the body and mind, patterns of use, treatment approaches, and legal and societal implications. The book is a valuable resource for healthcare professionals, researchers, law enforcement agencies, and individuals interested in understanding the complex issues surrounding drug abuse.

385. Christopher Madden; Margot Putukian; Eric McCarty; Craig Young (25 November 2013). Netter’s Sports Medicine. Elsevier Health Sciences. pp. 171–. ISBN 978-0-323-29615-1.
     View Summary +

     Netter’s Sports Medicine.
     

     The cited information refers to the book “Netter’s Sports Medicine” by Christopher Madden, Margot Putukian, Eric McCarty, and Craig Young. Published on November 25, 2013, the book is a comprehensive resource for sports medicine professionals, athletes, coaches, and trainers. It covers a wide range of topics related to sports injuries, including diagnosis, treatment, rehabilitation, and prevention. The book features detailed illustrations and photographs by Frank H. Netter, along with expert insights and evidence-based information on various sports-related conditions and procedures. It serves as a valuable reference for anyone involved in sports medicine and provides a thorough understanding of the field.